{
  "version": "0.1.0",
  "scopes": [
    {
      "scope_id": "clinical_signal_03",
      "episodes": [
        {
          "episode_id": "clinical_signal_03_ep_001",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-04T10:00:00",
          "text": "## 2024-03-04 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 40\n- Active: 40\n- Screen Failures Cumulative: 2\n- Withdrawals Cumulative: 0\n\n#### Sites\n- Site 01: \n  - Enrolled: 4\n  - Active: 4\n  - Statin Concomitant: 1\n- Site 02: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 03: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 04: \n  - Enrolled: 2\n  - Active: 2\n  - Statin Concomitant: 0\n- Site 05: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 06: \n  - Enrolled: 2\n  - Active: 2\n  - Statin Concomitant: 0\n- Site 07: \n  - Enrolled: 4\n  - Active: 4\n  - Statin Concomitant: 1\n- Site 08: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 09: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 10: \n  - Enrolled: 2\n  - Active: 2\n  - Statin Concomitant: 0\n- Site 11: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 12: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n\n### Lab Panels\n- Statin Subgroup:\n  - N: 53\n  - ALT (U/L) Mean: 25.5\n  - ALT (U/L) Median: 22.7\n  - AST (U/L) Mean: 26.4\n  - AST (U/L) Median: 24.4\n  - Bilirubin (mg/dL) Mean: 0.78\n  - Bilirubin (mg/dL) Median: 0.74\n  - ALP (U/L) Mean: 84.9\n  - ALP (U/L) Median: 76.7\n  - Creatinine (mg/dL) Mean: 1.06\n  - Creatinine (mg/dL) Median: 0.95\n  - BUN (mg/dL) Mean: 16.9\n  - BUN (mg/dL) Median: 15.1\n  - WBC (K) Mean: 5.9\n  - WBC (K) Median: 7.6\n  - Platelets (K) Mean: 233\n  - Platelets (K) Median: 242\n- Non-Statin Subgroup:\n  - N: 131\n  - ALT (U/L) Mean: 29.9\n  - ALT (U/L) Median: 28.9\n  - AST (U/L) Mean: 26.4\n  - AST (U/L) Median: 25.9\n  - Bilirubin (mg/dL) Mean: 0.73\n  - Bilirubin (mg/dL) Median: 0.7\n  - ALP (U/L) Mean: 71.9\n  - ALP (U/L) Median: 68.2\n  - Creatinine (mg/dL) Mean: 1.1\n  - Creatinine (mg/dL) Median: 0.98\n  - BUN (mg/dL) Mean: 16.8\n  - BUN (mg/dL) Median: 13.9\n  - WBC (K) Mean: 6.0\n  - WBC (K) Median: 7.8\n  - Platelets (K) Mean: 218\n  - Platelets (K) Median: 256\n\n### Adverse Events\n- AE ID: AE-0001\n  - Description: upper respiratory infection\n  - Grade: 1\n  - Relatedness: not related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0002\n  - Description: nausea\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: non_statin\n- AE ID: AE-0003\n  - Description: headache\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0004\n  - Description: diarrhea\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-001\n  - Description: Missed visit window (1 days late)\n  - Severity: minor\n  - Site: site_05\n- PD ID: PD-002\n  - Description: IP temperature excursion during shipment, 2h out of range\n  - Severity: moderate\n  - Site: site_11\n- PD ID: PD-003\n  - Description: Lab sample mislabeled, corrected same day\n  - Severity: minor\n  - Site: site_08\n\n### Investigator Notes\n- IEC/IRB annual renewal submitted on schedule\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- Central lab courier pickup schedule adjusted for holiday\n- Drug accountability audit at Site 08: no discrepancies\n\n### Notes\n- Week 1: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_001",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-04T10:30:00",
          "text": "## 2024-03-04 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 43\n- Active: 43\n- Screen Failures Cumulative: 3\n- Withdrawals Cumulative: 0\n\n### Enrollment By Treatment Arm\n- Multimodal: 14\n- Standard: 15\n- Placebo: 14\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 6.6\n- Multimodal VAS Pain Score SD: 1.8\n- Multimodal Morphine Equivalents (mg) Mean: 44.2\n- Multimodal Morphine Equivalents (mg) SD: 7.7\n- Multimodal Six Minute Walk Test (meters) Mean: 284.0\n- Multimodal Six Minute Walk Test (meters) SD: 36.0\n- Multimodal Grip Strength (kg) Mean: 22.5\n- Multimodal Grip Strength (kg) SD: 5.5\n- Multimodal Sleep Quality Index Mean: 4.4\n- Multimodal Sleep Quality Index SD: 1.2\n- Multimodal Rescue Med Doses per Week Mean: 5.3\n- Multimodal Rescue Med Doses per Week SD: 1.4\n\n- Standard VAS Pain Score Mean: 6.6\n- Standard VAS Pain Score SD: 1.4\n- Standard Morphine Equivalents (mg) Mean: 50.2\n- Standard Morphine Equivalents (mg) SD: 9.0\n- Standard Six Minute Walk Test (meters) Mean: 280.0\n- Standard Six Minute Walk Test (meters) SD: 52.0\n- Standard Grip Strength (kg) Mean: 20.9\n- Standard Grip Strength (kg) SD: 5.2\n- Standard Sleep Quality Index Mean: 3.9\n- Standard Sleep Quality Index SD: 1.4\n- Standard Rescue Med Doses per Week Mean: 5.7\n- Standard Rescue Med Doses per Week SD: 2.0\n\n- Placebo VAS Pain Score Mean: 6.6\n- Placebo VAS Pain Score SD: 1.6\n- Placebo Morphine Equivalents (mg) Mean: 47.0\n- Placebo Morphine Equivalents (mg) SD: 9.2\n- Placebo Six Minute Walk Test (meters) Mean: 266.0\n- Placebo Six Minute Walk Test (meters) SD: 42.0\n- Placebo Grip Strength (kg) Mean: 20.0\n- Placebo Grip Strength (kg) SD: 5.5\n- Placebo Sleep Quality Index Mean: 3.9\n- Placebo Sleep Quality Index SD: 1.3\n- Placebo Rescue Med Doses per Week Mean: 6.3\n- Placebo Rescue Med Doses per Week SD: 1.7\n\n### Physical Therapy\n- Sessions Scheduled: 88\n- Sessions Attended: 73\n- Attendance Rate (%): 92.4\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.4\n- Hemoglobin (g/dL) SD: 1.4\n- WBC (k) Mean: 6.1\n- WBC (k) SD: 1.1\n- Platelets (k) Mean: 247\n- Platelets (k) SD: 42\n- Serum Creatinine (mg/dL) Mean: 1.05\n- Serum Creatinine (mg/dL) SD: 0.14\n- Blood Glucose (mg/dL) Mean: 87.0\n- Blood Glucose (mg/dL) SD: 10.0\n- ESR (mm/hr) Mean: 19.0\n- ESR (mm/hr) SD: 9.0\n\n### Adverse Events\n- AE ID: PM-AE-0186, Description: nausea, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0102, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-0117, Description: headache, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- None\n\n### Events\n- Blinded interim efficacy data compiled for DSMB\n- Central pharmacy opioid supply reconciliation completed\n\n### Notes\n- Week 1: Pain management assessments on track. 43 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_002",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-06T10:30:00",
          "text": "## 2024-03-11 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 52\n- Active: 52\n- Screen Failures Cumulative: 5\n- Withdrawals Cumulative: 0\n- By Treatment Arm: \n  - Multimodal: 17\n  - Standard: 17\n  - Placebo: 18\n\n### Efficacy By Arm\n- Multimodal: \n  - VAS Pain Score Mean: 6.2\n  - VAS Pain Score SD: 1.1\n  - Morphine Equivalents mg Mean: 43.3\n  - Morphine Equivalents mg SD: 10.7\n  - Six MWT Meters Mean: 296.0\n  - Six MWT Meters SD: 31.0\n  - Grip Strength kg Mean: 21.6\n  - Grip Strength kg SD: 3.8\n  - Sleep Quality Index Mean: 4.7\n  - Sleep Quality Index SD: 1.2\n  - Rescue Med Doses per Week Mean: 5.2\n  - Rescue Med Doses per Week SD: 1.4\n- Standard: \n  - VAS Pain Score Mean: 6.2\n  - VAS Pain Score SD: 1.1\n  - Morphine Equivalents mg Mean: 49.5\n  - Morphine Equivalents mg SD: 10.4\n  - Six MWT Meters Mean: 279.0\n  - Six MWT Meters SD: 54.0\n  - Grip Strength kg Mean: 20.7\n  - Grip Strength kg SD: 3.5\n  - Sleep Quality Index Mean: 4.2\n  - Sleep Quality Index SD: 1.0\n  - Rescue Med Doses per Week Mean: 5.6\n  - Rescue Med Doses per Week SD: 2.4\n- Placebo: \n  - VAS Pain Score Mean: 7.1\n  - VAS Pain Score SD: 1.7\n  - Morphine Equivalents mg Mean: 50.0\n  - Morphine Equivalents mg SD: 10.6\n  - Six MWT Meters Mean: 251.0\n  - Six MWT Meters SD: 45.0\n  - Grip Strength kg Mean: 18.7\n  - Grip Strength kg SD: 5.1\n  - Sleep Quality Index Mean: 3.8\n  - Sleep Quality Index SD: 1.5\n  - Rescue Med Doses per Week Mean: 6.1\n  - Rescue Med Doses per Week SD: 2.2\n\n### Physical Therapy\n- Sessions Scheduled: 108\n- Sessions Attended: 89\n- Attendance Rate %: 87.6\n\n### Safety Labs\n- Hemoglobin g/dL Mean: 13.2\n- Hemoglobin g/dL SD: 1.3\n- WBC k Mean: 7.8\n- WBC k SD: 1.9\n- Platelets k Mean: 238\n- Platelets k SD: 47\n- Serum Creatinine mg/dL Mean: 1.11\n- Serum Creatinine mg/dL SD: 0.15\n- Blood Glucose mg/dL Mean: 99.0\n- Blood Glucose mg/dL SD: 10.0\n- ESR mm/hr Mean: 18.0\n- ESR mm/hr SD: 9.0\n\n### Adverse Events\n- AE ID: PM-AE-0220, Description: headache, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0255, Description: muscle spasm, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-0222, Description: Missed physical therapy session, not rescheduled within window, Severity: minor\n- PD ID: PM-PD-0219, Description: Rescue medication log incomplete for 1 subject, Severity: minor\n\n### Events\n- Blinded interim efficacy data compiled for DSMB\n- Opioid conversion table reference updated per FDA guidance\n\n### Notes\n- Week 2: Pain management assessments on track. 52 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_003",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-08T10:30:00",
          "text": "## 2024-03-18 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 66\n- Active: 66\n- Screen Failures Cumulative: 8\n- Withdrawals Cumulative: 0\n\n### Enrollment By Treatment Arm\n- Multimodal: 23\n- Standard: 21\n- Placebo: 22\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 6.1\n- Multimodal VAS Pain Score SD: 1.8\n- Multimodal Morphine Equivalents mg Mean: 44.3\n- Multimodal Morphine Equivalents mg SD: 8.2\n- Multimodal Six MWT Meters Mean: 283.0\n- Multimodal Six MWT Meters SD: 50.0\n- Multimodal Grip Strength kg Mean: 23.6\n- Multimodal Grip Strength kg SD: 4.8\n- Multimodal Sleep Quality Index Mean: 4.6\n- Multimodal Sleep Quality Index SD: 0.8\n- Multimodal Rescue Med Doses per Week Mean: 4.7\n- Multimodal Rescue Med Doses per Week SD: 1.9\n\n- Standard VAS Pain Score Mean: 6.1\n- Standard VAS Pain Score SD: 1.7\n- Standard Morphine Equivalents mg Mean: 50.1\n- Standard Morphine Equivalents mg SD: 12.0\n- Standard Six MWT Meters Mean: 278.0\n- Standard Six MWT Meters SD: 31.0\n- Standard Grip Strength kg Mean: 20.9\n- Standard Grip Strength kg SD: 3.8\n- Standard Sleep Quality Index Mean: 4.1\n- Standard Sleep Quality Index SD: 1.1\n- Standard Rescue Med Doses per Week Mean: 5.3\n- Standard Rescue Med Doses per Week SD: 1.8\n\n- Placebo VAS Pain Score Mean: 6.9\n- Placebo VAS Pain Score SD: 1.4\n- Placebo Morphine Equivalents mg Mean: 49.3\n- Placebo Morphine Equivalents mg SD: 8.1\n- Placebo Six MWT Meters Mean: 254.0\n- Placebo Six MWT Meters SD: 45.0\n- Placebo Grip Strength kg Mean: 18.3\n- Placebo Grip Strength kg SD: 5.4\n- Placebo Sleep Quality Index Mean: 3.9\n- Placebo Sleep Quality Index SD: 0.9\n- Placebo Rescue Med Doses per Week Mean: 6.8\n- Placebo Rescue Med Doses per Week SD: 2.1\n\n### Physical Therapy\n- Sessions Scheduled: 131\n- Sessions Attended: 125\n- Attendance Rate %: 83.9\n\n### Safety Labs\n- Hemoglobin g/dL Mean: 13.4\n- Hemoglobin g/dL SD: 1.1\n- WBC k Mean: 6.3\n- WBC k SD: 1.5\n- Platelets k Mean: 232\n- Platelets k SD: 49\n- Serum Creatinine mg/dL Mean: 0.94\n- Serum Creatinine mg/dL SD: 0.11\n- Blood Glucose mg/dL Mean: 95.0\n- Blood Glucose mg/dL SD: 20.0\n- ESR mm/hr Mean: 12.0\n- ESR mm/hr SD: 4.0\n\n### Adverse Events\n- AE ID: PM-AE-0336, Description: urinary retention, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-0345, Description: diaphoresis, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-0332, Description: dry mouth, Grade: 2, Relatedness: probably related, Resolved: false, Treatment Arm: multimodal\n- AE ID: PM-AE-0384, Description: fatigue, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0363, Description: muscle spasm, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- Pain diary electronic collection rate: 82%\n- Physical therapy schedule coordinated across 8 sites\n- Opioid conversion table reference updated per FDA guidance\n\n### Notes\n- Week 3: Pain management assessments on track. 66 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_004",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-10T10:30:00",
          "text": "## 2024-03-25 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 82\n- Active: 82\n- Screen Failures Cumulative: 11\n- Withdrawals Cumulative: 0\n\n### Enrollment By Treatment Arm\n- Multimodal: 28\n- Standard: 26\n- Placebo: 28\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 6.2\n- Multimodal VAS Pain Score SD: 1.5\n- Multimodal Morphine Equivalents (mg) Mean: 40.9\n- Multimodal Morphine Equivalents (mg) SD: 11.1\n- Multimodal Six MWT (meters) Mean: 289.0\n- Multimodal Six MWT (meters) SD: 60.0\n- Multimodal Grip Strength (kg) Mean: 23.1\n- Multimodal Grip Strength (kg) SD: 5.3\n- Multimodal Sleep Quality Index Mean: 4.8\n- Multimodal Sleep Quality Index SD: 1.4\n- Multimodal Rescue Med Doses per Week Mean: 4.9\n- Multimodal Rescue Med Doses per Week SD: 1.0\n\n- Standard VAS Pain Score Mean: 6.5\n- Standard VAS Pain Score SD: 1.1\n- Standard Morphine Equivalents (mg) Mean: 47.4\n- Standard Morphine Equivalents (mg) SD: 11.2\n- Standard Six MWT (meters) Mean: 288.0\n- Standard Six MWT (meters) SD: 45.0\n- Standard Grip Strength (kg) Mean: 20.8\n- Standard Grip Strength (kg) SD: 5.8\n- Standard Sleep Quality Index Mean: 4.2\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses per Week Mean: 5.8\n- Standard Rescue Med Doses per Week SD: 1.9\n\n- Placebo VAS Pain Score Mean: 6.5\n- Placebo VAS Pain Score SD: 1.6\n- Placebo Morphine Equivalents (mg) Mean: 49.6\n- Placebo Morphine Equivalents (mg) SD: 10.0\n- Placebo Six MWT (meters) Mean: 254.0\n- Placebo Six MWT (meters) SD: 40.0\n- Placebo Grip Strength (kg) Mean: 19.5\n- Placebo Grip Strength (kg) SD: 4.5\n- Placebo Sleep Quality Index Mean: 3.6\n- Placebo Sleep Quality Index SD: 0.9\n- Placebo Rescue Med Doses per Week Mean: 6.9\n- Placebo Rescue Med Doses per Week SD: 2.3\n\n### Physical Therapy\n- Sessions Scheduled: 159\n- Sessions Attended: 158\n- Attendance Rate (%): 88.1\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.0\n- Hemoglobin (g/dL) SD: 1.4\n- WBC (k) Mean: 8.4\n- WBC (k) SD: 1.3\n- Platelets (k) Mean: 234\n- Platelets (k) SD: 41\n- Serum Creatinine (mg/dL) Mean: 1.11\n- Serum Creatinine (mg/dL) SD: 0.18\n- Blood Glucose (mg/dL) Mean: 99.0\n- Blood Glucose (mg/dL) SD: 18.0\n- ESR (mm/hr) Mean: 10.0\n- ESR (mm/hr) SD: 7.0\n\n### Adverse Events\n- AE ID: PM-AE-0445, Description: dry mouth, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0471, Description: nausea, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-0460, Description: constipation, Grade: 2, Relatedness: probably related, Resolved: false, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-0419, Description: Rescue medication log incomplete for 1 subject, Severity: minor\n- PD ID: PM-PD-0423, Description: Rescue medication log incomplete for 1 subject, Severity: minor\n\n### Events\n- Pain diary electronic collection rate: 88%\n- Physical therapy schedule coordinated across 15 sites\n- Pain diary electronic collection rate: 85%\n\n### Notes\n- Week 4: Pain management assessments on track. 82 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_002",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-11T10:00:00",
          "text": "## 2024-03-11 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 60\n- Active: 60\n- Screen Failures Cumulative: 4\n- Withdrawals Cumulative: 0\n\n#### Sites\n- Site 01 Enrolled: 6\n- Site 01 Active: 6\n- Site 01 Statin Concomitant: 1\n- Site 02 Enrolled: 4\n- Site 02 Active: 4\n- Site 02 Statin Concomitant: 1\n- Site 03 Enrolled: 5\n- Site 03 Active: 5\n- Site 03 Statin Concomitant: 1\n- Site 04 Enrolled: 4\n- Site 04 Active: 4\n- Site 04 Statin Concomitant: 1\n- Site 05 Enrolled: 5\n- Site 05 Active: 5\n- Site 05 Statin Concomitant: 1\n- Site 06 Enrolled: 3\n- Site 06 Active: 3\n- Site 06 Statin Concomitant: 1\n- Site 07 Enrolled: 6\n- Site 07 Active: 6\n- Site 07 Statin Concomitant: 1\n- Site 08 Enrolled: 4\n- Site 08 Active: 4\n- Site 08 Statin Concomitant: 1\n- Site 09 Enrolled: 5\n- Site 09 Active: 5\n- Site 09 Statin Concomitant: 1\n- Site 10 Enrolled: 4\n- Site 10 Active: 4\n- Site 10 Statin Concomitant: 1\n- Site 11 Enrolled: 5\n- Site 11 Active: 5\n- Site 11 Statin Concomitant: 1\n- Site 12 Enrolled: 4\n- Site 12 Active: 4\n- Site 12 Statin Concomitant: 1\n\n### Lab Panels\n- Statin Subgroup N: 53\n- Statin Subgroup ALT (U/L) Mean: 26.8\n- Statin Subgroup ALT (U/L) Median: 26.3\n- Statin Subgroup AST (U/L) Mean: 22.1\n- Statin Subgroup AST (U/L) Median: 20.8\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.73\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.72\n- Statin Subgroup ALP (U/L) Mean: 71.0\n- Statin Subgroup ALP (U/L) Median: 75.0\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.85\n- Statin Subgroup Creatinine (mg/dL) Median: 0.93\n- Statin Subgroup BUN (mg/dL) Mean: 16.6\n- Statin Subgroup BUN (mg/dL) Median: 16.0\n- Statin Subgroup WBC (K) Mean: 7.5\n- Statin Subgroup WBC (K) Median: 7.0\n- Statin Subgroup Platelets (K) Mean: 236\n- Statin Subgroup Platelets (K) Median: 249\n- Non-Statin Subgroup N: 122\n- Non-Statin Subgroup ALT (U/L) Mean: 29.7\n- Non-Statin Subgroup ALT (U/L) Median: 28.0\n- Non-Statin Subgroup AST (U/L) Mean: 20.7\n- Non-Statin Subgroup AST (U/L) Median: 20.0\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.9\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.89\n- Non-Statin Subgroup ALP (U/L) Mean: 56.7\n- Non-Statin Subgroup ALP (U/L) Median: 60.5\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.92\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.82\n- Non-Statin Subgroup BUN (mg/dL) Mean: 16.0\n- Non-Statin Subgroup BUN (mg/dL) Median: 13.8\n- Non-Statin Subgroup WBC (K) Mean: 7.5\n- Non-Statin Subgroup WBC (K) Median: 6.8\n- Non-Statin Subgroup Platelets (K) Mean: 233\n- Non-Statin Subgroup Platelets (K) Median: 220\n\n### Adverse Events\n- AE ID: AE-0005, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0006, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0007, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-004, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_02\n- PD ID: PD-005, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_05\n- PD ID: PD-006, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_12\n\n### Investigator Notes\n- Site pharmacy inventory verified\n- Subject retention rate within protocol targets\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- Data management plan revision v2.5 distributed\n- Site 12 pharmacy temperature log reviewed: compliant\n\n### Notes\n- Week 2: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_005",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-13T10:30:00",
          "text": "## 2024-04-01 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 83\n- Active: 83\n- Screen Failures Cumulative: 14\n- Withdrawals Cumulative: 0\n\n### Enrollment By Treatment Arm\n- Multimodal: 28\n- Standard: 28\n- Placebo: 27\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 6.0\n- Multimodal VAS Pain Score SD: 1.7\n- Multimodal Morphine Equivalents (mg) Mean: 40.2\n- Multimodal Morphine Equivalents (mg) SD: 10.0\n- Multimodal Six MWT (meters) Mean: 307.0\n- Multimodal Six MWT (meters) SD: 36.0\n- Multimodal Grip Strength (kg) Mean: 22.5\n- Multimodal Grip Strength (kg) SD: 4.4\n- Multimodal Sleep Quality Index Mean: 4.8\n- Multimodal Sleep Quality Index SD: 1.3\n- Multimodal Rescue Med Doses per Week Mean: 4.1\n- Multimodal Rescue Med Doses per Week SD: 1.1\n\n- Standard VAS Pain Score Mean: 6.4\n- Standard VAS Pain Score SD: 1.4\n- Standard Morphine Equivalents (mg) Mean: 46.7\n- Standard Morphine Equivalents (mg) SD: 10.6\n- Standard Six MWT (meters) Mean: 283.0\n- Standard Six MWT (meters) SD: 44.0\n- Standard Grip Strength (kg) Mean: 21.1\n- Standard Grip Strength (kg) SD: 4.7\n- Standard Sleep Quality Index Mean: 4.0\n- Standard Sleep Quality Index SD: 1.3\n- Standard Rescue Med Doses per Week Mean: 5.4\n- Standard Rescue Med Doses per Week SD: 2.4\n\n- Placebo VAS Pain Score Mean: 6.5\n- Placebo VAS Pain Score SD: 1.3\n- Placebo Morphine Equivalents (mg) Mean: 45.8\n- Placebo Morphine Equivalents (mg) SD: 7.4\n- Placebo Six MWT (meters) Mean: 253.0\n- Placebo Six MWT (meters) SD: 56.0\n- Placebo Grip Strength (kg) Mean: 19.3\n- Placebo Grip Strength (kg) SD: 4.8\n- Placebo Sleep Quality Index Mean: 3.7\n- Placebo Sleep Quality Index SD: 1.5\n- Placebo Rescue Med Doses per Week Mean: 6.9\n- Placebo Rescue Med Doses per Week SD: 1.3\n\n### Physical Therapy\n- Sessions Scheduled: 169\n- Sessions Attended: 142\n- Attendance Rate (%): 90.4\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.8\n- Hemoglobin (g/dL) SD: 1.0\n- WBC (k) Mean: 8.0\n- WBC (k) SD: 1.8\n- Platelets (k) Mean: 237\n- Platelets (k) SD: 43\n- Serum Creatinine (mg/dL) Mean: 1.0\n- Serum Creatinine (mg/dL) SD: 0.18\n- Blood Glucose (mg/dL) Mean: 99.0\n- Blood Glucose (mg/dL) SD: 18.0\n- ESR (mm/hr) Mean: 8.0\n- ESR (mm/hr) SD: 8.0\n\n### Adverse Events\n- AE ID: PM-AE-0547, Description: urinary retention, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0565, Description: dry mouth, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0528, Description: nausea, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- None\n\n### Events\n- Pain diary electronic collection rate: 95%\n- Physical therapy schedule coordinated across 15 sites\n\n### Notes\n- Week 5: Pain management assessments on track. 83 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_006",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-15T10:30:00",
          "text": "## 2024-04-08 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 98\n- Active: 96\n- Screen Failures Cumulative: 16\n- Withdrawals Cumulative: 2\n\n### Enrollment By Treatment Arm\n- Multimodal: 31\n- Standard: 33\n- Placebo: 34\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 6.1\n- Multimodal VAS Pain Score SD: 1.9\n- Multimodal Morphine Equivalents (mg) Mean: 38.3\n- Multimodal Morphine Equivalents (mg) SD: 11.6\n- Multimodal Six MWT (meters) Mean: 303.0\n- Multimodal Six MWT (meters) SD: 31.0\n- Multimodal Grip Strength (kg) Mean: 24.5\n- Multimodal Grip Strength (kg) SD: 3.7\n- Multimodal Sleep Quality Index Mean: 4.7\n- Multimodal Sleep Quality Index SD: 1.5\n- Multimodal Rescue Med Doses Per Week Mean: 4.5\n- Multimodal Rescue Med Doses Per Week SD: 2.2\n\n- Standard VAS Pain Score Mean: 6.1\n- Standard VAS Pain Score SD: 1.5\n- Standard Morphine Equivalents (mg) Mean: 47.6\n- Standard Morphine Equivalents (mg) SD: 7.0\n- Standard Six MWT (meters) Mean: 275.0\n- Standard Six MWT (meters) SD: 36.0\n- Standard Grip Strength (kg) Mean: 20.4\n- Standard Grip Strength (kg) SD: 4.3\n- Standard Sleep Quality Index Mean: 4.3\n- Standard Sleep Quality Index SD: 1.1\n- Standard Rescue Med Doses Per Week Mean: 5.8\n- Standard Rescue Med Doses Per Week SD: 1.5\n\n- Placebo VAS Pain Score Mean: 6.7\n- Placebo VAS Pain Score SD: 1.3\n- Placebo Morphine Equivalents (mg) Mean: 45.0\n- Placebo Morphine Equivalents (mg) SD: 6.8\n- Placebo Six MWT (meters) Mean: 267.0\n- Placebo Six MWT (meters) SD: 51.0\n- Placebo Grip Strength (kg) Mean: 20.3\n- Placebo Grip Strength (kg) SD: 3.1\n- Placebo Sleep Quality Index Mean: 4.0\n- Placebo Sleep Quality Index SD: 1.3\n- Placebo Rescue Med Doses Per Week Mean: 6.4\n- Placebo Rescue Med Doses Per Week SD: 1.8\n\n### Physical Therapy\n- Sessions Scheduled: 201\n- Sessions Attended: 177\n- Attendance Rate (%): 84.3\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.1\n- Hemoglobin (g/dL) SD: 1.0\n- WBC (k) Mean: 7.7\n- WBC (k) SD: 1.3\n- Platelets (k) Mean: 231\n- Platelets (k) SD: 42\n- Serum Creatinine (mg/dL) Mean: 0.97\n- Serum Creatinine (mg/dL) SD: 0.16\n- Blood Glucose (mg/dL) Mean: 101.0\n- Blood Glucose (mg/dL) SD: 12.0\n- ESR (mm/hr) Mean: 24.0\n- ESR (mm/hr) SD: 6.0\n\n### Adverse Events\n- AE ID: PM-AE-0684, Description: constipation, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0695, Description: constipation, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0637, Description: pruritus, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-0645, Description: Rescue medication log incomplete for 1 subject, Severity: minor\n\n### Events\n- Blinded interim efficacy data compiled for DSMB\n- Pain diary electronic collection rate: 81%\n- Rescue medication supply restocked at 29 sites\n\n### Notes\n- Week 6: Pain management assessments on track. 98 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_007",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-17T10:30:00",
          "text": "## 2024-04-15 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 95\n- Active: 93\n- Screen Failures Cumulative: 20\n- Withdrawals Cumulative: 2\n\n### Enrollment By Treatment Arm\n- Multimodal: 31\n- Standard: 31\n- Placebo: 33\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 6.1\n- Multimodal VAS Pain Score SD: 1.3\n- Multimodal Morphine Equivalents (mg) Mean: 40.5\n- Multimodal Morphine Equivalents (mg) SD: 11.2\n- Multimodal Six MWT (meters) Mean: 316.0\n- Multimodal Six MWT (meters) SD: 40.0\n- Multimodal Grip Strength (kg) Mean: 24.4\n- Multimodal Grip Strength (kg) SD: 4.1\n- Multimodal Sleep Quality Index Mean: 5.0\n- Multimodal Sleep Quality Index SD: 1.4\n- Multimodal Rescue Med Doses per Week Mean: 4.5\n- Multimodal Rescue Med Doses per Week SD: 2.0\n\n- Standard VAS Pain Score Mean: 6.1\n- Standard VAS Pain Score SD: 1.9\n- Standard Morphine Equivalents (mg) Mean: 47.2\n- Standard Morphine Equivalents (mg) SD: 11.8\n- Standard Six MWT (meters) Mean: 293.0\n- Standard Six MWT (meters) SD: 52.0\n- Standard Grip Strength (kg) Mean: 20.1\n- Standard Grip Strength (kg) SD: 5.0\n- Standard Sleep Quality Index Mean: 4.3\n- Standard Sleep Quality Index SD: 1.1\n- Standard Rescue Med Doses per Week Mean: 6.0\n- Standard Rescue Med Doses per Week SD: 2.2\n\n- Placebo VAS Pain Score Mean: 6.9\n- Placebo VAS Pain Score SD: 1.1\n- Placebo Morphine Equivalents (mg) Mean: 49.6\n- Placebo Morphine Equivalents (mg) SD: 7.3\n- Placebo Six MWT (meters) Mean: 268.0\n- Placebo Six MWT (meters) SD: 38.0\n- Placebo Grip Strength (kg) Mean: 19.2\n- Placebo Grip Strength (kg) SD: 3.5\n- Placebo Sleep Quality Index Mean: 3.9\n- Placebo Sleep Quality Index SD: 1.1\n- Placebo Rescue Med Doses per Week Mean: 6.5\n- Placebo Rescue Med Doses per Week SD: 2.3\n\n### Physical Therapy\n- Sessions Scheduled: 191\n- Sessions Attended: 183\n- Attendance Rate (%): 87.1\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.8\n- Hemoglobin (g/dL) SD: 0.9\n- WBC (k) Mean: 7.1\n- WBC (k) SD: 1.5\n- Platelets (k) Mean: 221\n- Platelets (k) SD: 46\n- Serum Creatinine (mg/dL) Mean: 1.01\n- Serum Creatinine (mg/dL) SD: 0.19\n- Blood Glucose (mg/dL) Mean: 94.0\n- Blood Glucose (mg/dL) SD: 13.0\n- ESR (mm/hr) Mean: 24.0\n- ESR (mm/hr) SD: 6.0\n\n### Adverse Events\n- AE ID: PM-AE-0728, Description: Fatigue, Grade: 1, Relatedness: Probably Related, Resolved: Yes, Treatment Arm: Standard\n- AE ID: PM-AE-0797, Description: Urinary Retention, Grade: 1, Relatedness: Probably Related, Resolved: Yes, Treatment Arm: Multimodal\n- AE ID: PM-AE-0799, Description: Urinary Retention, Grade: 2, Relatedness: Unlikely Related, Resolved: Yes, Treatment Arm: Standard\n\n### Protocol Deviations\n- PD ID: PM-PD-0725, Description: VAS Assessment Outside Scheduled Window, Severity: Minor\n- PD ID: PM-PD-0701, Description: Rescue Medication Log Incomplete for 1 Subject, Severity: Minor\n\n### Events\n- Subject Retention Call Completed for 24 Overdue Visits\n- Blinded Interim Efficacy Data Compiled for DSMB\n\n### Notes\n- Week 7: Pain management assessments on track. 95 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_003",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-18T10:00:00",
          "text": "## 2024-03-18 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 80\n- Active: 80\n- Screen Failures Cumulative: 5\n- Withdrawals Cumulative: 0\n\n#### Sites\n- Site 01 Enrolled: 8\n- Site 01 Active: 8\n- Site 01 Statin Concomitant: 2\n- Site 02 Enrolled: 6\n- Site 02 Active: 6\n- Site 02 Statin Concomitant: 1\n- Site 03 Enrolled: 7\n- Site 03 Active: 7\n- Site 03 Statin Concomitant: 1\n- Site 04 Enrolled: 5\n- Site 04 Active: 5\n- Site 04 Statin Concomitant: 1\n- Site 05 Enrolled: 6\n- Site 05 Active: 6\n- Site 05 Statin Concomitant: 1\n- Site 06 Enrolled: 4\n- Site 06 Active: 4\n- Site 06 Statin Concomitant: 1\n- Site 07 Enrolled: 8\n- Site 07 Active: 8\n- Site 07 Statin Concomitant: 2\n- Site 08 Enrolled: 6\n- Site 08 Active: 6\n- Site 08 Statin Concomitant: 1\n- Site 09 Enrolled: 6\n- Site 09 Active: 6\n- Site 09 Statin Concomitant: 1\n- Site 10 Enrolled: 5\n- Site 10 Active: 5\n- Site 10 Statin Concomitant: 1\n- Site 11 Enrolled: 7\n- Site 11 Active: 7\n- Site 11 Statin Concomitant: 1\n- Site 12 Enrolled: 6\n- Site 12 Active: 6\n- Site 12 Statin Concomitant: 1\n\n### Lab Panels\n- Statin Subgroup N: 55\n- Statin Subgroup ALT (U/L) Mean: 26.0\n- Statin Subgroup ALT (U/L) Median: 24.3\n- Statin Subgroup AST (U/L) Mean: 27.9\n- Statin Subgroup AST (U/L) Median: 25.9\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.59\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.56\n- Statin Subgroup ALP (U/L) Mean: 79.3\n- Statin Subgroup ALP (U/L) Median: 57.2\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.04\n- Statin Subgroup Creatinine (mg/dL) Median: 0.9\n- Statin Subgroup BUN (mg/dL) Mean: 16.6\n- Statin Subgroup BUN (mg/dL) Median: 14.8\n- Statin Subgroup WBC (K) Mean: 5.9\n- Statin Subgroup WBC (K) Median: 6.5\n- Statin Subgroup Platelets (K) Mean: 245\n- Statin Subgroup Platelets (K) Median: 220\n- Non-Statin Subgroup N: 124\n- Non-Statin Subgroup ALT (U/L) Mean: 21.2\n- Non-Statin Subgroup ALT (U/L) Median: 20.6\n- Non-Statin Subgroup AST (U/L) Mean: 29.1\n- Non-Statin Subgroup AST (U/L) Median: 28.2\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.54\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.49\n- Non-Statin Subgroup ALP (U/L) Mean: 73.5\n- Non-Statin Subgroup ALP (U/L) Median: 63.4\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 1.0\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.99\n- Non-Statin Subgroup BUN (mg/dL) Mean: 17.2\n- Non-Statin Subgroup BUN (mg/dL) Median: 14.5\n- Non-Statin Subgroup WBC (K) Mean: 5.6\n- Non-Statin Subgroup WBC (K) Median: 6.4\n- Non-Statin Subgroup Platelets (K) Mean: 229\n- Non-Statin Subgroup Platelets (K) Median: 240\n\n### Adverse Events\n- AE ID: AE-0008, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0009, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0010, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 51\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 19\n- NSAID Count: 13\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-007, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_03\n- PD ID: PD-008, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_04\n\n### Investigator Notes\n- All CRFs current through prior visit cycle\n- Query resolution rate at 94%\n- Lab kits inventory adequate for next 4 weeks\n\n### Events\n- Central lab courier pickup schedule adjusted for holiday\n- Bioanalytical lab shipment tracking confirmed for 2 samples\n- Medical monitor weekly call completed\n\n### Notes\n- Week 3: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_008",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-19T10:30:00",
          "text": "## 2024-04-22 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 92\n- Active: 90\n- Screen Failures Cumulative: 22\n- Withdrawals Cumulative: 2\n\n### Enrollment By Treatment Arm\n- Multimodal: 28\n- Standard: 31\n- Placebo: 33\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.7\n- Multimodal VAS Pain Score SD: 1.9\n- Multimodal Morphine Equivalents (mg) Mean: 38.7\n- Multimodal Morphine Equivalents (mg) SD: 7.4\n- Multimodal Six Minute Walk Test (meters) Mean: 308.0\n- Multimodal Six Minute Walk Test (meters) SD: 49.0\n- Multimodal Grip Strength (kg) Mean: 24.5\n- Multimodal Grip Strength (kg) SD: 4.3\n- Multimodal Sleep Quality Index Mean: 4.9\n- Multimodal Sleep Quality Index SD: 1.1\n- Multimodal Rescue Med Doses Per Week Mean: 4.7\n- Multimodal Rescue Med Doses Per Week SD: 1.9\n\n- Standard VAS Pain Score Mean: 6.2\n- Standard VAS Pain Score SD: 1.2\n- Standard Morphine Equivalents (mg) Mean: 45.0\n- Standard Morphine Equivalents (mg) SD: 7.0\n- Standard Six Minute Walk Test (meters) Mean: 286.0\n- Standard Six Minute Walk Test (meters) SD: 45.0\n- Standard Grip Strength (kg) Mean: 21.5\n- Standard Grip Strength (kg) SD: 4.9\n- Standard Sleep Quality Index Mean: 4.2\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses Per Week Mean: 5.9\n- Standard Rescue Med Doses Per Week SD: 1.6\n\n- Placebo VAS Pain Score Mean: 6.8\n- Placebo VAS Pain Score SD: 1.1\n- Placebo Morphine Equivalents (mg) Mean: 49.9\n- Placebo Morphine Equivalents (mg) SD: 8.6\n- Placebo Six Minute Walk Test (meters) Mean: 265.0\n- Placebo Six Minute Walk Test (meters) SD: 33.0\n- Placebo Grip Strength (kg) Mean: 19.2\n- Placebo Grip Strength (kg) SD: 3.8\n- Placebo Sleep Quality Index Mean: 4.1\n- Placebo Sleep Quality Index SD: 1.3\n- Placebo Rescue Med Doses Per Week Mean: 6.1\n- Placebo Rescue Med Doses Per Week SD: 2.0\n\n### Physical Therapy\n- Sessions Scheduled: 182\n- Sessions Attended: 156\n- Attendance Rate (%): 87.6\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 12.8\n- Hemoglobin (g/dL) SD: 1.0\n- WBC (k) Mean: 6.0\n- WBC (k) SD: 1.4\n- Platelets (k) Mean: 253\n- Platelets (k) SD: 41\n- Serum Creatinine (mg/dL) Mean: 0.8\n- Serum Creatinine (mg/dL) SD: 0.12\n- Blood Glucose (mg/dL) Mean: 103.0\n- Blood Glucose (mg/dL) SD: 15.0\n- ESR (mm/hr) Mean: 19.0\n- ESR (mm/hr) SD: 9.0\n\n### Adverse Events\n- AE ID: PM-AE-0823, Description: dry mouth, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0831, Description: fatigue, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-0840, Description: headache, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-0872, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-0834, Description: Rescue medication log incomplete for 1 subject, Severity: minor\n\n### Events\n- Randomization module updated for new enrollment block\n- Site 04 monitoring visit completed, 2 findings\n- Rescue medication supply restocked at 21 sites\n\n### Notes\n- Week 8: Pain management assessments on track. 92 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_009",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-22T10:30:00",
          "text": "## 2024-04-29 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 91\n- Active: 87\n- Screen Failures Cumulative: 25\n- Withdrawals Cumulative: 4\n\n### Enrollment By Treatment Arm\n- Multimodal: 29\n- Standard: 31\n- Placebo: 31\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.7\n- Multimodal VAS Pain Score SD: 1.0\n- Multimodal Morphine Equivalents (mg) Mean: 38.5\n- Multimodal Morphine Equivalents (mg) SD: 6.5\n- Multimodal Six MWT (meters) Mean: 320.0\n- Multimodal Six MWT (meters) SD: 30.0\n- Multimodal Grip Strength (kg) Mean: 24.1\n- Multimodal Grip Strength (kg) SD: 3.8\n- Multimodal Sleep Quality Index Mean: 5.1\n- Multimodal Sleep Quality Index SD: 1.4\n- Multimodal Rescue Med Doses Per Week Mean: 3.6\n- Multimodal Rescue Med Doses Per Week SD: 2.3\n\n- Standard VAS Pain Score Mean: 6.4\n- Standard VAS Pain Score SD: 1.5\n- Standard Morphine Equivalents (mg) Mean: 45.0\n- Standard Morphine Equivalents (mg) SD: 5.8\n- Standard Six MWT (meters) Mean: 292.0\n- Standard Six MWT (meters) SD: 42.0\n- Standard Grip Strength (kg) Mean: 21.5\n- Standard Grip Strength (kg) SD: 4.9\n- Standard Sleep Quality Index Mean: 4.3\n- Standard Sleep Quality Index SD: 1.3\n- Standard Rescue Med Doses Per Week Mean: 5.7\n- Standard Rescue Med Doses Per Week SD: 2.0\n\n- Placebo VAS Pain Score Mean: 6.9\n- Placebo VAS Pain Score SD: 1.9\n- Placebo Morphine Equivalents (mg) Mean: 48.1\n- Placebo Morphine Equivalents (mg) SD: 5.9\n- Placebo Six MWT (meters) Mean: 260.0\n- Placebo Six MWT (meters) SD: 45.0\n- Placebo Grip Strength (kg) Mean: 19.6\n- Placebo Grip Strength (kg) SD: 4.7\n- Placebo Sleep Quality Index Mean: 3.9\n- Placebo Sleep Quality Index SD: 1.3\n- Placebo Rescue Med Doses Per Week Mean: 6.4\n- Placebo Rescue Med Doses Per Week SD: 1.8\n\n### Physical Therapy\n- Sessions Scheduled: 177\n- Sessions Attended: 158\n- Attendance Rate (%): 85.6\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.5\n- Hemoglobin (g/dL) SD: 1.3\n- WBC (k) Mean: 6.4\n- WBC (k) SD: 1.3\n- Platelets (k) Mean: 250\n- Platelets (k) SD: 48\n- Serum Creatinine (mg/dL) Mean: 1.09\n- Serum Creatinine (mg/dL) SD: 0.13\n- Blood Glucose (mg/dL) Mean: 107.0\n- Blood Glucose (mg/dL) SD: 16.0\n- ESR (mm/hr) Mean: 10.0\n- ESR (mm/hr) SD: 4.0\n\n### Adverse Events\n- AE ID: PM-AE-0977, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: false, Treatment Arm: standard\n- AE ID: PM-AE-0919, Description: insomnia, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-0912, Description: pruritus, Grade: 2, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-0969, Description: constipation, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-0948, Description: Sleep diary not returned by subject, Severity: minor\n\n### Events\n- Site 07 monitoring visit completed, 2 findings\n- Blinded interim efficacy data compiled for DSMB\n- Rescue medication supply restocked at 30 sites\n\n### Notes\n- Week 9: Pain management assessments on track. 91 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_010",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-24T10:30:00",
          "text": "## 2024-05-06 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 96\n- Active: 92\n- Screen Failures Cumulative: 24\n- Withdrawals Cumulative: 4\n\n### Enrollment By Treatment Arm\n- Multimodal: 31\n- Standard: 32\n- Placebo: 33\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.4\n- Multimodal VAS Pain Score SD: 1.2\n- Multimodal Morphine Equivalents (mg) Mean: 38.7\n- Multimodal Morphine Equivalents (mg) SD: 11.2\n- Multimodal Six MWT (meters) Mean: 324.0\n- Multimodal Six MWT (meters) SD: 57.0\n- Multimodal Grip Strength (kg) Mean: 25.6\n- Multimodal Grip Strength (kg) SD: 3.5\n- Multimodal Sleep Quality Index Mean: 5.1\n- Multimodal Sleep Quality Index SD: 1.2\n- Multimodal Rescue Med Doses Per Week Mean: 3.8\n- Multimodal Rescue Med Doses Per Week SD: 1.8\n\n- Standard VAS Pain Score Mean: 5.9\n- Standard VAS Pain Score SD: 1.9\n- Standard Morphine Equivalents (mg) Mean: 46.3\n- Standard Morphine Equivalents (mg) SD: 8.0\n- Standard Six MWT (meters) Mean: 285.0\n- Standard Six MWT (meters) SD: 39.0\n- Standard Grip Strength (kg) Mean: 20.6\n- Standard Grip Strength (kg) SD: 5.5\n- Standard Sleep Quality Index Mean: 4.4\n- Standard Sleep Quality Index SD: 1.4\n- Standard Rescue Med Doses Per Week Mean: 5.8\n- Standard Rescue Med Doses Per Week SD: 2.4\n\n- Placebo VAS Pain Score Mean: 6.6\n- Placebo VAS Pain Score SD: 1.5\n- Placebo Morphine Equivalents (mg) Mean: 47.1\n- Placebo Morphine Equivalents (mg) SD: 8.6\n- Placebo Six MWT (meters) Mean: 273.0\n- Placebo Six MWT (meters) SD: 60.0\n- Placebo Grip Strength (kg) Mean: 18.5\n- Placebo Grip Strength (kg) SD: 4.9\n- Placebo Sleep Quality Index Mean: 4.0\n- Placebo Sleep Quality Index SD: 1.1\n- Placebo Rescue Med Doses Per Week Mean: 6.1\n- Placebo Rescue Med Doses Per Week SD: 1.3\n\n### Physical Therapy\n- Sessions Scheduled: 182\n- Sessions Attended: 174\n- Attendance Rate (%): 82.2\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.0\n- Hemoglobin (g/dL) SD: 1.4\n- WBC (k) Mean: 7.1\n- WBC (k) SD: 1.2\n- Platelets (k) Mean: 257\n- Platelets (k) SD: 49\n- Serum Creatinine (mg/dL) Mean: 1.0\n- Serum Creatinine (mg/dL) SD: 0.15\n- Blood Glucose (mg/dL) Mean: 92.0\n- Blood Glucose (mg/dL) SD: 13.0\n- ESR (mm/hr) Mean: 11.0\n- ESR (mm/hr) SD: 6.0\n\n### Adverse Events\n- AE ID: PM-AE-1041, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1086, Description: insomnia, Grade: 1, Relatedness: probably related, Resolved: false, Treatment Arm: multimodal\n- AE ID: PM-AE-1024, Description: muscle spasm, Grade: 2, Relatedness: possibly related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1047, Description: dry mouth, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1022, Description: sedation, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-1040, Description: Rescue medication log incomplete for 1 subject, Severity: moderate\n- PD ID: PM-PD-1016, Description: Rescue medication log incomplete for 1 subject, Severity: moderate\n\n### Events\n- Central pharmacy opioid supply reconciliation completed\n- Pain diary electronic collection rate: 83%\n- Central pharmacy opioid supply reconciliation completed\n\n### Notes\n- Week 10: Pain management assessments on track. 96 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_004",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-25T10:00:00",
          "text": "## 2024-03-25 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 100\n- Active: 98\n- Screen Failures Cumulative: 11\n- Withdrawals Cumulative: 2\n\n#### Sites\n- Site 01\n  - Enrolled: 10\n  - Active: 10\n  - Statin Concomitant: 2\n- Site 02\n  - Enrolled: 7\n  - Active: 7\n  - Statin Concomitant: 1\n- Site 03\n  - Enrolled: 9\n  - Active: 9\n  - Statin Concomitant: 2\n- Site 04\n  - Enrolled: 6\n  - Active: 6\n  - Statin Concomitant: 1\n- Site 05\n  - Enrolled: 8\n  - Active: 8\n  - Statin Concomitant: 2\n- Site 06\n  - Enrolled: 5\n  - Active: 5\n  - Statin Concomitant: 1\n- Site 07\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 08\n  - Enrolled: 7\n  - Active: 7\n  - Statin Concomitant: 2\n- Site 09\n  - Enrolled: 8\n  - Active: 8\n  - Statin Concomitant: 2\n- Site 10\n  - Enrolled: 6\n  - Active: 6\n  - Statin Concomitant: 2\n- Site 11\n  - Enrolled: 9\n  - Active: 9\n  - Statin Concomitant: 2\n- Site 12\n  - Enrolled: 7\n  - Active: 7\n  - Statin Concomitant: 1\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 24.6\n- ALT (U/L) Median: 23.8\n- AST (U/L) Mean: 23.6\n- AST (U/L) Median: 23.2\n- Bilirubin (mg/dL) Mean: 0.86\n- Bilirubin (mg/dL) Median: 0.84\n- ALP (U/L) Mean: 73.7\n- ALP (U/L) Median: 63.8\n- Creatinine (mg/dL) Mean: 1.06\n- Creatinine (mg/dL) Median: 0.92\n- BUN (mg/dL) Mean: 13.3\n- BUN (mg/dL) Median: 13.0\n- WBC (K) Mean: 8.2\n- WBC (K) Median: 5.5\n- Platelets (K) Mean: 235\n- Platelets (K) Median: 234\n\n#### Non-Statin Subgroup\n- N: 122\n- ALT (U/L) Mean: 24.6\n- ALT (U/L) Median: 23.1\n- AST (U/L) Mean: 24.7\n- AST (U/L) Median: 22.8\n- Bilirubin (mg/dL) Mean: 0.7\n- Bilirubin (mg/dL) Median: 0.68\n- ALP (U/L) Mean: 59.4\n- ALP (U/L) Median: 54.2\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.8\n- BUN (mg/dL) Mean: 14.8\n- BUN (mg/dL) Median: 11.5\n- WBC (K) Mean: 7.6\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 243\n- Platelets (K) Median: 244\n\n### Adverse Events\n- AE ID: AE-0011, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0012, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-009, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_05\n- PD ID: PD-010, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_06\n- PD ID: PD-011, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_10\n\n### Investigator Notes\n- No new safety signals identified this week by local PI\n- Site pharmacy inventory verified\n- Query resolution rate at 94%\n\n### Events\n- Data management plan revision v2.2 distributed\n- IVRS system update deployed, randomization unaffected\n\n### Notes\n- Week 4: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_011",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-26T10:30:00",
          "text": "## 2024-05-13 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 91\n- Active: 87\n- Screen Failures Cumulative: 26\n- Withdrawals Cumulative: 4\n\n### Enrollment By Treatment Arm\n- Multimodal: 28\n- Standard: 32\n- Placebo: 31\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.4\n- Multimodal VAS Pain Score SD: 1.5\n- Multimodal Morphine Equivalents (mg) Mean: 37.0\n- Multimodal Morphine Equivalents (mg) SD: 8.2\n- Multimodal Six Minute Walk Test (meters) Mean: 325.0\n- Multimodal Six Minute Walk Test (meters) SD: 52.0\n- Multimodal Grip Strength (kg) Mean: 24.3\n- Multimodal Grip Strength (kg) SD: 5.6\n- Multimodal Sleep Quality Index Mean: 5.2\n- Multimodal Sleep Quality Index SD: 1.4\n- Multimodal Rescue Med Doses Per Week Mean: 4.2\n- Multimodal Rescue Med Doses Per Week SD: 2.4\n\n- Standard VAS Pain Score Mean: 6.2\n- Standard VAS Pain Score SD: 1.3\n- Standard Morphine Equivalents (mg) Mean: 47.2\n- Standard Morphine Equivalents (mg) SD: 5.9\n- Standard Six Minute Walk Test (meters) Mean: 283.0\n- Standard Six Minute Walk Test (meters) SD: 32.0\n- Standard Grip Strength (kg) Mean: 22.2\n- Standard Grip Strength (kg) SD: 3.5\n- Standard Sleep Quality Index Mean: 4.5\n- Standard Sleep Quality Index SD: 1.4\n- Standard Rescue Med Doses Per Week Mean: 5.3\n- Standard Rescue Med Doses Per Week SD: 1.4\n\n- Placebo VAS Pain Score Mean: 6.5\n- Placebo VAS Pain Score SD: 1.1\n- Placebo Morphine Equivalents (mg) Mean: 48.0\n- Placebo Morphine Equivalents (mg) SD: 10.9\n- Placebo Six Minute Walk Test (meters) Mean: 271.0\n- Placebo Six Minute Walk Test (meters) SD: 45.0\n- Placebo Grip Strength (kg) Mean: 19.1\n- Placebo Grip Strength (kg) SD: 5.6\n- Placebo Sleep Quality Index Mean: 3.9\n- Placebo Sleep Quality Index SD: 1.3\n- Placebo Rescue Med Doses Per Week Mean: 6.2\n- Placebo Rescue Med Doses Per Week SD: 2.0\n\n### Physical Therapy\n- Sessions Scheduled: 184\n- Sessions Attended: 149\n- Attendance Rate (%): 83.7\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.7\n- Hemoglobin (g/dL) SD: 0.9\n- WBC (k) Mean: 5.6\n- WBC (k) SD: 1.6\n- Platelets (k) Mean: 221\n- Platelets (k) SD: 43\n- Serum Creatinine (mg/dL) Mean: 0.98\n- Serum Creatinine (mg/dL) SD: 0.19\n- Blood Glucose (mg/dL) Mean: 104.0\n- Blood Glucose (mg/dL) SD: 18.0\n- ESR (mm/hr) Mean: 8.0\n- ESR (mm/hr) SD: 8.0\n\n### Adverse Events\n- AE ID: PM-AE-1155, Description: pruritus, Grade: 1, Relatedness: possibly related, Resolved: false, Treatment Arm: multimodal\n- AE ID: PM-AE-1126, Description: nausea, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1170, Description: muscle spasm, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1111, Description: nausea, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1195, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- Central pharmacy opioid supply reconciliation completed\n- Central pharmacy opioid supply reconciliation completed\n\n### Notes\n- Week: 11\n- Notes: Pain management assessments on track. 91 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_012",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-29T10:30:00",
          "text": "## 2024-05-20 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 93\n- Active: 89\n- Screen Failures Cumulative: 27\n- Withdrawals Cumulative: 4\n\n### Enrollment By Treatment Arm\n- Multimodal: 31\n- Standard: 31\n- Placebo: 31\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.3\n- Multimodal VAS Pain Score SD: 1.7\n- Multimodal Morphine Equivalents (mg) Mean: 35.7\n- Multimodal Morphine Equivalents (mg) SD: 8.0\n- Multimodal Six Minute Walk Test (meters) Mean: 336.0\n- Multimodal Six Minute Walk Test (meters) SD: 32.0\n- Multimodal Grip Strength (kg) Mean: 26.3\n- Multimodal Grip Strength (kg) SD: 4.8\n- Multimodal Sleep Quality Index Mean: 5.1\n- Multimodal Sleep Quality Index SD: 1.1\n- Multimodal Rescue Med Doses per Week Mean: 4.0\n- Multimodal Rescue Med Doses per Week SD: 1.4\n\n- Standard VAS Pain Score Mean: 6.3\n- Standard VAS Pain Score SD: 1.8\n- Standard Morphine Equivalents (mg) Mean: 44.3\n- Standard Morphine Equivalents (mg) SD: 9.6\n- Standard Six Minute Walk Test (meters) Mean: 288.0\n- Standard Six Minute Walk Test (meters) SD: 50.0\n- Standard Grip Strength (kg) Mean: 21.0\n- Standard Grip Strength (kg) SD: 4.4\n- Standard Sleep Quality Index Mean: 4.2\n- Standard Sleep Quality Index SD: 1.3\n- Standard Rescue Med Doses per Week Mean: 5.0\n- Standard Rescue Med Doses per Week SD: 1.3\n\n- Placebo VAS Pain Score Mean: 6.4\n- Placebo VAS Pain Score SD: 1.9\n- Placebo Morphine Equivalents (mg) Mean: 45.3\n- Placebo Morphine Equivalents (mg) SD: 6.4\n- Placebo Six Minute Walk Test (meters) Mean: 265.0\n- Placebo Six Minute Walk Test (meters) SD: 51.0\n- Placebo Grip Strength (kg) Mean: 19.8\n- Placebo Grip Strength (kg) SD: 3.1\n- Placebo Sleep Quality Index Mean: 3.7\n- Placebo Sleep Quality Index SD: 1.0\n- Placebo Rescue Med Doses per Week Mean: 6.2\n- Placebo Rescue Med Doses per Week SD: 1.7\n\n### Physical Therapy\n- Sessions Scheduled: 185\n- Sessions Attended: 178\n- Attendance Rate (%): 89.4\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.2\n- Hemoglobin (g/dL) SD: 1.0\n- WBC (k) Mean: 6.0\n- WBC (k) SD: 1.7\n- Platelets (k) Mean: 247\n- Platelets (k) SD: 43\n- Serum Creatinine (mg/dL) Mean: 1.07\n- Serum Creatinine (mg/dL) SD: 0.19\n- Blood Glucose (mg/dL) Mean: 91.0\n- Blood Glucose (mg/dL) SD: 19.0\n- ESR (mm/hr) Mean: 19.0\n- ESR (mm/hr) SD: 6.0\n\n### Adverse Events\n- AE ID: PM-AE-1235, Description: sedation, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1249, Description: pruritus, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-1226, Description: Sleep diary not returned by subject, Severity: minor\n\n### Events\n- Randomization module updated for new enrollment block\n- Opioid conversion table reference updated per FDA guidance\n\n### Notes\n- Week 12: Pain management assessments on track. 93 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_013",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-31T10:30:00",
          "text": "## 2024-05-27 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 107\n- Active: 101\n- Screen Failures Cumulative: 28\n- Withdrawals Cumulative: 6\n\n### Enrollment by Treatment Arm\n- Multimodal: 34\n- Standard: 37\n- Placebo: 36\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.3\n- Multimodal VAS Pain Score SD: 1.2\n- Multimodal Morphine Equivalents mg Mean: 33.4\n- Multimodal Morphine Equivalents mg SD: 5.4\n- Multimodal Six MWT Meters Mean: 330.0\n- Multimodal Six MWT Meters SD: 39.0\n- Multimodal Grip Strength kg Mean: 25.4\n- Multimodal Grip Strength kg SD: 5.0\n- Multimodal Sleep Quality Index Mean: 5.1\n- Multimodal Sleep Quality Index SD: 1.3\n- Multimodal Rescue Med Doses per Week Mean: 3.5\n- Multimodal Rescue Med Doses per Week SD: 1.9\n\n- Standard VAS Pain Score Mean: 6.2\n- Standard VAS Pain Score SD: 1.5\n- Standard Morphine Equivalents mg Mean: 43.2\n- Standard Morphine Equivalents mg SD: 7.3\n- Standard Six MWT Meters Mean: 297.0\n- Standard Six MWT Meters SD: 56.0\n- Standard Grip Strength kg Mean: 21.4\n- Standard Grip Strength kg SD: 5.6\n- Standard Sleep Quality Index Mean: 4.3\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses per Week Mean: 5.1\n- Standard Rescue Med Doses per Week SD: 1.3\n\n- Placebo VAS Pain Score Mean: 6.6\n- Placebo VAS Pain Score SD: 1.6\n- Placebo Morphine Equivalents mg Mean: 46.0\n- Placebo Morphine Equivalents mg SD: 9.1\n- Placebo Six MWT Meters Mean: 273.0\n- Placebo Six MWT Meters SD: 41.0\n- Placebo Grip Strength kg Mean: 19.0\n- Placebo Grip Strength kg SD: 3.7\n- Placebo Sleep Quality Index Mean: 4.1\n- Placebo Sleep Quality Index SD: 1.1\n- Placebo Rescue Med Doses per Week Mean: 6.7\n- Placebo Rescue Med Doses per Week SD: 1.4\n\n### Physical Therapy\n- Sessions Scheduled: 210\n- Sessions Attended: 172\n- Attendance Rate %: 84.0\n\n### Safety Labs\n- Hemoglobin g/dL Mean: 13.6\n- Hemoglobin g/dL SD: 0.8\n- WBC k Mean: 5.6\n- WBC k SD: 1.4\n- Platelets k Mean: 251\n- Platelets k SD: 49\n- Serum Creatinine mg/dL Mean: 0.84\n- Serum Creatinine mg/dL SD: 0.19\n- Blood Glucose mg/dL Mean: 101.0\n- Blood Glucose mg/dL SD: 18.0\n- ESR mm/hr Mean: 19.0\n- ESR mm/hr SD: 6.0\n\n### Adverse Events\n- AE ID: PM-AE-1328, Description: diaphoresis, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1396, Description: fatigue, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1314, Description: diaphoresis, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-1311, Description: Missed physical therapy session, not rescheduled within window, Severity: minor\n- PD ID: PM-PD-1338, Description: Sleep diary not returned by subject, Severity: minor\n\n### Events\n- Pain diary electronic collection rate: 91%\n- Rescue medication supply restocked at 14 sites\n\n### Notes\n- Week 13: Pain management assessments on track. 107 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_005",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-01T10:00:00",
          "text": "## 2024-04-01 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 120\n- Active: 118\n- Screen Failures Cumulative: 11\n- Withdrawals Cumulative: 2\n\n#### Sites\n- Site 01 Enrolled: 12\n- Site 01 Active: 12\n- Site 01 Statin Concomitant: 4\n- Site 02 Enrolled: 9\n- Site 02 Active: 9\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 11\n- Site 03 Active: 11\n- Site 03 Statin Concomitant: 3\n- Site 04 Enrolled: 8\n- Site 04 Active: 8\n- Site 04 Statin Concomitant: 2\n- Site 05 Enrolled: 10\n- Site 05 Active: 10\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 7\n- Site 06 Active: 7\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 13\n- Site 07 Active: 13\n- Site 07 Statin Concomitant: 3\n- Site 08 Enrolled: 9\n- Site 08 Active: 9\n- Site 08 Statin Concomitant: 2\n- Site 09 Enrolled: 10\n- Site 09 Active: 10\n- Site 09 Statin Concomitant: 3\n- Site 10 Enrolled: 8\n- Site 10 Active: 8\n- Site 10 Statin Concomitant: 2\n- Site 11 Enrolled: 11\n- Site 11 Active: 11\n- Site 11 Statin Concomitant: 3\n- Site 12 Enrolled: 9\n- Site 12 Active: 9\n- Site 12 Statin Concomitant: 2\n\n### Lab Panels\n#### Statin Subgroup\n- N: 56\n- ALT (U/L) Mean: 26.3\n- ALT (U/L) Median: 25.5\n- AST (U/L) Mean: 22.6\n- AST (U/L) Median: 22.4\n- Bilirubin (mg/dL) Mean: 0.67\n- Bilirubin (mg/dL) Median: 0.65\n- ALP (U/L) Mean: 68.6\n- ALP (U/L) Median: 79.7\n- Creatinine (mg/dL) Mean: 1.02\n- Creatinine (mg/dL) Median: 0.97\n- BUN (mg/dL) Mean: 17.6\n- BUN (mg/dL) Median: 11.1\n- WBC (K) Mean: 6.2\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 258\n- Platelets (K) Median: 256\n\n#### Non-Statin Subgroup\n- N: 128\n- ALT (U/L) Mean: 31.5\n- ALT (U/L) Median: 30.6\n- AST (U/L) Mean: 27.2\n- AST (U/L) Median: 25.6\n- Bilirubin (mg/dL) Mean: 0.7\n- Bilirubin (mg/dL) Median: 0.67\n- ALP (U/L) Mean: 73.4\n- ALP (U/L) Median: 53.9\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.98\n- BUN (mg/dL) Mean: 13.0\n- BUN (mg/dL) Median: 16.0\n- WBC (K) Mean: 8.4\n- WBC (K) Median: 6.4\n- Platelets (K) Mean: 251\n- Platelets (K) Median: 246\n\n### Adverse Events\n- AE ID: AE-0013, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0014, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0015, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0016, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-012, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_07\n- PD ID: PD-013, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_05\n\n### Investigator Notes\n- IEC/IRB annual renewal submitted on schedule\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- EDC system maintenance window: 2h downtime Saturday 02:00 UTC\n\n### Notes\n- Week 5: Enrollment target met. All hepatic and renal panels within normal limits. 2 minor protocol deviations.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_014",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-02T10:30:00",
          "text": "## 2024-06-03 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 108\n- Active: 100\n- Screen Failures Cumulative: 38\n- Withdrawals Cumulative: 8\n\n### Enrollment By Treatment Arm\n- Multimodal: 36\n- Standard: 36\n- Placebo: 36\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.6\n- Multimodal VAS Pain Score SD: 1.2\n- Multimodal Morphine Equivalents (mg) Mean: 33.7\n- Multimodal Morphine Equivalents (mg) SD: 8.0\n- Multimodal Six MWT (meters) Mean: 346.0\n- Multimodal Six MWT (meters) SD: 54.0\n- Multimodal Grip Strength (kg) Mean: 25.7\n- Multimodal Grip Strength (kg) SD: 3.1\n- Multimodal Sleep Quality Index Mean: 5.4\n- Multimodal Sleep Quality Index SD: 1.4\n- Multimodal Rescue Med Doses per Week Mean: 3.7\n- Multimodal Rescue Med Doses per Week SD: 2.3\n\n- Standard VAS Pain Score Mean: 5.8\n- Standard VAS Pain Score SD: 1.9\n- Standard Morphine Equivalents (mg) Mean: 44.4\n- Standard Morphine Equivalents (mg) SD: 7.7\n- Standard Six MWT (meters) Mean: 298.0\n- Standard Six MWT (meters) SD: 47.0\n- Standard Grip Strength (kg) Mean: 22.8\n- Standard Grip Strength (kg) SD: 3.4\n- Standard Sleep Quality Index Mean: 4.5\n- Standard Sleep Quality Index SD: 1.4\n- Standard Rescue Med Doses per Week Mean: 4.8\n- Standard Rescue Med Doses per Week SD: 1.3\n\n- Placebo VAS Pain Score Mean: 6.5\n- Placebo VAS Pain Score SD: 1.1\n- Placebo Morphine Equivalents (mg) Mean: 48.5\n- Placebo Morphine Equivalents (mg) SD: 5.7\n- Placebo Six MWT (meters) Mean: 266.0\n- Placebo Six MWT (meters) SD: 44.0\n- Placebo Grip Strength (kg) Mean: 20.4\n- Placebo Grip Strength (kg) SD: 3.1\n- Placebo Sleep Quality Index Mean: 3.7\n- Placebo Sleep Quality Index SD: 1.2\n- Placebo Rescue Med Doses per Week Mean: 6.7\n- Placebo Rescue Med Doses per Week SD: 1.5\n\n### Physical Therapy\n- Sessions Scheduled: 222\n- Sessions Attended: 197\n- Attendance Rate (%): 88.8\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.0\n- Hemoglobin (g/dL) SD: 1.0\n- WBC (k) Mean: 7.5\n- WBC (k) SD: 1.5\n- Platelets (k) Mean: 258\n- Platelets (k) SD: 48\n- Serum Creatinine (mg/dL) Mean: 1.0\n- Serum Creatinine (mg/dL) SD: 0.14\n- Blood Glucose (mg/dL) Mean: 89.0\n- Blood Glucose (mg/dL) SD: 11.0\n- ESR (mm/hr) Mean: 18.0\n- ESR (mm/hr) SD: 5.0\n\n### Adverse Events\n- AE ID: PM-AE-1453, Description: pruritus, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1403, Description: pruritus, Grade: 2, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1417, Description: fatigue, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1436, Description: diaphoresis, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-1407, Description: VAS assessment outside scheduled window, Severity: minor\n- PD ID: PM-PD-1447, Description: VAS assessment outside scheduled window, Severity: minor\n\n### Events\n- Pain diary electronic collection rate: 86%\n- Rescue medication supply restocked at 29 sites\n- Opioid conversion table reference updated per FDA guidance\n\n### Notes\n- Week 14: Pain management assessments on track. 108 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_015",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-04T10:30:00",
          "text": "## 2024-06-10 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 108\n- Active: 103\n- Screen Failures Cumulative: 37\n- Withdrawals Cumulative: 5\n\n### Enrollment By Treatment Arm\n- Multimodal: 35\n- Standard: 35\n- Placebo: 38\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.6\n- Multimodal VAS Pain Score SD: 1.9\n- Multimodal Morphine Equivalents (mg) Mean: 33.9\n- Multimodal Morphine Equivalents (mg) SD: 10.9\n- Multimodal Six MWT (meters) Mean: 345.0\n- Multimodal Six MWT (meters) SD: 49.0\n- Multimodal Grip Strength (kg) Mean: 26.2\n- Multimodal Grip Strength (kg) SD: 3.0\n- Multimodal Sleep Quality Index Mean: 5.4\n- Multimodal Sleep Quality Index SD: 0.9\n- Multimodal Rescue Med Doses per Week Mean: 3.1\n- Multimodal Rescue Med Doses per Week SD: 2.3\n\n- Standard VAS Pain Score Mean: 6.0\n- Standard VAS Pain Score SD: 1.1\n- Standard Morphine Equivalents (mg) Mean: 43.2\n- Standard Morphine Equivalents (mg) SD: 12.0\n- Standard Six MWT (meters) Mean: 297.0\n- Standard Six MWT (meters) SD: 46.0\n- Standard Grip Strength (kg) Mean: 21.9\n- Standard Grip Strength (kg) SD: 5.4\n- Standard Sleep Quality Index Mean: 4.6\n- Standard Sleep Quality Index SD: 0.9\n- Standard Rescue Med Doses per Week Mean: 5.3\n- Standard Rescue Med Doses per Week SD: 2.1\n\n- Placebo VAS Pain Score Mean: 6.4\n- Placebo VAS Pain Score SD: 1.8\n- Placebo Morphine Equivalents (mg) Mean: 49.0\n- Placebo Morphine Equivalents (mg) SD: 6.3\n- Placebo Six MWT (meters) Mean: 277.0\n- Placebo Six MWT (meters) SD: 59.0\n- Placebo Grip Strength (kg) Mean: 19.7\n- Placebo Grip Strength (kg) SD: 3.4\n- Placebo Sleep Quality Index Mean: 3.9\n- Placebo Sleep Quality Index SD: 1.2\n- Placebo Rescue Med Doses per Week Mean: 6.1\n- Placebo Rescue Med Doses per Week SD: 2.0\n\n### Physical Therapy\n- Sessions Scheduled: 209\n- Sessions Attended: 188\n- Attendance Rate (%): 85.6\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.3\n- Hemoglobin (g/dL) SD: 1.3\n- WBC (k) Mean: 6.9\n- WBC (k) SD: 1.1\n- Platelets (k) Mean: 240\n- Platelets (k) SD: 45\n- Serum Creatinine (mg/dL) Mean: 1.09\n- Serum Creatinine (mg/dL) SD: 0.15\n- Blood Glucose (mg/dL) Mean: 98.0\n- Blood Glucose (mg/dL) SD: 20.0\n- ESR (mm/hr) Mean: 11.0\n- ESR (mm/hr) SD: 8.0\n\n### Adverse Events\n- AE ID: PM-AE-1561, Description: dizziness, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1555, Description: constipation, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1543, Description: pruritus, Grade: 1, Relatedness: unlikely related, Resolved: false, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-1522, Description: 6MWT not performed due to facility scheduling, Severity: moderate\n- PD ID: PM-PD-1515, Description: Rescue medication log incomplete for 1 subject, Severity: minor\n\n### Events\n- Rescue medication supply restocked at 12 sites\n- Opioid conversion table reference updated per FDA guidance\n\n### Notes\n- Week 15: Pain management assessments on track. 108 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_016",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-07T10:30:00",
          "text": "## 2024-06-17 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 107\n- Active: 98\n- Screen Failures Cumulative: 42\n- Withdrawals Cumulative: 9\n\n### Enrollment By Treatment Arm\n- Multimodal: 35\n- Standard: 35\n- Placebo: 37\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.5\n- Multimodal VAS Pain Score SD: 1.1\n- Multimodal Morphine Equivalents (mg) Mean: 32.2\n- Multimodal Morphine Equivalents (mg) SD: 8.7\n- Multimodal Six MWT (meters) Mean: 335.0\n- Multimodal Six MWT (meters) SD: 38.0\n- Multimodal Grip Strength (kg) Mean: 26.8\n- Multimodal Grip Strength (kg) SD: 5.9\n- Multimodal Sleep Quality Index Mean: 5.6\n- Multimodal Sleep Quality Index SD: 0.9\n- Multimodal Rescue Med Doses per Week Mean: 3.2\n- Multimodal Rescue Med Doses per Week SD: 2.3\n\n- Standard VAS Pain Score Mean: 5.6\n- Standard VAS Pain Score SD: 1.5\n- Standard Morphine Equivalents (mg) Mean: 44.6\n- Standard Morphine Equivalents (mg) SD: 10.5\n- Standard Six MWT (meters) Mean: 304.0\n- Standard Six MWT (meters) SD: 51.0\n- Standard Grip Strength (kg) Mean: 23.1\n- Standard Grip Strength (kg) SD: 4.2\n- Standard Sleep Quality Index Mean: 4.4\n- Standard Sleep Quality Index SD: 1.0\n- Standard Rescue Med Doses per Week Mean: 5.5\n- Standard Rescue Med Doses per Week SD: 1.7\n\n- Placebo VAS Pain Score Mean: 6.7\n- Placebo VAS Pain Score SD: 1.7\n- Placebo Morphine Equivalents (mg) Mean: 46.8\n- Placebo Morphine Equivalents (mg) SD: 5.7\n- Placebo Six MWT (meters) Mean: 274.0\n- Placebo Six MWT (meters) SD: 38.0\n- Placebo Grip Strength (kg) Mean: 20.0\n- Placebo Grip Strength (kg) SD: 4.6\n- Placebo Sleep Quality Index Mean: 3.8\n- Placebo Sleep Quality Index SD: 0.8\n- Placebo Rescue Med Doses per Week Mean: 6.4\n- Placebo Rescue Med Doses per Week SD: 1.3\n\n### Physical Therapy\n- Sessions Scheduled: 218\n- Sessions Attended: 183\n- Attendance Rate (%): 89.7\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.5\n- Hemoglobin (g/dL) SD: 1.1\n- WBC (k) Mean: 5.7\n- WBC (k) SD: 1.3\n- Platelets (k) Mean: 223\n- Platelets (k) SD: 45\n- Serum Creatinine (mg/dL) Mean: 0.91\n- Serum Creatinine (mg/dL) SD: 0.17\n- Blood Glucose (mg/dL) Mean: 107.0\n- Blood Glucose (mg/dL) SD: 17.0\n- ESR (mm/hr) Mean: 11.0\n- ESR (mm/hr) SD: 9.0\n\n### Adverse Events\n- AE ID: PM-AE-1690, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1681, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-1605, Description: VAS assessment outside scheduled window, Severity: minor\n\n### Events\n- Physical therapy schedule coordinated across 19 sites\n- Randomization module updated for new enrollment block\n\n### Notes\n- Week 16: Pain management assessments on track. 107 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_006",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-08T10:00:00",
          "text": "## 2024-04-08 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 140\n- Active: 137\n- Screen Failures Cumulative: 11\n- Withdrawals Cumulative: 3\n\n#### Sites\n- Site 01 Enrolled: 14\n- Site 01 Active: 14\n- Site 01 Statin Concomitant: 4\n- Site 02 Enrolled: 10\n- Site 02 Active: 10\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 18\n- Site 03 Active: 17\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 9\n- Site 04 Active: 9\n- Site 04 Statin Concomitant: 2\n- Site 05 Enrolled: 11\n- Site 05 Active: 11\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 8\n- Site 06 Active: 8\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 15\n- Site 07 Active: 15\n- Site 07 Statin Concomitant: 4\n- Site 08 Enrolled: 10\n- Site 08 Active: 10\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 11\n- Site 09 Active: 11\n- Site 09 Statin Concomitant: 2\n- Site 10 Enrolled: 9\n- Site 10 Active: 9\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 13\n- Site 11 Active: 13\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 10\n- Site 12 Active: 10\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n- Statin Subgroup N: 53\n- Statin Subgroup ALT (U/L) Mean: 26.1\n- Statin Subgroup ALT (U/L) Median: 24.7\n- Statin Subgroup AST (U/L) Mean: 26.1\n- Statin Subgroup AST (U/L) Median: 25.3\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.83\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.8\n- Statin Subgroup ALP (U/L) Mean: 61.2\n- Statin Subgroup ALP (U/L) Median: 62.5\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.0\n- Statin Subgroup Creatinine (mg/dL) Median: 1.0\n- Statin Subgroup BUN (mg/dL) Mean: 13.6\n- Statin Subgroup BUN (mg/dL) Median: 14.3\n- Statin Subgroup WBC (K) Mean: 5.7\n- Statin Subgroup WBC (K) Median: 7.4\n- Statin Subgroup Platelets (K) Mean: 253\n- Statin Subgroup Platelets (K) Median: 229\n- Non-Statin Subgroup N: 131\n- Non-Statin Subgroup ALT (U/L) Mean: 22.6\n- Non-Statin Subgroup ALT (U/L) Median: 22.0\n- Non-Statin Subgroup AST (U/L) Mean: 28.8\n- Non-Statin Subgroup AST (U/L) Median: 28.1\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.48\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.44\n- Non-Statin Subgroup ALP (U/L) Mean: 72.8\n- Non-Statin Subgroup ALP (U/L) Median: 59.0\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.83\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.99\n- Non-Statin Subgroup BUN (mg/dL) Mean: 13.5\n- Non-Statin Subgroup BUN (mg/dL) Median: 13.3\n- Non-Statin Subgroup WBC (K) Mean: 7.4\n- Non-Statin Subgroup WBC (K) Median: 6.4\n- Non-Statin Subgroup Platelets (K) Mean: 249\n- Non-Statin Subgroup Platelets (K) Median: 226\n\n### Adverse Events\n- AE ID: AE-0017, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0018, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0019, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 27\n- Metformin Count: 21\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-014, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_10\n- PD ID: PD-015, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_12\n- PD ID: PD-016, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_04\n\n### Investigator Notes\n- All CRFs current through prior visit cycle\n- Query resolution rate at 94%\n\n### Events\n- IRT randomization system verified, no anomalies\n- Bioanalytical lab shipment tracking confirmed for 1 samples\n- CRO quarterly oversight report submitted\n\n### Notes\n- Week 6: Enrollment target met. All hepatic and renal panels within normal limits. 4 minor protocol deviations.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_017",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-09T10:30:00",
          "text": "## 2024-06-24 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 110\n- Active: 101\n- Screen Failures Cumulative: 47\n- Withdrawals Cumulative: 9\n\n### Enrollment By Treatment Arm\n- Multimodal: 36\n- Standard: 37\n- Placebo: 37\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.2\n- Multimodal VAS Pain Score SD: 1.9\n- Multimodal Morphine Equivalents (mg) Mean: 30.0\n- Multimodal Morphine Equivalents (mg) SD: 11.5\n- Multimodal Six Minute Walk Test (meters) Mean: 343.0\n- Multimodal Six Minute Walk Test (meters) SD: 34.0\n- Multimodal Grip Strength (kg) Mean: 26.7\n- Multimodal Grip Strength (kg) SD: 4.2\n- Multimodal Sleep Quality Index Mean: 5.7\n- Multimodal Sleep Quality Index SD: 0.9\n- Multimodal Rescue Med Doses Per Week Mean: 2.9\n- Multimodal Rescue Med Doses Per Week SD: 1.1\n\n- Standard VAS Pain Score Mean: 6.0\n- Standard VAS Pain Score SD: 1.1\n- Standard Morphine Equivalents (mg) Mean: 44.6\n- Standard Morphine Equivalents (mg) SD: 10.5\n- Standard Six Minute Walk Test (meters) Mean: 298.0\n- Standard Six Minute Walk Test (meters) SD: 55.0\n- Standard Grip Strength (kg) Mean: 22.8\n- Standard Grip Strength (kg) SD: 4.0\n- Standard Sleep Quality Index Mean: 4.4\n- Standard Sleep Quality Index SD: 1.5\n- Standard Rescue Med Doses Per Week Mean: 4.6\n- Standard Rescue Med Doses Per Week SD: 1.3\n\n- Placebo VAS Pain Score Mean: 6.3\n- Placebo VAS Pain Score SD: 1.8\n- Placebo Morphine Equivalents (mg) Mean: 45.0\n- Placebo Morphine Equivalents (mg) SD: 11.6\n- Placebo Six Minute Walk Test (meters) Mean: 269.0\n- Placebo Six Minute Walk Test (meters) SD: 33.0\n- Placebo Grip Strength (kg) Mean: 19.7\n- Placebo Grip Strength (kg) SD: 5.4\n- Placebo Sleep Quality Index Mean: 4.1\n- Placebo Sleep Quality Index SD: 1.4\n- Placebo Rescue Med Doses Per Week Mean: 6.0\n- Placebo Rescue Med Doses Per Week SD: 1.9\n\n### Physical Therapy\n- Sessions Scheduled: 224\n- Sessions Attended: 194\n- Attendance Rate (%): 88.5\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.3\n- Hemoglobin (g/dL) SD: 1.3\n- WBC (k) Mean: 7.0\n- WBC (k) SD: 1.2\n- Platelets (k) Mean: 234\n- Platelets (k) SD: 41\n- Serum Creatinine (mg/dL) Mean: 0.86\n- Serum Creatinine (mg/dL) SD: 0.19\n- Blood Glucose (mg/dL) Mean: 103.0\n- Blood Glucose (mg/dL) SD: 11.0\n- ESR (mm/hr) Mean: 12.0\n- ESR (mm/hr) SD: 7.0\n\n### Adverse Events\n- AE ID: PM-AE-1702, Description: nausea, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1758, Description: diaphoresis, Grade: 1, Relatedness: possibly related, Resolved: false, Treatment Arm: standard\n- AE ID: PM-AE-1749, Description: pruritus, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1776, Description: diaphoresis, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-1745, Description: VAS assessment outside scheduled window, Severity: minor\n\n### Events\n- Site 01 monitoring visit completed, 1 findings\n- Blinded interim efficacy data compiled for DSMB\n\n### Notes\n- Week 17: Pain management assessments on track. 110 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_018",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-11T10:30:00",
          "text": "## 2024-07-01 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 108\n- Active: 101\n- Screen Failures Cumulative: 47\n- Withdrawals Cumulative: 7\n\n### Enrollment by Treatment Arm\n- Multimodal: 36\n- Standard: 35\n- Placebo: 37\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.2\n- Multimodal VAS Pain Score SD: 1.7\n- Multimodal Morphine Equivalents (mg) Mean: 29.2\n- Multimodal Morphine Equivalents (mg) SD: 6.3\n- Multimodal Six Minute Walk Test (meters) Mean: 349.0\n- Multimodal Six Minute Walk Test (meters) SD: 46.0\n- Multimodal Grip Strength (kg) Mean: 27.5\n- Multimodal Grip Strength (kg) SD: 4.1\n- Multimodal Sleep Quality Index Mean: 5.6\n- Multimodal Sleep Quality Index SD: 1.2\n- Multimodal Rescue Med Doses per Week Mean: 3.7\n- Multimodal Rescue Med Doses per Week SD: 2.5\n\n- Standard VAS Pain Score Mean: 5.9\n- Standard VAS Pain Score SD: 1.6\n- Standard Morphine Equivalents (mg) Mean: 44.1\n- Standard Morphine Equivalents (mg) SD: 5.3\n- Standard Six Minute Walk Test (meters) Mean: 310.0\n- Standard Six Minute Walk Test (meters) SD: 56.0\n- Standard Grip Strength (kg) Mean: 22.3\n- Standard Grip Strength (kg) SD: 5.2\n- Standard Sleep Quality Index Mean: 4.4\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses per Week Mean: 5.1\n- Standard Rescue Med Doses per Week SD: 1.4\n\n- Placebo VAS Pain Score Mean: 6.7\n- Placebo VAS Pain Score SD: 1.4\n- Placebo Morphine Equivalents (mg) Mean: 50.9\n- Placebo Morphine Equivalents (mg) SD: 10.2\n- Placebo Six Minute Walk Test (meters) Mean: 274.0\n- Placebo Six Minute Walk Test (meters) SD: 36.0\n- Placebo Grip Strength (kg) Mean: 20.2\n- Placebo Grip Strength (kg) SD: 4.5\n- Placebo Sleep Quality Index Mean: 3.8\n- Placebo Sleep Quality Index SD: 1.4\n- Placebo Rescue Med Doses per Week Mean: 6.9\n- Placebo Rescue Med Doses per Week SD: 2.5\n\n### Physical Therapy\n- Sessions Scheduled: 221\n- Sessions Attended: 210\n- Attendance Rate (%): 91.9\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.2\n- Hemoglobin (g/dL) SD: 1.4\n- WBC (k) Mean: 7.9\n- WBC (k) SD: 1.8\n- Platelets (k) Mean: 237\n- Platelets (k) SD: 47\n- Serum Creatinine (mg/dL) Mean: 1.19\n- Serum Creatinine (mg/dL) SD: 0.12\n- Blood Glucose (mg/dL) Mean: 98.0\n- Blood Glucose (mg/dL) SD: 17.0\n- ESR (mm/hr) Mean: 19.0\n- ESR (mm/hr) SD: 5.0\n\n### Adverse Events\n- AE ID: PM-AE-1846, Description: urinary retention, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1827, Description: diaphoresis, Grade: 2, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1843, Description: fatigue, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1877, Description: fatigue, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1846, Description: pruritus, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-1843, Description: Rescue medication log incomplete for 1 subject, Severity: minor\n- PD ID: PM-PD-1834, Description: 6MWT not performed due to facility scheduling, Severity: moderate\n\n### Events\n- Physical therapy schedule coordinated across 22 sites\n- Physical therapy schedule coordinated across 15 sites\n\n### Notes\n- Week 18: Pain management assessments on track. 108 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_019",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-14T10:30:00",
          "text": "## 2024-07-08 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 109\n- Active: 99\n- Screen Failures Cumulative: 52\n- Withdrawals Cumulative: 10\n\n### Enrollment By Treatment Arm\n- Multimodal: 35\n- Standard: 37\n- Placebo: 37\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 5.2\n- Multimodal VAS Pain Score SD: 1.4\n- Multimodal Morphine Equivalents (mg) Mean: 27.8\n- Multimodal Morphine Equivalents (mg) SD: 9.5\n- Multimodal Six MWT (meters) Mean: 346.0\n- Multimodal Six MWT (meters) SD: 55.0\n- Multimodal Grip Strength (kg) Mean: 27.9\n- Multimodal Grip Strength (kg) SD: 4.6\n- Multimodal Sleep Quality Index Mean: 5.7\n- Multimodal Sleep Quality Index SD: 0.9\n- Multimodal Rescue Med Doses per Week Mean: 3.0\n- Multimodal Rescue Med Doses per Week SD: 2.2\n\n- Standard VAS Pain Score Mean: 5.5\n- Standard VAS Pain Score SD: 1.5\n- Standard Morphine Equivalents (mg) Mean: 40.4\n- Standard Morphine Equivalents (mg) SD: 8.0\n- Standard Six MWT (meters) Mean: 303.0\n- Standard Six MWT (meters) SD: 57.0\n- Standard Grip Strength (kg) Mean: 22.1\n- Standard Grip Strength (kg) SD: 3.4\n- Standard Sleep Quality Index Mean: 4.5\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses per Week Mean: 4.9\n- Standard Rescue Med Doses per Week SD: 1.4\n\n- Placebo VAS Pain Score Mean: 6.3\n- Placebo VAS Pain Score SD: 1.5\n- Placebo Morphine Equivalents (mg) Mean: 46.1\n- Placebo Morphine Equivalents (mg) SD: 6.4\n- Placebo Six MWT (meters) Mean: 267.0\n- Placebo Six MWT (meters) SD: 35.0\n- Placebo Grip Strength (kg) Mean: 19.1\n- Placebo Grip Strength (kg) SD: 3.4\n- Placebo Sleep Quality Index Mean: 3.8\n- Placebo Sleep Quality Index SD: 1.4\n- Placebo Rescue Med Doses per Week Mean: 6.8\n- Placebo Rescue Med Doses per Week SD: 1.1\n\n### Physical Therapy\n- Sessions Scheduled: 220\n- Sessions Attended: 201\n- Attendance Rate (%): 87.5\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.4\n- Hemoglobin (g/dL) SD: 1.0\n- WBC (k) Mean: 5.9\n- WBC (k) SD: 1.6\n- Platelets (k) Mean: 245\n- Platelets (k) SD: 43\n- Serum Creatinine (mg/dL) Mean: 1.05\n- Serum Creatinine (mg/dL) SD: 0.18\n- Blood Glucose (mg/dL) Mean: 100.0\n- Blood Glucose (mg/dL) SD: 14.0\n- ESR (mm/hr) Mean: 18.0\n- ESR (mm/hr) SD: 10.0\n\n### Adverse Events\n- AE ID: PM-AE-1997, Description: pruritus, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1940, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: false, Treatment Arm: standard\n- AE ID: PM-AE-1940, Description: constipation, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-1977, Description: constipation, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-1925, Description: dry mouth, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-1944, Description: VAS assessment outside scheduled window, Severity: minor\n\n### Events\n- Rescue medication supply restocked at 17 sites\n- Subject retention call completed for 21 overdue visits\n- Pain diary electronic collection rate: 84%\n\n### Notes\n- Week 19: Pain management assessments on track. 109 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_007",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-15T10:00:00",
          "text": "## 2024-04-15 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 160\n- Active: 156\n- Screen Failures Cumulative: 15\n- Withdrawals Cumulative: 4\n\n#### Sites\n- Site 01 Enrolled: 16\n- Site 01 Active: 16\n- Site 01 Statin Concomitant: 4\n- Site 02 Enrolled: 12\n- Site 02 Active: 12\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 15\n- Site 03 Active: 15\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 10\n- Site 04 Active: 10\n- Site 04 Statin Concomitant: 2\n- Site 05 Enrolled: 13\n- Site 05 Active: 13\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 9\n- Site 06 Active: 9\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 17\n- Site 07 Active: 17\n- Site 07 Statin Concomitant: 4\n- Site 08 Enrolled: 12\n- Site 08 Active: 12\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 13\n- Site 09 Active: 13\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 10\n- Site 10 Active: 10\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 15\n- Site 11 Active: 15\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 12\n- Site 12 Active: 12\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 26.8\n- ALT (U/L) Median: 24.1\n- AST (U/L) Mean: 27.3\n- AST (U/L) Median: 26.7\n- Bilirubin (mg/dL) Mean: 0.64\n- Bilirubin (mg/dL) Median: 0.63\n- ALP (U/L) Mean: 80.7\n- ALP (U/L) Median: 63.0\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.91\n- BUN (mg/dL) Mean: 15.3\n- BUN (mg/dL) Median: 16.6\n- WBC (K) Mean: 7.0\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 239\n- Platelets (K) Median: 248\n\n#### Non-Statin Subgroup\n- N: 120\n- ALT (U/L) Mean: 30.1\n- ALT (U/L) Median: 29.6\n- AST (U/L) Mean: 24.4\n- AST (U/L) Median: 24.3\n- Bilirubin (mg/dL) Mean: 0.76\n- Bilirubin (mg/dL) Median: 0.74\n- ALP (U/L) Mean: 56.6\n- ALP (U/L) Median: 50.4\n- Creatinine (mg/dL) Mean: 0.91\n- Creatinine (mg/dL) Median: 0.95\n- BUN (mg/dL) Mean: 17.1\n- BUN (mg/dL) Median: 15.7\n- WBC (K) Mean: 8.2\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 248\n- Platelets (K) Median: 226\n\n### Adverse Events\n- AE ID: AE-0020, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0021, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0022, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 30\n- Metformin Count: 22\n- PPI Count: 19\n- NSAID Count: 11\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-017, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_05\n- PD ID: PD-018, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_12\n\n### Investigator Notes\n- All SAE narratives submitted within reporting window\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- Site 04 pharmacy temperature log reviewed: compliant\n- CRO quarterly oversight report submitted\n- EDC system maintenance window: 2h downtime Saturday 02:00 UTC\n\n### Notes\n- Week 7: Enrollment target met.\n- All hepatic and renal panels within normal limits.\n- 3 minor protocol deviations.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_020",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-16T10:30:00",
          "text": "## 2024-07-15 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 109\n- Active: 96\n- Screen Failures Cumulative: 43\n- Withdrawals Cumulative: 13\n\n### Enrollment By Treatment Arm\n- Multimodal: 35\n- Standard: 36\n- Placebo: 38\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.9\n- Multimodal VAS Pain Score SD: 1.2\n- Multimodal Morphine Equivalents (mg) Mean: 29.7\n- Multimodal Morphine Equivalents (mg) SD: 7.1\n- Multimodal Six Minute Walk Test (meters) Mean: 350.0\n- Multimodal Six Minute Walk Test (meters) SD: 36.0\n- Multimodal Grip Strength (kg) Mean: 27.0\n- Multimodal Grip Strength (kg) SD: 5.5\n- Multimodal Sleep Quality Index Mean: 5.6\n- Multimodal Sleep Quality Index SD: 1.3\n- Multimodal Rescue Med Doses Per Week Mean: 3.5\n- Multimodal Rescue Med Doses Per Week SD: 1.5\n\n- Standard VAS Pain Score Mean: 5.6\n- Standard VAS Pain Score SD: 1.0\n- Standard Morphine Equivalents (mg) Mean: 41.1\n- Standard Morphine Equivalents (mg) SD: 11.7\n- Standard Six Minute Walk Test (meters) Mean: 310.0\n- Standard Six Minute Walk Test (meters) SD: 50.0\n- Standard Grip Strength (kg) Mean: 23.6\n- Standard Grip Strength (kg) SD: 5.4\n- Standard Sleep Quality Index Mean: 4.7\n- Standard Sleep Quality Index SD: 0.9\n- Standard Rescue Med Doses Per Week Mean: 4.6\n- Standard Rescue Med Doses Per Week SD: 1.9\n\n- Placebo VAS Pain Score Mean: 6.5\n- Placebo VAS Pain Score SD: 1.4\n- Placebo Morphine Equivalents (mg) Mean: 48.2\n- Placebo Morphine Equivalents (mg) SD: 7.7\n- Placebo Six Minute Walk Test (meters) Mean: 262.0\n- Placebo Six Minute Walk Test (meters) SD: 38.0\n- Placebo Grip Strength (kg) Mean: 19.1\n- Placebo Grip Strength (kg) SD: 5.2\n- Placebo Sleep Quality Index Mean: 4.0\n- Placebo Sleep Quality Index SD: 1.1\n- Placebo Rescue Med Doses Per Week Mean: 6.1\n- Placebo Rescue Med Doses Per Week SD: 2.0\n\n### Physical Therapy\n- Sessions Scheduled: 209\n- Sessions Attended: 202\n- Attendance Rate (%): 85.7\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.9\n- Hemoglobin (g/dL) SD: 1.2\n- WBC (k) Mean: 7.0\n- WBC (k) SD: 1.0\n- Platelets (k) Mean: 258\n- Platelets (k) SD: 48\n- Serum Creatinine (mg/dL) Mean: 0.96\n- Serum Creatinine (mg/dL) SD: 0.18\n- Blood Glucose (mg/dL) Mean: 97.0\n- Blood Glucose (mg/dL) SD: 17.0\n- ESR (mm/hr) Mean: 22.0\n- ESR (mm/hr) SD: 8.0\n\n### Adverse Events\n- AE ID: PM-AE-2075, Description: headache, Grade: 2, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2008, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2027, Description: dry mouth, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2052, Description: diaphoresis, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-2012, Description: Sleep diary not returned by subject, Severity: moderate\n\n### Events\n- Subject retention call completed for 20 overdue visits\n- Opioid conversion table reference updated per FDA guidance\n- Blinded interim efficacy data compiled for DSMB\n\n### Notes\n- Week 20: Pain management assessments on track. 109 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_021",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-18T10:30:00",
          "text": "## 2024-07-22 Daily Operations Summary\n\n### Enrollment\n- Total enrolled: 110\n- Active: 96\n- Screen failures cumulative: 51\n- Withdrawals cumulative: 14\n- By treatment arm: \n  - Multimodal: 35\n  - Standard: 37\n  - Placebo: 38\n\n### Efficacy By Arm\n- Multimodal: \n  - VAS pain score mean: 4.8\n  - VAS pain score SD: 1.2\n  - Morphine equivalents mg mean: 30.2\n  - Morphine equivalents mg SD: 11.9\n  - Six MWT meters mean: 359.0\n  - Six MWT meters SD: 51.0\n  - Grip strength kg mean: 28.6\n  - Grip strength kg SD: 3.9\n  - Sleep quality index mean: 5.8\n  - Sleep quality index SD: 1.4\n  - Rescue med doses per week mean: 2.4\n  - Rescue med doses per week SD: 1.7\n- Standard: \n  - VAS pain score mean: 5.6\n  - VAS pain score SD: 2.0\n  - Morphine equivalents mg mean: 41.6\n  - Morphine equivalents mg SD: 5.1\n  - Six MWT meters mean: 302.0\n  - Six MWT meters SD: 52.0\n  - Grip strength kg mean: 24.0\n  - Grip strength kg SD: 3.4\n  - Sleep quality index mean: 4.5\n  - Sleep quality index SD: 0.8\n  - Rescue med doses per week mean: 4.6\n  - Rescue med doses per week SD: 2.3\n- Placebo: \n  - VAS pain score mean: 6.4\n  - VAS pain score SD: 1.7\n  - Morphine equivalents mg mean: 49.0\n  - Morphine equivalents mg SD: 8.4\n  - Six MWT meters mean: 266.0\n  - Six MWT meters SD: 51.0\n  - Grip strength kg mean: 19.9\n  - Grip strength kg SD: 3.7\n  - Sleep quality index mean: 4.0\n  - Sleep quality index SD: 1.3\n  - Rescue med doses per week mean: 6.0\n  - Rescue med doses per week SD: 1.7\n\n### Physical Therapy\n- Sessions scheduled: 218\n- Sessions attended: 205\n- Attendance rate %: 84.2\n\n### Safety Labs\n- Hemoglobin g/dL mean: 13.2\n- Hemoglobin g/dL SD: 1.2\n- WBC k mean: 7.4\n- WBC k SD: 1.7\n- Platelets k mean: 234\n- Platelets k SD: 41\n- Serum creatinine mg/dL mean: 0.8\n- Serum creatinine mg/dL SD: 0.13\n- Blood glucose mg/dL mean: 107.0\n- Blood glucose mg/dL SD: 18.0\n- ESR mm/hr mean: 19.0\n- ESR mm/hr SD: 6.0\n\n### Adverse Events\n- AE ID: PM-AE-2160, Description: nausea, Grade: 1, Relatedness: probably related, Resolved: true, Treatment arm: multimodal\n- AE ID: PM-AE-2118, Description: sedation, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-2105, Description: Rescue medication log incomplete for 1 subject, Severity: minor\n\n### Events\n- Subject retention call completed for 20 overdue visits\n- Central pharmacy opioid supply reconciliation completed\n\n### Notes\n- Week 21: Pain management assessments on track. 110 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_022",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-20T10:30:00",
          "text": "## 2024-07-29 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 108\n- Active: 95\n- Screen Failures Cumulative: 63\n- Withdrawals Cumulative: 13\n\n### Enrollment By Treatment Arm\n- Multimodal: 34\n- Standard: 36\n- Placebo: 38\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.9\n- Multimodal VAS Pain Score SD: 1.8\n- Multimodal Morphine Equivalents (mg) Mean: 27.5\n- Multimodal Morphine Equivalents (mg) SD: 9.8\n- Multimodal Six MWT (meters) Mean: 358.0\n- Multimodal Six MWT (meters) SD: 47.0\n- Multimodal Grip Strength (kg) Mean: 28.1\n- Multimodal Grip Strength (kg) SD: 5.3\n- Multimodal Sleep Quality Index Mean: 5.7\n- Multimodal Sleep Quality Index SD: 0.8\n- Multimodal Rescue Med Doses per Week Mean: 2.7\n- Multimodal Rescue Med Doses per Week SD: 2.3\n\n- Standard VAS Pain Score Mean: 5.6\n- Standard VAS Pain Score SD: 1.8\n- Standard Morphine Equivalents (mg) Mean: 40.5\n- Standard Morphine Equivalents (mg) SD: 10.9\n- Standard Six MWT (meters) Mean: 322.0\n- Standard Six MWT (meters) SD: 43.0\n- Standard Grip Strength (kg) Mean: 22.2\n- Standard Grip Strength (kg) SD: 4.7\n- Standard Sleep Quality Index Mean: 4.7\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses per Week Mean: 5.2\n- Standard Rescue Med Doses per Week SD: 2.3\n\n- Placebo VAS Pain Score Mean: 6.7\n- Placebo VAS Pain Score SD: 1.6\n- Placebo Morphine Equivalents (mg) Mean: 46.8\n- Placebo Morphine Equivalents (mg) SD: 8.1\n- Placebo Six MWT (meters) Mean: 277.0\n- Placebo Six MWT (meters) SD: 41.0\n- Placebo Grip Strength (kg) Mean: 20.2\n- Placebo Grip Strength (kg) SD: 4.0\n- Placebo Sleep Quality Index Mean: 4.2\n- Placebo Sleep Quality Index SD: 0.9\n- Placebo Rescue Med Doses per Week Mean: 6.5\n- Placebo Rescue Med Doses per Week SD: 2.0\n\n### Physical Therapy\n- Sessions Scheduled: 216\n- Sessions Attended: 188\n- Attendance Rate (%): 90.4\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.3\n- Hemoglobin (g/dL) SD: 0.8\n- WBC (K) Mean: 6.8\n- WBC (K) SD: 1.4\n- Platelets (K) Mean: 248\n- Platelets (K) SD: 44\n- Serum Creatinine (mg/dL) Mean: 0.96\n- Serum Creatinine (mg/dL) SD: 0.16\n- Blood Glucose (mg/dL) Mean: 102.0\n- Blood Glucose (mg/dL) SD: 11.0\n- ESR (mm/hr) Mean: 21.0\n- ESR (mm/hr) SD: 7.0\n\n### Adverse Events\n- AE ID: PM-AE-2224, Description: pruritus, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-2276, Description: dry mouth, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2209, Description: sedation, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2213, Description: pruritus, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2201, Description: urinary retention, Grade: 1, Relatedness: probably related, Resolved: false, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-2220, Description: Missed physical therapy session, not rescheduled within window, Severity: minor\n\n### Events\n- Subject retention call completed for 17 overdue visits\n- Randomization module updated for new enrollment block\n- Subject retention call completed for 22 overdue visits\n\n### Notes\n- Week 22: Pain management assessments on track. 108 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_008",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-22T10:00:00",
          "text": "## 2024-04-22 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 180\n- Active: 177\n- Screen Failures Cumulative: 13\n- Withdrawals Cumulative: 3\n\n#### Sites\n- Site 01 Enrolled: 18\n- Site 01 Active: 18\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 13\n- Site 02 Active: 13\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 16\n- Site 03 Active: 16\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 12\n- Site 04 Active: 12\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 15\n- Site 05 Active: 15\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 10\n- Site 06 Active: 10\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 19\n- Site 07 Active: 19\n- Site 07 Statin Concomitant: 5\n- Site 08 Enrolled: 13\n- Site 08 Active: 13\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 15\n- Site 09 Active: 15\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 12\n- Site 10 Active: 12\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 16\n- Site 11 Active: 16\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 13\n- Site 12 Active: 13\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 25.0\n- ALT (U/L) Median: 22.3\n- AST (U/L) Mean: 20.6\n- AST (U/L) Median: 19.0\n- Bilirubin (mg/dL) Mean: 0.73\n- Bilirubin (mg/dL) Median: 0.7\n- ALP (U/L) Mean: 73.1\n- ALP (U/L) Median: 76.4\n- Creatinine (mg/dL) Mean: 0.81\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 15.6\n- BUN (mg/dL) Median: 12.5\n- WBC (K) Mean: 6.0\n- WBC (K) Median: 6.3\n- Platelets (K) Mean: 242\n- Platelets (K) Median: 244\n\n#### Non-Statin Subgroup\n- N: 130\n- ALT (U/L) Mean: 28.6\n- ALT (U/L) Median: 26.8\n- AST (U/L) Mean: 22.5\n- AST (U/L) Median: 20.5\n- Bilirubin (mg/dL) Mean: 0.57\n- Bilirubin (mg/dL) Median: 0.54\n- ALP (U/L) Mean: 50.6\n- ALP (U/L) Median: 66.5\n- Creatinine (mg/dL) Mean: 1.07\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 17.3\n- BUN (mg/dL) Median: 16.2\n- WBC (K) Mean: 6.8\n- WBC (K) Median: 5.6\n- Platelets (K) Mean: 238\n- Platelets (K) Median: 233\n\n### Adverse Events\n- AE ID: AE-0023, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0024, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n\n### Concomitant Meds\n- Statin Count: 56\n- ACE Inhibitor Count: 29\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 33\n\n### Protocol Deviations\n- PD ID: PD-019, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_09\n- PD ID: PD-020, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_04\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- All SAE narratives submitted within reporting window\n- No new safety signals identified this week by local PI\n\n### Events\n- Site 06 monitoring visit completed, 2 findings\n- Regulatory submission packet sent to Site 05\n- IP resupply shipped to Sites 11, 12\n\n### Notes\n- Week 8: Enrollment target met. All hepatic and renal panels within normal limits. 2 minor protocol deviations.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_023",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-23T10:30:00",
          "text": "## 2024-08-05 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 107\n- Active: 96\n- Screen Failures Cumulative: 65\n- Withdrawals Cumulative: 11\n\n### Enrollment By Treatment Arm\n- Multimodal: 34\n- Standard: 36\n- Placebo: 37\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.7\n- Multimodal VAS Pain Score SD: 1.6\n- Multimodal Morphine Equivalents (mg) Mean: 28.5\n- Multimodal Morphine Equivalents (mg) SD: 10.5\n- Multimodal Six MWT (meters) Mean: 371.0\n- Multimodal Six MWT (meters) SD: 31.0\n- Multimodal Grip Strength (kg) Mean: 28.0\n- Multimodal Grip Strength (kg) SD: 5.4\n- Multimodal Sleep Quality Index Mean: 5.8\n- Multimodal Sleep Quality Index SD: 1.1\n- Multimodal Rescue Med Doses per Week Mean: 2.9\n- Multimodal Rescue Med Doses per Week SD: 1.5\n\n- Standard VAS Pain Score Mean: 5.9\n- Standard VAS Pain Score SD: 1.5\n- Standard Morphine Equivalents (mg) Mean: 40.3\n- Standard Morphine Equivalents (mg) SD: 11.1\n- Standard Six MWT (meters) Mean: 319.0\n- Standard Six MWT (meters) SD: 35.0\n- Standard Grip Strength (kg) Mean: 23.9\n- Standard Grip Strength (kg) SD: 5.5\n- Standard Sleep Quality Index Mean: 4.7\n- Standard Sleep Quality Index SD: 1.3\n- Standard Rescue Med Doses per Week Mean: 4.9\n- Standard Rescue Med Doses per Week SD: 1.6\n\n- Placebo VAS Pain Score Mean: 6.7\n- Placebo VAS Pain Score SD: 1.4\n- Placebo Morphine Equivalents (mg) Mean: 48.5\n- Placebo Morphine Equivalents (mg) SD: 7.6\n- Placebo Six MWT (meters) Mean: 268.0\n- Placebo Six MWT (meters) SD: 40.0\n- Placebo Grip Strength (kg) Mean: 19.3\n- Placebo Grip Strength (kg) SD: 4.6\n- Placebo Sleep Quality Index Mean: 4.2\n- Placebo Sleep Quality Index SD: 0.9\n- Placebo Rescue Med Doses per Week Mean: 6.4\n- Placebo Rescue Med Doses per Week SD: 1.2\n\n### Physical Therapy\n- Sessions Scheduled: 218\n- Sessions Attended: 180\n- Attendance Rate (%): 93.0\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.7\n- Hemoglobin (g/dL) SD: 1.4\n- WBC (k) Mean: 7.8\n- WBC (k) SD: 1.6\n- Platelets (k) Mean: 242\n- Platelets (k) SD: 41\n- Serum Creatinine (mg/dL) Mean: 0.82\n- Serum Creatinine (mg/dL) SD: 0.17\n- Blood Glucose (mg/dL) Mean: 92.0\n- Blood Glucose (mg/dL) SD: 18.0\n- ESR (mm/hr) Mean: 18.0\n- ESR (mm/hr) SD: 6.0\n\n### Adverse Events\n- AE ID: PM-AE-2393, Description: constipation, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2390, Description: muscle spasm, Grade: 2, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-2396, Description: sedation, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-2329, Description: Grip strength dynamometer calibration overdue by 3 days, Severity: moderate\n- PD ID: PM-PD-2348, Description: Sleep diary not returned by subject, Severity: minor\n\n### Events\n- Pain diary electronic collection rate: 90%\n- Rescue medication supply restocked at 23 sites\n\n### Notes\n- Week 23: Pain management assessments on track. 107 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_024",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-25T10:30:00",
          "text": "## 2024-08-12 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 108\n- Active: 92\n- Screen Failures Cumulative: 69\n- Withdrawals Cumulative: 16\n\n### Enrollment By Treatment Arm\n- Multimodal: 35\n- Standard: 37\n- Placebo: 36\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.8\n- Multimodal VAS Pain Score SD: 1.1\n- Multimodal Morphine Equivalents (mg) Mean: 26.4\n- Multimodal Morphine Equivalents (mg) SD: 5.6\n- Multimodal Six MWT (meters) Mean: 367.0\n- Multimodal Six MWT (meters) SD: 48.0\n- Multimodal Grip Strength (kg) Mean: 27.3\n- Multimodal Grip Strength (kg) SD: 5.6\n- Multimodal Sleep Quality Index Mean: 5.9\n- Multimodal Sleep Quality Index SD: 1.0\n- Multimodal Rescue Med Doses per Week Mean: 2.6\n- Multimodal Rescue Med Doses per Week SD: 1.1\n\n- Standard VAS Pain Score Mean: 5.4\n- Standard VAS Pain Score SD: 1.5\n- Standard Morphine Equivalents (mg) Mean: 39.2\n- Standard Morphine Equivalents (mg) SD: 7.6\n- Standard Six MWT (meters) Mean: 320.0\n- Standard Six MWT (meters) SD: 45.0\n- Standard Grip Strength (kg) Mean: 23.7\n- Standard Grip Strength (kg) SD: 5.0\n- Standard Sleep Quality Index Mean: 4.7\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses per Week Mean: 4.1\n- Standard Rescue Med Doses per Week SD: 2.4\n\n- Placebo VAS Pain Score Mean: 6.7\n- Placebo VAS Pain Score SD: 1.2\n- Placebo Morphine Equivalents (mg) Mean: 50.8\n- Placebo Morphine Equivalents (mg) SD: 9.2\n- Placebo Six MWT (meters) Mean: 271.0\n- Placebo Six MWT (meters) SD: 52.0\n- Placebo Grip Strength (kg) Mean: 19.9\n- Placebo Grip Strength (kg) SD: 3.6\n- Placebo Sleep Quality Index Mean: 4.2\n- Placebo Sleep Quality Index SD: 1.2\n- Placebo Rescue Med Doses per Week Mean: 6.9\n- Placebo Rescue Med Doses per Week SD: 1.9\n\n### Physical Therapy\n- Sessions Scheduled: 218\n- Sessions Attended: 188\n- Attendance Rate (%): 82.2\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.2\n- Hemoglobin (g/dL) SD: 0.8\n- WBC (K) Mean: 7.4\n- WBC (K) SD: 1.0\n- Platelets (K) Mean: 237\n- Platelets (K) SD: 42\n- Serum Creatinine (mg/dL) Mean: 0.91\n- Serum Creatinine (mg/dL) SD: 0.19\n- Blood Glucose (mg/dL) Mean: 109.0\n- Blood Glucose (mg/dL) SD: 19.0\n- ESR (mm/hr) Mean: 25.0\n- ESR (mm/hr) SD: 7.0\n\n### Adverse Events\n- AE ID: PM-AE-2480, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: false, Treatment Arm: multimodal\n- AE ID: PM-AE-2433, Description: sedation, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2499, Description: muscle spasm, Grade: 2, Relatedness: unlikely related, Resolved: false, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-2450, Description: VAS assessment outside scheduled window, Severity: moderate\n- PD ID: PM-PD-2432, Description: Missed physical therapy session, not rescheduled within window, Severity: moderate\n\n### Events\n- Opioid conversion table reference updated per FDA guidance\n- Rescue medication supply restocked at 16 sites\n- Physical therapy schedule coordinated across 16 sites\n\n### Notes\n- Week 24: Pain management assessments on track. 108 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_025",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-27T10:30:00",
          "text": "## 2024-08-19 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 110\n- Active: 94\n- Screen Failures Cumulative: 69\n- Withdrawals Cumulative: 16\n\n### Enrollment By Treatment Arm\n- Multimodal: 36\n- Standard: 36\n- Placebo: 38\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.7\n- Multimodal VAS Pain Score SD: 1.3\n- Multimodal Morphine Equivalents (mg) Mean: 25.9\n- Multimodal Morphine Equivalents (mg) SD: 10.2\n- Multimodal Six MWT (meters) Mean: 384.0\n- Multimodal Six MWT (meters) SD: 43.0\n- Multimodal Grip Strength (kg) Mean: 27.5\n- Multimodal Grip Strength (kg) SD: 3.6\n- Multimodal Sleep Quality Index Mean: 5.8\n- Multimodal Sleep Quality Index SD: 1.0\n- Multimodal Rescue Med Doses per Week Mean: 2.2\n- Multimodal Rescue Med Doses per Week SD: 1.6\n\n- Standard VAS Pain Score Mean: 5.4\n- Standard VAS Pain Score SD: 1.3\n- Standard Morphine Equivalents (mg) Mean: 40.7\n- Standard Morphine Equivalents (mg) SD: 9.3\n- Standard Six MWT (meters) Mean: 314.0\n- Standard Six MWT (meters) SD: 42.0\n- Standard Grip Strength (kg) Mean: 23.7\n- Standard Grip Strength (kg) SD: 5.2\n- Standard Sleep Quality Index Mean: 4.8\n- Standard Sleep Quality Index SD: 0.9\n- Standard Rescue Med Doses per Week Mean: 4.9\n- Standard Rescue Med Doses per Week SD: 1.9\n\n- Placebo VAS Pain Score Mean: 6.6\n- Placebo VAS Pain Score SD: 1.4\n- Placebo Morphine Equivalents (mg) Mean: 48.1\n- Placebo Morphine Equivalents (mg) SD: 7.6\n- Placebo Six MWT (meters) Mean: 271.0\n- Placebo Six MWT (meters) SD: 42.0\n- Placebo Grip Strength (kg) Mean: 20.0\n- Placebo Grip Strength (kg) SD: 3.3\n- Placebo Sleep Quality Index Mean: 4.1\n- Placebo Sleep Quality Index SD: 1.4\n- Placebo Rescue Med Doses per Week Mean: 6.7\n- Placebo Rescue Med Doses per Week SD: 1.2\n\n### Physical Therapy\n- Sessions Scheduled: 212\n- Sessions Attended: 188\n- Attendance Rate (%): 85.1\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.2\n- Hemoglobin (g/dL) SD: 1.1\n- WBC (k) Mean: 7.3\n- WBC (k) SD: 1.7\n- Platelets (k) Mean: 231\n- Platelets (k) SD: 44\n- Serum Creatinine (mg/dL) Mean: 0.94\n- Serum Creatinine (mg/dL) SD: 0.18\n- Blood Glucose (mg/dL) Mean: 103.0\n- Blood Glucose (mg/dL) SD: 12.0\n- ESR (mm/hr) Mean: 8.0\n- ESR (mm/hr) SD: 9.0\n\n### Adverse Events\n- AE ID: PM-AE-2504\n- Description: sedation\n- Grade: 1\n- Relatedness: unlikely related\n- Resolved: true\n- Treatment Arm: standard\n\n- AE ID: PM-AE-2511\n- Description: urinary retention\n- Grade: 1\n- Relatedness: probably related\n- Resolved: true\n- Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-2539\n- Description: VAS assessment outside scheduled window\n- Severity: minor\n\n### Events\n- Pain diary electronic collection rate: 83%\n- Opioid conversion table reference updated per FDA guidance\n\n### Notes\n- Week 25: Pain management assessments on track. 110 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_009",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-29T10:00:00",
          "text": "## 2024-04-29 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 185\n- Active: 180\n- Screen Failures Cumulative: 22\n- Withdrawals Cumulative: 5\n\n#### Sites\n- Site 01 Enrolled: 18\n- Site 01 Active: 18\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 14\n- Site 02 Active: 14\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 17\n- Site 03 Active: 17\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 12\n- Site 04 Active: 12\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 15\n- Site 05 Active: 15\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 11\n- Site 06 Active: 11\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 20\n- Site 07 Active: 20\n- Site 07 Statin Concomitant: 5\n- Site 08 Enrolled: 14\n- Site 08 Active: 14\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 15\n- Site 09 Active: 15\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 12\n- Site 10 Active: 12\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 17\n- Site 11 Active: 17\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 14\n- Site 12 Active: 14\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 32.3\n- ALT (U/L) Median: 31.9\n- AST (U/L) Mean: 31.2\n- AST (U/L) Median: 31.2\n- Bilirubin (mg/dL) Mean: 0.56\n- Bilirubin (mg/dL) Median: 0.56\n- ALP (U/L) Mean: 66.5\n- ALP (U/L) Median: 70.2\n- Creatinine (mg/dL) Mean: 0.96\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 17.3\n- BUN (mg/dL) Median: 11.3\n- WBC (K) Mean: 6.9\n- WBC (K) Median: 7.6\n- Platelets (K) Mean: 238\n- Platelets (K) Median: 223\n\n#### Non-Statin Subgroup\n- N: 125\n- ALT (U/L) Mean: 29.6\n- ALT (U/L) Median: 28.4\n- AST (U/L) Mean: 26.8\n- AST (U/L) Median: 25.8\n- Bilirubin (mg/dL) Mean: 0.84\n- Bilirubin (mg/dL) Median: 0.82\n- ALP (U/L) Mean: 59.9\n- ALP (U/L) Median: 61.5\n- Creatinine (mg/dL) Mean: 0.99\n- Creatinine (mg/dL) Median: 0.95\n- BUN (mg/dL) Mean: 13.4\n- BUN (mg/dL) Median: 14.2\n- WBC (K) Mean: 6.6\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 220\n- Platelets (K) Median: 212\n\n### Adverse Events\n- AE ID: AE-0025, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0026, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0027, Description: abdominal discomfort, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0028, Description: abdominal discomfort, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-021, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_08\n- PD ID: PD-022, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_10\n- PD ID: PD-023, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_05\n\n### Investigator Notes\n- Enrollment on track per protocol timeline\n- Subject retention rate within protocol targets\n\n### Events\n- Medical monitor weekly call completed\n- CRO quarterly oversight report submitted\n\n### Notes\n- Week 9: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_026",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-30T10:30:00",
          "text": "## 2024-08-26 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 109\n- Active: 95\n- Screen Failures Cumulative: 74\n- Withdrawals Cumulative: 14\n\n### Enrollment by Treatment Arm\n- Multimodal: 36\n- Standard: 35\n- Placebo: 38\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.5\n- Multimodal VAS Pain Score SD: 1.1\n- Multimodal Morphine Equivalents (mg) Mean: 23.4\n- Multimodal Morphine Equivalents (mg) SD: 6.5\n- Multimodal Six MWT (meters) Mean: 382.0\n- Multimodal Six MWT (meters) SD: 31.0\n- Multimodal Grip Strength (kg) Mean: 27.6\n- Multimodal Grip Strength (kg) SD: 4.0\n- Multimodal Sleep Quality Index Mean: 6.0\n- Multimodal Sleep Quality Index SD: 1.2\n- Multimodal Rescue Med Doses per Week Mean: 2.0\n- Multimodal Rescue Med Doses per Week SD: 1.8\n\n- Standard VAS Pain Score Mean: 5.7\n- Standard VAS Pain Score SD: 1.2\n- Standard Morphine Equivalents (mg) Mean: 39.0\n- Standard Morphine Equivalents (mg) SD: 9.5\n- Standard Six MWT (meters) Mean: 328.0\n- Standard Six MWT (meters) SD: 43.0\n- Standard Grip Strength (kg) Mean: 23.8\n- Standard Grip Strength (kg) SD: 5.3\n- Standard Sleep Quality Index Mean: 4.9\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses per Week Mean: 4.2\n- Standard Rescue Med Doses per Week SD: 1.6\n\n- Placebo VAS Pain Score Mean: 6.2\n- Placebo VAS Pain Score SD: 1.0\n- Placebo Morphine Equivalents (mg) Mean: 50.6\n- Placebo Morphine Equivalents (mg) SD: 5.5\n- Placebo Six MWT (meters) Mean: 267.0\n- Placebo Six MWT (meters) SD: 41.0\n- Placebo Grip Strength (kg) Mean: 20.9\n- Placebo Grip Strength (kg) SD: 5.0\n- Placebo Sleep Quality Index Mean: 3.9\n- Placebo Sleep Quality Index SD: 0.9\n- Placebo Rescue Med Doses per Week Mean: 7.0\n- Placebo Rescue Med Doses per Week SD: 1.7\n\n### Physical Therapy\n- Sessions Scheduled: 223\n- Sessions Attended: 191\n- Attendance Rate (%): 89.1\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.4\n- Hemoglobin (g/dL) SD: 1.2\n- WBC (k) Mean: 6.9\n- WBC (k) SD: 1.3\n- Platelets (k) Mean: 257\n- Platelets (k) SD: 48\n- Serum Creatinine (mg/dL) Mean: 0.82\n- Serum Creatinine (mg/dL) SD: 0.17\n- Blood Glucose (mg/dL) Mean: 93.0\n- Blood Glucose (mg/dL) SD: 19.0\n- ESR (mm/hr) Mean: 21.0\n- ESR (mm/hr) SD: 9.0\n\n### Adverse Events\n- AE ID: PM-AE-2671, Description: constipation, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-2616, Description: dizziness, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-2652, Description: sedation, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2611, Description: pruritus, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2677, Description: dizziness, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-2634, Description: VAS assessment outside scheduled window, Severity: minor\n\n### Events\n- Subject retention call completed for 17 overdue visits\n- Randomization module updated for new enrollment block\n\n### Notes\n- Week 26: Pain management assessments on track. 109 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_027",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-02T10:30:00",
          "text": "## 2024-09-02 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 110\n- Active: 98\n- Screen Failures Cumulative: 60\n- Withdrawals Cumulative: 12\n\n### Enrollment By Treatment Arm\n- Multimodal: 35\n- Standard: 37\n- Placebo: 38\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.4\n- Multimodal VAS Pain Score SD: 1.4\n- Multimodal Morphine Equivalents (mg) Mean: 24.6\n- Multimodal Morphine Equivalents (mg) SD: 9.5\n- Multimodal Six MWT (meters) Mean: 379.0\n- Multimodal Six MWT (meters) SD: 59.0\n- Multimodal Grip Strength (kg) Mean: 29.0\n- Multimodal Grip Strength (kg) SD: 5.1\n- Multimodal Sleep Quality Index Mean: 6.2\n- Multimodal Sleep Quality Index SD: 1.0\n- Multimodal Rescue Med Doses per Week Mean: 2.8\n- Multimodal Rescue Med Doses per Week SD: 1.9\n\n- Standard VAS Pain Score Mean: 5.4\n- Standard VAS Pain Score SD: 1.4\n- Standard Morphine Equivalents (mg) Mean: 40.0\n- Standard Morphine Equivalents (mg) SD: 6.4\n- Standard Six MWT (meters) Mean: 324.0\n- Standard Six MWT (meters) SD: 51.0\n- Standard Grip Strength (kg) Mean: 22.9\n- Standard Grip Strength (kg) SD: 4.0\n- Standard Sleep Quality Index Mean: 4.9\n- Standard Sleep Quality Index SD: 1.4\n- Standard Rescue Med Doses per Week Mean: 4.5\n- Standard Rescue Med Doses per Week SD: 1.5\n\n- Placebo VAS Pain Score Mean: 6.6\n- Placebo VAS Pain Score SD: 1.2\n- Placebo Morphine Equivalents (mg) Mean: 49.5\n- Placebo Morphine Equivalents (mg) SD: 11.5\n- Placebo Six MWT (meters) Mean: 263.0\n- Placebo Six MWT (meters) SD: 57.0\n- Placebo Grip Strength (kg) Mean: 20.0\n- Placebo Grip Strength (kg) SD: 5.8\n- Placebo Sleep Quality Index Mean: 4.0\n- Placebo Sleep Quality Index SD: 0.9\n- Placebo Rescue Med Doses per Week Mean: 6.4\n- Placebo Rescue Med Doses per Week SD: 1.4\n\n### Physical Therapy\n- Sessions Scheduled: 229\n- Sessions Attended: 179\n- Attendance Rate (%): 90.2\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.9\n- Hemoglobin (g/dL) SD: 1.2\n- WBC (k) Mean: 5.6\n- WBC (k) SD: 1.5\n- Platelets (k) Mean: 236\n- Platelets (k) SD: 48\n- Serum Creatinine (mg/dL) Mean: 0.97\n- Serum Creatinine (mg/dL) SD: 0.12\n- Blood Glucose (mg/dL) Mean: 87.0\n- Blood Glucose (mg/dL) SD: 11.0\n- ESR (mm/hr) Mean: 13.0\n- ESR (mm/hr) SD: 9.0\n\n### Adverse Events\n- AE ID: PM-AE-2708, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: false, Treatment Arm: standard\n- AE ID: PM-AE-2744, Description: dry mouth, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2766, Description: pruritus, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-2731, Description: headache, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2723, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-2736, Description: Grip strength dynamometer calibration overdue by 3 days, Severity: moderate\n\n### Events\n- Blinded interim efficacy data compiled for DSMB\n- Site 02 monitoring visit completed, 0 findings\n- Randomization module updated for new enrollment block\n\n### Notes\n- Week 27: Pain management assessments on track. 110 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_028",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-04T10:30:00",
          "text": "## 2024-09-09 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 107\n- Active: 94\n- Screen Failures Cumulative: 60\n- Withdrawals Cumulative: 13\n\n### Enrollment by Treatment Arm\n- Multimodal: 36\n- Standard: 35\n- Placebo: 36\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.6\n- Multimodal VAS Pain Score SD: 1.8\n- Multimodal Morphine Equivalents (mg) Mean: 23.9\n- Multimodal Morphine Equivalents (mg) SD: 10.4\n- Multimodal Six MWT (meters) Mean: 373.0\n- Multimodal Six MWT (meters) SD: 55.0\n- Multimodal Grip Strength (kg) Mean: 27.8\n- Multimodal Grip Strength (kg) SD: 3.3\n- Multimodal Sleep Quality Index Mean: 6.0\n- Multimodal Sleep Quality Index SD: 1.2\n- Multimodal Rescue Med Doses per Week Mean: 1.7\n- Multimodal Rescue Med Doses per Week SD: 1.1\n\n- Standard VAS Pain Score Mean: 5.6\n- Standard VAS Pain Score SD: 1.7\n- Standard Morphine Equivalents (mg) Mean: 39.9\n- Standard Morphine Equivalents (mg) SD: 7.9\n- Standard Six MWT (meters) Mean: 326.0\n- Standard Six MWT (meters) SD: 42.0\n- Standard Grip Strength (kg) Mean: 24.0\n- Standard Grip Strength (kg) SD: 3.5\n- Standard Sleep Quality Index Mean: 4.7\n- Standard Sleep Quality Index SD: 1.2\n- Standard Rescue Med Doses per Week Mean: 4.8\n- Standard Rescue Med Doses per Week SD: 2.5\n\n- Placebo VAS Pain Score Mean: 6.2\n- Placebo VAS Pain Score SD: 1.3\n- Placebo Morphine Equivalents (mg) Mean: 49.3\n- Placebo Morphine Equivalents (mg) SD: 5.1\n- Placebo Six MWT (meters) Mean: 271.0\n- Placebo Six MWT (meters) SD: 48.0\n- Placebo Grip Strength (kg) Mean: 19.1\n- Placebo Grip Strength (kg) SD: 5.4\n- Placebo Sleep Quality Index Mean: 4.1\n- Placebo Sleep Quality Index SD: 1.2\n- Placebo Rescue Med Doses per Week Mean: 7.0\n- Placebo Rescue Med Doses per Week SD: 1.5\n\n### Physical Therapy\n- Sessions Scheduled: 224\n- Sessions Attended: 168\n- Attendance Rate (%): 82.9\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.6\n- Hemoglobin (g/dL) SD: 0.9\n- WBC (k) Mean: 8.0\n- WBC (k) SD: 1.7\n- Platelets (k) Mean: 226\n- Platelets (k) SD: 48\n- Serum Creatinine (mg/dL) Mean: 0.85\n- Serum Creatinine (mg/dL) SD: 0.19\n- Blood Glucose (mg/dL) Mean: 100.0\n- Blood Glucose (mg/dL) SD: 16.0\n- ESR (mm/hr) Mean: 10.0\n- ESR (mm/hr) SD: 9.0\n\n### Adverse Events\n- AE ID: PM-AE-2851, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2806, Description: constipation, Grade: 2, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2831, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-2854, Description: nausea, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: multimodal\n\n### Protocol Deviations\n- PD ID: PM-PD-2821, Description: Missed physical therapy session, not rescheduled within window, Severity: moderate\n- PD ID: PM-PD-2841, Description: Missed physical therapy session, not rescheduled within window, Severity: moderate\n\n### Events\n- Site 06 monitoring visit completed, 1 findings\n- Site 08 monitoring visit completed, 2 findings\n- Rescue medication supply restocked at 22 sites\n\n### Notes\n- Week 28: Pain management assessments on track. 107 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_010",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-06T10:00:00",
          "text": "## 2024-05-06 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 184\n- Active: 182\n- Screen Failures Cumulative: 20\n- Withdrawals Cumulative: 2\n\n#### Sites\n- Site 01 Enrolled: 18\n- Site 01 Active: 18\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 14\n- Site 02 Active: 14\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 17\n- Site 03 Active: 17\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 12\n- Site 04 Active: 12\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 15\n- Site 05 Active: 15\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 11\n- Site 06 Active: 11\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 20\n- Site 07 Active: 20\n- Site 07 Statin Concomitant: 5\n- Site 08 Enrolled: 14\n- Site 08 Active: 14\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 15\n- Site 09 Active: 15\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 12\n- Site 10 Active: 12\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 17\n- Site 11 Active: 17\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 14\n- Site 12 Active: 14\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 37.2\n- ALT (U/L) Median: 35.2\n- AST (U/L) Mean: 32.1\n- AST (U/L) Median: 30.9\n- Bilirubin (mg/dL) Mean: 0.68\n- Bilirubin (mg/dL) Median: 0.65\n- ALP (U/L) Mean: 65.1\n- ALP (U/L) Median: 62.3\n- Creatinine (mg/dL) Mean: 1.09\n- Creatinine (mg/dL) Median: 0.88\n- BUN (mg/dL) Mean: 17.8\n- BUN (mg/dL) Median: 16.4\n- WBC (K/\u00b5L) Mean: 6.3\n- WBC (K/\u00b5L) Median: 6.7\n- Platelets (K/\u00b5L) Mean: 245\n- Platelets (K/\u00b5L) Median: 228\n\n#### Non-Statin Subgroup\n- N: 132\n- ALT (U/L) Mean: 23.2\n- ALT (U/L) Median: 22.4\n- AST (U/L) Mean: 27.8\n- AST (U/L) Median: 25.9\n- Bilirubin (mg/dL) Mean: 0.4\n- Bilirubin (mg/dL) Median: 0.39\n- ALP (U/L) Mean: 59.6\n- ALP (U/L) Median: 48.6\n- Creatinine (mg/dL) Mean: 0.81\n- Creatinine (mg/dL) Median: 0.98\n- BUN (mg/dL) Mean: 13.4\n- BUN (mg/dL) Median: 12.1\n- WBC (K/\u00b5L) Mean: 8.4\n- WBC (K/\u00b5L) Median: 7.1\n- Platelets (K/\u00b5L) Mean: 261\n- Platelets (K/\u00b5L) Median: 236\n\n### Adverse Events\n- AE ID: AE-0029, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0030, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0031, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0032, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 30\n- Metformin Count: 24\n- PPI Count: 17\n- NSAID Count: 13\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-024, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_07\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- Subject retention rate within protocol targets\n- Statin subgroup lab review: ALT mean 42 U/L, within 1.5x ULN; monitoring per protocol\n\n### Events\n- EDC system maintenance window: 2h downtime Saturday 02:00 UTC\n- IP resupply shipped to Sites 11, 12\n- Site 12 monitoring visit completed, 4 findings\n\n### Notes\n- Week 10: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_029",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-06T10:30:00",
          "text": "## 2024-09-16 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 110\n- Active: 95\n- Screen Failures Cumulative: 68\n- Withdrawals Cumulative: 15\n\n### Enrollment By Treatment Arm\n- Multimodal: 36\n- Standard: 37\n- Placebo: 37\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.4\n- Multimodal VAS Pain Score SD: 1.5\n- Multimodal Morphine Equivalents (mg) Mean: 22.2\n- Multimodal Morphine Equivalents (mg) SD: 8.8\n- Multimodal Six Minute Walk Test (meters) Mean: 370.0\n- Multimodal Six Minute Walk Test (meters) SD: 40.0\n- Multimodal Grip Strength (kg) Mean: 27.8\n- Multimodal Grip Strength (kg) SD: 4.6\n- Multimodal Sleep Quality Index Mean: 6.2\n- Multimodal Sleep Quality Index SD: 1.3\n- Multimodal Rescue Med Doses per Week Mean: 2.2\n- Multimodal Rescue Med Doses per Week SD: 1.0\n\n- Standard VAS Pain Score Mean: 5.8\n- Standard VAS Pain Score SD: 1.1\n- Standard Morphine Equivalents (mg) Mean: 36.9\n- Standard Morphine Equivalents (mg) SD: 7.0\n- Standard Six Minute Walk Test (meters) Mean: 321.0\n- Standard Six Minute Walk Test (meters) SD: 44.0\n- Standard Grip Strength (kg) Mean: 23.6\n- Standard Grip Strength (kg) SD: 4.5\n- Standard Sleep Quality Index Mean: 4.9\n- Standard Sleep Quality Index SD: 1.0\n- Standard Rescue Med Doses per Week Mean: 3.8\n- Standard Rescue Med Doses per Week SD: 2.2\n\n- Placebo VAS Pain Score Mean: 6.2\n- Placebo VAS Pain Score SD: 1.9\n- Placebo Morphine Equivalents (mg) Mean: 48.9\n- Placebo Morphine Equivalents (mg) SD: 6.8\n- Placebo Six Minute Walk Test (meters) Mean: 263.0\n- Placebo Six Minute Walk Test (meters) SD: 39.0\n- Placebo Grip Strength (kg) Mean: 20.5\n- Placebo Grip Strength (kg) SD: 4.7\n- Placebo Sleep Quality Index Mean: 4.0\n- Placebo Sleep Quality Index SD: 0.8\n- Placebo Rescue Med Doses per Week Mean: 6.3\n- Placebo Rescue Med Doses per Week SD: 1.6\n\n### Physical Therapy\n- Sessions Scheduled: 214\n- Sessions Attended: 212\n- Attendance Rate (%): 89.3\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.2\n- Hemoglobin (g/dL) SD: 1.2\n- WBC (k) Mean: 7.3\n- WBC (k) SD: 1.1\n- Platelets (k) Mean: 228\n- Platelets (k) SD: 41\n- Serum Creatinine (mg/dL) Mean: 0.97\n- Serum Creatinine (mg/dL) SD: 0.16\n- Blood Glucose (mg/dL) Mean: 99.0\n- Blood Glucose (mg/dL) SD: 18.0\n- ESR (mm/hr) Mean: 9.0\n- ESR (mm/hr) SD: 4.0\n\n### Adverse Events\n- AE ID: PM-AE-2917, Description: muscle spasm, Grade: 1, Relatedness: probably related, Resolved: true, Treatment Arm: standard\n- AE ID: PM-AE-2986, Description: constipation, Grade: 2, Relatedness: possibly related, Resolved: false, Treatment Arm: standard\n- AE ID: PM-AE-2903, Description: diaphoresis, Grade: 2, Relatedness: possibly related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-2911, Description: Missed physical therapy session, not rescheduled within window, Severity: minor\n\n### Events\n- Site 07 monitoring visit completed, 0 findings\n- Opioid conversion table reference updated per FDA guidance\n\n### Notes\n- Week 29: Pain management assessments on track. 110 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_030",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-09T10:30:00",
          "text": "## 2024-09-23 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 108\n- Active: 95\n- Screen Failures Cumulative: 68\n- Withdrawals Cumulative: 13\n\n### Enrollment By Treatment Arm\n- Multimodal: 35\n- Standard: 35\n- Placebo: 38\n\n### Efficacy By Arm\n- Multimodal VAS Pain Score Mean: 4.4\n- Multimodal VAS Pain Score SD: 1.1\n- Multimodal Morphine Equivalents (mg) Mean: 21.0\n- Multimodal Morphine Equivalents (mg) SD: 8.5\n- Multimodal Six Minute Walk Test (meters) Mean: 381.0\n- Multimodal Six Minute Walk Test (meters) SD: 44.0\n- Multimodal Grip Strength (kg) Mean: 27.1\n- Multimodal Grip Strength (kg) SD: 4.6\n- Multimodal Sleep Quality Index Mean: 5.8\n- Multimodal Sleep Quality Index SD: 1.2\n- Multimodal Rescue Med Doses per Week Mean: 1.5\n- Multimodal Rescue Med Doses per Week SD: 2.5\n\n- Standard VAS Pain Score Mean: 5.6\n- Standard VAS Pain Score SD: 1.9\n- Standard Morphine Equivalents (mg) Mean: 39.7\n- Standard Morphine Equivalents (mg) SD: 11.2\n- Standard Six Minute Walk Test (meters) Mean: 322.0\n- Standard Six Minute Walk Test (meters) SD: 31.0\n- Standard Grip Strength (kg) Mean: 22.5\n- Standard Grip Strength (kg) SD: 5.4\n- Standard Sleep Quality Index Mean: 4.7\n- Standard Sleep Quality Index SD: 1.3\n- Standard Rescue Med Doses per Week Mean: 4.1\n- Standard Rescue Med Doses per Week SD: 1.7\n\n- Placebo VAS Pain Score Mean: 6.1\n- Placebo VAS Pain Score SD: 1.1\n- Placebo Morphine Equivalents (mg) Mean: 46.8\n- Placebo Morphine Equivalents (mg) SD: 8.2\n- Placebo Six Minute Walk Test (meters) Mean: 263.0\n- Placebo Six Minute Walk Test (meters) SD: 34.0\n- Placebo Grip Strength (kg) Mean: 20.5\n- Placebo Grip Strength (kg) SD: 5.5\n- Placebo Sleep Quality Index Mean: 4.2\n- Placebo Sleep Quality Index SD: 1.5\n- Placebo Rescue Med Doses per Week Mean: 6.2\n- Placebo Rescue Med Doses per Week SD: 1.3\n\n### Physical Therapy\n- Sessions Scheduled: 207\n- Sessions Attended: 178\n- Attendance Rate (%): 87.3\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 12.9\n- Hemoglobin (g/dL) SD: 1.0\n- WBC (k) Mean: 6.9\n- WBC (k) SD: 1.4\n- Platelets (k) Mean: 252\n- Platelets (k) SD: 42\n- Serum Creatinine (mg/dL) Mean: 0.97\n- Serum Creatinine (mg/dL) SD: 0.15\n- Blood Glucose (mg/dL) Mean: 108.0\n- Blood Glucose (mg/dL) SD: 17.0\n- ESR (mm/hr) Mean: 18.0\n- ESR (mm/hr) SD: 6.0\n\n### Adverse Events\n- AE ID: PM-AE-3013, Description: insomnia, Grade: 1, Relatedness: possibly related, Resolved: true, Treatment Arm: multimodal\n- AE ID: PM-AE-3069, Description: diaphoresis, Grade: 1, Relatedness: unlikely related, Resolved: true, Treatment Arm: standard\n\n### Protocol Deviations\n- PD ID: PM-PD-3031, Description: Missed physical therapy session, not rescheduled within window, Severity: minor\n- PD ID: PM-PD-3041, Description: Sleep diary not returned by subject, Severity: minor\n\n### Events\n- Blinded interim efficacy data compiled for DSMB\n- Functional assessment battery completed for 24 subjects this week\n- Pain diary electronic collection rate: 94%\n\n### Notes\n- Week 30: Pain management assessments on track. 108 subjects enrolled across treatment arms. Functional outcomes within expected ranges.",
          "meta": {
            "episode_type": "distractor",
            "theme": "pain_management_trial"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_031",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-11T10:30:00",
          "text": "## 2024-03-04 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 37\n- Active: 37\n- Screen Failures Cumulative: 2\n- Withdrawals Cumulative: 0\n\n#### By Cohort\n- 10mg: 6\n- 25mg: 9\n- 50mg: 10\n- 100mg: 12\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 0.95\n- KIM-1 (ng/mL) SD: 0.22\n- NGAL (ng/mL) Mean: 42.2\n- NGAL (ng/mL) SD: 12.6\n- Cystatin C (mg/L) Mean: 0.91\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 56.5\n- eGFR (mL/min) SD: 9.2\n- UACR (mg/g) Mean: 89.7\n- UACR (mg/g) SD: 27.5\n- Serum Creatinine (mg/dL) Mean: 1.33\n- Serum Creatinine (mg/dL) SD: 0.25\n- Urine Protein (mg/dL) Mean: 10.6\n- Urine Protein (mg/dL) SD: 4.4\n- Urine Output (mL/24h) Mean: 1716\n- Urine Output (mL/24h) SD: 389\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.58\n- KIM-1 (ng/mL) SD: 0.41\n- NGAL (ng/mL) Mean: 81.7\n- NGAL (ng/mL) SD: 17.0\n- Cystatin C (mg/L) Mean: 0.84\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 59.5\n- eGFR (mL/min) SD: 8.6\n- UACR (mg/g) Mean: 97.5\n- UACR (mg/g) SD: 18.3\n- Serum Creatinine (mg/dL) Mean: 1.04\n- Serum Creatinine (mg/dL) SD: 0.27\n- Urine Protein (mg/dL) Mean: 32.8\n- Urine Protein (mg/dL) SD: 8.6\n- Urine Output (mL/24h) Mean: 1783\n- Urine Output (mL/24h) SD: 391\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.54\n- KIM-1 (ng/mL) SD: 0.46\n- NGAL (ng/mL) Mean: 92.0\n- NGAL (ng/mL) SD: 19.9\n- Cystatin C (mg/L) Mean: 0.88\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 76.7\n- eGFR (mL/min) SD: 14.8\n- UACR (mg/g) Mean: 48.2\n- UACR (mg/g) SD: 24.8\n- Serum Creatinine (mg/dL) Mean: 1.17\n- Serum Creatinine (mg/dL) SD: 0.1\n- Urine Protein (mg/dL) Mean: 26.3\n- Urine Protein (mg/dL) SD: 8.6\n- Urine Output (mL/24h) Mean: 1876\n- Urine Output (mL/24h) SD: 402\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.05\n- KIM-1 (ng/mL) SD: 0.43\n- NGAL (ng/mL) Mean: 63.0\n- NGAL (ng/mL) SD: 12.6\n- Cystatin C (mg/L) Mean: 1.05\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 69.2\n- eGFR (mL/min) SD: 12.6\n- UACR (mg/g) Mean: 35.1\n- UACR (mg/g) SD: 26.7\n- Serum Creatinine (mg/dL) Mean: 1.28\n- Serum Creatinine (mg/dL) SD: 0.11\n- Urine Protein (mg/dL) Mean: 25.0\n- Urine Protein (mg/dL) SD: 6.1\n- Urine Output (mL/24h) Mean: 1794\n- Urine Output (mL/24h) SD: 363\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.482\n- NGAL Dose Correlation (r): 0.313\n- eGFR Dose Correlation (r): -0.214\n- UACR Dose Correlation (r): 0.355\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.0\n- Hemoglobin (g/dL) SD: 1.1\n- Hematocrit (%) Mean: 43.8\n- Hematocrit (%) SD: 2.7\n- WBC (k/\u00b5L) Mean: 6.0\n- WBC (k/\u00b5L) SD: 1.3\n- Platelets (k/\u00b5L) Mean: 238\n- Platelets (k/\u00b5L) SD: 41\n- Sodium (mEq/L) Mean: 139.9\n- Sodium (mEq/L) SD: 1.7\n- Potassium (mEq/L) Mean: 4.3\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 27.4\n- Bicarbonate (mEq/L) SD: 2.5\n- Phosphorus (mg/dL) Mean: 3.8\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-0176, Description: constipation, Grade: 2, Relatedness: unlikely related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-0173, Description: urinary tract infection, Grade: 1, Relatedness: possibly related, Resolved: true, Cohort: 50mg\n\n### Protocol Deviations\n- PD ID: RB-PD-0135, Description: Blood pressure measurement not recorded at visit, Severity: minor\n- PD ID: RB-PD-0112, Description: Lab kit expired, replacement used, Severity: minor\n\n### Events\n- Protocol training refresher completed for site coordinators\n- Site 01 monitoring visit completed, 3 findings\n- eCRF query resolution: 14 queries closed this week\n\n### Notes\n- Week 1: Renal biomarker collection on schedule. 37 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_011",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-13T10:00:00",
          "text": "## 2024-05-13 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 189\n- Active: 182\n- Screen Failures Cumulative: 27\n- Withdrawals Cumulative: 7\n\n#### Sites\n- Site 01\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 02\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 03\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 12\n  - Active: 12\n  - Statin Concomitant: 3\n- Site 05\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 06\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 21\n  - Active: 21\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 09\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 10\n  - Enrolled: 12\n  - Active: 12\n  - Statin Concomitant: 3\n- Site 11\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 5\n- Site 12\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 55\n- ALT (U/L) Mean: 47.6\n- ALT (U/L) Median: 47.4\n- AST (U/L) Mean: 35.8\n- AST (U/L) Median: 34.3\n- Bilirubin (mg/dL) Mean: 0.7\n- Bilirubin (mg/dL) Median: 0.67\n- ALP (U/L) Mean: 67.5\n- ALP (U/L) Median: 61.8\n- Creatinine (mg/dL) Mean: 0.8\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 13.5\n- BUN (mg/dL) Median: 15.1\n- WBC (K) Mean: 6.7\n- WBC (K) Median: 5.6\n- Platelets (K) Mean: 258\n- Platelets (K) Median: 256\n\n#### Non-Statin Subgroup\n- N: 132\n- ALT (U/L) Mean: 29.3\n- ALT (U/L) Median: 29.2\n- AST (U/L) Mean: 25.5\n- AST (U/L) Median: 25.2\n- Bilirubin (mg/dL) Mean: 0.46\n- Bilirubin (mg/dL) Median: 0.44\n- ALP (U/L) Mean: 53.2\n- ALP (U/L) Median: 50.8\n- Creatinine (mg/dL) Mean: 0.96\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 17.5\n- BUN (mg/dL) Median: 11.1\n- WBC (K) Mean: 6.7\n- WBC (K) Median: 7.4\n- Platelets (K) Mean: 247\n- Platelets (K) Median: 232\n\n### Adverse Events\n- AE ID: AE-0033\n  - Description: nausea\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0034\n  - Description: insomnia\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Subject Group: non_statin\n- AE ID: AE-0035\n  - Description: transaminase measurement out of range\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 51\n- ACE Inhibitor Count: 26\n- Metformin Count: 22\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 34\n\n### Protocol Deviations\n- PD ID: PD-025\n  - Description: Concomitant medication not recorded at visit\n  - Severity: minor\n  - Site: site_01\n\n### Investigator Notes\n- Subject retention rate within protocol targets\n- EDC data entry backlog cleared, queries resolved\n\n### Events\n- Drug accountability audit at Site 04: no discrepancies\n- Site 09 pharmacy temperature log reviewed: compliant\n- Central lab courier pickup schedule adjusted for holiday\n\n### Notes\n- Week 11: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_032",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-13T10:30:00",
          "text": "## 2024-03-11 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 46\n- Active: 46\n- Screen Failures Cumulative: 4\n- Withdrawals Cumulative: 0\n\n### Enrollment By Cohort\n- 10mg: 9\n- 25mg: 11\n- 50mg: 12\n- 100mg: 14\n\n### Biomarkers By Cohort\n- 10mg\n  - KIM1 (ng/mL) Mean: 1.45\n  - KIM1 (ng/mL) SD: 0.49\n  - NGAL (ng/mL) Mean: 83.2\n  - NGAL (ng/mL) SD: 13.6\n  - Cystatin C (mg/L) Mean: 0.86\n  - Cystatin C (mg/L) SD: 0.1\n  - eGFR (mL/min) Mean: 57.5\n  - eGFR (mL/min) SD: 14.1\n  - UACR (mg/g) Mean: 66.9\n  - UACR (mg/g) SD: 19.4\n  - Serum Creatinine (mg/dL) Mean: 1.48\n  - Serum Creatinine (mg/dL) SD: 0.29\n  - Urine Protein (mg/dL) Mean: 29.7\n  - Urine Protein (mg/dL) SD: 9.6\n  - Urine Output (mL/24h) Mean: 1641\n  - Urine Output (mL/24h) SD: 308\n- 25mg\n  - KIM1 (ng/mL) Mean: 1.74\n  - KIM1 (ng/mL) SD: 0.28\n  - NGAL (ng/mL) Mean: 45.7\n  - NGAL (ng/mL) SD: 15.5\n  - Cystatin C (mg/L) Mean: 1.04\n  - Cystatin C (mg/L) SD: 0.11\n  - eGFR (mL/min) Mean: 61.5\n  - eGFR (mL/min) SD: 10.9\n  - UACR (mg/g) Mean: 47.2\n  - UACR (mg/g) SD: 21.4\n  - Serum Creatinine (mg/dL) Mean: 1.4\n  - Serum Creatinine (mg/dL) SD: 0.14\n  - Urine Protein (mg/dL) Mean: 13.1\n  - Urine Protein (mg/dL) SD: 3.3\n  - Urine Output (mL/24h) Mean: 1991\n  - Urine Output (mL/24h) SD: 360\n- 50mg\n  - KIM1 (ng/mL) Mean: 1.1\n  - KIM1 (ng/mL) SD: 0.39\n  - NGAL (ng/mL) Mean: 48.2\n  - NGAL (ng/mL) SD: 18.6\n  - Cystatin C (mg/L) Mean: 0.93\n  - Cystatin C (mg/L) SD: 0.11\n  - eGFR (mL/min) Mean: 73.1\n  - eGFR (mL/min) SD: 8.6\n  - UACR (mg/g) Mean: 81.6\n  - UACR (mg/g) SD: 13.5\n  - Serum Creatinine (mg/dL) Mean: 1.31\n  - Serum Creatinine (mg/dL) SD: 0.24\n  - Urine Protein (mg/dL) Mean: 15.7\n  - Urine Protein (mg/dL) SD: 3.7\n  - Urine Output (mL/24h) Mean: 1651\n  - Urine Output (mL/24h) SD: 355\n- 100mg\n  - KIM1 (ng/mL) Mean: 2.69\n  - KIM1 (ng/mL) SD: 0.5\n  - NGAL (ng/mL) Mean: 73.4\n  - NGAL (ng/mL) SD: 10.6\n  - Cystatin C (mg/L) Mean: 1.26\n  - Cystatin C (mg/L) SD: 0.12\n  - eGFR (mL/min) Mean: 65.1\n  - eGFR (mL/min) SD: 10.0\n  - UACR (mg/g) Mean: 89.6\n  - UACR (mg/g) SD: 26.5\n  - Serum Creatinine (mg/dL) Mean: 1.4\n  - Serum Creatinine (mg/dL) SD: 0.24\n  - Urine Protein (mg/dL) Mean: 11.6\n  - Urine Protein (mg/dL) SD: 9.6\n  - Urine Output (mL/24h) Mean: 2016\n  - Urine Output (mL/24h) SD: 400\n\n### Dose Response\n- KIM1 Dose Correlation (r): 0.446\n- NGAL Dose Correlation (r): 0.514\n- eGFR Dose Correlation (r): -0.284\n- UACR Dose Correlation (r): 0.369\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.0\n- Hemoglobin (g/dL) SD: 0.8\n- Hematocrit (%) Mean: 43.6\n- Hematocrit (%) SD: 3.6\n- WBC (k/\u00b5L) Mean: 7.8\n- WBC (k/\u00b5L) SD: 1.1\n- Platelets (k/\u00b5L) Mean: 227\n- Platelets (k/\u00b5L) SD: 44\n- Sodium (mEq/L) Mean: 141.6\n- Sodium (mEq/L) SD: 2.2\n- Potassium (mEq/L) Mean: 4.7\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 24.9\n- Bicarbonate (mEq/L) SD: 2.4\n- Phosphorus (mg/dL) Mean: 3.8\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-0282, Description: urinary tract infection, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-0248, Description: nausea, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 25mg\n- AE ID: RB-AE-0282, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Cohort: 10mg\n\n### Protocol Deviations\n- PD ID: RB-PD-0226, Description: GFR measurement repeated due to hemolyzed sample, Severity: minor\n\n### Events\n- Protocol training refresher completed for site coordinators\n- Bioanalytical lab shipment: 33 frozen urine aliquots dispatched\n\n### Notes\n- Week 2: Renal biomarker collection on schedule. 46 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_033",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-15T10:30:00",
          "text": "## 2024-03-18 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 54\n- Active: 54\n- Screen Failures Cumulative: 6\n- Withdrawals Cumulative: 0\n\n### Enrollment By Cohort\n- 10mg: 10\n- 25mg: 13\n- 50mg: 15\n- 100mg: 16\n\n### Biomarkers By Cohort\n- 10mg\n  - KIM-1 (ng/ml) Mean: 1.58\n  - KIM-1 (ng/ml) SD: 0.38\n  - NGAL (ng/ml) Mean: 56.7\n  - NGAL (ng/ml) SD: 18.6\n  - Cystatin C (mg/L) Mean: 0.84\n  - Cystatin C (mg/L) SD: 0.1\n  - eGFR (ml/min) Mean: 63.6\n  - eGFR (ml/min) SD: 9.0\n  - UACR (mg/g) Mean: 57.4\n  - UACR (mg/g) SD: 32.9\n  - Serum Creatinine (mg/dl) Mean: 1.12\n  - Serum Creatinine (mg/dl) SD: 0.17\n  - Urine Protein (mg/dl) Mean: 36.6\n  - Urine Protein (mg/dl) SD: 5.2\n  - Urine Output (ml/24h) Mean: 1971\n  - Urine Output (ml/24h) SD: 361\n- 25mg\n  - KIM-1 (ng/ml) Mean: 1.06\n  - KIM-1 (ng/ml) SD: 0.47\n  - NGAL (ng/ml) Mean: 83.4\n  - NGAL (ng/ml) SD: 14.3\n  - Cystatin C (mg/L) Mean: 1.07\n  - Cystatin C (mg/L) SD: 0.11\n  - eGFR (ml/min) Mean: 52.4\n  - eGFR (ml/min) SD: 9.7\n  - UACR (mg/g) Mean: 89.0\n  - UACR (mg/g) SD: 31.5\n  - Serum Creatinine (mg/dl) Mean: 1.21\n  - Serum Creatinine (mg/dl) SD: 0.21\n  - Urine Protein (mg/dl) Mean: 32.0\n  - Urine Protein (mg/dl) SD: 3.7\n  - Urine Output (ml/24h) Mean: 1794\n  - Urine Output (ml/24h) SD: 312\n- 50mg\n  - KIM-1 (ng/ml) Mean: 2.72\n  - KIM-1 (ng/ml) SD: 0.38\n  - NGAL (ng/ml) Mean: 64.1\n  - NGAL (ng/ml) SD: 17.5\n  - Cystatin C (mg/L) Mean: 0.84\n  - Cystatin C (mg/L) SD: 0.09\n  - eGFR (ml/min) Mean: 57.7\n  - eGFR (ml/min) SD: 9.4\n  - UACR (mg/g) Mean: 80.1\n  - UACR (mg/g) SD: 30.2\n  - Serum Creatinine (mg/dl) Mean: 1.41\n  - Serum Creatinine (mg/dl) SD: 0.28\n  - Urine Protein (mg/dl) Mean: 16.9\n  - Urine Protein (mg/dl) SD: 9.4\n  - Urine Output (ml/24h) Mean: 1758\n  - Urine Output (ml/24h) SD: 305\n- 100mg\n  - KIM-1 (ng/ml) Mean: 1.59\n  - KIM-1 (ng/ml) SD: 0.28\n  - NGAL (ng/ml) Mean: 95.0\n  - NGAL (ng/ml) SD: 9.5\n  - Cystatin C (mg/L) Mean: 1.03\n  - Cystatin C (mg/L) SD: 0.12\n  - eGFR (ml/min) Mean: 51.5\n  - eGFR (ml/min) SD: 13.9\n  - UACR (mg/g) Mean: 85.1\n  - UACR (mg/g) SD: 18.1\n  - Serum Creatinine (mg/dl) Mean: 1.33\n  - Serum Creatinine (mg/dl) SD: 0.23\n  - Urine Protein (mg/dl) Mean: 22.3\n  - Urine Protein (mg/dl) SD: 7.8\n  - Urine Output (ml/24h) Mean: 1774\n  - Urine Output (ml/24h) SD: 396\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.565\n- NGAL Dose Correlation (r): 0.261\n- eGFR Dose Correlation (r): -0.348\n- UACR Dose Correlation (r): 0.24\n\n### Safety Labs\n- Hemoglobin (g/dl) Mean: 14.6\n- Hemoglobin (g/dl) SD: 1.0\n- Hematocrit (%) Mean: 39.2\n- Hematocrit (%) SD: 3.7\n- WBC (k) Mean: 8.1\n- WBC (k) SD: 1.2\n- Platelets (k) Mean: 214\n- Platelets (k) SD: 45\n- Sodium (meq/L) Mean: 138.3\n- Sodium (meq/L) SD: 2.3\n- Potassium (meq/L) Mean: 4.1\n- Potassium (meq/L) SD: 0.3\n- Bicarbonate (meq/L) Mean: 26.4\n- Bicarbonate (meq/L) SD: 2.9\n- Phosphorus (mg/dl) Mean: 3.3\n- Phosphorus (mg/dl) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-0306, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Cohort: 25mg\n- AE ID: RB-AE-0336, Description: headache, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 50mg\n\n### Protocol Deviations\n- PD ID: RB-PD-0332, Description: Urine sample collection outside 24h window, Severity: moderate\n- PD ID: RB-PD-0330, Description: Dose adjustment documentation incomplete, Severity: moderate\n\n### Events\n- Central lab urine biomarker batch analysis completed for Week 3\n- DSMB safety data snapshot prepared\n- Central lab urine biomarker batch analysis completed for Week 3\n\n### Notes\n- Week 3: Renal biomarker collection on schedule. 54 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_034",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-18T10:30:00",
          "text": "## 2024-03-25 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 64\n- Active: 63\n- Screen Failures Cumulative: 7\n- Withdrawals Cumulative: 1\n\n### Enrollment By Cohort\n- 10mg: 14\n- 25mg: 16\n- 50mg: 16\n- 100mg: 18\n\n### Biomarkers By Cohort\n- 10mg\n  - KIM-1 (ng/mL) Mean: 2.31\n  - KIM-1 (ng/mL) SD: 0.25\n  - NGAL (ng/mL) Mean: 70.9\n  - NGAL (ng/mL) SD: 11.9\n  - Cys-C (mg/L) Mean: 1.02\n  - Cys-C (mg/L) SD: 0.1\n  - eGFR (mL/min) Mean: 74.2\n  - eGFR (mL/min) SD: 10.8\n  - UACR (mg/g) Mean: 82.7\n  - UACR (mg/g) SD: 29.9\n  - Serum Creatinine (mg/dL) Mean: 1.27\n  - Serum Creatinine (mg/dL) SD: 0.16\n  - Urine Protein (mg/dL) Mean: 31.1\n  - Urine Protein (mg/dL) SD: 9.0\n  - Urine Output (mL/24h) Mean: 1814\n  - Urine Output (mL/24h) SD: 366\n- 25mg\n  - KIM-1 (ng/mL) Mean: 0.9\n  - KIM-1 (ng/mL) SD: 0.31\n  - NGAL (ng/mL) Mean: 42.6\n  - NGAL (ng/mL) SD: 12.8\n  - Cys-C (mg/L) Mean: 0.95\n  - Cys-C (mg/L) SD: 0.14\n  - eGFR (mL/min) Mean: 55.6\n  - eGFR (mL/min) SD: 14.5\n  - UACR (mg/g) Mean: 83.7\n  - UACR (mg/g) SD: 32.9\n  - Serum Creatinine (mg/dL) Mean: 1.24\n  - Serum Creatinine (mg/dL) SD: 0.13\n  - Urine Protein (mg/dL) Mean: 23.1\n  - Urine Protein (mg/dL) SD: 3.5\n  - Urine Output (mL/24h) Mean: 1892\n  - Urine Output (mL/24h) SD: 370\n- 50mg\n  - KIM-1 (ng/mL) Mean: 2.55\n  - KIM-1 (ng/mL) SD: 0.29\n  - NGAL (ng/mL) Mean: 88.0\n  - NGAL (ng/mL) SD: 15.7\n  - Cys-C (mg/L) Mean: 0.79\n  - Cys-C (mg/L) SD: 0.12\n  - eGFR (mL/min) Mean: 57.2\n  - eGFR (mL/min) SD: 14.8\n  - UACR (mg/g) Mean: 44.2\n  - UACR (mg/g) SD: 10.6\n  - Serum Creatinine (mg/dL) Mean: 1.49\n  - Serum Creatinine (mg/dL) SD: 0.28\n  - Urine Protein (mg/dL) Mean: 39.8\n  - Urine Protein (mg/dL) SD: 9.5\n  - Urine Output (mL/24h) Mean: 1713\n  - Urine Output (mL/24h) SD: 301\n- 100mg\n  - KIM-1 (ng/mL) Mean: 1.3\n  - KIM-1 (ng/mL) SD: 0.28\n  - NGAL (ng/mL) Mean: 51.0\n  - NGAL (ng/mL) SD: 11.6\n  - Cys-C (mg/L) Mean: 0.82\n  - Cys-C (mg/L) SD: 0.08\n  - eGFR (mL/min) Mean: 52.9\n  - eGFR (mL/min) SD: 14.0\n  - UACR (mg/g) Mean: 124.4\n  - UACR (mg/g) SD: 21.4\n  - Serum Creatinine (mg/dL) Mean: 1.42\n  - Serum Creatinine (mg/dL) SD: 0.24\n  - Urine Protein (mg/dL) Mean: 28.9\n  - Urine Protein (mg/dL) SD: 4.7\n  - Urine Output (mL/24h) Mean: 1927\n  - Urine Output (mL/24h) SD: 361\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.316\n- NGAL Dose Correlation (r): 0.452\n- eGFR Dose Correlation (r): -0.451\n- UACR Dose Correlation (r): 0.254\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.2\n- Hemoglobin (g/dL) SD: 1.4\n- Hematocrit (%) Mean: 43.9\n- Hematocrit (%) SD: 3.0\n- WBC (k/\u00b5L) Mean: 7.1\n- WBC (k/\u00b5L) SD: 1.1\n- Platelets (k/\u00b5L) Mean: 234\n- Platelets (k/\u00b5L) SD: 42\n- Sodium (mEq/L) Mean: 138.6\n- Sodium (mEq/L) SD: 2.6\n- Potassium (mEq/L) Mean: 4.2\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 23.5\n- Bicarbonate (mEq/L) SD: 2.5\n- Phosphorus (mg/dL) Mean: 3.6\n- Phosphorus (mg/dL) SD: 0.4\n\n### Adverse Events\n- AE ID: RB-AE-0474, Description: urinary tract infection, Grade: 1, Relatedness: possibly related, Resolved: true, Cohort: 25mg\n- AE ID: RB-AE-0455, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-0416, Description: muscle cramp, Grade: 2, Relatedness: not related, Resolved: true, Cohort: 100mg\n\n### Protocol Deviations\n- PD ID: RB-PD-0428, Description: GFR measurement repeated due to hemolyzed sample, Severity: moderate\n- PD ID: RB-PD-0432, Description: Urine sample collection outside 24h window, Severity: minor\n\n### Events\n- Site 01 monitoring visit completed, 1 findings\n- Lab kit resupply dispatched to sites with low inventory\n- Lab kit resupply dispatched to sites with low inventory\n\n### Notes\n- Week 4: Renal biomarker collection on schedule. 64 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_012",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-20T10:00:00",
          "text": "## 2024-05-20 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 192\n- Active: 186\n- Screen Failures Cumulative: 21\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 02\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 03\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 3\n- Site 05\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 21\n  - Active: 21\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 4\n- Site 12\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n\n### Lab Panels\n- Statin Subgroup\n  - N: 51\n  - ALT (U/L) Mean: 47.2\n  - ALT (U/L) Median: 45.7\n  - AST (U/L) Mean: 41.0\n  - AST (U/L) Median: 41.0\n  - Bilirubin (mg/dL) Mean: 0.73\n  - Bilirubin (mg/dL) Median: 0.72\n  - ALP (U/L) Mean: 61.9\n  - ALP (U/L) Median: 56.0\n  - Creatinine (mg/dL) Mean: 1.07\n  - Creatinine (mg/dL) Median: 0.92\n  - BUN (mg/dL) Mean: 16.8\n  - BUN (mg/dL) Median: 15.4\n  - WBC (K) Mean: 7.7\n  - WBC (K) Median: 7.1\n  - Platelets (K) Mean: 257\n  - Platelets (K) Median: 250\n- Non-Statin Subgroup\n  - N: 123\n  - ALT (U/L) Mean: 22.0\n  - ALT (U/L) Median: 21.4\n  - AST (U/L) Mean: 23.5\n  - AST (U/L) Median: 22.1\n  - Bilirubin (mg/dL) Mean: 0.66\n  - Bilirubin (mg/dL) Median: 0.61\n  - ALP (U/L) Mean: 55.2\n  - ALP (U/L) Median: 61.9\n  - Creatinine (mg/dL) Mean: 1.06\n  - Creatinine (mg/dL) Median: 0.98\n  - BUN (mg/dL) Mean: 14.8\n  - BUN (mg/dL) Median: 12.3\n  - WBC (K) Mean: 6.7\n  - WBC (K) Median: 5.6\n  - Platelets (K) Mean: 234\n  - Platelets (K) Median: 221\n\n### Adverse Events\n- AE ID: AE-0036\n  - Description: insomnia\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0037\n  - Description: upper respiratory infection\n  - Grade: 1\n  - Relatedness: not related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0038\n  - Description: abdominal discomfort\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0039\n  - Description: transaminase measurement out of range\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 54\n- ACE Inhibitor Count: 30\n- Metformin Count: 23\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-026\n  - Description: Dose modification without documented PI approval\n  - Severity: moderate\n  - Site: site_07\n\n### Investigator Notes\n- Source document verification complete for prior monitoring visit\n- EDC data entry backlog cleared, queries resolved\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- Bioanalytical lab shipment tracking confirmed for 2 samples\n- Site 03 new coordinator onboarding completed\n\n### Notes\n- Week 12: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_035",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-20T10:30:00",
          "text": "## 2024-04-01 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 70\n- Active: 68\n- Screen Failures Cumulative: 10\n- Withdrawals Cumulative: 2\n\n### Enrollment by Cohort\n- 10mg: 14\n- 25mg: 16\n- 50mg: 19\n- 100mg: 21\n\n### Biomarkers By Cohort\n- 10mg\n  - KIM1 (ng/mL) Mean: 1.93\n  - KIM1 (ng/mL) SD: 0.22\n  - NGAL (ng/mL) Mean: 78.9\n  - NGAL (ng/mL) SD: 19.1\n  - Cystatin C (mg/L) Mean: 1.09\n  - Cystatin C (mg/L) SD: 0.08\n  - eGFR (mL/min) Mean: 64.9\n  - eGFR (mL/min) SD: 11.5\n  - UACR (mg/g) Mean: 40.3\n  - UACR (mg/g) SD: 31.6\n  - Serum Creatinine (mg/dL) Mean: 1.06\n  - Serum Creatinine (mg/dL) SD: 0.29\n  - Urine Protein (mg/dL) Mean: 14.0\n  - Urine Protein (mg/dL) SD: 3.9\n  - Urine Output (mL/24h) Mean: 1795\n  - Urine Output (mL/24h) SD: 326\n- 25mg\n  - KIM1 (ng/mL) Mean: 1.23\n  - KIM1 (ng/mL) SD: 0.44\n  - NGAL (ng/mL) Mean: 92.8\n  - NGAL (ng/mL) SD: 12.6\n  - Cystatin C (mg/L) Mean: 1.07\n  - Cystatin C (mg/L) SD: 0.09\n  - eGFR (mL/min) Mean: 53.7\n  - eGFR (mL/min) SD: 13.4\n  - UACR (mg/g) Mean: 81.8\n  - UACR (mg/g) SD: 22.8\n  - Serum Creatinine (mg/dL) Mean: 1.23\n  - Serum Creatinine (mg/dL) SD: 0.17\n  - Urine Protein (mg/dL) Mean: 25.1\n  - Urine Protein (mg/dL) SD: 5.4\n  - Urine Output (mL/24h) Mean: 1647\n  - Urine Output (mL/24h) SD: 397\n- 50mg\n  - KIM1 (ng/mL) Mean: 1.46\n  - KIM1 (ng/mL) SD: 0.24\n  - NGAL (ng/mL) Mean: 53.4\n  - NGAL (ng/mL) SD: 16.7\n  - Cystatin C (mg/L) Mean: 1.0\n  - Cystatin C (mg/L) SD: 0.14\n  - eGFR (mL/min) Mean: 66.6\n  - eGFR (mL/min) SD: 12.7\n  - UACR (mg/g) Mean: 115.9\n  - UACR (mg/g) SD: 30.6\n  - Serum Creatinine (mg/dL) Mean: 1.45\n  - Serum Creatinine (mg/dL) SD: 0.19\n  - Urine Protein (mg/dL) Mean: 31.5\n  - Urine Protein (mg/dL) SD: 6.4\n  - Urine Output (mL/24h) Mean: 1818\n  - Urine Output (mL/24h) SD: 387\n- 100mg\n  - KIM1 (ng/mL) Mean: 1.34\n  - KIM1 (ng/mL) SD: 0.55\n  - NGAL (ng/mL) Mean: 60.5\n  - NGAL (ng/mL) SD: 16.9\n  - Cystatin C (mg/L) Mean: 1.04\n  - Cystatin C (mg/L) SD: 0.09\n  - eGFR (mL/min) Mean: 55.1\n  - eGFR (mL/min) SD: 11.6\n  - UACR (mg/g) Mean: 115.3\n  - UACR (mg/g) SD: 21.6\n  - Serum Creatinine (mg/dL) Mean: 1.28\n  - Serum Creatinine (mg/dL) SD: 0.11\n  - Urine Protein (mg/dL) Mean: 23.9\n  - Urine Protein (mg/dL) SD: 6.4\n  - Urine Output (mL/24h) Mean: 1668\n  - Urine Output (mL/24h) SD: 349\n\n### Dose Response\n- KIM1 Dose Correlation (r): 0.325\n- NGAL Dose Correlation (r): 0.21\n- eGFR Dose Correlation (r): -0.316\n- UACR Dose Correlation (r): 0.438\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.6\n- Hemoglobin (g/dL) SD: 1.4\n- Hematocrit (%) Mean: 41.8\n- Hematocrit (%) SD: 2.4\n- WBC (k/\u00b5L) Mean: 5.6\n- WBC (k/\u00b5L) SD: 1.8\n- Platelets (k/\u00b5L) Mean: 248\n- Platelets (k/\u00b5L) SD: 48\n- Sodium (mEq/L) Mean: 142.5\n- Sodium (mEq/L) SD: 1.9\n- Potassium (mEq/L) Mean: 3.9\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 24.8\n- Bicarbonate (mEq/L) SD: 2.6\n- Phosphorus (mg/dL) Mean: 3.4\n- Phosphorus (mg/dL) SD: 0.6\n\n### Adverse Events\n- AE ID: RB-AE-0549, Description: hyperkalemia, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-0541, Description: constipation, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 50mg\n\n### Protocol Deviations\n- PD ID: RB-PD-0547, Description: Urine sample collection outside 24h window, Severity: minor\n\n### Events\n- Lab kit resupply dispatched to sites with low inventory\n- Central lab urine biomarker batch analysis completed for Week 5\n- Renal ultrasound images uploaded to central imaging core\n\n### Notes\n- Week 5: Renal biomarker collection on schedule. 70 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_036",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-22T10:30:00",
          "text": "## 2024-04-08 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 73\n- Active: 71\n- Screen Failures Cumulative: 10\n- Withdrawals Cumulative: 2\n\n### Enrollment By Cohort\n- 10mg: 16\n- 25mg: 17\n- 50mg: 18\n- 100mg: 22\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 1.86\n- KIM-1 (ng/mL) SD: 0.33\n- NGAL (ng/mL) Mean: 54.1\n- NGAL (ng/mL) SD: 13.8\n- Cystatin C (mg/L) Mean: 0.85\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 73.8\n- eGFR (mL/min) SD: 11.7\n- UACR (mg/g) Mean: 52.4\n- UACR (mg/g) SD: 17.7\n- Serum Creatinine (mg/dL) Mean: 1.44\n- Serum Creatinine (mg/dL) SD: 0.23\n- Urine Protein (mg/dL) Mean: 14.3\n- Urine Protein (mg/dL) SD: 4.7\n- Urine Output (mL/24h) Mean: 1954\n- Urine Output (mL/24h) SD: 400\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 2.24\n- KIM-1 (ng/mL) SD: 0.46\n- NGAL (ng/mL) Mean: 90.8\n- NGAL (ng/mL) SD: 16.6\n- Cystatin C (mg/L) Mean: 1.14\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 58.8\n- eGFR (mL/min) SD: 14.9\n- UACR (mg/g) Mean: 74.3\n- UACR (mg/g) SD: 26.3\n- Serum Creatinine (mg/dL) Mean: 1.34\n- Serum Creatinine (mg/dL) SD: 0.12\n- Urine Protein (mg/dL) Mean: 28.9\n- Urine Protein (mg/dL) SD: 9.6\n- Urine Output (mL/24h) Mean: 1666\n- Urine Output (mL/24h) SD: 341\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.72\n- KIM-1 (ng/mL) SD: 0.4\n- NGAL (ng/mL) Mean: 54.1\n- NGAL (ng/mL) SD: 19.7\n- Cystatin C (mg/L) Mean: 1.01\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 76.3\n- eGFR (mL/min) SD: 14.2\n- UACR (mg/g) Mean: 69.6\n- UACR (mg/g) SD: 28.6\n- Serum Creatinine (mg/dL) Mean: 1.13\n- Serum Creatinine (mg/dL) SD: 0.1\n- Urine Protein (mg/dL) Mean: 17.0\n- Urine Protein (mg/dL) SD: 7.4\n- Urine Output (mL/24h) Mean: 1899\n- Urine Output (mL/24h) SD: 298\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.63\n- KIM-1 (ng/mL) SD: 0.57\n- NGAL (ng/mL) Mean: 62.6\n- NGAL (ng/mL) SD: 8.5\n- Cystatin C (mg/L) Mean: 1.07\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 61.0\n- eGFR (mL/min) SD: 10.2\n- UACR (mg/g) Mean: 104.9\n- UACR (mg/g) SD: 16.2\n- Serum Creatinine (mg/dL) Mean: 1.24\n- Serum Creatinine (mg/dL) SD: 0.24\n- Urine Protein (mg/dL) Mean: 22.0\n- Urine Protein (mg/dL) SD: 4.6\n- Urine Output (mL/24h) Mean: 1872\n- Urine Output (mL/24h) SD: 384\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.545\n- NGAL Dose Correlation (r): 0.334\n- eGFR Dose Correlation (r): -0.165\n- UACR Dose Correlation (r): 0.279\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.6\n- Hemoglobin (g/dL) SD: 1.3\n- Hematocrit (%) Mean: 42.3\n- Hematocrit (%) SD: 3.2\n- WBC (k/\u00b5L) Mean: 7.5\n- WBC (k/\u00b5L) SD: 1.8\n- Platelets (k/\u00b5L) Mean: 237\n- Platelets (k/\u00b5L) SD: 41\n- Sodium (mEq/L) Mean: 137.9\n- Sodium (mEq/L) SD: 1.7\n- Potassium (mEq/L) Mean: 4.4\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 27.0\n- Bicarbonate (mEq/L) SD: 2.4\n- Phosphorus (mg/dL) Mean: 4.1\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-0638, Description: dizziness, Grade: 2, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-0610, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 25mg\n\n### Protocol Deviations\n- PD ID: RB-PD-0641, Description: Dose adjustment documentation incomplete, Severity: minor\n- PD ID: RB-PD-0619, Description: Dose adjustment documentation incomplete, Severity: minor\n\n### Events\n- Site 03 monitoring visit completed, 0 findings\n- eCRF query resolution: 13 queries closed this week\n\n### Notes\n- Week 6: Renal biomarker collection on schedule. 73 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_037",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-25T10:30:00",
          "text": "## 2024-04-15 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 71\n- Active: 68\n- Screen Failures Cumulative: 13\n- Withdrawals Cumulative: 3\n\n#### By Cohort\n- 10mg: 15\n- 25mg: 16\n- 50mg: 18\n- 100mg: 22\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 2.32\n- KIM-1 (ng/mL) SD: 0.5\n- NGAL (ng/mL) Mean: 54.1\n- NGAL (ng/mL) SD: 18.7\n- Cystatin C (mg/L) Mean: 1.04\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 59.5\n- eGFR (mL/min) SD: 10.1\n- UACR (mg/g) Mean: 102.9\n- UACR (mg/g) SD: 23.0\n- Serum Creatinine (mg/dL) Mean: 1.43\n- Serum Creatinine (mg/dL) SD: 0.23\n- Urine Protein (mg/dL) Mean: 44.1\n- Urine Protein (mg/dL) SD: 3.5\n- Urine Output (mL/24h) Mean: 1928\n- Urine Output (mL/24h) SD: 339\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 2.14\n- KIM-1 (ng/mL) SD: 0.43\n- NGAL (ng/mL) Mean: 83.0\n- NGAL (ng/mL) SD: 16.2\n- Cystatin C (mg/L) Mean: 0.83\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 66.8\n- eGFR (mL/min) SD: 14.8\n- UACR (mg/g) Mean: 72.9\n- UACR (mg/g) SD: 12.5\n- Serum Creatinine (mg/dL) Mean: 1.45\n- Serum Creatinine (mg/dL) SD: 0.19\n- Urine Protein (mg/dL) Mean: 23.1\n- Urine Protein (mg/dL) SD: 5.6\n- Urine Output (mL/24h) Mean: 1778\n- Urine Output (mL/24h) SD: 345\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 2.27\n- KIM-1 (ng/mL) SD: 0.32\n- NGAL (ng/mL) Mean: 70.3\n- NGAL (ng/mL) SD: 10.5\n- Cystatin C (mg/L) Mean: 1.0\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 69.5\n- eGFR (mL/min) SD: 9.3\n- UACR (mg/g) Mean: 123.0\n- UACR (mg/g) SD: 26.7\n- Serum Creatinine (mg/dL) Mean: 1.3\n- Serum Creatinine (mg/dL) SD: 0.16\n- Urine Protein (mg/dL) Mean: 30.6\n- Urine Protein (mg/dL) SD: 9.2\n- Urine Output (mL/24h) Mean: 1927\n- Urine Output (mL/24h) SD: 341\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.36\n- KIM-1 (ng/mL) SD: 0.57\n- NGAL (ng/mL) Mean: 64.1\n- NGAL (ng/mL) SD: 19.6\n- Cystatin C (mg/L) Mean: 1.24\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 48.8\n- eGFR (mL/min) SD: 10.5\n- UACR (mg/g) Mean: 112.0\n- UACR (mg/g) SD: 20.6\n- Serum Creatinine (mg/dL) Mean: 1.26\n- Serum Creatinine (mg/dL) SD: 0.29\n- Urine Protein (mg/dL) Mean: 30.6\n- Urine Protein (mg/dL) SD: 6.0\n- Urine Output (mL/24h) Mean: 1739\n- Urine Output (mL/24h) SD: 396\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.36\n- NGAL Dose Correlation (r): 0.293\n- eGFR Dose Correlation (r): -0.405\n- UACR Dose Correlation (r): 0.348\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.1\n- Hemoglobin (g/dL) SD: 1.4\n- Hematocrit (%) Mean: 41.6\n- Hematocrit (%) SD: 2.3\n- WBC (k/\u00b5L) Mean: 6.3\n- WBC (k/\u00b5L) SD: 1.6\n- Platelets (k/\u00b5L) Mean: 231\n- Platelets (k/\u00b5L) SD: 42\n- Sodium (mEq/L) Mean: 141.5\n- Sodium (mEq/L) SD: 1.5\n- Potassium (mEq/L) Mean: 4.2\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 22.5\n- Bicarbonate (mEq/L) SD: 1.5\n- Phosphorus (mg/dL) Mean: 3.5\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-0747, Description: back pain, Grade: 1, Relatedness: possibly related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-0755, Description: nausea, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 25mg\n\n### Protocol Deviations\n- PD ID: RB-PD-0730, Description: Dose adjustment documentation incomplete, Severity: minor\n\n### Events\n- eCRF query resolution: 20 queries closed this week\n- Site 06 monitoring visit completed, 3 findings\n- Lab kit resupply dispatched to sites with low inventory\n\n### Notes\n- Week 7: Renal biomarker collection on schedule. 71 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_013",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-27T10:00:00",
          "text": "## 2024-05-27 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 195\n- Active: 191\n- Screen Failures Cumulative: 29\n- Withdrawals Cumulative: 4\n\n#### Sites\n- Site 01\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 02\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 03\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 05\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 06\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 21\n  - Active: 21\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 12\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 52.4\n- ALT (U/L) Median: 50.8\n- AST (U/L) Mean: 45.0\n- AST (U/L) Median: 44.3\n- Bilirubin (mg/dL) Mean: 0.84\n- Bilirubin (mg/dL) Median: 0.82\n- ALP (U/L) Mean: 63.5\n- ALP (U/L) Median: 55.7\n- Creatinine (mg/dL) Mean: 0.83\n- Creatinine (mg/dL) Median: 0.85\n- BUN (mg/dL) Mean: 17.5\n- BUN (mg/dL) Median: 12.2\n- WBC (K) Mean: 8.4\n- WBC (K) Median: 5.7\n- Platelets (K) Mean: 238\n- Platelets (K) Median: 231\n\n#### Non-Statin Subgroup\n- N: 124\n- ALT (U/L) Mean: 20.7\n- ALT (U/L) Median: 20.4\n- AST (U/L) Mean: 18.1\n- AST (U/L) Median: 17.2\n- Bilirubin (mg/dL) Mean: 0.69\n- Bilirubin (mg/dL) Median: 0.66\n- ALP (U/L) Mean: 68.1\n- ALP (U/L) Median: 60.8\n- Creatinine (mg/dL) Mean: 0.84\n- Creatinine (mg/dL) Median: 0.88\n- BUN (mg/dL) Mean: 17.1\n- BUN (mg/dL) Median: 14.5\n- WBC (K) Mean: 8.5\n- WBC (K) Median: 5.6\n- Platelets (K) Mean: 218\n- Platelets (K) Median: 232\n\n### Adverse Events\n- AE ID: AE-0040, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0041, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0042, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0043, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0044, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 29\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-027, Description: Missed visit window (3 days late), Severity: minor, Site: site_01\n- PD ID: PD-028, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_08\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- All CRFs current through prior visit cycle\n- Statin co-administered cohort ALT mean 58 U/L; values remain below 2x ULN action threshold\n\n### Events\n- IP resupply shipped to Sites 06, 02\n- Site 10 monitoring visit completed, 2 findings\n\n### Notes\n- Week 13: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_038",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-27T10:30:00",
          "text": "## 2024-04-22 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 73\n- Active: 70\n- Screen Failures Cumulative: 18\n- Withdrawals Cumulative: 3\n\n### Enrollment By Cohort\n- 10mg: 14\n- 25mg: 18\n- 50mg: 20\n- 100mg: 21\n\n### Biomarkers By Cohort\n- 10mg\n  - KIM1 (ng/mL) Mean: 1.84\n  - KIM1 (ng/mL) SD: 0.58\n  - NGAL (ng/mL) Mean: 73.1\n  - NGAL (ng/mL) SD: 14.2\n  - CysC (mg/L) Mean: 1.07\n  - CysC (mg/L) SD: 0.09\n  - eGFR (mL/min) Mean: 73.8\n  - eGFR (mL/min) SD: 13.4\n  - UACR (mg/g) Mean: 32.6\n  - UACR (mg/g) SD: 10.2\n  - Serum Creatinine (mg/dL) Mean: 1.24\n  - Serum Creatinine (mg/dL) SD: 0.21\n  - Urine Protein (mg/dL) Mean: 36.7\n  - Urine Protein (mg/dL) SD: 4.7\n  - Urine Output (mL/24h) Mean: 1686\n  - Urine Output (mL/24h) SD: 376\n- 25mg\n  - KIM1 (ng/mL) Mean: 1.1\n  - KIM1 (ng/mL) SD: 0.23\n  - NGAL (ng/mL) Mean: 54.0\n  - NGAL (ng/mL) SD: 19.6\n  - CysC (mg/L) Mean: 0.94\n  - CysC (mg/L) SD: 0.1\n  - eGFR (mL/min) Mean: 79.8\n  - eGFR (mL/min) SD: 9.3\n  - UACR (mg/g) Mean: 109.1\n  - UACR (mg/g) SD: 33.5\n  - Serum Creatinine (mg/dL) Mean: 1.33\n  - Serum Creatinine (mg/dL) SD: 0.14\n  - Urine Protein (mg/dL) Mean: 21.2\n  - Urine Protein (mg/dL) SD: 9.5\n  - Urine Output (mL/24h) Mean: 1613\n  - Urine Output (mL/24h) SD: 301\n- 50mg\n  - KIM1 (ng/mL) Mean: 1.55\n  - KIM1 (ng/mL) SD: 0.27\n  - NGAL (ng/mL) Mean: 69.2\n  - NGAL (ng/mL) SD: 8.4\n  - CysC (mg/L) Mean: 1.09\n  - CysC (mg/L) SD: 0.13\n  - eGFR (mL/min) Mean: 69.4\n  - eGFR (mL/min) SD: 10.2\n  - UACR (mg/g) Mean: 55.0\n  - UACR (mg/g) SD: 11.1\n  - Serum Creatinine (mg/dL) Mean: 1.22\n  - Serum Creatinine (mg/dL) SD: 0.26\n  - Urine Protein (mg/dL) Mean: 36.6\n  - Urine Protein (mg/dL) SD: 4.7\n  - Urine Output (mL/24h) Mean: 1821\n  - Urine Output (mL/24h) SD: 380\n- 100mg\n  - KIM1 (ng/mL) Mean: 2.74\n  - KIM1 (ng/mL) SD: 0.21\n  - NGAL (ng/mL) Mean: 87.8\n  - NGAL (ng/mL) SD: 18.6\n  - CysC (mg/L) Mean: 0.89\n  - CysC (mg/L) SD: 0.12\n  - eGFR (mL/min) Mean: 49.1\n  - eGFR (mL/min) SD: 11.0\n  - UACR (mg/g) Mean: 62.7\n  - UACR (mg/g) SD: 28.8\n  - Serum Creatinine (mg/dL) Mean: 1.41\n  - Serum Creatinine (mg/dL) SD: 0.22\n  - Urine Protein (mg/dL) Mean: 38.4\n  - Urine Protein (mg/dL) SD: 8.7\n  - Urine Output (mL/24h) Mean: 1948\n  - Urine Output (mL/24h) SD: 320\n\n### Dose Response\n- KIM1 Dose Correlation (r): 0.524\n- NGAL Dose Correlation (r): 0.257\n- eGFR Dose Correlation (r): -0.357\n- UACR Dose Correlation (r): 0.313\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.4\n- Hemoglobin (g/dL) SD: 1.3\n- Hematocrit (%) Mean: 38.2\n- Hematocrit (%) SD: 4.0\n- WBC (k/\u00b5L) Mean: 8.5\n- WBC (k/\u00b5L) SD: 1.1\n- Platelets (k/\u00b5L) Mean: 226\n- Platelets (k/\u00b5L) SD: 42\n- Sodium (mEq/L) Mean: 138.9\n- Sodium (mEq/L) SD: 3.0\n- Potassium (mEq/L) Mean: 4.5\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 22.8\n- Bicarbonate (mEq/L) SD: 1.8\n- Phosphorus (mg/dL) Mean: 3.9\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-0866, Description: fatigue, Grade: 2, Relatedness: not related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-0861, Description: dizziness, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 100mg\n\n### Protocol Deviations\n- PD ID: RB-PD-0841, Description: Missed scheduled renal ultrasound, rescheduled, Severity: moderate\n\n### Events\n- Cohort 100mg enrollment status reviewed at sponsor call\n- Drug supply reconciliation completed at 40 sites\n- Cohort 50mg enrollment status reviewed at sponsor call\n\n### Notes\n- Week 8: Renal biomarker collection on schedule. 73 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_039",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-29T10:30:00",
          "text": "## 2024-04-29 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 74\n- Active: 69\n- Screen Failures Cumulative: 18\n- Withdrawals Cumulative: 5\n\n### Enrollment By Cohort\n- 10mg: 16\n- 25mg: 16\n- 50mg: 20\n- 100mg: 22\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 2.14\n- KIM-1 (ng/mL) SD: 0.58\n- NGAL (ng/mL) Mean: 81.2\n- NGAL (ng/mL) SD: 15.4\n- Cystatin C (mg/L) Mean: 0.92\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 84.6\n- eGFR (mL/min) SD: 9.9\n- UACR (mg/g) Mean: 119.3\n- UACR (mg/g) SD: 30.8\n- Serum Creatinine (mg/dL) Mean: 1.23\n- Serum Creatinine (mg/dL) SD: 0.12\n- Urine Protein (mg/dL) Mean: 17.4\n- Urine Protein (mg/dL) SD: 7.7\n- Urine Output (mL/24h) Mean: 1908\n- Urine Output (mL/24h) SD: 368\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.06\n- KIM-1 (ng/mL) SD: 0.33\n- NGAL (ng/mL) Mean: 51.7\n- NGAL (ng/mL) SD: 17.3\n- Cystatin C (mg/L) Mean: 0.97\n- Cystatin C (mg/L) SD: 0.08\n- eGFR (mL/min) Mean: 52.5\n- eGFR (mL/min) SD: 14.9\n- UACR (mg/g) Mean: 108.6\n- UACR (mg/g) SD: 27.5\n- Serum Creatinine (mg/dL) Mean: 1.36\n- Serum Creatinine (mg/dL) SD: 0.27\n- Urine Protein (mg/dL) Mean: 43.8\n- Urine Protein (mg/dL) SD: 8.6\n- Urine Output (mL/24h) Mean: 1807\n- Urine Output (mL/24h) SD: 334\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.38\n- KIM-1 (ng/mL) SD: 0.5\n- NGAL (ng/mL) Mean: 95.9\n- NGAL (ng/mL) SD: 8.6\n- Cystatin C (mg/L) Mean: 0.91\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 60.4\n- eGFR (mL/min) SD: 14.2\n- UACR (mg/g) Mean: 101.6\n- UACR (mg/g) SD: 14.4\n- Serum Creatinine (mg/dL) Mean: 1.4\n- Serum Creatinine (mg/dL) SD: 0.21\n- Urine Protein (mg/dL) Mean: 37.1\n- Urine Protein (mg/dL) SD: 4.5\n- Urine Output (mL/24h) Mean: 1656\n- Urine Output (mL/24h) SD: 366\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.36\n- KIM-1 (ng/mL) SD: 0.35\n- NGAL (ng/mL) Mean: 68.3\n- NGAL (ng/mL) SD: 11.5\n- Cystatin C (mg/L) Mean: 0.88\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 55.7\n- eGFR (mL/min) SD: 8.8\n- UACR (mg/g) Mean: 129.4\n- UACR (mg/g) SD: 21.5\n- Serum Creatinine (mg/dL) Mean: 1.38\n- Serum Creatinine (mg/dL) SD: 0.3\n- Urine Protein (mg/dL) Mean: 43.8\n- Urine Protein (mg/dL) SD: 6.0\n- Urine Output (mL/24h) Mean: 1915\n- Urine Output (mL/24h) SD: 331\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.604\n- NGAL Dose Correlation (r): 0.376\n- eGFR Dose Correlation (r): -0.39\n- UACR Dose Correlation (r): 0.198\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.2\n- Hemoglobin (g/dL) SD: 1.0\n- Hematocrit (%) Mean: 42.8\n- Hematocrit (%) SD: 2.6\n- WBC (k/\u00b5L) Mean: 6.3\n- WBC (k/\u00b5L) SD: 2.0\n- Platelets (k/\u00b5L) Mean: 240\n- Platelets (k/\u00b5L) SD: 49\n- Sodium (mEq/L) Mean: 140.4\n- Sodium (mEq/L) SD: 1.8\n- Potassium (mEq/L) Mean: 3.9\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 26.6\n- Bicarbonate (mEq/L) SD: 1.6\n- Phosphorus (mg/dL) Mean: 3.2\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-0989, Description: muscle cramp, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 25mg\n- AE ID: RB-AE-0961, Description: constipation, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-0904, Description: peripheral edema, Grade: 2, Relatedness: possibly related, Resolved: false, Cohort: 100mg\n- AE ID: RB-AE-0981, Description: urinary tract infection, Grade: 2, Relatedness: possibly related, Resolved: true, Cohort: 100mg\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- Bioanalytical lab shipment: 34 frozen urine aliquots dispatched\n- DSMB safety data snapshot prepared\n\n### Notes\n- Week 9: Renal biomarker collection on schedule. 74 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_040",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-31T10:30:00",
          "text": "## 2024-05-06 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 72\n- Active: 68\n- Screen Failures Cumulative: 20\n- Withdrawals Cumulative: 4\n\n#### By Cohort\n- 10mg: 15\n- 25mg: 16\n- 50mg: 20\n- 100mg: 21\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM1 (ng/mL) Mean: 2.27\n- KIM1 (ng/mL) SD: 0.42\n- NGAL (ng/mL) Mean: 60.2\n- NGAL (ng/mL) SD: 17.9\n- Cystatin C (mg/L) Mean: 0.79\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 55.3\n- eGFR (mL/min) SD: 10.6\n- UACR (mg/g) Mean: 58.7\n- UACR (mg/g) SD: 11.9\n- Serum Creatinine (mg/dL) Mean: 1.25\n- Serum Creatinine (mg/dL) SD: 0.29\n- Urine Protein (mg/dL) Mean: 15.1\n- Urine Protein (mg/dL) SD: 6.0\n- Urine Output (mL/24h) Mean: 1898\n- Urine Output (mL/24h) SD: 347\n\n#### 25mg\n- KIM1 (ng/mL) Mean: 1.46\n- KIM1 (ng/mL) SD: 0.58\n- NGAL (ng/mL) Mean: 70.2\n- NGAL (ng/mL) SD: 14.3\n- Cystatin C (mg/L) Mean: 0.83\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 54.4\n- eGFR (mL/min) SD: 13.6\n- UACR (mg/g) Mean: 53.8\n- UACR (mg/g) SD: 25.1\n- Serum Creatinine (mg/dL) Mean: 1.05\n- Serum Creatinine (mg/dL) SD: 0.19\n- Urine Protein (mg/dL) Mean: 36.7\n- Urine Protein (mg/dL) SD: 3.8\n- Urine Output (mL/24h) Mean: 1644\n- Urine Output (mL/24h) SD: 392\n\n#### 50mg\n- KIM1 (ng/mL) Mean: 2.67\n- KIM1 (ng/mL) SD: 0.27\n- NGAL (ng/mL) Mean: 82.7\n- NGAL (ng/mL) SD: 10.2\n- Cystatin C (mg/L) Mean: 0.94\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 76.0\n- eGFR (mL/min) SD: 14.8\n- UACR (mg/g) Mean: 121.9\n- UACR (mg/g) SD: 17.4\n- Serum Creatinine (mg/dL) Mean: 1.45\n- Serum Creatinine (mg/dL) SD: 0.14\n- Urine Protein (mg/dL) Mean: 10.4\n- Urine Protein (mg/dL) SD: 3.9\n- Urine Output (mL/24h) Mean: 1911\n- Urine Output (mL/24h) SD: 331\n\n#### 100mg\n- KIM1 (ng/mL) Mean: 2.03\n- KIM1 (ng/mL) SD: 0.25\n- NGAL (ng/mL) Mean: 78.4\n- NGAL (ng/mL) SD: 8.3\n- Cystatin C (mg/L) Mean: 1.13\n- Cystatin C (mg/L) SD: 0.15\n- eGFR (mL/min) Mean: 71.5\n- eGFR (mL/min) SD: 9.7\n- UACR (mg/g) Mean: 108.2\n- UACR (mg/g) SD: 18.9\n- Serum Creatinine (mg/dL) Mean: 1.43\n- Serum Creatinine (mg/dL) SD: 0.18\n- Urine Protein (mg/dL) Mean: 19.0\n- Urine Protein (mg/dL) SD: 3.0\n- Urine Output (mL/24h) Mean: 1655\n- Urine Output (mL/24h) SD: 331\n\n### Dose Response\n- KIM1 Dose Correlation (r): 0.303\n- NGAL Dose Correlation (r): 0.459\n- eGFR Dose Correlation (r): -0.362\n- UACR Dose Correlation (r): 0.215\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.7\n- Hemoglobin (g/dL) SD: 1.3\n- Hematocrit (%) Mean: 38.3\n- Hematocrit (%) SD: 3.8\n- WBC (k/\u00b5L) Mean: 8.0\n- WBC (k/\u00b5L) SD: 1.2\n- Platelets (k/\u00b5L) Mean: 225\n- Platelets (k/\u00b5L) SD: 48\n- Sodium (mEq/L) Mean: 138.0\n- Sodium (mEq/L) SD: 1.8\n- Potassium (mEq/L) Mean: 4.5\n- Potassium (mEq/L) SD: 0.3\n- Bicarbonate (mEq/L) Mean: 22.3\n- Bicarbonate (mEq/L) SD: 1.8\n- Phosphorus (mg/dL) Mean: 4.4\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-1021, Description: hyperkalemia, Grade: 1, Relatedness: unlikely related, Resolved: false, Cohort: 50mg\n- AE ID: RB-AE-1078, Description: urinary tract infection, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 25mg\n- AE ID: RB-AE-1008, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 50mg\n\n### Protocol Deviations\n- PD ID: RB-PD-1015, Description: Lab kit expired, replacement used, Severity: minor\n\n### Events\n- Drug supply reconciliation completed at 25 sites\n- Bioanalytical lab shipment: 25 frozen urine aliquots dispatched\n- Drug supply reconciliation completed at 43 sites\n\n### Notes\n- Week 10: Renal biomarker collection on schedule. 72 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_014",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-03T10:00:00",
          "text": "## 2024-06-03 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 192\n- Active: 182\n- Screen Failures Cumulative: 28\n- Withdrawals Cumulative: 10\n\n#### Sites\n- Site 01 Enrolled: 19\n- Site 01 Active: 19\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 14\n- Site 02 Active: 14\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 18\n- Site 03 Active: 18\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 13\n- Site 04 Active: 13\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 16\n- Site 05 Active: 16\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 11\n- Site 06 Active: 11\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 21\n- Site 07 Active: 21\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 14\n- Site 08 Active: 14\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 16\n- Site 09 Active: 16\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 13\n- Site 10 Active: 13\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 18\n- Site 11 Active: 18\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 14\n- Site 12 Active: 14\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n#### Statin Subgroup\n- N: 53\n- ALT (U/L) Mean: 57.6\n- ALT (U/L) Median: 56.0\n- AST (U/L) Mean: 45.7\n- AST (U/L) Median: 45.7\n- Bilirubin (mg/dL) Mean: 0.86\n- Bilirubin (mg/dL) Median: 0.83\n- ALP (U/L) Mean: 65.4\n- ALP (U/L) Median: 57.0\n- Creatinine (mg/dL) Mean: 0.89\n- Creatinine (mg/dL) Median: 0.85\n- BUN (mg/dL) Mean: 14.7\n- BUN (mg/dL) Median: 13.1\n- WBC (K) Mean: 6.2\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 223\n- Platelets (K) Median: 223\n\n#### Non-Statin Subgroup\n- N: 124\n- ALT (U/L) Mean: 29.4\n- ALT (U/L) Median: 27.5\n- AST (U/L) Mean: 26.6\n- AST (U/L) Median: 25.1\n- Bilirubin (mg/dL) Mean: 0.43\n- Bilirubin (mg/dL) Median: 0.41\n- ALP (U/L) Mean: 74.1\n- ALP (U/L) Median: 70.2\n- Creatinine (mg/dL) Mean: 0.98\n- Creatinine (mg/dL) Median: 0.96\n- BUN (mg/dL) Mean: 17.8\n- BUN (mg/dL) Median: 12.4\n- WBC (K) Mean: 7.7\n- WBC (K) Median: 6.6\n- Platelets (K) Mean: 259\n- Platelets (K) Median: 226\n\n### Adverse Events\n- AE ID: AE-0045, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0046, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0047, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0048, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0049, Description: abdominal discomfort, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-029, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_06\n- PD ID: PD-030, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_02\n\n### Investigator Notes\n- Lab kits inventory adequate for next 4 weeks\n- Subject retention rate within protocol targets\n- EDC data entry backlog cleared, queries resolved\n\n### Events\n- CRO quarterly oversight report submitted\n- Medical monitor weekly call completed\n- Central lab courier pickup schedule adjusted for holiday\n- Site 07: ALT analyzer service notification, recalibration pending\n\n### Notes\n- Week 14: Site 07 ALT analyzer flagged for recalibration. Statin subgroup ALT values at 1.5-2x ULN.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_041",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-03T10:30:00",
          "text": "## 2024-05-13 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 87\n- Active: 81\n- Screen Failures Cumulative: 23\n- Withdrawals Cumulative: 6\n\n### Enrollment By Cohort\n- 10mg\n  - Enrolled: 19\n- 25mg\n  - Enrolled: 21\n- 50mg\n  - Enrolled: 23\n- 100mg\n  - Enrolled: 24\n\n### Biomarkers By Cohort\n- 10mg\n  - KIM-1 (ng/mL) Mean: 1.7\n  - KIM-1 (ng/mL) SD: 0.48\n  - NGAL (ng/mL) Mean: 54.2\n  - NGAL (ng/mL) SD: 12.9\n  - Cystatin C (mg/L) Mean: 0.83\n  - Cystatin C (mg/L) SD: 0.08\n  - eGFR (mL/min) Mean: 75.5\n  - eGFR (mL/min) SD: 12.8\n  - UACR (mg/g) Mean: 47.8\n  - UACR (mg/g) SD: 11.8\n  - Serum Creatinine (mg/dL) Mean: 1.38\n  - Serum Creatinine (mg/dL) SD: 0.23\n  - Urine Protein (mg/dL) Mean: 34.4\n  - Urine Protein (mg/dL) SD: 7.3\n  - Urine Output (mL/24h) Mean: 1589\n  - Urine Output (mL/24h) SD: 302\n- 25mg\n  - KIM-1 (ng/mL) Mean: 1.58\n  - KIM-1 (ng/mL) SD: 0.42\n  - NGAL (ng/mL) Mean: 64.8\n  - NGAL (ng/mL) SD: 14.2\n  - Cystatin C (mg/L) Mean: 0.82\n  - Cystatin C (mg/L) SD: 0.08\n  - eGFR (mL/min) Mean: 62.4\n  - eGFR (mL/min) SD: 12.9\n  - UACR (mg/g) Mean: 40.7\n  - UACR (mg/g) SD: 13.3\n  - Serum Creatinine (mg/dL) Mean: 1.06\n  - Serum Creatinine (mg/dL) SD: 0.27\n  - Urine Protein (mg/dL) Mean: 40.2\n  - Urine Protein (mg/dL) SD: 4.4\n  - Urine Output (mL/24h) Mean: 1754\n  - Urine Output (mL/24h) SD: 308\n- 50mg\n  - KIM-1 (ng/mL) Mean: 2.44\n  - KIM-1 (ng/mL) SD: 0.35\n  - NGAL (ng/mL) Mean: 91.4\n  - NGAL (ng/mL) SD: 13.5\n  - Cystatin C (mg/L) Mean: 1.13\n  - Cystatin C (mg/L) SD: 0.13\n  - eGFR (mL/min) Mean: 52.4\n  - eGFR (mL/min) SD: 10.4\n  - UACR (mg/g) Mean: 40.9\n  - UACR (mg/g) SD: 24.9\n  - Serum Creatinine (mg/dL) Mean: 1.09\n  - Serum Creatinine (mg/dL) SD: 0.28\n  - Urine Protein (mg/dL) Mean: 24.3\n  - Urine Protein (mg/dL) SD: 7.3\n  - Urine Output (mL/24h) Mean: 1675\n  - Urine Output (mL/24h) SD: 341\n- 100mg\n  - KIM-1 (ng/mL) Mean: 2.03\n  - KIM-1 (ng/mL) SD: 0.36\n  - NGAL (ng/mL) Mean: 81.0\n  - NGAL (ng/mL) SD: 15.7\n  - Cystatin C (mg/L) Mean: 1.19\n  - Cystatin C (mg/L) SD: 0.1\n  - eGFR (mL/min) Mean: 65.2\n  - eGFR (mL/min) SD: 8.4\n  - UACR (mg/g) Mean: 74.3\n  - UACR (mg/g) SD: 11.8\n  - Serum Creatinine (mg/dL) Mean: 1.11\n  - Serum Creatinine (mg/dL) SD: 0.29\n  - Urine Protein (mg/dL) Mean: 17.6\n  - Urine Protein (mg/dL) SD: 6.3\n  - Urine Output (mL/24h) Mean: 1889\n  - Urine Output (mL/24h) SD: 301\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.466\n- NGAL Dose Correlation (r): 0.494\n- eGFR Dose Correlation (r): -0.207\n- UACR Dose Correlation (r): 0.345\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 12.7\n- Hemoglobin (g/dL) SD: 0.9\n- Hematocrit (%) Mean: 38.8\n- Hematocrit (%) SD: 2.5\n- WBC (k/\u00b5L) Mean: 7.3\n- WBC (k/\u00b5L) SD: 1.4\n- Platelets (k/\u00b5L) Mean: 225\n- Platelets (k/\u00b5L) SD: 47\n- Sodium (mEq/L) Mean: 137.2\n- Sodium (mEq/L) SD: 2.8\n- Potassium (mEq/L) Mean: 4.6\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 23.9\n- Bicarbonate (mEq/L) SD: 2.4\n- Phosphorus (mg/dL) Mean: 3.9\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-1153, Description: constipation, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-1178, Description: constipation, Grade: 2, Relatedness: possibly related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-1113, Description: urinary tract infection, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 50mg\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- eCRF query resolution: 21 queries closed this week\n- eCRF query resolution: 12 queries closed this week\n- Bioanalytical lab shipment: 31 frozen urine aliquots dispatched\n\n### Notes\n- Week 11: Renal biomarker collection on schedule. 87 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_042",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-05T10:30:00",
          "text": "## 2024-05-20 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 85\n- Active: 79\n- Screen Failures Cumulative: 26\n- Withdrawals Cumulative: 6\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 20\n- 50mg: 22\n- 100mg: 23\n\n### Biomarkers By Cohort\n\n#### 10mg\n- KIM-1 (ng/mL) Mean: 1.68\n- KIM-1 (ng/mL) SD: 0.42\n- NGAL (ng/mL) Mean: 44.4\n- NGAL (ng/mL) SD: 16.4\n- Cystatin C (mg/L) Mean: 0.89\n- Cystatin C (mg/L) SD: 0.15\n- eGFR (mL/min) Mean: 75.1\n- eGFR (mL/min) SD: 13.3\n- UACR (mg/g) Mean: 102.9\n- UACR (mg/g) SD: 24.3\n- Serum Creatinine (mg/dL) Mean: 1.15\n- Serum Creatinine (mg/dL) SD: 0.17\n- Urine Protein (mg/dL) Mean: 17.8\n- Urine Protein (mg/dL) SD: 8.3\n- Urine Output (mL/24h) Mean: 1809\n- Urine Output (mL/24h) SD: 298\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.95\n- KIM-1 (ng/mL) SD: 0.29\n- NGAL (ng/mL) Mean: 85.8\n- NGAL (ng/mL) SD: 17.9\n- Cystatin C (mg/L) Mean: 0.76\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 54.5\n- eGFR (mL/min) SD: 8.6\n- UACR (mg/g) Mean: 101.9\n- UACR (mg/g) SD: 10.2\n- Serum Creatinine (mg/dL) Mean: 1.13\n- Serum Creatinine (mg/dL) SD: 0.23\n- Urine Protein (mg/dL) Mean: 15.6\n- Urine Protein (mg/dL) SD: 8.7\n- Urine Output (mL/24h) Mean: 1701\n- Urine Output (mL/24h) SD: 316\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 2.67\n- KIM-1 (ng/mL) SD: 0.37\n- NGAL (ng/mL) Mean: 95.1\n- NGAL (ng/mL) SD: 13.4\n- Cystatin C (mg/L) Mean: 0.95\n- Cystatin C (mg/L) SD: 0.08\n- eGFR (mL/min) Mean: 63.6\n- eGFR (mL/min) SD: 12.9\n- UACR (mg/g) Mean: 55.2\n- UACR (mg/g) SD: 13.1\n- Serum Creatinine (mg/dL) Mean: 1.14\n- Serum Creatinine (mg/dL) SD: 0.29\n- Urine Protein (mg/dL) Mean: 11.6\n- Urine Protein (mg/dL) SD: 6.3\n- Urine Output (mL/24h) Mean: 1609\n- Urine Output (mL/24h) SD: 344\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 1.09\n- KIM-1 (ng/mL) SD: 0.59\n- NGAL (ng/mL) Mean: 89.5\n- NGAL (ng/mL) SD: 17.7\n- Cystatin C (mg/L) Mean: 0.97\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 69.4\n- eGFR (mL/min) SD: 8.2\n- UACR (mg/g) Mean: 94.5\n- UACR (mg/g) SD: 23.2\n- Serum Creatinine (mg/dL) Mean: 1.11\n- Serum Creatinine (mg/dL) SD: 0.18\n- Urine Protein (mg/dL) Mean: 16.0\n- Urine Protein (mg/dL) SD: 6.4\n- Urine Output (mL/24h) Mean: 1708\n- Urine Output (mL/24h) SD: 305\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.55\n- NGAL Dose Correlation (r): 0.332\n- eGFR Dose Correlation (r): -0.373\n- UACR Dose Correlation (r): 0.347\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.1\n- Hemoglobin (g/dL) SD: 1.1\n- Hematocrit (%) Mean: 39.1\n- Hematocrit (%) SD: 2.9\n- WBC (k/\u00b5L) Mean: 7.7\n- WBC (k/\u00b5L) SD: 1.2\n- Platelets (k/\u00b5L) Mean: 222\n- Platelets (k/\u00b5L) SD: 42\n- Sodium (mEq/L) Mean: 140.3\n- Sodium (mEq/L) SD: 2.7\n- Potassium (mEq/L) Mean: 4.1\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 27.3\n- Bicarbonate (mEq/L) SD: 2.8\n- Phosphorus (mg/dL) Mean: 3.2\n- Phosphorus (mg/dL) SD: 0.7\n\n### Adverse Events\n- AE ID: RB-AE-1204, Description: constipation, Grade: 1, Relatedness: unlikely related, Resolved: false, Cohort: 100mg\n- AE ID: RB-AE-1235, Description: peripheral edema, Grade: 2, Relatedness: not related, Resolved: true, Cohort: 100mg\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- Site 04 monitoring visit completed, 0 findings\n- DSMB safety data snapshot prepared\n- Renal ultrasound images uploaded to central imaging core\n\n### Notes\n- Week 12: Renal biomarker collection on schedule. 85 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_043",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-07T10:30:00",
          "text": "## 2024-05-27 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 85\n- Active: 79\n- Screen Failures Cumulative: 24\n- Withdrawals Cumulative: 6\n\n### Enrollment By Cohort\n- 10mg: 20\n- 25mg: 21\n- 50mg: 21\n- 100mg: 23\n\n### Biomarkers By Cohort\n- 10mg\n  - KIM1 (ng/ml) Mean: 0.98\n  - KIM1 (ng/ml) SD: 0.54\n  - NGAL (ng/ml) Mean: 52.1\n  - NGAL (ng/ml) SD: 19.8\n  - Cystatin C (mg/L) Mean: 0.75\n  - Cystatin C (mg/L) SD: 0.1\n  - eGFR (ml/min) Mean: 65.8\n  - eGFR (ml/min) SD: 9.6\n  - UACR (mg/g) Mean: 75.3\n  - UACR (mg/g) SD: 29.4\n  - Serum Creatinine (mg/dl) Mean: 1.47\n  - Serum Creatinine (mg/dl) SD: 0.16\n  - Urine Protein (mg/dl) Mean: 22.9\n  - Urine Protein (mg/dl) SD: 9.5\n  - Urine Output (ml/24h) Mean: 1741\n  - Urine Output (ml/24h) SD: 360\n- 25mg\n  - KIM1 (ng/ml) Mean: 1.12\n  - KIM1 (ng/ml) SD: 0.32\n  - NGAL (ng/ml) Mean: 94.2\n  - NGAL (ng/ml) SD: 18.1\n  - Cystatin C (mg/L) Mean: 0.81\n  - Cystatin C (mg/L) SD: 0.11\n  - eGFR (ml/min) Mean: 79.0\n  - eGFR (ml/min) SD: 11.0\n  - UACR (mg/g) Mean: 50.2\n  - UACR (mg/g) SD: 10.5\n  - Serum Creatinine (mg/dl) Mean: 1.37\n  - Serum Creatinine (mg/dl) SD: 0.21\n  - Urine Protein (mg/dl) Mean: 44.4\n  - Urine Protein (mg/dl) SD: 9.7\n  - Urine Output (ml/24h) Mean: 1796\n  - Urine Output (ml/24h) SD: 315\n- 50mg\n  - KIM1 (ng/ml) Mean: 1.47\n  - KIM1 (ng/ml) SD: 0.3\n  - NGAL (ng/ml) Mean: 71.8\n  - NGAL (ng/ml) SD: 8.3\n  - Cystatin C (mg/L) Mean: 1.15\n  - Cystatin C (mg/L) SD: 0.14\n  - eGFR (ml/min) Mean: 71.0\n  - eGFR (ml/min) SD: 11.6\n  - UACR (mg/g) Mean: 103.5\n  - UACR (mg/g) SD: 27.4\n  - Serum Creatinine (mg/dl) Mean: 1.49\n  - Serum Creatinine (mg/dl) SD: 0.2\n  - Urine Protein (mg/dl) Mean: 12.4\n  - Urine Protein (mg/dl) SD: 9.0\n  - Urine Output (ml/24h) Mean: 1691\n  - Urine Output (ml/24h) SD: 351\n- 100mg\n  - KIM1 (ng/ml) Mean: 1.84\n  - KIM1 (ng/ml) SD: 0.22\n  - NGAL (ng/ml) Mean: 46.2\n  - NGAL (ng/ml) SD: 19.4\n  - Cystatin C (mg/L) Mean: 1.2\n  - Cystatin C (mg/L) SD: 0.14\n  - eGFR (ml/min) Mean: 48.8\n  - eGFR (ml/min) SD: 12.8\n  - UACR (mg/g) Mean: 50.5\n  - UACR (mg/g) SD: 21.3\n  - Serum Creatinine (mg/dl) Mean: 1.1\n  - Serum Creatinine (mg/dl) SD: 0.12\n  - Urine Protein (mg/dl) Mean: 40.2\n  - Urine Protein (mg/dl) SD: 5.4\n  - Urine Output (ml/24h) Mean: 1808\n  - Urine Output (ml/24h) SD: 315\n\n### Dose Response\n- KIM1 Dose Correlation (r): 0.504\n- NGAL Dose Correlation (r): 0.417\n- eGFR Dose Correlation (r): -0.193\n- UACR Dose Correlation (r): 0.238\n\n### Safety Labs\n- Hemoglobin (g/dl) Mean: 13.6\n- Hemoglobin (g/dl) SD: 1.2\n- Hematocrit (%) Mean: 42.6\n- Hematocrit (%) SD: 3.1\n- WBC (k) Mean: 6.7\n- WBC (k) SD: 1.2\n- Platelets (k) Mean: 213\n- Platelets (k) SD: 48\n- Sodium (meq/l) Mean: 138.7\n- Sodium (meq/l) SD: 2.1\n- Potassium (meq/l) Mean: 4.6\n- Potassium (meq/l) SD: 0.5\n- Bicarbonate (meq/l) Mean: 25.2\n- Bicarbonate (meq/l) SD: 2.7\n- Phosphorus (mg/dl) Mean: 3.1\n- Phosphorus (mg/dl) SD: 0.6\n\n### Adverse Events\n- AE ID: RB-AE-1353, Description: dizziness, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-1371, Description: headache, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 50mg\n- AE ID: RB-AE-1333, Description: nausea, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 25mg\n\n### Protocol Deviations\n- PD ID: RB-PD-1335, Description: Dose adjustment documentation incomplete, Severity: minor\n\n### Events\n- Renal ultrasound images uploaded to central imaging core\n- Drug supply reconciliation completed at 56 sites\n\n### Notes\n- Week 13: Renal biomarker collection on schedule. 85 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_015",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-10T10:00:00",
          "text": "## 2024-06-10 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 215\n- Active: 208\n- Screen Failures Cumulative: 33\n- Withdrawals Cumulative: 7\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 23\n- Site 07 Active: 23\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 62.2\n- ALT (U/L) Median: 61.3\n- AST (U/L) Mean: 51.0\n- AST (U/L) Median: 50.3\n- Bilirubin (mg/dL) Mean: 0.89\n- Bilirubin (mg/dL) Median: 0.86\n- ALP (U/L) Mean: 58.6\n- ALP (U/L) Median: 78.4\n- Creatinine (mg/dL) Mean: 0.97\n- Creatinine (mg/dL) Median: 0.8\n- BUN (mg/dL) Mean: 14.8\n- BUN (mg/dL) Median: 16.3\n- WBC (K) Mean: 6.4\n- WBC (K) Median: 7.9\n- Platelets (K) Mean: 241\n- Platelets (K) Median: 212\n\n#### Non-Statin Subgroup\n- N: 125\n- ALT (U/L) Mean: 26.0\n- ALT (U/L) Median: 25.2\n- AST (U/L) Mean: 22.2\n- AST (U/L) Median: 21.0\n- Bilirubin (mg/dL) Mean: 0.64\n- Bilirubin (mg/dL) Median: 0.59\n- ALP (U/L) Mean: 65.4\n- ALP (U/L) Median: 71.5\n- Creatinine (mg/dL) Mean: 0.86\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 12.5\n- BUN (mg/dL) Median: 16.1\n- WBC (K) Mean: 5.9\n- WBC (K) Median: 6.9\n- Platelets (K) Mean: 229\n- Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0050, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0051, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0052, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0053, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0054, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-031, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_11\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- Central lab results received within 48h turnaround\n- Site 07 ALT re-assay ordered for 8 specimens, calibration offset confirmed\n\n### Events\n- Drug accountability audit at Site 12: no discrepancies\n- IP resupply shipped to Sites 07, 03\n- Site 07 lab re-assay requested for 8 specimens flagged during calibration review\n\n### Notes\n- Week 15: Site 07 re-assay ordered. Statin subgroup hepatic values persist across sites.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_044",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-10T10:30:00",
          "text": "## 2024-06-03 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 84\n- Active: 77\n- Screen Failures Cumulative: 28\n- Withdrawals Cumulative: 7\n\n### Enrollment By Cohort\n- 10mg: 19\n- 25mg: 21\n- 50mg: 22\n- 100mg: 22\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 2.37\n- KIM-1 (ng/mL) SD: 0.5\n- NGAL (ng/mL) Mean: 73.7\n- NGAL (ng/mL) SD: 17.4\n- Cystatin C (mg/L) Mean: 0.78\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 61.9\n- eGFR (mL/min) SD: 11.9\n- UACR (mg/g) Mean: 72.2\n- UACR (mg/g) SD: 25.7\n- Serum Creatinine (mg/dL) Mean: 1.07\n- Serum Creatinine (mg/dL) SD: 0.18\n- Urine Protein (mg/dL) Mean: 26.2\n- Urine Protein (mg/dL) SD: 6.9\n- Urine Output (mL/24h) Mean: 1953\n- Urine Output (mL/24h) SD: 327\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 2.46\n- KIM-1 (ng/mL) SD: 0.46\n- NGAL (ng/mL) Mean: 70.9\n- NGAL (ng/mL) SD: 13.9\n- Cystatin C (mg/L) Mean: 1.03\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 54.5\n- eGFR (mL/min) SD: 8.8\n- UACR (mg/g) Mean: 59.7\n- UACR (mg/g) SD: 31.7\n- Serum Creatinine (mg/dL) Mean: 1.22\n- Serum Creatinine (mg/dL) SD: 0.27\n- Urine Protein (mg/dL) Mean: 18.0\n- Urine Protein (mg/dL) SD: 6.5\n- Urine Output (mL/24h) Mean: 1632\n- Urine Output (mL/24h) SD: 386\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 2.26\n- KIM-1 (ng/mL) SD: 0.38\n- NGAL (ng/mL) Mean: 71.0\n- NGAL (ng/mL) SD: 16.9\n- Cystatin C (mg/L) Mean: 0.8\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 54.1\n- eGFR (mL/min) SD: 10.0\n- UACR (mg/g) Mean: 70.0\n- UACR (mg/g) SD: 15.4\n- Serum Creatinine (mg/dL) Mean: 1.07\n- Serum Creatinine (mg/dL) SD: 0.2\n- Urine Protein (mg/dL) Mean: 10.1\n- Urine Protein (mg/dL) SD: 6.8\n- Urine Output (mL/24h) Mean: 1908\n- Urine Output (mL/24h) SD: 307\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 1.43\n- KIM-1 (ng/mL) SD: 0.43\n- NGAL (ng/mL) Mean: 95.0\n- NGAL (ng/mL) SD: 12.9\n- Cystatin C (mg/L) Mean: 1.06\n- Cystatin C (mg/L) SD: 0.15\n- eGFR (mL/min) Mean: 57.6\n- eGFR (mL/min) SD: 15.0\n- UACR (mg/g) Mean: 96.7\n- UACR (mg/g) SD: 23.8\n- Serum Creatinine (mg/dL) Mean: 1.13\n- Serum Creatinine (mg/dL) SD: 0.29\n- Urine Protein (mg/dL) Mean: 12.4\n- Urine Protein (mg/dL) SD: 3.6\n- Urine Output (mL/24h) Mean: 1884\n- Urine Output (mL/24h) SD: 348\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.533\n- NGAL Dose Correlation (r): 0.255\n- eGFR Dose Correlation (r): -0.223\n- UACR Dose Correlation (r): 0.22\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.1\n- Hemoglobin (g/dL) SD: 1.2\n- Hematocrit (%) Mean: 39.4\n- Hematocrit (%) SD: 3.4\n- WBC (k/\u00b5L) Mean: 6.3\n- WBC (k/\u00b5L) SD: 1.6\n- Platelets (k/\u00b5L) Mean: 230\n- Platelets (k/\u00b5L) SD: 48\n- Sodium (mEq/L) Mean: 138.1\n- Sodium (mEq/L) SD: 2.5\n- Potassium (mEq/L) Mean: 3.9\n- Potassium (mEq/L) SD: 0.3\n- Bicarbonate (mEq/L) Mean: 23.7\n- Bicarbonate (mEq/L) SD: 2.7\n- Phosphorus (mg/dL) Mean: 3.1\n- Phosphorus (mg/dL) SD: 0.8\n\n### Adverse Events\n- AE ID: RB-AE-1419\n- Description: Urinary tract infection\n- Grade: 1\n- Relatedness: Not related\n- Resolved: True\n- Cohort: 100mg\n- AE ID: RB-AE-1472\n- Description: Peripheral edema\n- Grade: 2\n- Relatedness: Not related\n- Resolved: True\n- Cohort: 25mg\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- Drug supply reconciliation completed at 21 sites.\n- Bioanalytical lab shipment: 58 frozen urine aliquots dispatched.\n\n### Notes\n- Week 14: Renal biomarker collection on schedule. \n- 84 subjects enrolled across 4 cohorts. \n- eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_045",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-12T10:30:00",
          "text": "## 2024-06-10 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 86\n- Active: 77\n- Screen Failures Cumulative: 28\n- Withdrawals Cumulative: 9\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 21\n- 50mg: 22\n- 100mg: 23\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM1 (ng/ml) Mean: 1.98\n- KIM1 (ng/ml) SD: 0.43\n- NGAL (ng/ml) Mean: 61.2\n- NGAL (ng/ml) SD: 13.4\n- Cystatin C (mg/L) Mean: 0.98\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (ml/min) Mean: 72.8\n- eGFR (ml/min) SD: 8.3\n- UACR (mg/g) Mean: 96.9\n- UACR (mg/g) SD: 20.7\n- Serum Creatinine (mg/dl) Mean: 1.3\n- Serum Creatinine (mg/dl) SD: 0.19\n- Urine Protein (mg/dl) Mean: 10.4\n- Urine Protein (mg/dl) SD: 7.3\n- Urine Output (ml/24h) Mean: 1729\n- Urine Output (ml/24h) SD: 369\n\n#### 25mg\n- KIM1 (ng/ml) Mean: 1.82\n- KIM1 (ng/ml) SD: 0.33\n- NGAL (ng/ml) Mean: 81.4\n- NGAL (ng/ml) SD: 13.7\n- Cystatin C (mg/L) Mean: 0.79\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (ml/min) Mean: 75.1\n- eGFR (ml/min) SD: 12.5\n- UACR (mg/g) Mean: 46.5\n- UACR (mg/g) SD: 10.8\n- Serum Creatinine (mg/dl) Mean: 1.34\n- Serum Creatinine (mg/dl) SD: 0.12\n- Urine Protein (mg/dl) Mean: 18.4\n- Urine Protein (mg/dl) SD: 9.8\n- Urine Output (ml/24h) Mean: 1946\n- Urine Output (ml/24h) SD: 380\n\n#### 50mg\n- KIM1 (ng/ml) Mean: 1.88\n- KIM1 (ng/ml) SD: 0.21\n- NGAL (ng/ml) Mean: 84.0\n- NGAL (ng/ml) SD: 10.8\n- Cystatin C (mg/L) Mean: 1.09\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (ml/min) Mean: 75.3\n- eGFR (ml/min) SD: 8.4\n- UACR (mg/g) Mean: 34.6\n- UACR (mg/g) SD: 32.8\n- Serum Creatinine (mg/dl) Mean: 1.35\n- Serum Creatinine (mg/dl) SD: 0.25\n- Urine Protein (mg/dl) Mean: 34.4\n- Urine Protein (mg/dl) SD: 5.3\n- Urine Output (ml/24h) Mean: 1945\n- Urine Output (ml/24h) SD: 337\n\n#### 100mg\n- KIM1 (ng/ml) Mean: 2.83\n- KIM1 (ng/ml) SD: 0.58\n- NGAL (ng/ml) Mean: 88.5\n- NGAL (ng/ml) SD: 8.4\n- Cystatin C (mg/L) Mean: 1.09\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (ml/min) Mean: 55.1\n- eGFR (ml/min) SD: 10.8\n- UACR (mg/g) Mean: 34.8\n- UACR (mg/g) SD: 30.0\n- Serum Creatinine (mg/dl) Mean: 1.12\n- Serum Creatinine (mg/dl) SD: 0.16\n- Urine Protein (mg/dl) Mean: 25.5\n- Urine Protein (mg/dl) SD: 5.7\n- Urine Output (ml/24h) Mean: 1985\n- Urine Output (ml/24h) SD: 377\n\n### Dose Response\n- KIM1 Dose Correlation (r): 0.323\n- NGAL Dose Correlation (r): 0.526\n- eGFR Dose Correlation (r): -0.497\n- UACR Dose Correlation (r): 0.274\n\n### Safety Labs\n- Hemoglobin (g/dl) Mean: 12.9\n- Hemoglobin (g/dl) SD: 1.3\n- Hematocrit (%) Mean: 38.0\n- Hematocrit (%) SD: 2.7\n- WBC (k) Mean: 5.6\n- WBC (k) SD: 1.8\n- Platelets (k) Mean: 235\n- Platelets (k) SD: 45\n- Sodium (meq/L) Mean: 137.0\n- Sodium (meq/L) SD: 2.7\n- Potassium (meq/L) Mean: 4.0\n- Potassium (meq/L) SD: 0.5\n- Bicarbonate (meq/L) Mean: 25.2\n- Bicarbonate (meq/L) SD: 2.3\n- Phosphorus (mg/dl) Mean: 3.2\n- Phosphorus (mg/dl) SD: 0.7\n\n### Adverse Events\n- AE ID: RB-AE-1523, Description: muscle cramp, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 25mg\n- AE ID: RB-AE-1583, Description: back pain, Grade: 2, Relatedness: possibly related, Resolved: true, Cohort: 50mg\n- AE ID: RB-AE-1567, Description: urinary tract infection, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 50mg\n\n### Protocol Deviations\n- None\n\n### Events\n- Drug supply reconciliation completed at 36 sites\n- Bioanalytical lab shipment: 58 frozen urine aliquots dispatched\n- Renal ultrasound images uploaded to central imaging core\n\n### Notes\n- Week 15: Renal biomarker collection on schedule. 86 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_046",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-14T10:30:00",
          "text": "## 2024-06-17 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 85\n- Active: 79\n- Screen Failures Cumulative: 30\n- Withdrawals Cumulative: 6\n\n#### By Cohort\n- 10mg: 19\n- 25mg: 21\n- 50mg: 22\n- 100mg: 23\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 2.4\n- KIM-1 (ng/mL) SD: 0.43\n- NGAL (ng/mL) Mean: 44.2\n- NGAL (ng/mL) SD: 18.1\n- Cystatin C (mg/L) Mean: 0.92\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 64.0\n- eGFR (mL/min) SD: 8.1\n- UACR (mg/g) Mean: 42.8\n- UACR (mg/g) SD: 27.9\n- Serum Creatinine (mg/dL) Mean: 1.1\n- Serum Creatinine (mg/dL) SD: 0.21\n- Urine Protein (mg/dL) Mean: 19.3\n- Urine Protein (mg/dL) SD: 8.2\n- Urine Output (mL/24h) Mean: 1667\n- Urine Output (mL/24h) SD: 400\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.05\n- KIM-1 (ng/mL) SD: 0.47\n- NGAL (ng/mL) Mean: 50.1\n- NGAL (ng/mL) SD: 11.9\n- Cystatin C (mg/L) Mean: 1.1\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 66.0\n- eGFR (mL/min) SD: 12.8\n- UACR (mg/g) Mean: 45.6\n- UACR (mg/g) SD: 12.8\n- Serum Creatinine (mg/dL) Mean: 1.26\n- Serum Creatinine (mg/dL) SD: 0.26\n- Urine Protein (mg/dL) Mean: 18.6\n- Urine Protein (mg/dL) SD: 8.1\n- Urine Output (mL/24h) Mean: 2015\n- Urine Output (mL/24h) SD: 342\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 2.35\n- KIM-1 (ng/mL) SD: 0.58\n- NGAL (ng/mL) Mean: 62.2\n- NGAL (ng/mL) SD: 13.7\n- Cystatin C (mg/L) Mean: 1.2\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 64.4\n- eGFR (mL/min) SD: 9.5\n- UACR (mg/g) Mean: 47.4\n- UACR (mg/g) SD: 31.5\n- Serum Creatinine (mg/dL) Mean: 1.0\n- Serum Creatinine (mg/dL) SD: 0.25\n- Urine Protein (mg/dL) Mean: 23.1\n- Urine Protein (mg/dL) SD: 4.9\n- Urine Output (mL/24h) Mean: 1627\n- Urine Output (mL/24h) SD: 392\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.77\n- KIM-1 (ng/mL) SD: 0.55\n- NGAL (ng/mL) Mean: 79.4\n- NGAL (ng/mL) SD: 19.8\n- Cystatin C (mg/L) Mean: 1.04\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 69.1\n- eGFR (mL/min) SD: 9.2\n- UACR (mg/g) Mean: 73.4\n- UACR (mg/g) SD: 31.7\n- Serum Creatinine (mg/dL) Mean: 1.14\n- Serum Creatinine (mg/dL) SD: 0.24\n- Urine Protein (mg/dL) Mean: 19.6\n- Urine Protein (mg/dL) SD: 3.7\n- Urine Output (mL/24h) Mean: 1869\n- Urine Output (mL/24h) SD: 338\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.361\n- NGAL Dose Correlation (r): 0.404\n- eGFR Dose Correlation (r): -0.49\n- UACR Dose Correlation (r): 0.408\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 12.5\n- Hemoglobin (g/dL) SD: 1.5\n- Hematocrit (%) Mean: 38.1\n- Hematocrit (%) SD: 3.4\n- WBC (k/\u00b5L) Mean: 7.6\n- WBC (k/\u00b5L) SD: 1.8\n- Platelets (k/\u00b5L) Mean: 218\n- Platelets (k/\u00b5L) SD: 47\n- Sodium (mEq/L) Mean: 141.6\n- Sodium (mEq/L) SD: 2.7\n- Potassium (mEq/L) Mean: 4.3\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 27.4\n- Bicarbonate (mEq/L) SD: 2.5\n- Phosphorus (mg/dL) Mean: 3.8\n- Phosphorus (mg/dL) SD: 0.4\n\n### Adverse Events\n- AE ID: RB-AE-1666\n  - Description: headache\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: false\n  - Cohort: 50mg\n- AE ID: RB-AE-1674\n  - Description: dizziness\n  - Grade: 1\n  - Relatedness: not related\n  - Resolved: true\n  - Cohort: 100mg\n\n### Protocol Deviations\n- None\n\n### Events\n- Renal ultrasound images uploaded to central imaging core\n- eCRF query resolution: 10 queries closed this week\n\n### Notes\n- Week 16: Renal biomarker collection on schedule. 85 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_047",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-16T10:30:00",
          "text": "## 2024-06-24 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 89\n- Active: 79\n- Screen Failures Cumulative: 34\n- Withdrawals Cumulative: 10\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 22\n- 50mg: 23\n- 100mg: 24\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 1.66\n- KIM-1 (ng/mL) SD: 0.3\n- NGAL (ng/mL) Mean: 40.3\n- NGAL (ng/mL) SD: 12.6\n- Cys-C (mg/L) Mean: 1.01\n- Cys-C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 65.1\n- eGFR (mL/min) SD: 9.9\n- UACR (mg/g) Mean: 52.2\n- UACR (mg/g) SD: 11.7\n- Serum Creatinine (mg/dL) Mean: 1.05\n- Serum Creatinine (mg/dL) SD: 0.16\n- Urine Protein (mg/dL) Mean: 37.0\n- Urine Protein (mg/dL) SD: 9.0\n- Urine Output (mL/24h) Mean: 1695\n- Urine Output (mL/24h) SD: 397\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.03\n- KIM-1 (ng/mL) SD: 0.57\n- NGAL (ng/mL) Mean: 57.3\n- NGAL (ng/mL) SD: 13.4\n- Cys-C (mg/L) Mean: 0.88\n- Cys-C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 77.2\n- eGFR (mL/min) SD: 10.6\n- UACR (mg/g) Mean: 124.7\n- UACR (mg/g) SD: 22.2\n- Serum Creatinine (mg/dL) Mean: 1.45\n- Serum Creatinine (mg/dL) SD: 0.17\n- Urine Protein (mg/dL) Mean: 11.8\n- Urine Protein (mg/dL) SD: 3.4\n- Urine Output (mL/24h) Mean: 1674\n- Urine Output (mL/24h) SD: 384\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 2.0\n- KIM-1 (ng/mL) SD: 0.26\n- NGAL (ng/mL) Mean: 54.1\n- NGAL (ng/mL) SD: 15.2\n- Cys-C (mg/L) Mean: 0.96\n- Cys-C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 71.9\n- eGFR (mL/min) SD: 10.9\n- UACR (mg/g) Mean: 33.6\n- UACR (mg/g) SD: 10.1\n- Serum Creatinine (mg/dL) Mean: 1.19\n- Serum Creatinine (mg/dL) SD: 0.24\n- Urine Protein (mg/dL) Mean: 34.9\n- Urine Protein (mg/dL) SD: 9.3\n- Urine Output (mL/24h) Mean: 2005\n- Urine Output (mL/24h) SD: 351\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 1.2\n- KIM-1 (ng/mL) SD: 0.5\n- NGAL (ng/mL) Mean: 55.1\n- NGAL (ng/mL) SD: 13.6\n- Cys-C (mg/L) Mean: 0.89\n- Cys-C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 62.3\n- eGFR (mL/min) SD: 9.8\n- UACR (mg/g) Mean: 110.5\n- UACR (mg/g) SD: 21.2\n- Serum Creatinine (mg/dL) Mean: 1.11\n- Serum Creatinine (mg/dL) SD: 0.13\n- Urine Protein (mg/dL) Mean: 38.3\n- Urine Protein (mg/dL) SD: 9.0\n- Urine Output (mL/24h) Mean: 1649\n- Urine Output (mL/24h) SD: 312\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.548\n- NGAL Dose Correlation (r): 0.242\n- eGFR Dose Correlation (r): -0.353\n- UACR Dose Correlation (r): 0.349\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.1\n- Hemoglobin (g/dL) SD: 1.0\n- Hematocrit (%) Mean: 40.9\n- Hematocrit (%) SD: 4.0\n- WBC (k/\u00b5L) Mean: 8.0\n- WBC (k/\u00b5L) SD: 1.6\n- Platelets (k/\u00b5L) Mean: 225\n- Platelets (k/\u00b5L) SD: 46\n- Sodium (mEq/L) Mean: 140.0\n- Sodium (mEq/L) SD: 2.2\n- Potassium (mEq/L) Mean: 4.0\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 22.1\n- Bicarbonate (mEq/L) SD: 2.4\n- Phosphorus (mg/dL) Mean: 3.5\n- Phosphorus (mg/dL) SD: 0.4\n\n### Adverse Events\n- AE ID: RB-AE-1725\n  - Description: hyperkalemia\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Cohort: 10mg\n- AE ID: RB-AE-1727\n  - Description: peripheral edema\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Cohort: 50mg\n- AE ID: RB-AE-1796\n  - Description: back pain\n  - Grade: 2\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Cohort: 25mg\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- Protocol training refresher completed for site coordinators.\n- Renal ultrasound images uploaded to central imaging core.\n\n### Notes\n- Week 17: Renal biomarker collection on schedule. 89 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_016",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-17T10:00:00",
          "text": "## 2024-06-17 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 204\n- Active: 198\n- Screen Failures Cumulative: 47\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 02\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 4\n- Site 03\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 05\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 12\n  - Active: 12\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 3\n- Site 09\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 4\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 6\n- Site 12\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 56\n- ALT (U/L) Mean: 76.2\n- ALT (U/L) Median: 75.3\n- AST (U/L) Mean: 59.0\n- AST (U/L) Median: 57.6\n- Bilirubin (mg/dL) Mean: 1.02\n- Bilirubin (mg/dL) Median: 0.99\n- ALP (U/L) Mean: 76.1\n- ALP (U/L) Median: 69.4\n- Creatinine (mg/dL) Mean: 0.99\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 12.2\n- BUN (mg/dL) Median: 14.8\n- WBC (K) Mean: 7.0\n- WBC (K) Median: 6.4\n- Platelets (K) Mean: 233\n- Platelets (K) Median: 230\n\n#### Non-Statin Subgroup\n- N: 129\n- ALT (U/L) Mean: 24.7\n- ALT (U/L) Median: 22.8\n- AST (U/L) Mean: 21.9\n- AST (U/L) Median: 20.9\n- Bilirubin (mg/dL) Mean: 0.64\n- Bilirubin (mg/dL) Median: 0.62\n- ALP (U/L) Mean: 71.7\n- ALP (U/L) Median: 56.6\n- Creatinine (mg/dL) Mean: 0.93\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 16.1\n- BUN (mg/dL) Median: 14.2\n- WBC (K) Mean: 7.1\n- WBC (K) Median: 7.4\n- Platelets (K) Mean: 245\n- Platelets (K) Median: 230\n\n### Adverse Events\n- AE ID: AE-0055, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0056, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0057, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0058, Description: nausea, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 51\n- ACE Inhibitor Count: 26\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-032, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_09\n- PD ID: PD-033, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_02\n- PD ID: PD-034, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_03\n\n### Investigator Notes\n- No new safety signals identified this week by local PI\n- Study drug accountability reconciled, no discrepancies\n- Regulatory binder audit: all documents current\n- Site 07 re-assay results: 6/8 specimens confirmed within 5% of original, 2 specimens offset by 12-15%\n\n### Events\n- Central lab courier pickup schedule adjusted for holiday\n- Medical monitor weekly call completed\n\n### Notes\n- Week 16: Site 07 re-assay complete; instrument offset confirmed for 2 of 8 specimens. Statin subgroup ALT approaching 2-3x ULN at multiple sites.",
          "meta": {
            "episode_type": "signal",
            "phase": "red_herring",
            "signal_density": "medium"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_048",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-19T10:30:00",
          "text": "## 2024-07-01 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 86\n- Active: 80\n- Screen Failures Cumulative: 37\n- Withdrawals Cumulative: 6\n\n### Enrollment By Cohort\n- 10mg: 19\n- 25mg: 22\n- 50mg: 23\n- 100mg: 22\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 1.46\n- KIM-1 (ng/mL) SD: 0.22\n- NGAL (ng/mL) Mean: 58.9\n- NGAL (ng/mL) SD: 13.5\n- Cystatin C (mg/L) Mean: 0.9\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 75.2\n- eGFR (mL/min) SD: 8.8\n- UACR (mg/g) Mean: 51.8\n- UACR (mg/g) SD: 19.1\n- Serum Creatinine (mg/dL) Mean: 1.2\n- Serum Creatinine (mg/dL) SD: 0.2\n- Urine Protein (mg/dL) Mean: 23.1\n- Urine Protein (mg/dL) SD: 7.5\n- Urine Output (mL/24h) Mean: 1812\n- Urine Output (mL/24h) SD: 366\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.35\n- KIM-1 (ng/mL) SD: 0.2\n- NGAL (ng/mL) Mean: 53.3\n- NGAL (ng/mL) SD: 10.2\n- Cystatin C (mg/L) Mean: 0.95\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 73.7\n- eGFR (mL/min) SD: 8.2\n- UACR (mg/g) Mean: 87.4\n- UACR (mg/g) SD: 14.9\n- Serum Creatinine (mg/dL) Mean: 1.28\n- Serum Creatinine (mg/dL) SD: 0.25\n- Urine Protein (mg/dL) Mean: 23.8\n- Urine Protein (mg/dL) SD: 6.9\n- Urine Output (mL/24h) Mean: 1841\n- Urine Output (mL/24h) SD: 382\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.72\n- KIM-1 (ng/mL) SD: 0.32\n- NGAL (ng/mL) Mean: 66.9\n- NGAL (ng/mL) SD: 12.7\n- Cystatin C (mg/L) Mean: 0.9\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 74.2\n- eGFR (mL/min) SD: 10.0\n- UACR (mg/g) Mean: 60.0\n- UACR (mg/g) SD: 25.3\n- Serum Creatinine (mg/dL) Mean: 1.43\n- Serum Creatinine (mg/dL) SD: 0.29\n- Urine Protein (mg/dL) Mean: 16.1\n- Urine Protein (mg/dL) SD: 7.2\n- Urine Output (mL/24h) Mean: 1770\n- Urine Output (mL/24h) SD: 365\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.42\n- KIM-1 (ng/mL) SD: 0.4\n- NGAL (ng/mL) Mean: 89.8\n- NGAL (ng/mL) SD: 16.1\n- Cystatin C (mg/L) Mean: 0.9\n- Cystatin C (mg/L) SD: 0.15\n- eGFR (mL/min) Mean: 55.2\n- eGFR (mL/min) SD: 9.2\n- UACR (mg/g) Mean: 107.0\n- UACR (mg/g) SD: 33.0\n- Serum Creatinine (mg/dL) Mean: 1.05\n- Serum Creatinine (mg/dL) SD: 0.28\n- Urine Protein (mg/dL) Mean: 28.3\n- Urine Protein (mg/dL) SD: 6.5\n- Urine Output (mL/24h) Mean: 1906\n- Urine Output (mL/24h) SD: 378\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.321\n- NGAL Dose Correlation (r): 0.212\n- eGFR Dose Correlation (r): -0.212\n- UACR Dose Correlation (r): 0.179\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.0\n- Hemoglobin (g/dL) SD: 1.2\n- Hematocrit (%) Mean: 42.1\n- Hematocrit (%) SD: 2.6\n- WBC (x10^3/\u00b5L) Mean: 6.2\n- WBC (x10^3/\u00b5L) SD: 1.1\n- Platelets (x10^3/\u00b5L) Mean: 245\n- Platelets (x10^3/\u00b5L) SD: 41\n- Sodium (mEq/L) Mean: 137.0\n- Sodium (mEq/L) SD: 2.2\n- Potassium (mEq/L) Mean: 3.9\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 22.8\n- Bicarbonate (mEq/L) SD: 1.5\n- Phosphorus (mg/dL) Mean: 3.5\n- Phosphorus (mg/dL) SD: 0.7\n\n### Adverse Events\n- AE ID: RB-AE-1814, Description: peripheral edema, Grade: 2, Relatedness: unlikely related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-1872, Description: peripheral edema, Grade: 2, Relatedness: possibly related, Resolved: true, Cohort: 50mg\n\n### Protocol Deviations\n- PD ID: RB-PD-1833, Description: Blood pressure measurement not recorded at visit, Severity: minor\n- PD ID: RB-PD-1826, Description: Urine sample collection outside 24h window, Severity: moderate\n\n### Events\n- Central lab urine biomarker batch analysis completed for Week 18\n- DSMB safety data snapshot prepared\n\n### Notes\n- Week 18: Renal biomarker collection on schedule. 86 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_049",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-21T10:30:00",
          "text": "## 2024-07-08 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 87\n- Active: 76\n- Screen Failures Cumulative: 43\n- Withdrawals Cumulative: 11\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 22\n- 50mg: 22\n- 100mg: 23\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 2.03\n- KIM-1 (ng/mL) SD: 0.35\n- NGAL (ng/mL) Mean: 73.8\n- NGAL (ng/mL) SD: 15.6\n- Cystatin C (mg/L) Mean: 1.09\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 61.2\n- eGFR (mL/min) SD: 13.5\n- UACR (mg/g) Mean: 83.9\n- UACR (mg/g) SD: 27.8\n- Serum Creatinine (mg/dL) Mean: 1.01\n- Serum Creatinine (mg/dL) SD: 0.1\n- Urine Protein (mg/dL) Mean: 27.2\n- Urine Protein (mg/dL) SD: 7.5\n- Urine Output (mL/24h) Mean: 1739\n- Urine Output (mL/24h) SD: 376\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 2.5\n- KIM-1 (ng/mL) SD: 0.52\n- NGAL (ng/mL) Mean: 75.9\n- NGAL (ng/mL) SD: 14.5\n- Cystatin C (mg/L) Mean: 0.92\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 72.2\n- eGFR (mL/min) SD: 10.4\n- UACR (mg/g) Mean: 118.5\n- UACR (mg/g) SD: 24.2\n- Serum Creatinine (mg/dL) Mean: 1.17\n- Serum Creatinine (mg/dL) SD: 0.16\n- Urine Protein (mg/dL) Mean: 34.1\n- Urine Protein (mg/dL) SD: 7.2\n- Urine Output (mL/24h) Mean: 1614\n- Urine Output (mL/24h) SD: 364\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.21\n- KIM-1 (ng/mL) SD: 0.34\n- NGAL (ng/mL) Mean: 89.3\n- NGAL (ng/mL) SD: 10.5\n- Cystatin C (mg/L) Mean: 1.16\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 53.4\n- eGFR (mL/min) SD: 8.6\n- UACR (mg/g) Mean: 97.7\n- UACR (mg/g) SD: 10.5\n- Serum Creatinine (mg/dL) Mean: 1.21\n- Serum Creatinine (mg/dL) SD: 0.22\n- Urine Protein (mg/dL) Mean: 24.5\n- Urine Protein (mg/dL) SD: 5.0\n- Urine Output (mL/24h) Mean: 1902\n- Urine Output (mL/24h) SD: 379\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.83\n- KIM-1 (ng/mL) SD: 0.38\n- NGAL (ng/mL) Mean: 87.1\n- NGAL (ng/mL) SD: 13.4\n- Cystatin C (mg/L) Mean: 0.87\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 54.9\n- eGFR (mL/min) SD: 11.9\n- UACR (mg/g) Mean: 109.4\n- UACR (mg/g) SD: 10.6\n- Serum Creatinine (mg/dL) Mean: 1.26\n- Serum Creatinine (mg/dL) SD: 0.29\n- Urine Protein (mg/dL) Mean: 35.0\n- Urine Protein (mg/dL) SD: 9.6\n- Urine Output (mL/24h) Mean: 1989\n- Urine Output (mL/24h) SD: 402\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.428\n- NGAL Dose Correlation (r): 0.449\n- eGFR Dose Correlation (r): -0.391\n- UACR Dose Correlation (r): 0.397\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 12.7\n- Hemoglobin (g/dL) SD: 0.9\n- Hematocrit (%) Mean: 43.4\n- Hematocrit (%) SD: 3.7\n- WBC (k/\u00b5L) Mean: 6.6\n- WBC (k/\u00b5L) SD: 1.4\n- Platelets (k/\u00b5L) Mean: 239\n- Platelets (k/\u00b5L) SD: 47\n- Sodium (mEq/L) Mean: 142.7\n- Sodium (mEq/L) SD: 2.4\n- Potassium (mEq/L) Mean: 4.2\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 27.2\n- Bicarbonate (mEq/L) SD: 1.7\n- Phosphorus (mg/dL) Mean: 3.7\n- Phosphorus (mg/dL) SD: 0.6\n\n### Adverse Events\n- AE ID: RB-AE-1959, Description: headache, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 25mg\n- AE ID: RB-AE-1926, Description: peripheral edema, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 25mg\n\n### Protocol Deviations\n- PD ID: RB-PD-1924, Description: Urine sample collection outside 24h window, Severity: minor\n\n### Events\n- Renal ultrasound images uploaded to central imaging core\n- eCRF query resolution: 16 queries closed this week\n\n### Notes\n- Week 19: Renal biomarker collection on schedule. 87 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_050",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-23T10:30:00",
          "text": "## 2024-07-15 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 86\n- Active: 75\n- Screen Failures Cumulative: 41\n- Withdrawals Cumulative: 11\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 20\n- 50mg: 22\n- 100mg: 24\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM1 (ng/mL) Mean: 2.11\n- KIM1 (ng/mL) SD: 0.46\n- NGAL (ng/mL) Mean: 44.2\n- NGAL (ng/mL) SD: 9.4\n- Cystatin C (mg/L) Mean: 0.97\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 68.1\n- eGFR (mL/min) SD: 12.1\n- UACR (mg/g) Mean: 74.8\n- UACR (mg/g) SD: 14.2\n- Serum Creatinine (mg/dL) Mean: 1.18\n- Serum Creatinine (mg/dL) SD: 0.21\n- Urine Protein (mg/dL) Mean: 13.4\n- Urine Protein (mg/dL) SD: 6.9\n- Urine Output (mL/24h) Mean: 1907\n- Urine Output (mL/24h) SD: 348\n\n#### 25mg\n- KIM1 (ng/mL) Mean: 1.86\n- KIM1 (ng/mL) SD: 0.4\n- NGAL (ng/mL) Mean: 50.8\n- NGAL (ng/mL) SD: 9.9\n- Cystatin C (mg/L) Mean: 1.06\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 74.3\n- eGFR (mL/min) SD: 14.4\n- UACR (mg/g) Mean: 61.4\n- UACR (mg/g) SD: 21.6\n- Serum Creatinine (mg/dL) Mean: 1.33\n- Serum Creatinine (mg/dL) SD: 0.17\n- Urine Protein (mg/dL) Mean: 28.4\n- Urine Protein (mg/dL) SD: 9.9\n- Urine Output (mL/24h) Mean: 1627\n- Urine Output (mL/24h) SD: 371\n\n#### 50mg\n- KIM1 (ng/mL) Mean: 1.83\n- KIM1 (ng/mL) SD: 0.59\n- NGAL (ng/mL) Mean: 90.4\n- NGAL (ng/mL) SD: 19.6\n- Cystatin C (mg/L) Mean: 0.77\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 56.9\n- eGFR (mL/min) SD: 9.6\n- UACR (mg/g) Mean: 52.5\n- UACR (mg/g) SD: 30.8\n- Serum Creatinine (mg/dL) Mean: 1.42\n- Serum Creatinine (mg/dL) SD: 0.18\n- Urine Protein (mg/dL) Mean: 26.3\n- Urine Protein (mg/dL) SD: 6.1\n- Urine Output (mL/24h) Mean: 1737\n- Urine Output (mL/24h) SD: 378\n\n#### 100mg\n- KIM1 (ng/mL) Mean: 1.44\n- KIM1 (ng/mL) SD: 0.35\n- NGAL (ng/mL) Mean: 55.0\n- NGAL (ng/mL) SD: 17.7\n- Cystatin C (mg/L) Mean: 1.23\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 49.3\n- eGFR (mL/min) SD: 11.8\n- UACR (mg/g) Mean: 115.5\n- UACR (mg/g) SD: 12.8\n- Serum Creatinine (mg/dL) Mean: 1.18\n- Serum Creatinine (mg/dL) SD: 0.22\n- Urine Protein (mg/dL) Mean: 37.2\n- Urine Protein (mg/dL) SD: 3.4\n- Urine Output (mL/24h) Mean: 1956\n- Urine Output (mL/24h) SD: 398\n\n### Dose Response\n- KIM1 Dose Correlation (r): 0.46\n- NGAL Dose Correlation (r): 0.386\n- eGFR Dose Correlation (r): -0.209\n- UACR Dose Correlation (r): 0.43\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.1\n- Hemoglobin (g/dL) SD: 0.9\n- Hematocrit (%) Mean: 42.8\n- Hematocrit (%) SD: 3.1\n- WBC (k/\u00b5L) Mean: 7.5\n- WBC (k/\u00b5L) SD: 1.4\n- Platelets (k/\u00b5L) Mean: 243\n- Platelets (k/\u00b5L) SD: 42\n- Sodium (mEq/L) Mean: 141.5\n- Sodium (mEq/L) SD: 1.7\n- Potassium (mEq/L) Mean: 4.0\n- Potassium (mEq/L) SD: 0.3\n- Bicarbonate (mEq/L) Mean: 26.8\n- Bicarbonate (mEq/L) SD: 2.0\n- Phosphorus (mg/dL) Mean: 3.8\n- Phosphorus (mg/dL) SD: 0.7\n\n### Adverse Events\n- AE ID: RB-AE-2007, Description: back pain, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 50mg\n- AE ID: RB-AE-2072, Description: hyperkalemia, Grade: 2, Relatedness: possibly related, Resolved: true, Cohort: 25mg\n- AE ID: RB-AE-2020, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 50mg\n- AE ID: RB-AE-2035, Description: dizziness, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 25mg\n\n### Protocol Deviations\n- PD ID: RB-PD-2047, Description: Lab kit expired, replacement used, Severity: moderate\n- PD ID: RB-PD-2050, Description: GFR measurement repeated due to hemolyzed sample, Severity: minor\n\n### Events\n- Lab kit resupply dispatched to sites with low inventory\n- Central lab urine biomarker batch analysis completed for Week 20\n- eCRF query resolution: 24 queries closed this week\n\n### Notes\n- Week 20: Renal biomarker collection on schedule. 86 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_017",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-24T10:00:00",
          "text": "## 2024-06-24 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 225\n- Active: 214\n- Screen Failures Cumulative: 30\n- Withdrawals Cumulative: 11\n\n#### Sites\n- Site 01 Enrolled: 23\n- Site 01 Active: 23\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 17\n- Site 02 Active: 17\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 21\n- Site 03 Active: 21\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 19\n- Site 05 Active: 19\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 13\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 19\n- Site 09 Active: 19\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 15\n- Site 10 Active: 15\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 21\n- Site 11 Active: 21\n- Site 11 Statin Concomitant: 7\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 53\n- ALT (U/L) Mean: 89.1\n- ALT (U/L) Median: 86.5\n- AST (U/L) Mean: 65.7\n- AST (U/L) Median: 63.9\n- Bilirubin (mg/dL) Mean: 1.13\n- Bilirubin (mg/dL) Median: 1.1\n- ALP (U/L) Mean: 80.0\n- ALP (U/L) Median: 75.0\n- Creatinine (mg/dL) Mean: 0.88\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 16.0\n- BUN (mg/dL) Median: 16.5\n- WBC (K) Mean: 7.9\n- WBC (K) Median: 6.9\n- Platelets (K) Mean: 249\n- Platelets (K) Median: 243\n\n#### Non-Statin Subgroup\n- N: 130\n- ALT (U/L) Mean: 29.6\n- ALT (U/L) Median: 29.5\n- AST (U/L) Mean: 21.7\n- AST (U/L) Median: 20.8\n- Bilirubin (mg/dL) Mean: 0.46\n- Bilirubin (mg/dL) Median: 0.42\n- ALP (U/L) Mean: 68.4\n- ALP (U/L) Median: 62.2\n- Creatinine (mg/dL) Mean: 0.9\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 15.7\n- BUN (mg/dL) Median: 15.3\n- WBC (K) Mean: 8.0\n- WBC (K) Median: 5.7\n- Platelets (K) Mean: 252\n- Platelets (K) Median: 230\n\n### Adverse Events\n- AE ID: AE-0059, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0060, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0061, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0062, Description: nausea, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0063, Description: abdominal pain, Grade: 2, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 54\n- ACE Inhibitor Count: 26\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 34\n\n### Protocol Deviations\n- PD ID: PD-035, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_10\n- PD ID: PD-036, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_04\n\n### Investigator Notes\n- Lab kits inventory adequate for next 4 weeks\n- Enrollment on track per protocol timeline\n- Site pharmacy inventory verified\n\n### Events\n- Medical monitor weekly call completed\n- Central lab courier pickup schedule adjusted for holiday\n\n### Notes\n- Week 17: Statin subgroup hepatic enzymes 2-3x ULN across sites. SAE reports under review. Non-statin subgroup within range.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_051",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-26T10:30:00",
          "text": "## 2024-07-22 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 86\n- Active: 78\n- Screen Failures Cumulative: 44\n- Withdrawals Cumulative: 8\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 21\n- 50mg: 23\n- 100mg: 22\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 1.0\n- KIM-1 (ng/mL) SD: 0.47\n- NGAL (ng/mL) Mean: 68.5\n- NGAL (ng/mL) SD: 11.4\n- Cystatin C (mg/L) Mean: 0.77\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 62.0\n- eGFR (mL/min) SD: 13.1\n- UACR (mg/g) Mean: 86.7\n- UACR (mg/g) SD: 14.6\n- Serum Creatinine (mg/dL) Mean: 1.12\n- Serum Creatinine (mg/dL) SD: 0.16\n- Urine Protein (mg/dL) Mean: 27.7\n- Urine Protein (mg/dL) SD: 5.0\n- Urine Output (mL/24h) Mean: 1836\n- Urine Output (mL/24h) SD: 324\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 2.28\n- KIM-1 (ng/mL) SD: 0.25\n- NGAL (ng/mL) Mean: 84.8\n- NGAL (ng/mL) SD: 13.2\n- Cystatin C (mg/L) Mean: 0.75\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 80.1\n- eGFR (mL/min) SD: 12.4\n- UACR (mg/g) Mean: 105.0\n- UACR (mg/g) SD: 12.7\n- Serum Creatinine (mg/dL) Mean: 1.45\n- Serum Creatinine (mg/dL) SD: 0.12\n- Urine Protein (mg/dL) Mean: 22.6\n- Urine Protein (mg/dL) SD: 6.8\n- Urine Output (mL/24h) Mean: 1921\n- Urine Output (mL/24h) SD: 380\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.66\n- KIM-1 (ng/mL) SD: 0.2\n- NGAL (ng/mL) Mean: 60.3\n- NGAL (ng/mL) SD: 17.1\n- Cystatin C (mg/L) Mean: 0.94\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 53.1\n- eGFR (mL/min) SD: 8.3\n- UACR (mg/g) Mean: 122.5\n- UACR (mg/g) SD: 20.4\n- Serum Creatinine (mg/dL) Mean: 1.45\n- Serum Creatinine (mg/dL) SD: 0.17\n- Urine Protein (mg/dL) Mean: 27.5\n- Urine Protein (mg/dL) SD: 6.7\n- Urine Output (mL/24h) Mean: 2001\n- Urine Output (mL/24h) SD: 393\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 1.78\n- KIM-1 (ng/mL) SD: 0.57\n- NGAL (ng/mL) Mean: 102.6\n- NGAL (ng/mL) SD: 16.7\n- Cystatin C (mg/L) Mean: 0.84\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 67.0\n- eGFR (mL/min) SD: 12.1\n- UACR (mg/g) Mean: 76.9\n- UACR (mg/g) SD: 17.5\n- Serum Creatinine (mg/dL) Mean: 1.28\n- Serum Creatinine (mg/dL) SD: 0.26\n- Urine Protein (mg/dL) Mean: 12.8\n- Urine Protein (mg/dL) SD: 6.7\n- Urine Output (mL/24h) Mean: 1921\n- Urine Output (mL/24h) SD: 324\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.46\n- NGAL Dose Correlation (r): 0.498\n- eGFR Dose Correlation (r): -0.337\n- UACR Dose Correlation (r): 0.373\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 12.7\n- Hemoglobin (g/dL) SD: 1.4\n- Hematocrit (%) Mean: 40.8\n- Hematocrit (%) SD: 3.1\n- WBC (k/\u00b5L) Mean: 5.9\n- WBC (k/\u00b5L) SD: 1.9\n- Platelets (k/\u00b5L) Mean: 226\n- Platelets (k/\u00b5L) SD: 48\n- Sodium (mEq/L) Mean: 142.3\n- Sodium (mEq/L) SD: 2.1\n- Potassium (mEq/L) Mean: 4.5\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 26.3\n- Bicarbonate (mEq/L) SD: 2.8\n- Phosphorus (mg/dL) Mean: 3.3\n- Phosphorus (mg/dL) SD: 0.4\n\n### Adverse Events\n- AE ID: RB-AE-2132, Description: back pain, Grade: 2, Relatedness: not related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-2159, Description: hyperkalemia, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 50mg\n- AE ID: RB-AE-2113, Description: fatigue, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-2177, Description: constipation, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 25mg\n\n### Protocol Deviations\n- None\n\n### Events\n- Renal ultrasound images uploaded to central imaging core\n- Protocol training refresher completed for site coordinators\n\n### Notes\n- Week 21: Renal biomarker collection on schedule. 86 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_052",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-28T10:30:00",
          "text": "## 2024-07-29 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 87\n- Active: 78\n- Screen Failures Cumulative: 39\n- Withdrawals Cumulative: 9\n\n#### By Cohort\n- 10mg: 19\n- 25mg: 22\n- 50mg: 23\n- 100mg: 23\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 0.86\n- KIM-1 (ng/mL) SD: 0.23\n- NGAL (ng/mL) Mean: 66.5\n- NGAL (ng/mL) SD: 8.6\n- Cystatin C (mg/L) Mean: 0.71\n- Cystatin C (mg/L) SD: 0.08\n- eGFR (mL/min) Mean: 82.6\n- eGFR (mL/min) SD: 12.5\n- UACR (mg/g) Mean: 112.8\n- UACR (mg/g) SD: 25.1\n- Serum Creatinine (mg/dL) Mean: 1.44\n- Serum Creatinine (mg/dL) SD: 0.17\n- Urine Protein (mg/dL) Mean: 34.0\n- Urine Protein (mg/dL) SD: 4.0\n- Urine Output (mL/24h) Mean: 1920\n- Urine Output (mL/24h) SD: 350\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 2.24\n- KIM-1 (ng/mL) SD: 0.59\n- NGAL (ng/mL) Mean: 63.9\n- NGAL (ng/mL) SD: 12.6\n- Cystatin C (mg/L) Mean: 1.02\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 65.5\n- eGFR (mL/min) SD: 11.7\n- UACR (mg/g) Mean: 77.0\n- UACR (mg/g) SD: 30.2\n- Serum Creatinine (mg/dL) Mean: 1.37\n- Serum Creatinine (mg/dL) SD: 0.19\n- Urine Protein (mg/dL) Mean: 41.1\n- Urine Protein (mg/dL) SD: 6.0\n- Urine Output (mL/24h) Mean: 1822\n- Urine Output (mL/24h) SD: 354\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.31\n- KIM-1 (ng/mL) SD: 0.22\n- NGAL (ng/mL) Mean: 51.5\n- NGAL (ng/mL) SD: 17.3\n- Cystatin C (mg/L) Mean: 1.12\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 50.0\n- eGFR (mL/min) SD: 12.3\n- UACR (mg/g) Mean: 76.9\n- UACR (mg/g) SD: 21.7\n- Serum Creatinine (mg/dL) Mean: 1.04\n- Serum Creatinine (mg/dL) SD: 0.19\n- Urine Protein (mg/dL) Mean: 25.9\n- Urine Protein (mg/dL) SD: 6.0\n- Urine Output (mL/24h) Mean: 1933\n- Urine Output (mL/24h) SD: 383\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 1.72\n- KIM-1 (ng/mL) SD: 0.49\n- NGAL (ng/mL) Mean: 82.4\n- NGAL (ng/mL) SD: 10.6\n- Cystatin C (mg/L) Mean: 1.04\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 55.9\n- eGFR (mL/min) SD: 9.3\n- UACR (mg/g) Mean: 104.3\n- UACR (mg/g) SD: 32.8\n- Serum Creatinine (mg/dL) Mean: 1.25\n- Serum Creatinine (mg/dL) SD: 0.25\n- Urine Protein (mg/dL) Mean: 17.8\n- Urine Protein (mg/dL) SD: 6.8\n- Urine Output (mL/24h) Mean: 1624\n- Urine Output (mL/24h) SD: 323\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.372\n- NGAL Dose Correlation (r): 0.535\n- eGFR Dose Correlation (r): -0.384\n- UACR Dose Correlation (r): 0.321\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.4\n- Hemoglobin (g/dL) SD: 1.0\n- Hematocrit (%) Mean: 40.5\n- Hematocrit (%) SD: 2.2\n- WBC (k/\u00b5L) Mean: 7.1\n- WBC (k/\u00b5L) SD: 1.8\n- Platelets (k/\u00b5L) Mean: 213\n- Platelets (k/\u00b5L) SD: 46\n- Sodium (mEq/L) Mean: 141.7\n- Sodium (mEq/L) SD: 2.0\n- Potassium (mEq/L) Mean: 4.6\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 22.6\n- Bicarbonate (mEq/L) SD: 2.2\n- Phosphorus (mg/dL) Mean: 4.2\n- Phosphorus (mg/dL) SD: 0.5\n\n### Adverse Events\n- AE ID: RB-AE-2205, Description: nausea, Grade: 2, Relatedness: possibly related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-2215, Description: muscle cramp, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-2247, Description: dizziness, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 100mg\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- Central lab urine biomarker batch analysis completed for Week 22\n- Cohort 25mg enrollment status reviewed at sponsor call\n\n### Notes\n- Week 22: Renal biomarker collection on schedule. 87 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_053",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-30T10:30:00",
          "text": "## 2024-08-05 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 84\n- Active: 73\n- Screen Failures Cumulative: 41\n- Withdrawals Cumulative: 11\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 20\n- 50mg: 21\n- 100mg: 23\n\n### Biomarkers By Cohort\n\n#### 10mg\n- KIM-1 (ng/mL) Mean: 2.49\n- KIM-1 (ng/mL) SD: 0.3\n- NGAL (ng/mL) Mean: 62.7\n- NGAL (ng/mL) SD: 14.0\n- Cystatin C (mg/L) Mean: 0.97\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 57.9\n- eGFR (mL/min) SD: 9.0\n- UACR (mg/g) Mean: 109.8\n- UACR (mg/g) SD: 12.5\n- Serum Creatinine (mg/dL) Mean: 1.28\n- Serum Creatinine (mg/dL) SD: 0.12\n- Urine Protein (mg/dL) Mean: 26.1\n- Urine Protein (mg/dL) SD: 4.7\n- Urine Output (mL/24h) Mean: 1858\n- Urine Output (mL/24h) SD: 332\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.46\n- KIM-1 (ng/mL) SD: 0.22\n- NGAL (ng/mL) Mean: 42.2\n- NGAL (ng/mL) SD: 12.0\n- Cystatin C (mg/L) Mean: 1.11\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 69.7\n- eGFR (mL/min) SD: 11.3\n- UACR (mg/g) Mean: 107.0\n- UACR (mg/g) SD: 28.6\n- Serum Creatinine (mg/dL) Mean: 1.26\n- Serum Creatinine (mg/dL) SD: 0.24\n- Urine Protein (mg/dL) Mean: 27.6\n- Urine Protein (mg/dL) SD: 5.5\n- Urine Output (mL/24h) Mean: 1809\n- Urine Output (mL/24h) SD: 326\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.73\n- KIM-1 (ng/mL) SD: 0.39\n- NGAL (ng/mL) Mean: 87.2\n- NGAL (ng/mL) SD: 12.7\n- Cystatin C (mg/L) Mean: 1.08\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 53.8\n- eGFR (mL/min) SD: 14.5\n- UACR (mg/g) Mean: 77.0\n- UACR (mg/g) SD: 33.8\n- Serum Creatinine (mg/dL) Mean: 1.4\n- Serum Creatinine (mg/dL) SD: 0.17\n- Urine Protein (mg/dL) Mean: 17.5\n- Urine Protein (mg/dL) SD: 3.1\n- Urine Output (mL/24h) Mean: 1877\n- Urine Output (mL/24h) SD: 360\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.25\n- KIM-1 (ng/mL) SD: 0.49\n- NGAL (ng/mL) Mean: 101.0\n- NGAL (ng/mL) SD: 16.3\n- Cystatin C (mg/L) Mean: 0.85\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 64.1\n- eGFR (mL/min) SD: 8.3\n- UACR (mg/g) Mean: 41.0\n- UACR (mg/g) SD: 13.2\n- Serum Creatinine (mg/dL) Mean: 1.07\n- Serum Creatinine (mg/dL) SD: 0.22\n- Urine Protein (mg/dL) Mean: 20.1\n- Urine Protein (mg/dL) SD: 8.2\n- Urine Output (mL/24h) Mean: 1975\n- Urine Output (mL/24h) SD: 305\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.347\n- NGAL Dose Correlation (r): 0.423\n- eGFR Dose Correlation (r): -0.222\n- UACR Dose Correlation (r): 0.271\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.3\n- Hemoglobin (g/dL) SD: 1.2\n- Hematocrit (%) Mean: 42.7\n- Hematocrit (%) SD: 2.9\n- WBC (k/\u00b5L) Mean: 7.1\n- WBC (k/\u00b5L) SD: 2.0\n- Platelets (k/\u00b5L) Mean: 234\n- Platelets (k/\u00b5L) SD: 44\n- Sodium (mEq/L) Mean: 138.4\n- Sodium (mEq/L) SD: 1.8\n- Potassium (mEq/L) Mean: 4.4\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 27.5\n- Bicarbonate (mEq/L) SD: 2.4\n- Phosphorus (mg/dL) Mean: 3.8\n- Phosphorus (mg/dL) SD: 0.4\n\n### Adverse Events\n- AE ID: RB-AE-2309, Description: nausea, Grade: 2, Relatedness: not related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-2364, Description: peripheral edema, Grade: 1, Relatedness: possibly related, Resolved: true, Cohort: 10mg\n\n### Protocol Deviations\n- PD ID: RB-PD-2341, Description: Dose adjustment documentation incomplete, Severity: minor\n- PD ID: RB-PD-2311, Description: Missed scheduled renal ultrasound, rescheduled, Severity: minor\n\n### Events\n- Renal ultrasound images uploaded to central imaging core\n- eCRF query resolution: 13 queries closed this week\n- DSMB safety data snapshot prepared\n\n### Notes\n- Week 23: Renal biomarker collection on schedule. 84 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_018",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-01T10:00:00",
          "text": "## 2024-07-01 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 210\n- Active: 204\n- Screen Failures Cumulative: 53\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01 Enrolled: 21\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 19\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 17\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 4\n- Site 07 Enrolled: 23\n- Site 07 Active: 23\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 17\n- Site 09 Active: 17\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 19\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup N: 53\n- Statin Subgroup ALT Mean (U/L): 90.2\n- Statin Subgroup ALT Median (U/L): 88.7\n- Statin Subgroup AST Mean (U/L): 69.2\n- Statin Subgroup AST Median (U/L): 69.1\n- Statin Subgroup Bilirubin Mean (mg/dL): 1.44\n- Statin Subgroup Bilirubin Median (mg/dL): 1.43\n- Statin Subgroup ALP Mean (U/L): 83.4\n- Statin Subgroup ALP Median (U/L): 76.7\n- Statin Subgroup Creatinine Mean (mg/dL): 0.85\n- Statin Subgroup Creatinine Median (mg/dL): 0.87\n- Statin Subgroup BUN Mean (mg/dL): 17.2\n- Statin Subgroup BUN Median (mg/dL): 14.6\n- Statin Subgroup WBC Mean (K/uL): 6.8\n- Statin Subgroup WBC Median (K/uL): 7.6\n- Statin Subgroup Platelets Mean (K/uL): 225\n- Statin Subgroup Platelets Median (K/uL): 215\n- Non-Statin Subgroup N: 120\n- Non-Statin Subgroup ALT Mean (U/L): 25.7\n- Non-Statin Subgroup ALT Median (U/L): 23.9\n- Non-Statin Subgroup AST Mean (U/L): 18.7\n- Non-Statin Subgroup AST Median (U/L): 17.5\n- Non-Statin Subgroup Bilirubin Mean (mg/dL): 0.64\n- Non-Statin Subgroup Bilirubin Median (mg/dL): 0.64\n- Non-Statin Subgroup ALP Mean (U/L): 52.5\n- Non-Statin Subgroup ALP Median (U/L): 54.2\n- Non-Statin Subgroup Creatinine Mean (mg/dL): 0.87\n- Non-Statin Subgroup Creatinine Median (mg/dL): 0.95\n- Non-Statin Subgroup BUN Mean (mg/dL): 17.1\n- Non-Statin Subgroup BUN Median (mg/dL): 16.5\n- Non-Statin Subgroup WBC Mean (K/uL): 6.6\n- Non-Statin Subgroup WBC Median (K/uL): 6.9\n- Non-Statin Subgroup Platelets Mean (K/uL): 256\n- Non-Statin Subgroup Platelets Median (K/uL): 255\n\n### Adverse Events\n- AE ID: AE-0064, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0065, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0066, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0067, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0068, Description: abdominal pain, Grade: 2, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0069, Description: fatigue, Grade: 2, Relatedness: possibly related, Resolved: false, Subject Group: statin\n- AE ID: AE-0070, Description: Hy's Law case: ALT 4.2x ULN, total bilirubin 2.8x ULN, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 26\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 13\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-037, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_06\n- PD ID: PD-038, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_10\n- PD ID: PD-039, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_10\n\n### Investigator Notes\n- Central lab results received within 48h turnaround\n- Source document verification complete for prior monitoring visit\n- Site pharmacy inventory verified\n- SAE report filed: subject 07-118, statin subgroup, ALT 4.2x ULN with bilirubin 2.8x ULN\n- Statin subgroup hepatic panel mean ALT 95 U/L across 8 sites\n\n### Events\n- Data management plan revision v2.5 distributed\n- Data management plan revision v2.2 distributed\n- Site 08 monitoring visit completed, 3 findings\n- SAE report submitted to sponsor safety group within 24h\n\n### Notes\n- Week 18: Statin subgroup hepatic enzymes 2-3x ULN across sites. SAE reports under review. Non-statin subgroup within range.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_054",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-02T10:30:00",
          "text": "## 2024-08-12 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 84\n- Active: 69\n- Screen Failures Cumulative: 44\n- Withdrawals Cumulative: 15\n\n### Enrollment by Cohort\n- 10mg: 20\n- 25mg: 21\n- 50mg: 21\n- 100mg: 22\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 2.36\n- KIM-1 (ng/mL) SD: 0.4\n- NGAL (ng/mL) Mean: 83.1\n- NGAL (ng/mL) SD: 15.2\n- Cystatin C (mg/L) Mean: 0.85\n- Cystatin C (mg/L) SD: 0.08\n- eGFR (mL/min) Mean: 76.9\n- eGFR (mL/min) SD: 12.8\n- UACR (mg/g) Mean: 61.0\n- UACR (mg/g) SD: 27.0\n- Serum Creatinine (mg/dL) Mean: 1.19\n- Serum Creatinine (mg/dL) SD: 0.11\n- Urine Protein (mg/dL) Mean: 11.0\n- Urine Protein (mg/dL) SD: 6.9\n- Urine Output (mL/24h) Mean: 1896\n- Urine Output (mL/24h) SD: 303\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.73\n- KIM-1 (ng/mL) SD: 0.44\n- NGAL (ng/mL) Mean: 44.1\n- NGAL (ng/mL) SD: 15.7\n- Cystatin C (mg/L) Mean: 0.8\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 78.5\n- eGFR (mL/min) SD: 9.8\n- UACR (mg/g) Mean: 89.5\n- UACR (mg/g) SD: 26.4\n- Serum Creatinine (mg/dL) Mean: 1.37\n- Serum Creatinine (mg/dL) SD: 0.3\n- Urine Protein (mg/dL) Mean: 29.9\n- Urine Protein (mg/dL) SD: 9.3\n- Urine Output (mL/24h) Mean: 1905\n- Urine Output (mL/24h) SD: 324\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.81\n- KIM-1 (ng/mL) SD: 0.25\n- NGAL (ng/mL) Mean: 77.7\n- NGAL (ng/mL) SD: 10.8\n- Cystatin C (mg/L) Mean: 1.2\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 59.7\n- eGFR (mL/min) SD: 8.6\n- UACR (mg/g) Mean: 87.4\n- UACR (mg/g) SD: 20.2\n- Serum Creatinine (mg/dL) Mean: 1.2\n- Serum Creatinine (mg/dL) SD: 0.19\n- Urine Protein (mg/dL) Mean: 42.4\n- Urine Protein (mg/dL) SD: 9.4\n- Urine Output (mL/24h) Mean: 1787\n- Urine Output (mL/24h) SD: 335\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 1.74\n- KIM-1 (ng/mL) SD: 0.48\n- NGAL (ng/mL) Mean: 69.9\n- NGAL (ng/mL) SD: 16.3\n- Cystatin C (mg/L) Mean: 0.95\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 62.6\n- eGFR (mL/min) SD: 13.6\n- UACR (mg/g) Mean: 125.0\n- UACR (mg/g) SD: 14.8\n- Serum Creatinine (mg/dL) Mean: 1.03\n- Serum Creatinine (mg/dL) SD: 0.29\n- Urine Protein (mg/dL) Mean: 19.2\n- Urine Protein (mg/dL) SD: 9.2\n- Urine Output (mL/24h) Mean: 1932\n- Urine Output (mL/24h) SD: 352\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.615\n- NGAL Dose Correlation (r): 0.292\n- eGFR Dose Correlation (r): -0.347\n- UACR Dose Correlation (r): 0.394\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 12.9\n- Hemoglobin (g/dL) SD: 1.2\n- Hematocrit (%) Mean: 41.5\n- Hematocrit (%) SD: 3.0\n- WBC (k/\u00b5L) Mean: 7.1\n- WBC (k/\u00b5L) SD: 1.0\n- Platelets (k/\u00b5L) Mean: 227\n- Platelets (k/\u00b5L) SD: 42\n- Sodium (mEq/L) Mean: 139.6\n- Sodium (mEq/L) SD: 2.0\n- Potassium (mEq/L) Mean: 4.7\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 22.5\n- Bicarbonate (mEq/L) SD: 2.1\n- Phosphorus (mg/dL) Mean: 3.8\n- Phosphorus (mg/dL) SD: 0.6\n\n### Adverse Events\n- AE ID: RB-AE-2461\n  - Description: constipation\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Cohort: 25mg\n- AE ID: RB-AE-2437\n  - Description: hyperkalemia\n  - Grade: 1\n  - Relatedness: not related\n  - Resolved: true\n  - Cohort: 25mg\n\n### Protocol Deviations\n- No protocol deviations reported.\n\n### Events\n- eCRF query resolution: 18 queries closed this week\n- Protocol training refresher completed for site coordinators\n- Cohort 50mg enrollment status reviewed at sponsor call\n\n### Notes\n- Week 24: Renal biomarker collection on schedule. 84 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_055",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-05T10:30:00",
          "text": "## 2024-08-19 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 82\n- Active: 68\n- Screen Failures Cumulative: 47\n- Withdrawals Cumulative: 14\n\n#### By Cohort\n- 10mg: 19\n- 25mg: 20\n- 50mg: 21\n- 100mg: 22\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 2.2\n- KIM-1 (ng/mL) SD: 0.23\n- NGAL (ng/mL) Mean: 64.0\n- NGAL (ng/mL) SD: 12.4\n- Cystatin C (mg/L) Mean: 0.72\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 80.3\n- eGFR (mL/min) SD: 8.8\n- UACR (mg/g) Mean: 52.2\n- UACR (mg/g) SD: 15.3\n- Serum Creatinine (mg/dL) Mean: 1.36\n- Serum Creatinine (mg/dL) SD: 0.15\n- Urine Protein (mg/dL) Mean: 22.5\n- Urine Protein (mg/dL) SD: 9.3\n- Urine Output (mL/24h) Mean: 2010\n- Urine Output (mL/24h) SD: 384\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 1.5\n- KIM-1 (ng/mL) SD: 0.26\n- NGAL (ng/mL) Mean: 50.8\n- NGAL (ng/mL) SD: 16.0\n- Cystatin C (mg/L) Mean: 1.0\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 74.5\n- eGFR (mL/min) SD: 12.8\n- UACR (mg/g) Mean: 83.6\n- UACR (mg/g) SD: 33.2\n- Serum Creatinine (mg/dL) Mean: 1.43\n- Serum Creatinine (mg/dL) SD: 0.21\n- Urine Protein (mg/dL) Mean: 11.2\n- Urine Protein (mg/dL) SD: 7.7\n- Urine Output (mL/24h) Mean: 1966\n- Urine Output (mL/24h) SD: 310\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 1.04\n- KIM-1 (ng/mL) SD: 0.48\n- NGAL (ng/mL) Mean: 96.5\n- NGAL (ng/mL) SD: 16.8\n- Cystatin C (mg/L) Mean: 0.96\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 55.4\n- eGFR (mL/min) SD: 9.0\n- UACR (mg/g) Mean: 40.9\n- UACR (mg/g) SD: 15.5\n- Serum Creatinine (mg/dL) Mean: 1.46\n- Serum Creatinine (mg/dL) SD: 0.28\n- Urine Protein (mg/dL) Mean: 12.3\n- Urine Protein (mg/dL) SD: 7.3\n- Urine Output (mL/24h) Mean: 1800\n- Urine Output (mL/24h) SD: 306\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.09\n- KIM-1 (ng/mL) SD: 0.22\n- NGAL (ng/mL) Mean: 75.2\n- NGAL (ng/mL) SD: 14.9\n- Cystatin C (mg/L) Mean: 1.04\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 70.9\n- eGFR (mL/min) SD: 14.5\n- UACR (mg/g) Mean: 91.6\n- UACR (mg/g) SD: 10.6\n- Serum Creatinine (mg/dL) Mean: 1.06\n- Serum Creatinine (mg/dL) SD: 0.13\n- Urine Protein (mg/dL) Mean: 35.6\n- Urine Protein (mg/dL) SD: 5.3\n- Urine Output (mL/24h) Mean: 1954\n- Urine Output (mL/24h) SD: 332\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.463\n- NGAL Dose Correlation (r): 0.427\n- eGFR Dose Correlation (r): -0.372\n- UACR Dose Correlation (r): 0.152\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 12.7\n- Hemoglobin (g/dL) SD: 1.1\n- Hematocrit (%) Mean: 43.6\n- Hematocrit (%) SD: 3.0\n- WBC (k/\u00b5L) Mean: 6.2\n- WBC (k/\u00b5L) SD: 1.7\n- Platelets (k/\u00b5L) Mean: 213\n- Platelets (k/\u00b5L) SD: 45\n- Sodium (mEq/L) Mean: 138.8\n- Sodium (mEq/L) SD: 2.4\n- Potassium (mEq/L) Mean: 3.8\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 25.3\n- Bicarbonate (mEq/L) SD: 2.4\n- Phosphorus (mg/dL) Mean: 4.4\n- Phosphorus (mg/dL) SD: 0.7\n\n### Adverse Events\n- AE ID: RB-AE-2547, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-2521, Description: peripheral edema, Grade: 2, Relatedness: possibly related, Resolved: true, Cohort: 25mg\n\n### Protocol Deviations\n- PD ID: RB-PD-2540, Description: Dose adjustment documentation incomplete, Severity: minor\n- PD ID: RB-PD-2537, Description: Blood pressure measurement not recorded at visit, Severity: minor\n\n### Events\n- Protocol training refresher completed for site coordinators\n- Bioanalytical lab shipment: 42 frozen urine aliquots dispatched\n- DSMB safety data snapshot prepared\n\n### Notes\n- Week 25: Renal biomarker collection on schedule. 82 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_056",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-07T10:30:00",
          "text": "## 2024-08-26 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 85\n- Active: 73\n- Screen Failures Cumulative: 48\n- Withdrawals Cumulative: 12\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 21\n- 50mg: 21\n- 100mg: 23\n\n### Biomarkers By Cohort\n\n#### 10mg\n- KIM-1 (ng/mL) Mean: 1.24\n- KIM-1 (ng/mL) SD: 0.5\n- NGAL (ng/mL) Mean: 60.6\n- NGAL (ng/mL) SD: 9.7\n- Cystatin C (mg/L) Mean: 0.91\n- Cystatin C (mg/L) SD: 0.15\n- eGFR (mL/min) Mean: 57.0\n- eGFR (mL/min) SD: 11.6\n- UACR (mg/g) Mean: 114.0\n- UACR (mg/g) SD: 20.3\n- Serum Creatinine (mg/dL) Mean: 1.07\n- Serum Creatinine (mg/dL) SD: 0.25\n- Urine Protein (mg/dL) Mean: 29.1\n- Urine Protein (mg/dL) SD: 7.3\n- Urine Output (mL/24h) Mean: 1630\n- Urine Output (mL/24h) SD: 372\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 2.28\n- KIM-1 (ng/mL) SD: 0.44\n- NGAL (ng/mL) Mean: 48.7\n- NGAL (ng/mL) SD: 13.9\n- Cystatin C (mg/L) Mean: 0.87\n- Cystatin C (mg/L) SD: 0.09\n- eGFR (mL/min) Mean: 73.6\n- eGFR (mL/min) SD: 8.1\n- UACR (mg/g) Mean: 75.3\n- UACR (mg/g) SD: 13.6\n- Serum Creatinine (mg/dL) Mean: 1.41\n- Serum Creatinine (mg/dL) SD: 0.12\n- Urine Protein (mg/dL) Mean: 16.1\n- Urine Protein (mg/dL) SD: 7.4\n- Urine Output (mL/24h) Mean: 1755\n- Urine Output (mL/24h) SD: 381\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 2.31\n- KIM-1 (ng/mL) SD: 0.36\n- NGAL (ng/mL) Mean: 85.8\n- NGAL (ng/mL) SD: 11.6\n- Cystatin C (mg/L) Mean: 1.0\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 67.8\n- eGFR (mL/min) SD: 10.1\n- UACR (mg/g) Mean: 109.5\n- UACR (mg/g) SD: 28.5\n- Serum Creatinine (mg/dL) Mean: 1.24\n- Serum Creatinine (mg/dL) SD: 0.24\n- Urine Protein (mg/dL) Mean: 20.1\n- Urine Protein (mg/dL) SD: 4.8\n- Urine Output (mL/24h) Mean: 1914\n- Urine Output (mL/24h) SD: 346\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 2.15\n- KIM-1 (ng/mL) SD: 0.37\n- NGAL (ng/mL) Mean: 74.6\n- NGAL (ng/mL) SD: 11.5\n- Cystatin C (mg/L) Mean: 1.24\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 65.8\n- eGFR (mL/min) SD: 9.4\n- UACR (mg/g) Mean: 132.0\n- UACR (mg/g) SD: 16.2\n- Serum Creatinine (mg/dL) Mean: 1.11\n- Serum Creatinine (mg/dL) SD: 0.3\n- Urine Protein (mg/dL) Mean: 17.8\n- Urine Protein (mg/dL) SD: 5.5\n- Urine Output (mL/24h) Mean: 1768\n- Urine Output (mL/24h) SD: 354\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.314\n- NGAL Dose Correlation (r): 0.409\n- eGFR Dose Correlation (r): -0.357\n- UACR Dose Correlation (r): 0.437\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 14.8\n- Hemoglobin (g/dL) SD: 1.2\n- Hematocrit (%) Mean: 40.0\n- Hematocrit (%) SD: 3.7\n- WBC (k/\u00b5L) Mean: 8.2\n- WBC (k/\u00b5L) SD: 1.5\n- Platelets (k/\u00b5L) Mean: 242\n- Platelets (k/\u00b5L) SD: 44\n- Sodium (mEq/L) Mean: 142.6\n- Sodium (mEq/L) SD: 1.7\n- Potassium (mEq/L) Mean: 4.5\n- Potassium (mEq/L) SD: 0.5\n- Bicarbonate (mEq/L) Mean: 25.5\n- Bicarbonate (mEq/L) SD: 2.4\n- Phosphorus (mg/dL) Mean: 4.4\n- Phosphorus (mg/dL) SD: 0.6\n\n### Adverse Events\n- AE ID: RB-AE-2620, Description: dizziness, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-2680, Description: nausea, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-2652, Description: muscle cramp, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 50mg\n- AE ID: RB-AE-2651, Description: constipation, Grade: 2, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n\n### Protocol Deviations\n- No protocol deviations recorded.\n\n### Events\n- Bioanalytical lab shipment: 44 frozen urine aliquots dispatched\n- Drug supply reconciliation completed at 23 sites\n\n### Notes\n- Week 26: Renal biomarker collection on schedule. 85 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_019",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-08T10:00:00",
          "text": "## 2024-07-08 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 202\n- Active: 196\n- Screen Failures Cumulative: 37\n- Withdrawals Cumulative: 6\n\n### Sites\n- Site 01\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 02\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 3\n- Site 03\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 3\n- Site 05\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 12\n  - Active: 12\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 7\n- Site 08\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 4\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 3\n- Site 11\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 12\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup\n  - N: 54\n  - ALT (U/L) Mean: 103.2\n  - ALT (U/L) Median: 100.3\n  - AST (U/L) Mean: 73.7\n  - AST (U/L) Median: 73.6\n  - Bilirubin (mg/dL) Mean: 1.56\n  - Bilirubin (mg/dL) Median: 1.53\n  - ALP (U/L) Mean: 74.1\n  - ALP (U/L) Median: 69.1\n  - Creatinine (mg/dL) Mean: 0.82\n  - Creatinine (mg/dL) Median: 0.95\n  - BUN (mg/dL) Mean: 13.4\n  - BUN (mg/dL) Median: 13.0\n  - WBC (K) Mean: 7.8\n  - WBC (K) Median: 5.9\n  - Platelets (K) Mean: 262\n  - Platelets (K) Median: 233\n- Non-Statin Subgroup\n  - N: 120\n  - ALT (U/L) Mean: 24.5\n  - ALT (U/L) Median: 23.8\n  - AST (U/L) Mean: 23.2\n  - AST (U/L) Median: 22.3\n  - Bilirubin (mg/dL) Mean: 0.64\n  - Bilirubin (mg/dL) Median: 0.62\n  - ALP (U/L) Mean: 50.8\n  - ALP (U/L) Median: 56.3\n  - Creatinine (mg/dL) Mean: 1.04\n  - Creatinine (mg/dL) Median: 0.95\n  - BUN (mg/dL) Mean: 15.2\n  - BUN (mg/dL) Median: 12.9\n  - WBC (K) Mean: 5.7\n  - WBC (K) Median: 7.1\n  - Platelets (K) Mean: 242\n  - Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0071\n  - Description: insomnia\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0072\n  - Description: headache\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0073\n  - Description: fatigue\n  - Grade: 2\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0074\n  - Description: fatigue\n  - Grade: 2\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-040\n  - Description: IP temperature excursion during shipment, 2h out of range\n  - Severity: moderate\n  - Site: site_08\n- PD ID: PD-041\n  - Description: Concomitant medication not recorded at visit\n  - Severity: minor\n  - Site: site_07\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- EDC data entry backlog cleared, queries resolved\n- Cross-site review: statin subgroup ALT out of range at Sites 01, 03, 05, 07, 09, 11; non-statin subgroup within reference range at all sites\n\n### Events\n- Drug accountability audit at Site 04: no discrepancies\n- IVRS system update deployed, randomization unaffected\n- Medical monitor weekly call completed\n\n### Notes\n- Week 19: Statin subgroup hepatic enzymes 2-3x ULN across sites. SAE reports under review. Non-statin subgroup within range.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_057",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-09T10:30:00",
          "text": "## 2024-09-02 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 86\n- Active: 73\n- Screen Failures Cumulative: 62\n- Withdrawals Cumulative: 13\n\n### Enrollment by Cohort\n- 10mg: 20\n- 25mg: 21\n- 50mg: 22\n- 100mg: 23\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/ml) Mean: 0.85\n- KIM-1 (ng/ml) SD: 0.35\n- NGAL (ng/ml) Mean: 71.4\n- NGAL (ng/ml) SD: 17.2\n- Cystatin C (mg/L) Mean: 0.79\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (ml/min) Mean: 76.9\n- eGFR (ml/min) SD: 14.3\n- UACR (mg/g) Mean: 47.3\n- UACR (mg/g) SD: 18.2\n- Serum Creatinine (mg/dl) Mean: 1.43\n- Serum Creatinine (mg/dl) SD: 0.17\n- Urine Protein (mg/dl) Mean: 18.7\n- Urine Protein (mg/dl) SD: 9.4\n- Urine Output (ml/24h) Mean: 1722\n- Urine Output (ml/24h) SD: 313\n\n#### 25mg\n- KIM-1 (ng/ml) Mean: 1.0\n- KIM-1 (ng/ml) SD: 0.22\n- NGAL (ng/ml) Mean: 91.9\n- NGAL (ng/ml) SD: 10.4\n- Cystatin C (mg/L) Mean: 0.95\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (ml/min) Mean: 67.0\n- eGFR (ml/min) SD: 8.2\n- UACR (mg/g) Mean: 87.0\n- UACR (mg/g) SD: 25.4\n- Serum Creatinine (mg/dl) Mean: 1.33\n- Serum Creatinine (mg/dl) SD: 0.24\n- Urine Protein (mg/dl) Mean: 38.7\n- Urine Protein (mg/dl) SD: 8.8\n- Urine Output (ml/24h) Mean: 1803\n- Urine Output (ml/24h) SD: 303\n\n#### 50mg\n- KIM-1 (ng/ml) Mean: 2.49\n- KIM-1 (ng/ml) SD: 0.42\n- NGAL (ng/ml) Mean: 76.8\n- NGAL (ng/ml) SD: 18.4\n- Cystatin C (mg/L) Mean: 1.02\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (ml/min) Mean: 76.7\n- eGFR (ml/min) SD: 14.3\n- UACR (mg/g) Mean: 38.4\n- UACR (mg/g) SD: 17.8\n- Serum Creatinine (mg/dl) Mean: 1.24\n- Serum Creatinine (mg/dl) SD: 0.14\n- Urine Protein (mg/dl) Mean: 34.2\n- Urine Protein (mg/dl) SD: 8.4\n- Urine Output (ml/24h) Mean: 1614\n- Urine Output (ml/24h) SD: 381\n\n#### 100mg\n- KIM-1 (ng/ml) Mean: 1.12\n- KIM-1 (ng/ml) SD: 0.23\n- NGAL (ng/ml) Mean: 72.9\n- NGAL (ng/ml) SD: 11.1\n- Cystatin C (mg/L) Mean: 1.16\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (ml/min) Mean: 48.0\n- eGFR (ml/min) SD: 11.2\n- UACR (mg/g) Mean: 79.2\n- UACR (mg/g) SD: 17.0\n- Serum Creatinine (mg/dl) Mean: 1.07\n- Serum Creatinine (mg/dl) SD: 0.2\n- Urine Protein (mg/dl) Mean: 43.6\n- Urine Protein (mg/dl) SD: 5.1\n- Urine Output (ml/24h) Mean: 1912\n- Urine Output (ml/24h) SD: 362\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.459\n- NGAL Dose Correlation (r): 0.257\n- eGFR Dose Correlation (r): -0.19\n- UACR Dose Correlation (r): 0.178\n\n### Safety Labs\n- Hemoglobin (g/dl) Mean: 14.1\n- Hemoglobin (g/dl) SD: 1.2\n- Hematocrit (%) Mean: 40.2\n- Hematocrit (%) SD: 3.7\n- WBC (k) Mean: 6.7\n- WBC (k) SD: 1.2\n- Platelets (k) Mean: 243\n- Platelets (k) SD: 48\n- Sodium (meq/L) Mean: 138.6\n- Sodium (meq/L) SD: 3.0\n- Potassium (meq/L) Mean: 4.4\n- Potassium (meq/L) SD: 0.4\n- Bicarbonate (meq/L) Mean: 23.3\n- Bicarbonate (meq/L) SD: 2.7\n- Phosphorus (mg/dl) Mean: 3.7\n- Phosphorus (mg/dl) SD: 0.8\n\n### Adverse Events\n- AE ID: RB-AE-2714, Description: dizziness, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-2744, Description: headache, Grade: 2, Relatedness: not related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-2720, Description: headache, Grade: 1, Relatedness: not related, Resolved: true, Cohort: 25mg\n\n### Protocol Deviations\n- PD ID: RB-PD-2750, Description: Missed scheduled renal ultrasound, rescheduled, Severity: minor\n\n### Events\n- Lab kit resupply dispatched to sites with low inventory\n- Bioanalytical lab shipment: 28 frozen urine aliquots dispatched\n- Bioanalytical lab shipment: 20 frozen urine aliquots dispatched\n\n### Notes\n- Week 27: Renal biomarker collection on schedule. 86 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_058",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-12T10:30:00",
          "text": "## 2024-09-09 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 84\n- Active: 68\n- Screen Failures Cumulative: 55\n- Withdrawals Cumulative: 16\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 20\n- 50mg: 21\n- 100mg: 23\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM1 (ng/mL) Mean: 2.01\n- KIM1 (ng/mL) SD: 0.31\n- NGAL (ng/mL) Mean: 70.9\n- NGAL (ng/mL) SD: 8.2\n- Cystatin C (mg/L) Mean: 0.79\n- Cystatin C (mg/L) SD: 0.12\n- eGFR (mL/min) Mean: 76.8\n- eGFR (mL/min) SD: 10.9\n- UACR (mg/g) Mean: 41.5\n- UACR (mg/g) SD: 16.0\n- Serum Creatinine (mg/dL) Mean: 1.15\n- Serum Creatinine (mg/dL) SD: 0.2\n- Urine Protein (mg/dL) Mean: 27.5\n- Urine Protein (mg/dL) SD: 8.2\n- Urine Output (mL/24h) Mean: 1707\n- Urine Output (mL/24h) SD: 388\n\n#### 25mg\n- KIM1 (ng/mL) Mean: 2.57\n- KIM1 (ng/mL) SD: 0.59\n- NGAL (ng/mL) Mean: 52.3\n- NGAL (ng/mL) SD: 19.5\n- Cystatin C (mg/L) Mean: 1.08\n- Cystatin C (mg/L) SD: 0.14\n- eGFR (mL/min) Mean: 60.0\n- eGFR (mL/min) SD: 10.9\n- UACR (mg/g) Mean: 47.1\n- UACR (mg/g) SD: 13.0\n- Serum Creatinine (mg/dL) Mean: 1.45\n- Serum Creatinine (mg/dL) SD: 0.25\n- Urine Protein (mg/dL) Mean: 38.5\n- Urine Protein (mg/dL) SD: 5.4\n- Urine Output (mL/24h) Mean: 1756\n- Urine Output (mL/24h) SD: 305\n\n#### 50mg\n- KIM1 (ng/mL) Mean: 2.48\n- KIM1 (ng/mL) SD: 0.47\n- NGAL (ng/mL) Mean: 44.5\n- NGAL (ng/mL) SD: 9.8\n- Cystatin C (mg/L) Mean: 0.99\n- Cystatin C (mg/L) SD: 0.1\n- eGFR (mL/min) Mean: 70.8\n- eGFR (mL/min) SD: 9.5\n- UACR (mg/g) Mean: 53.6\n- UACR (mg/g) SD: 11.2\n- Serum Creatinine (mg/dL) Mean: 1.4\n- Serum Creatinine (mg/dL) SD: 0.28\n- Urine Protein (mg/dL) Mean: 28.1\n- Urine Protein (mg/dL) SD: 7.5\n- Urine Output (mL/24h) Mean: 2014\n- Urine Output (mL/24h) SD: 316\n\n#### 100mg\n- KIM1 (ng/mL) Mean: 1.54\n- KIM1 (ng/mL) SD: 0.46\n- NGAL (ng/mL) Mean: 81.1\n- NGAL (ng/mL) SD: 10.2\n- Cystatin C (mg/L) Mean: 1.18\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 67.0\n- eGFR (mL/min) SD: 11.3\n- UACR (mg/g) Mean: 59.4\n- UACR (mg/g) SD: 19.6\n- Serum Creatinine (mg/dL) Mean: 1.15\n- Serum Creatinine (mg/dL) SD: 0.2\n- Urine Protein (mg/dL) Mean: 30.2\n- Urine Protein (mg/dL) SD: 4.1\n- Urine Output (mL/24h) Mean: 1985\n- Urine Output (mL/24h) SD: 363\n\n### Dose Response\n- KIM1 Dose Correlation (r): 0.619\n- NGAL Dose Correlation (r): 0.227\n- eGFR Dose Correlation (r): -0.152\n- UACR Dose Correlation (r): 0.413\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.9\n- Hemoglobin (g/dL) SD: 0.9\n- Hematocrit (%) Mean: 42.5\n- Hematocrit (%) SD: 2.3\n- WBC (k/\u00b5L) Mean: 6.1\n- WBC (k/\u00b5L) SD: 1.1\n- Platelets (k/\u00b5L) Mean: 221\n- Platelets (k/\u00b5L) SD: 41\n- Sodium (mEq/L) Mean: 139.6\n- Sodium (mEq/L) SD: 2.5\n- Potassium (mEq/L) Mean: 4.2\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 22.8\n- Bicarbonate (mEq/L) SD: 1.6\n- Phosphorus (mg/dL) Mean: 3.6\n- Phosphorus (mg/dL) SD: 0.7\n\n### Adverse Events\n- AE ID: RB-AE-2878, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: false, Cohort: 25mg\n- AE ID: RB-AE-2818, Description: urinary tract infection, Grade: 1, Relatedness: possibly related, Resolved: true, Cohort: 10mg\n- AE ID: RB-AE-2834, Description: hyperkalemia, Grade: 1, Relatedness: possibly related, Resolved: true, Cohort: 100mg\n\n### Protocol Deviations\n- PD ID: RB-PD-2828, Description: GFR measurement repeated due to hemolyzed sample, Severity: moderate\n- PD ID: RB-PD-2826, Description: Missed scheduled renal ultrasound, rescheduled, Severity: moderate\n\n### Events\n- Lab kit resupply dispatched to sites with low inventory\n- Site 04 monitoring visit completed, 3 findings\n- Central lab urine biomarker batch analysis completed for Week 28\n\n### Notes\n- Week 28: Renal biomarker collection on schedule. 84 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_059",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-14T10:30:00",
          "text": "## 2024-09-16 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 88\n- Active: 76\n- Screen Failures Cumulative: 64\n- Withdrawals Cumulative: 12\n\n### Enrollment By Cohort\n- 10mg: 21\n- 25mg: 21\n- 50mg: 23\n- 100mg: 23\n\n### Biomarkers By Cohort\n- 10mg\n  - KIM-1 (ng/ml) Mean: 1.82\n  - KIM-1 (ng/ml) SD: 0.36\n  - NGAL (ng/ml) Mean: 68.4\n  - NGAL (ng/ml) SD: 16.2\n  - Cystatin C (mg/L) Mean: 0.84\n  - Cystatin C (mg/L) SD: 0.13\n  - eGFR (ml/min) Mean: 62.2\n  - eGFR (ml/min) SD: 10.1\n  - UACR (mg/g) Mean: 34.9\n  - UACR (mg/g) SD: 27.1\n  - Serum Creatinine (mg/dl) Mean: 1.15\n  - Serum Creatinine (mg/dl) SD: 0.15\n  - Urine Protein (mg/dl) Mean: 17.3\n  - Urine Protein (mg/dl) SD: 3.1\n  - Urine Output (ml/24h) Mean: 1752\n  - Urine Output (ml/24h) SD: 389\n- 25mg\n  - KIM-1 (ng/ml) Mean: 1.95\n  - KIM-1 (ng/ml) SD: 0.42\n  - NGAL (ng/ml) Mean: 55.1\n  - NGAL (ng/ml) SD: 13.8\n  - Cystatin C (mg/L) Mean: 0.77\n  - Cystatin C (mg/L) SD: 0.13\n  - eGFR (ml/min) Mean: 64.4\n  - eGFR (ml/min) SD: 9.1\n  - UACR (mg/g) Mean: 82.9\n  - UACR (mg/g) SD: 15.5\n  - Serum Creatinine (mg/dl) Mean: 1.38\n  - Serum Creatinine (mg/dl) SD: 0.12\n  - Urine Protein (mg/dl) Mean: 15.9\n  - Urine Protein (mg/dl) SD: 5.8\n  - Urine Output (ml/24h) Mean: 1790\n  - Urine Output (ml/24h) SD: 344\n- 50mg\n  - KIM-1 (ng/ml) Mean: 1.68\n  - KIM-1 (ng/ml) SD: 0.55\n  - NGAL (ng/ml) Mean: 47.9\n  - NGAL (ng/ml) SD: 13.7\n  - Cystatin C (mg/L) Mean: 0.90\n  - Cystatin C (mg/L) SD: 0.12\n  - eGFR (ml/min) Mean: 71.6\n  - eGFR (ml/min) SD: 10.6\n  - UACR (mg/g) Mean: 98.5\n  - UACR (mg/g) SD: 34.8\n  - Serum Creatinine (mg/dl) Mean: 1.41\n  - Serum Creatinine (mg/dl) SD: 0.25\n  - Urine Protein (mg/dl) Mean: 41.8\n  - Urine Protein (mg/dl) SD: 5.5\n  - Urine Output (ml/24h) Mean: 1648\n  - Urine Output (ml/24h) SD: 356\n- 100mg\n  - KIM-1 (ng/ml) Mean: 1.23\n  - KIM-1 (ng/ml) SD: 0.46\n  - NGAL (ng/ml) Mean: 101.5\n  - NGAL (ng/ml) SD: 9.7\n  - Cystatin C (mg/L) Mean: 1.18\n  - Cystatin C (mg/L) SD: 0.11\n  - eGFR (ml/min) Mean: 56.9\n  - eGFR (ml/min) SD: 8.5\n  - UACR (mg/g) Mean: 122.5\n  - UACR (mg/g) SD: 20.3\n  - Serum Creatinine (mg/dl) Mean: 1.00\n  - Serum Creatinine (mg/dl) SD: 0.20\n  - Urine Protein (mg/dl) Mean: 34.3\n  - Urine Protein (mg/dl) SD: 7.0\n  - Urine Output (ml/24h) Mean: 1743\n  - Urine Output (ml/24h) SD: 330\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.414\n- NGAL Dose Correlation (r): 0.285\n- eGFR Dose Correlation (r): -0.155\n- UACR Dose Correlation (r): 0.221\n\n### Safety Labs\n- Hemoglobin (g/dl) Mean: 13.8\n- Hemoglobin (g/dl) SD: 1.0\n- Hematocrit (%) Mean: 39.6\n- Hematocrit (%) SD: 3.8\n- WBC (k) Mean: 6.8\n- WBC (k) SD: 1.1\n- Platelets (k) Mean: 243\n- Platelets (k) SD: 43\n- Sodium (meq/L) Mean: 139.0\n- Sodium (meq/L) SD: 2.6\n- Potassium (meq/L) Mean: 4.2\n- Potassium (meq/L) SD: 0.4\n- Bicarbonate (meq/L) Mean: 25.5\n- Bicarbonate (meq/L) SD: 1.5\n- Phosphorus (mg/dl) Mean: 4.1\n- Phosphorus (mg/dl) SD: 0.6\n\n### Adverse Events\n- AE ID: RB-AE-2904, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-2951, Description: nausea, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n- AE ID: RB-AE-2984, Description: dizziness, Grade: 1, Relatedness: unlikely related, Resolved: true, Cohort: 100mg\n\n### Protocol Deviations\n- None\n\n### Events\n- DSMB safety data snapshot prepared\n- Cohort 50mg enrollment status reviewed at sponsor call\n\n### Notes\n- Week 29: Renal biomarker collection on schedule. 88 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_020",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-15T10:00:00",
          "text": "## 2024-07-15 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 216\n- Active: 206\n- Screen Failures Cumulative: 45\n- Withdrawals Cumulative: 10\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 103.2\n- ALT (U/L) Median: 102.1\n- AST (U/L) Mean: 82.6\n- AST (U/L) Median: 81.2\n- Bilirubin (mg/dL) Mean: 1.87\n- Bilirubin (mg/dL) Median: 1.85\n- ALP (U/L) Mean: 79.2\n- ALP (U/L) Median: 55.7\n- Creatinine (mg/dL) Mean: 0.99\n- Creatinine (mg/dL) Median: 1.0\n- BUN (mg/dL) Mean: 16.9\n- BUN (mg/dL) Median: 12.8\n- WBC (K) Mean: 6.2\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 219\n- Platelets (K) Median: 257\n\n#### Non-Statin Subgroup\n- N: 123\n- ALT (U/L) Mean: 21.8\n- ALT (U/L) Median: 20.2\n- AST (U/L) Mean: 18.5\n- AST (U/L) Median: 16.6\n- Bilirubin (mg/dL) Mean: 0.67\n- Bilirubin (mg/dL) Median: 0.66\n- ALP (U/L) Mean: 64.9\n- ALP (U/L) Median: 53.5\n- Creatinine (mg/dL) Mean: 1.03\n- Creatinine (mg/dL) Median: 0.97\n- BUN (mg/dL) Mean: 13.2\n- BUN (mg/dL) Median: 12.7\n- WBC (K) Mean: 8.5\n- WBC (K) Median: 7.6\n- Platelets (K) Mean: 257\n- Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0075, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0076, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0077, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0078, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0079, Description: Hy's Law case: ALT 3.8x ULN, total bilirubin 2.3x ULN, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 33\n\n### Protocol Deviations\n- PD ID: PD-042, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_07\n- PD ID: PD-043, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_06\n\n### Investigator Notes\n- Central lab results received within 48h turnaround\n- Lab kits inventory adequate for next 4 weeks\n- SAE report filed: subject 03-042, statin subgroup, ALT 3.8x ULN with bilirubin 2.3x ULN\n- Pharmacology consult requested: CYP3A4 inhibition profile of LNS-4821 under review\n\n### Events\n- Site 07 monitoring visit completed, 3 findings\n- Bioanalytical lab shipment tracking confirmed for 1 samples\n- Central lab courier pickup schedule adjusted for holiday\n- SAE report submitted to sponsor safety group and regulatory authority\n\n### Notes\n- Week 20: Cross-site statin subgroup hepatic signal confirmed. DDI pharmacology review in progress.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_060",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-16T10:30:00",
          "text": "## 2024-09-23 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 87\n- Active: 74\n- Screen Failures Cumulative: 61\n- Withdrawals Cumulative: 13\n\n#### By Cohort\n- 10mg: 20\n- 25mg: 21\n- 50mg: 23\n- 100mg: 23\n\n### Biomarkers By Cohort\n#### 10mg\n- KIM-1 (ng/mL) Mean: 1.81\n- KIM-1 (ng/mL) SD: 0.49\n- NGAL (ng/mL) Mean: 41.7\n- NGAL (ng/mL) SD: 13.9\n- Cystatin C (mg/L) Mean: 0.91\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 78.3\n- eGFR (mL/min) SD: 12.4\n- UACR (mg/g) Mean: 51.6\n- UACR (mg/g) SD: 19.2\n- Serum Creatinine (mg/dL) Mean: 1.19\n- Serum Creatinine (mg/dL) SD: 0.11\n- Urine Protein (mg/dL) Mean: 30.4\n- Urine Protein (mg/dL) SD: 8.9\n- Urine Output (mL/24h) Mean: 1946\n- Urine Output (mL/24h) SD: 323\n\n#### 25mg\n- KIM-1 (ng/mL) Mean: 0.9\n- KIM-1 (ng/mL) SD: 0.2\n- NGAL (ng/mL) Mean: 93.0\n- NGAL (ng/mL) SD: 12.1\n- Cystatin C (mg/L) Mean: 0.8\n- Cystatin C (mg/L) SD: 0.11\n- eGFR (mL/min) Mean: 65.3\n- eGFR (mL/min) SD: 11.9\n- UACR (mg/g) Mean: 122.1\n- UACR (mg/g) SD: 10.2\n- Serum Creatinine (mg/dL) Mean: 1.2\n- Serum Creatinine (mg/dL) SD: 0.28\n- Urine Protein (mg/dL) Mean: 15.7\n- Urine Protein (mg/dL) SD: 3.3\n- Urine Output (mL/24h) Mean: 1599\n- Urine Output (mL/24h) SD: 355\n\n#### 50mg\n- KIM-1 (ng/mL) Mean: 2.47\n- KIM-1 (ng/mL) SD: 0.47\n- NGAL (ng/mL) Mean: 94.0\n- NGAL (ng/mL) SD: 10.3\n- Cystatin C (mg/L) Mean: 1.01\n- Cystatin C (mg/L) SD: 0.15\n- eGFR (mL/min) Mean: 71.6\n- eGFR (mL/min) SD: 14.5\n- UACR (mg/g) Mean: 58.7\n- UACR (mg/g) SD: 11.8\n- Serum Creatinine (mg/dL) Mean: 1.16\n- Serum Creatinine (mg/dL) SD: 0.1\n- Urine Protein (mg/dL) Mean: 39.0\n- Urine Protein (mg/dL) SD: 6.2\n- Urine Output (mL/24h) Mean: 1958\n- Urine Output (mL/24h) SD: 369\n\n#### 100mg\n- KIM-1 (ng/mL) Mean: 1.31\n- KIM-1 (ng/mL) SD: 0.34\n- NGAL (ng/mL) Mean: 57.5\n- NGAL (ng/mL) SD: 11.4\n- Cystatin C (mg/L) Mean: 0.88\n- Cystatin C (mg/L) SD: 0.13\n- eGFR (mL/min) Mean: 73.9\n- eGFR (mL/min) SD: 13.9\n- UACR (mg/g) Mean: 120.4\n- UACR (mg/g) SD: 15.3\n- Serum Creatinine (mg/dL) Mean: 1.2\n- Serum Creatinine (mg/dL) SD: 0.13\n- Urine Protein (mg/dL) Mean: 24.0\n- Urine Protein (mg/dL) SD: 6.2\n- Urine Output (mL/24h) Mean: 2010\n- Urine Output (mL/24h) SD: 363\n\n### Dose Response\n- KIM-1 Dose Correlation (r): 0.634\n- NGAL Dose Correlation (r): 0.386\n- eGFR Dose Correlation (r): -0.488\n- UACR Dose Correlation (r): 0.364\n\n### Safety Labs\n- Hemoglobin (g/dL) Mean: 13.2\n- Hemoglobin (g/dL) SD: 1.5\n- Hematocrit (%) Mean: 41.4\n- Hematocrit (%) SD: 2.4\n- WBC (k/\u00b5L) Mean: 7.6\n- WBC (k/\u00b5L) SD: 1.0\n- Platelets (k/\u00b5L) Mean: 218\n- Platelets (k/\u00b5L) SD: 48\n- Sodium (mEq/L) Mean: 139.7\n- Sodium (mEq/L) SD: 2.7\n- Potassium (mEq/L) Mean: 4.4\n- Potassium (mEq/L) SD: 0.4\n- Bicarbonate (mEq/L) Mean: 26.3\n- Bicarbonate (mEq/L) SD: 2.1\n- Phosphorus (mg/dL) Mean: 3.2\n- Phosphorus (mg/dL) SD: 0.4\n\n### Adverse Events\n- AE ID: RB-AE-3030, Description: dizziness, Grade: 1, Relatedness: not related, Resolved: false, Cohort: 25mg\n- AE ID: RB-AE-3061, Description: hyperkalemia, Grade: 2, Relatedness: not related, Resolved: true, Cohort: 10mg\n\n### Protocol Deviations\n- PD ID: RB-PD-3022, Description: Urine sample collection outside 24h window, Severity: moderate\n- PD ID: RB-PD-3033, Description: Blood pressure measurement not recorded at visit, Severity: minor\n\n### Events\n- Renal ultrasound images uploaded to central imaging core\n- Protocol training refresher completed for site coordinators\n- Lab kit resupply dispatched to sites with low inventory\n\n### Notes\n- Week 30: Renal biomarker collection on schedule. 87 subjects enrolled across 4 cohorts. eGFR and urinary biomarkers within expected variability.",
          "meta": {
            "episode_type": "distractor",
            "theme": "renal_biomarker_study"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_061",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-18T10:30:00",
          "text": "## 2024-03-04 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 45\n- Active: 45\n- Screen Failures Cumulative: 1\n- Withdrawals Cumulative: 0\n\n#### By Dose Group\n- Low Dose: 12\n- Mid Dose: 10\n- High Dose: 12\n- Placebo: 11\n\n### Immunogenicity By Group\n\n#### Low Dose\n- IgG Titer (GMU) Mean: 20.2\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 14.0\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 40.3\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC per 10^6) Mean: 64.0\n- CD4 Response (SFC per 10^6) SD: 15.0\n- CD8 Response (SFC per 10^6) Mean: 38.0\n- CD8 Response (SFC per 10^6) SD: 11.0\n- Seroconversion Percentage: 9.0\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 38.6\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 20.5\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 70.7\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC per 10^6) Mean: 104.0\n- CD4 Response (SFC per 10^6) SD: 24.0\n- CD8 Response (SFC per 10^6) Mean: 73.0\n- CD8 Response (SFC per 10^6) SD: 18.0\n- Seroconversion Percentage: 16.0\n\n#### High Dose\n- IgG Titer (GMU) Mean: 51.7\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 30.0\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 91.9\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC per 10^6) Mean: 134.0\n- CD4 Response (SFC per 10^6) SD: 33.0\n- CD8 Response (SFC per 10^6) Mean: 89.0\n- CD8 Response (SFC per 10^6) SD: 24.0\n- Seroconversion Percentage: 26.9\n\n#### Placebo\n- IgG Titer (GMU) Mean: 1.8\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 3.8\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 4.0\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC per 10^6) Mean: 5.0\n- CD4 Response (SFC per 10^6) SD: 3.0\n- CD8 Response (SFC per 10^6) Mean: 3.0\n- CD8 Response (SFC per 10^6) SD: 2.0\n- Seroconversion Percentage: 1.9\n\n### Injection Site Reactions\n- Pain Percentage: 62.5\n- Erythema Percentage: 23.4\n- Swelling Percentage: 8.3\n- Induration Percentage: 9.7\n- Mean Pain Duration (Hours): 46.1\n\n### Systemic Reactogenicity\n- Fever Percentage: 16.8\n- Fatigue Percentage: 20.1\n- Myalgia Percentage: 20.3\n- Headache Percentage: 16.0\n- Chills Percentage: 6.3\n\n### Safety Labs\n\n#### WBC\n- Mean: 7.5\n- SD: 1.2\n\n#### Lymphocyte Percentage\n- Mean: 30.5\n- SD: 7.3\n\n#### Neutrophil Percentage\n- Mean: 53.9\n- SD: 9.7\n\n#### Platelets\n- Mean: 222\n- SD: 43\n\n#### CRP\n- Mean: 6.4\n- SD: 1.5\n\n#### Hemoglobin\n- Mean: 14.1\n- SD: 0.9\n\n### Adverse Events\n- AE ID: VI-AE-0187, Description: arthralgia, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-0156, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Site 05 monitoring visit, 2 minor findings\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n- Serum sample aliquoting completed for 14 subjects\n\n### Notes\n- Week 1: Immunogenicity assessments on schedule. 45 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_062",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-21T10:30:00",
          "text": "## 2024-03-11 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 55\n- Active: 55\n- Screen Failures Cumulative: 3\n- Withdrawals Cumulative: 0\n\n### Enrollment By Dose Group\n- Low Dose: 14\n- Mid Dose: 14\n- High Dose: 13\n- Placebo: 14\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 24.1\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 14.3\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 32.3\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 65.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 42.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 5.8\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 40.1\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 17.6\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 67.5\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 94.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 74.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 11.3\n\n#### High Dose\n- IgG Titer (GMU) Mean: 50.5\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 24.9\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 82.0\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 125.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 95.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 19.9\n\n#### Placebo\n- IgG Titer (GMU) Mean: 6.7\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 0.2\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 1.3\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 5.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 2.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 0\n\n### Injection Site Reactions\n- Pain Percentage: 44.4\n- Erythema Percentage: 12.8\n- Swelling Percentage: 6.8\n- Induration Percentage: 10.9\n- Mean Pain Duration (hours): 12.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 13.9\n- Fatigue Percentage: 43.5\n- Myalgia Percentage: 24.5\n- Headache Percentage: 29.3\n- Chills Percentage: 7.2\n\n### Safety Labs\n- WBC (K): Mean: 7.6\n- WBC (K) SD: 2.0\n- Lymphocyte Percentage: Mean: 37.7\n- Lymphocyte Percentage SD: 5.2\n- Neutrophil Percentage: Mean: 61.7\n- Neutrophil Percentage SD: 9.6\n- Platelets (K): Mean: 250\n- Platelets (K) SD: 42\n- CRP (mg/L): Mean: 5.0\n- CRP (mg/L) SD: 1.2\n- Hemoglobin (g/dL): Mean: 13.1\n- Hemoglobin (g/dL) SD: 0.8\n\n### Adverse Events\n- AE ID: VI-AE-0287, Description: lymphadenopathy, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-0212, Description: chills, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-0254, Description: injection site pain, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0286, Description: lymphadenopathy, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- Site 03 monitoring visit, 1 minor findings\n- T-cell assay batch B02 processed, results QC'd\n\n### Notes\n- Week 2: Immunogenicity assessments on schedule. 55 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_021",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-22T10:00:00",
          "text": "## 2024-07-22 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 219\n- Active: 209\n- Screen Failures Cumulative: 35\n- Withdrawals Cumulative: 10\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 13\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 111.7\n- ALT (U/L) Median: 110.7\n- AST (U/L) Mean: 86.1\n- AST (U/L) Median: 84.4\n- Bilirubin (mg/dL) Mean: 1.91\n- Bilirubin (mg/dL) Median: 1.9\n- ALP (U/L) Mean: 84.1\n- ALP (U/L) Median: 61.6\n- Creatinine (mg/dL) Mean: 1.06\n- Creatinine (mg/dL) Median: 0.95\n- BUN (mg/dL) Mean: 15.3\n- BUN (mg/dL) Median: 15.5\n- WBC (K) Mean: 6.9\n- WBC (K) Median: 7.1\n- Platelets (K) Mean: 239\n- Platelets (K) Median: 236\n\n#### Non-Statin Subgroup\n- N: 120\n- ALT (U/L) Mean: 25.8\n- ALT (U/L) Median: 24.8\n- AST (U/L) Mean: 28.8\n- AST (U/L) Median: 27.5\n- Bilirubin (mg/dL) Mean: 0.71\n- Bilirubin (mg/dL) Median: 0.71\n- ALP (U/L) Mean: 57.8\n- ALP (U/L) Median: 48.6\n- Creatinine (mg/dL) Mean: 0.87\n- Creatinine (mg/dL) Median: 0.84\n- BUN (mg/dL) Mean: 16.8\n- BUN (mg/dL) Median: 15.3\n- WBC (K) Mean: 8.4\n- WBC (K) Median: 6.0\n- Platelets (K) Mean: 225\n- Platelets (K) Median: 253\n\n### Adverse Events\n- AE ID: AE-0080, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0081, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0082, Description: nausea, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0083, Description: fatigue, Grade: 2, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 56\n- ACE Inhibitor Count: 29\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-044, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_03\n- PD ID: PD-045, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_10\n\n### Investigator Notes\n- No new safety signals identified this week by local PI\n- Study drug accountability reconciled, no discrepancies\n- Multi-site pattern confirmed: ALT out of range in statin co-administered patients independent of site\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- Regulatory submission packet sent to Site 08\n\n### Notes\n- Week 21: Cross-site statin subgroup hepatic signal confirmed. DDI pharmacology review in progress.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_063",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-23T10:30:00",
          "text": "## 2024-03-18 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 67\n- Active: 67\n- Screen Failures Cumulative: 5\n- Withdrawals Cumulative: 0\n\n### Enrollment By Dose Group\n- Low Dose: 18\n- Mid Dose: 17\n- High Dose: 16\n- Placebo: 16\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 24.8\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 14.9\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 38.8\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 65.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 45.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 11.9\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 48.1\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 24.3\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 72.3\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 106.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 77.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 14.5\n\n#### High Dose\n- IgG Titer (GMU) Mean: 63.5\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 30.5\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 95.5\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 152.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 108.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 29.4\n\n#### Placebo\n- IgG Titer (GMU) Mean: 10.7\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 2.9\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 4.6\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 5.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 7.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 6.9\n\n### Injection Site Reactions\n- Pain Percentage: 51.7\n- Erythema Percentage: 14.6\n- Swelling Percentage: 7.8\n- Induration Percentage: 10.0\n- Mean Pain Duration (Hours): 25.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 18.2\n- Fatigue Percentage: 32.7\n- Myalgia Percentage: 25.9\n- Headache Percentage: 17.3\n- Chills Percentage: 14.8\n\n### Safety Labs\n- WBC (K) Mean: 8.9\n- WBC (K) SD: 1.9\n- Lymphocyte Percentage Mean: 28.7\n- Lymphocyte Percentage SD: 6.8\n- Neutrophil Percentage Mean: 62.2\n- Neutrophil Percentage SD: 6.2\n- Platelets (K) Mean: 216\n- Platelets (K) SD: 39\n- CRP (mg/L) Mean: 6.3\n- CRP (mg/L) SD: 1.9\n- Hemoglobin (g/dL) Mean: 13.8\n- Hemoglobin (g/dL) SD: 1.3\n\n### Adverse Events\n- AE ID: VI-AE-0303, Description: lymphadenopathy, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-0346, Description: fever, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-0386, Description: injection site pain, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Serum sample aliquoting completed for 25 subjects\n- Serum sample aliquoting completed for 19 subjects\n\n### Notes\n- Week 3: Immunogenicity assessments on schedule. 67 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_064",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-25T10:30:00",
          "text": "## 2024-03-25 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 80\n- Active: 80\n- Screen Failures Cumulative: 6\n- Withdrawals Cumulative: 0\n\n### Enrollment By Dose Group\n- Low Dose: 20\n- Mid Dose: 21\n- High Dose: 20\n- Placebo: 19\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 32.6\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 16.9\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 46.4\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 85.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 54.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 12.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 52.1\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 25.3\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 80.7\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 120.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 90.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 19.6\n- High Dose\n  - IgG Titer (GMU) Mean: 71.3\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 33.2\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 122.2\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 178.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 121.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 25.2\n- Placebo\n  - IgG Titer (GMU) Mean: 11.3\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 0.7\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 8.0\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 25.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 10.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 0.9\n\n### Injection Site Reactions\n- Pain Percentage: 53.7\n- Erythema Percentage: 12.6\n- Swelling Percentage: 17.6\n- Induration Percentage: 4.4\n- Mean Pain Duration (Hours): 18.8\n\n### Systemic Reactogenicity\n- Fever Percentage: 19.9\n- Fatigue Percentage: 38.1\n- Myalgia Percentage: 30.2\n- Headache Percentage: 27.5\n- Chills Percentage: 10.1\n\n### Safety Labs\n- WBC (K) Mean: 7.1\n- WBC (K) SD: 1.3\n- Lymphocyte Percentage Mean: 32.0\n- Lymphocyte Percentage SD: 5.2\n- Neutrophil Percentage Mean: 63.7\n- Neutrophil Percentage SD: 5.4\n- Platelets (K) Mean: 218\n- Platelets (K) SD: 41\n- CRP (mg/L) Mean: 7.7\n- CRP (mg/L) SD: 1.9\n- Hemoglobin (g/dL) Mean: 14.2\n- Hemoglobin (g/dL) SD: 1.2\n\n### Adverse Events\n- AE ID: VI-AE-0417, Description: lymphadenopathy, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0429, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0425, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Vaccination day 1: 21 subjects received scheduled dose\n- Immunology core lab QC report received\n\n### Notes\n- Week 4: Immunogenicity assessments on schedule. 80 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_065",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-27T10:30:00",
          "text": "## 2024-04-01 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 92\n- Active: 90\n- Screen Failures Cumulative: 9\n- Withdrawals Cumulative: 2\n\n### Enrollment By Dose Group\n- Low Dose: 21\n- Mid Dose: 25\n- High Dose: 24\n- Placebo: 22\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 40.4\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 16.0\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 54.7\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC per 10^6) Mean: 97.0\n- CD4 Response (SFC per 10^6) SD: 15.0\n- CD8 Response (SFC per 10^6) Mean: 65.0\n- CD8 Response (SFC per 10^6) SD: 11.0\n- Seroconversion Percentage: 17.1\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 57.4\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 30.2\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 98.3\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC per 10^6) Mean: 140.0\n- CD4 Response (SFC per 10^6) SD: 24.0\n- CD8 Response (SFC per 10^6) Mean: 98.0\n- CD8 Response (SFC per 10^6) SD: 18.0\n- Seroconversion Percentage: 19.4\n\n#### High Dose\n- IgG Titer (GMU) Mean: 75.4\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 37.1\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 129.5\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC per 10^6) Mean: 201.0\n- CD4 Response (SFC per 10^6) SD: 33.0\n- CD8 Response (SFC per 10^6) Mean: 129.0\n- CD8 Response (SFC per 10^6) SD: 24.0\n- Seroconversion Percentage: 34.8\n\n#### Placebo\n- IgG Titer (GMU) Mean: 4.9\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 5.6\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 5.0\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC per 10^6) Mean: 8.0\n- CD4 Response (SFC per 10^6) SD: 3.0\n- CD8 Response (SFC per 10^6) Mean: 16.0\n- CD8 Response (SFC per 10^6) SD: 2.0\n- Seroconversion Percentage: 5.4\n\n### Injection Site Reactions\n- Pain Percentage: 52.9\n- Erythema Percentage: 26.9\n- Swelling Percentage: 7.8\n- Induration Percentage: 9.4\n- Mean Pain Duration (Hours): 23.0\n\n### Systemic Reactogenicity\n- Fever Percentage: 21.4\n- Fatigue Percentage: 33.9\n- Myalgia Percentage: 34.2\n- Headache Percentage: 16.1\n- Chills Percentage: 14.3\n\n### Safety Labs\n- WBC (K) Mean: 8.8\n- WBC (K) SD: 1.4\n- Lymphocyte Percentage Mean: 28.8\n- Lymphocyte Percentage SD: 7.7\n- Neutrophil Percentage Mean: 58.6\n- Neutrophil Percentage SD: 6.5\n- Platelets (K) Mean: 244\n- Platelets (K) SD: 38\n- CRP (mg/L) Mean: 1.6\n- CRP (mg/L) SD: 1.7\n- Hemoglobin (g/dL) Mean: 13.4\n- Hemoglobin (g/dL) SD: 0.8\n\n### Adverse Events\n- AE ID: VI-AE-0507, Description: myalgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0573, Description: lymphadenopathy, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-0595, Description: lymphadenopathy, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-0591, Description: injection site pain, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- Serology samples shipped to central immunology lab\n- Vaccination day 6: 17 subjects received scheduled dose\n\n### Notes\n- Week 5: Immunogenicity assessments on schedule. 92 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_022",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-29T10:00:00",
          "text": "## 2024-07-29 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 236\n- Active: 230\n- Screen Failures Cumulative: 50\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01\n  - Enrolled: 24\n  - Active: 24\n  - Statin Concomitant: 7\n- Site 02\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 03\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 7\n- Site 04\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 05\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 06\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 26\n  - Active: 26\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 10\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 7\n- Site 12\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 123.1\n- ALT (U/L) Median: 121.0\n- AST (U/L) Mean: 89.3\n- AST (U/L) Median: 88.8\n- Bilirubin (mg/dL) Mean: 2.2\n- Bilirubin (mg/dL) Median: 2.2\n- ALP (U/L) Mean: 77.8\n- ALP (U/L) Median: 67.6\n- Creatinine (mg/dL) Mean: 0.97\n- Creatinine (mg/dL) Median: 0.88\n- BUN (mg/dL) Mean: 13.8\n- BUN (mg/dL) Median: 11.6\n- WBC (K) Mean: 7.7\n- WBC (K) Median: 6.7\n- Platelets (K) Mean: 261\n- Platelets (K) Median: 243\n\n#### Non-Statin Subgroup\n- N: 129\n- ALT (U/L) Mean: 28.6\n- ALT (U/L) Median: 27.4\n- AST (U/L) Mean: 30.0\n- AST (U/L) Median: 29.0\n- Bilirubin (mg/dL) Mean: 0.53\n- Bilirubin (mg/dL) Median: 0.51\n- ALP (U/L) Mean: 54.6\n- ALP (U/L) Median: 58.8\n- Creatinine (mg/dL) Mean: 1.1\n- Creatinine (mg/dL) Median: 0.9\n- BUN (mg/dL) Mean: 17.2\n- BUN (mg/dL) Median: 12.5\n- WBC (K) Mean: 7.1\n- WBC (K) Median: 6.6\n- Platelets (K) Mean: 247\n- Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0084, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0085, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0086, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0087, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0088, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 30\n- Metformin Count: 24\n- PPI Count: 17\n- NSAID Count: 13\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-046, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_10\n\n### Investigator Notes\n- Central lab results received within 48h turnaround\n- All SAE narratives submitted within reporting window\n- IEC/IRB annual renewal submitted on schedule\n\n### Events\n- Site 09 new coordinator onboarding completed\n- Regulatory submission packet sent to Site 11\n- Site 01 new coordinator onboarding completed\n\n### Notes\n- Week 22: Cross-site statin subgroup hepatic signal confirmed. DDI pharmacology review in progress.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_066",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-30T10:30:00",
          "text": "## 2024-04-08 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 106\n- Active: 105\n- Screen Failures Cumulative: 10\n- Withdrawals Cumulative: 1\n\n#### By Dose Group\n- Low Dose: 27\n- Mid Dose: 26\n- High Dose: 28\n- Placebo: 25\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 35.4\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 20.3\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 71.9\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 92.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 62.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 17.9\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 64.4\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 32.2\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 104.8\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 156.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 105.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 26.5\n\n#### High Dose\n- IgG Titer (GMU) Mean: 93.0\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 41.0\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 141.8\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 212.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 151.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 31.8\n\n#### Placebo\n- IgG Titer (GMU) Mean: 11.3\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 4.9\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 16.7\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 12.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 19.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 3.6\n\n### Injection Site Reactions\n- Pain Percentage: 61.8\n- Erythema Percentage: 13.9\n- Swelling Percentage: 16.7\n- Induration Percentage: 6.4\n- Mean Pain Duration (Hours): 19.6\n\n### Systemic Reactogenicity\n- Fever Percentage: 21.2\n- Fatigue Percentage: 42.9\n- Myalgia Percentage: 31.4\n- Headache Percentage: 18.9\n- Chills Percentage: 5.7\n\n### Safety Labs\n- WBC (K) Mean: 5.5\n- WBC (K) SD: 1.7\n- Lymphocyte Percentage Mean: 37.5\n- Lymphocyte Percentage SD: 4.7\n- Neutrophil Percentage Mean: 57.9\n- Neutrophil Percentage SD: 7.9\n- Platelets (K) Mean: 220\n- Platelets (K) SD: 40\n- CRP (mg/L) Mean: 7.5\n- CRP (mg/L) SD: 0.6\n- Hemoglobin (g/dL) Mean: 13.7\n- Hemoglobin (g/dL) SD: 1.3\n\n### Adverse Events\n- AE ID: VI-AE-0627, Description: fatigue, Grade: 1, Relatedness: related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-0632, Description: lymphadenopathy, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-0610, Description: arthralgia, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Serology samples shipped to central immunology lab\n- DSMB safety review teleconference completed\n- Serum sample aliquoting completed for 15 subjects\n\n### Notes\n- Week 6: Immunogenicity assessments on schedule. 106 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_067",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-01T10:30:00",
          "text": "## 2024-04-15 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 105\n- Active: 103\n- Screen Failures Cumulative: 12\n- Withdrawals Cumulative: 2\n\n### Enrollment by Dose Group\n- Low Dose: 25\n- Mid Dose: 25\n- High Dose: 27\n- Placebo: 28\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 48.5\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 16.4\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 62.3\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 109.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 68.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 21.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 73.5\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 29.0\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 115.2\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 165.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 125.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 28.7\n- High Dose\n  - IgG Titer (GMU) Mean: 100.6\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 42.0\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 147.4\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 235.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 162.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 41.4\n- Placebo\n  - IgG Titer (GMU) Mean: 6.8\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 5.1\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 14.0\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 25.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 16.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 5.5\n\n### Injection Site Reactions\n- Pain Percentage: 50.9\n- Erythema Percentage: 28.9\n- Swelling Percentage: 9.9\n- Induration Percentage: 8.8\n- Mean Pain Duration (hours): 34.2\n\n### Systemic Reactogenicity\n- Fever Percentage: 16.6\n- Fatigue Percentage: 23.1\n- Myalgia Percentage: 27.9\n- Headache Percentage: 19.5\n- Chills Percentage: 14.4\n\n### Safety Labs\n- WBC (K) Mean: 9.0\n- WBC (K) SD: 1.5\n- Lymphocyte Percentage Mean: 39.9\n- Lymphocyte Percentage SD: 7.8\n- Neutrophil Percentage Mean: 56.0\n- Neutrophil Percentage SD: 6.5\n- Platelets (K) Mean: 237\n- Platelets (K) SD: 43\n- CRP (mg/L) Mean: 5.5\n- CRP (mg/L) SD: 1.6\n- Hemoglobin (g/dL) Mean: 13.9\n- Hemoglobin (g/dL) SD: 0.8\n\n### Adverse Events\n- AE ID: VI-AE-0771, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-0765, Description: injection site pain, Grade: 1, Relatedness: related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0749, Description: headache, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-0701, Description: fatigue, Grade: 1, Relatedness: related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Serum sample aliquoting completed for 20 subjects\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n\n### Notes\n- Week 7: Immunogenicity assessments on schedule. 105 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_068",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-03T10:30:00",
          "text": "## 2024-04-22 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 107\n- Active: 105\n- Screen Failures Cumulative: 12\n- Withdrawals Cumulative: 2\n\n### Enrollment by Dose Group\n- Low Dose: 25\n- Mid Dose: 27\n- High Dose: 26\n- Placebo: 29\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 45.6\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 17.8\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 74.3\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 121.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 82.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 16.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 83.3\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 33.0\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 120.8\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 191.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 130.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 36.0\n- High Dose\n  - IgG Titer (GMU) Mean: 106.0\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 40.8\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 176.1\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 257.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 180.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 45.0\n- Placebo\n  - IgG Titer (GMU) Mean: 5.9\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 3.4\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 10.9\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 21.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 17.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 7.7\n\n### Injection Site Reactions\n- Pain Percentage: 47.4\n- Erythema Percentage: 19.4\n- Swelling Percentage: 14.5\n- Induration Percentage: 8.8\n- Mean Pain Duration (hours): 17.7\n\n### Systemic Reactogenicity\n- Fever Percentage: 15.2\n- Fatigue Percentage: 31.9\n- Myalgia Percentage: 19.0\n- Headache Percentage: 26.4\n- Chills Percentage: 5.3\n\n### Safety Labs\n- WBC (K) Mean: 7.2\n- WBC (K) SD: 1.8\n- Lymphocyte Percentage Mean: 26.0\n- Lymphocyte Percentage SD: 5.8\n- Neutrophil Percentage Mean: 52.9\n- Neutrophil Percentage SD: 6.9\n- Platelets (K) Mean: 219\n- Platelets (K) SD: 39\n- CRP (mg/L) Mean: 2.0\n- CRP (mg/L) SD: 1.2\n- Hemoglobin (g/dL) Mean: 14.6\n- Hemoglobin (g/dL) SD: 1.4\n\n### Adverse Events\n- AE ID: VI-AE-0818\n  - Description: lymphadenopathy\n  - Grade: 2\n  - Relatedness: possibly related\n  - Resolved: true\n  - Dose Group: high_dose\n- AE ID: VI-AE-0817\n  - Description: malaise\n  - Grade: 2\n  - Relatedness: possibly related\n  - Resolved: true\n  - Dose Group: mid_dose\n\n### Events\n- Reactogenicity diary card collection rate: 95%\n- Vaccine lot VX-645 temperature excursion assessed: within acceptable range\n\n### Notes\n- Week 8: Immunogenicity assessments on schedule. 107 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_023",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-05T10:00:00",
          "text": "## 2024-08-05 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 210\n- Active: 196\n- Screen Failures Cumulative: 58\n- Withdrawals Cumulative: 14\n\n### Sites\n- Site 01 Enrolled: 21\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 19\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 17\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 23\n- Site 07 Active: 22\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 15\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 17\n- Site 09 Active: 17\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 19\n- Site 11 Active: 18\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n- Statin Subgroup N: 52\n- Statin Subgroup ALT (U/L) Mean: 127.9\n- Statin Subgroup ALT (U/L) Median: 125.2\n- Statin Subgroup AST (U/L) Mean: 91.5\n- Statin Subgroup AST (U/L) Median: 91.0\n- Statin Subgroup Bilirubin (mg/dL) Mean: 1.92\n- Statin Subgroup Bilirubin (mg/dL) Median: 1.9\n- Statin Subgroup ALP (U/L) Mean: 64.0\n- Statin Subgroup ALP (U/L) Median: 73.5\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.95\n- Statin Subgroup Creatinine (mg/dL) Median: 0.91\n- Statin Subgroup BUN (mg/dL) Mean: 13.8\n- Statin Subgroup BUN (mg/dL) Median: 11.3\n- Statin Subgroup WBC (K) Mean: 6.7\n- Statin Subgroup WBC (K) Median: 6.4\n- Statin Subgroup Platelets (K) Mean: 257\n- Statin Subgroup Platelets (K) Median: 235\n- Non-Statin Subgroup N: 127\n- Non-Statin Subgroup ALT (U/L) Mean: 27.9\n- Non-Statin Subgroup ALT (U/L) Median: 27.8\n- Non-Statin Subgroup AST (U/L) Mean: 27.3\n- Non-Statin Subgroup AST (U/L) Median: 26.0\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.51\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.49\n- Non-Statin Subgroup ALP (U/L) Mean: 61.8\n- Non-Statin Subgroup ALP (U/L) Median: 54.5\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.94\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.81\n- Non-Statin Subgroup BUN (mg/dL) Mean: 16.2\n- Non-Statin Subgroup BUN (mg/dL) Median: 14.7\n- Non-Statin Subgroup WBC (K) Mean: 7.7\n- Non-Statin Subgroup WBC (K) Median: 7.0\n- Non-Statin Subgroup Platelets (K) Mean: 231\n- Non-Statin Subgroup Platelets (K) Median: 214\n\n### Adverse Events\n- AE ID: AE-0089, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0090, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0091, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0092, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0093, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0094, Description: drug-induced liver injury, Grade: 3, Relatedness: definitely related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 29\n- Metformin Count: 21\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-047, Description: Missed visit window (2 days late), Severity: minor, Site: site_11\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- Lab kits inventory adequate for next 4 weeks\n- No new safety signals identified this week by local PI\n- PK sub-study interim: LNS-4821 plasma concentration data consistent with CYP3A4 inhibition; atorvastatin AUC 3.2x in co-administered subjects\n\n### Events\n- CRO quarterly oversight report submitted\n- Drug accountability audit at Site 04: no discrepancies\n- PK sub-study interim data package distributed to DSMB members\n\n### Notes\n- Week 23: PK data supports CYP3A4 inhibition mechanism. Statin subgroup ALT 3-4x ULN.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_069",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-06T10:30:00",
          "text": "## 2024-04-29 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 106\n- Active: 104\n- Screen Failures Cumulative: 12\n- Withdrawals Cumulative: 2\n\n### Enrollment By Dose Group\n- Low Dose: 25\n- Mid Dose: 25\n- High Dose: 28\n- Placebo: 28\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 56.0\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 19.1\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 94.3\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 136.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 97.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 25.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 94.6\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 29.4\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 147.2\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 212.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 161.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 32.4\n- High Dose\n  - IgG Titer (GMU) Mean: 121.7\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 38.8\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 200.1\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 300.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 216.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 51.1\n- Placebo\n  - IgG Titer (GMU) Mean: 6.5\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 3.5\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 17.2\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 25.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 25.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 4.5\n\n### Injection Site Reactions\n- Pain Percentage: 54.3\n- Erythema Percentage: 21.9\n- Swelling Percentage: 17.9\n- Induration Percentage: 7.8\n- Mean Pain Duration (Hours): 39.4\n\n### Systemic Reactogenicity\n- Fever Percentage: 12.8\n- Fatigue Percentage: 40.6\n- Myalgia Percentage: 23.2\n- Headache Percentage: 29.7\n- Chills Percentage: 8.4\n\n### Safety Labs\n- WBC (K) Mean: 6.5\n- WBC (K) SD: 1.7\n- Lymphocyte Percentage Mean: 25.0\n- Lymphocyte Percentage SD: 4.1\n- Neutrophil Percentage Mean: 46.9\n- Neutrophil Percentage SD: 8.0\n- Platelets (K) Mean: 220\n- Platelets (K) SD: 41\n- CRP (mg/L) Mean: 5.7\n- CRP (mg/L) SD: 1.1\n- Hemoglobin (g/dL) Mean: 13.4\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-0932, Description: myalgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0962, Description: lymphadenopathy, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-0971, Description: chills, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- T-cell assay batch B09 processed, results QC'd\n- DSMB safety review teleconference completed\n\n### Notes\n- Week 9: Immunogenicity assessments on schedule. 106 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_070",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-08T10:30:00",
          "text": "## 2024-05-06 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 107\n- Active: 103\n- Screen Failures Cumulative: 17\n- Withdrawals Cumulative: 4\n\n### Enrollment By Dose Group\n- Low Dose: 26\n- Mid Dose: 26\n- High Dose: 26\n- Placebo: 29\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 63.5\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 16.4\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 105.4\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 156.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 114.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 30.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 103.9\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 31.1\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 161.3\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 243.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 175.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 37.0\n- High Dose\n  - IgG Titer (GMU) Mean: 141.4\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 39.1\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 230.0\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 352.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 246.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 56.7\n- Placebo\n  - IgG Titer (GMU) Mean: 17.6\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 2.4\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 21.8\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 34.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 23.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 1.3\n\n### Injection Site Reactions\n- Pain Percentage: 58.1\n- Erythema Percentage: 18.6\n- Swelling Percentage: 15.6\n- Induration Percentage: 8.1\n- Mean Pain Duration (Hours): 40.9\n\n### Systemic Reactogenicity\n- Fever Percentage: 12.1\n- Fatigue Percentage: 25.9\n- Myalgia Percentage: 18.5\n- Headache Percentage: 15.8\n- Chills Percentage: 14.0\n\n### Safety Labs\n- WBC (K) Mean: 7.1\n- WBC (K) SD: 1.7\n- Lymphocyte Percentage Mean: 39.6\n- Lymphocyte Percentage SD: 5.4\n- Neutrophil Percentage Mean: 61.7\n- Neutrophil Percentage SD: 9.4\n- Platelets (K) Mean: 245\n- Platelets (K) SD: 36\n- CRP (mg/L) Mean: 3.2\n- CRP (mg/L) SD: 1.9\n- Hemoglobin (g/dL) Mean: 14.4\n- Hemoglobin (g/dL) SD: 1.5\n\n### Adverse Events\n- AE ID: VI-AE-1045, Description: myalgia, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-1045, Description: injection site pain, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1025, Description: fatigue, Grade: 1, Relatedness: related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Vaccination day 4: 12 subjects received scheduled dose\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n- T-cell assay batch B10 processed, results QC'd\n\n### Notes\n- Week 10: Immunogenicity assessments on schedule. 107 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_071",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-10T10:30:00",
          "text": "## 2024-05-13 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 105\n- Active: 101\n- Screen Failures Cumulative: 19\n- Withdrawals Cumulative: 4\n\n### Enrollment by Dose Group\n- Low Dose: 25\n- Mid Dose: 26\n- High Dose: 27\n- Placebo: 27\n\n### Immunogenicity By Group\n- Low Dose\n  - IGG Titer (GMU) Mean: 74.5\n  - IGG Titer (GMU) SD: 6.0\n  - IGM Titer (GMU) Mean: 16.8\n  - IGM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 108.0\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 180.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 131.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 32.4\n- Mid Dose\n  - IGG Titer (GMU) Mean: 115.0\n  - IGG Titer (GMU) SD: 9.6\n  - IGM Titer (GMU) Mean: 27.9\n  - IGM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 185.7\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 283.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 192.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 48.9\n- High Dose\n  - IGG Titer (GMU) Mean: 162.4\n  - IGG Titer (GMU) SD: 13.2\n  - IGM Titer (GMU) Mean: 38.4\n  - IGM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 250.2\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 392.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 263.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 60.6\n- Placebo\n  - IGG Titer (GMU) Mean: 10.1\n  - IGG Titer (GMU) SD: 1.2\n  - IGM Titer (GMU) Mean: 2.9\n  - IGM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 29.8\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 35.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 31.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 8.4\n\n### Injection Site Reactions\n- Pain Percentage: 43.4\n- Erythema Percentage: 21.1\n- Swelling Percentage: 5.5\n- Induration Percentage: 7.2\n- Mean Pain Duration (Hours): 27.6\n\n### Systemic Reactogenicity\n- Fever Percentage: 22.3\n- Fatigue Percentage: 32.0\n- Myalgia Percentage: 23.1\n- Headache Percentage: 23.9\n- Chills Percentage: 8.7\n\n### Safety Labs\n- WBC (K) Mean: 8.7\n- WBC (K) SD: 1.4\n- Lymphocyte Percentage Mean: 34.2\n- Lymphocyte Percentage SD: 7.6\n- Neutrophil Percentage Mean: 63.8\n- Neutrophil Percentage SD: 8.3\n- Platelets (K) Mean: 245\n- Platelets (K) SD: 42\n- CRP (mg/L) Mean: 3.6\n- CRP (mg/L) SD: 0.6\n- Hemoglobin (g/dL) Mean: 13.1\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-1137, Description: injection site pain, Grade: 1, Relatedness: related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1163, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1182, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Site 04 monitoring visit, 0 minor findings\n- DSMB safety review teleconference completed\n- Vaccination day 6: 22 subjects received scheduled dose\n\n### Notes\n- Week 11: Immunogenicity assessments on schedule. 105 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_024",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-12T10:00:00",
          "text": "## 2024-08-12 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 244\n- Active: 236\n- Screen Failures Cumulative: 49\n- Withdrawals Cumulative: 8\n\n### Sites\n- Site 01\n  - Enrolled: 25\n  - Active: 25\n  - Statin Concomitant: 6\n- Site 02\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 03\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 7\n- Site 04\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 05\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 07\n  - Enrolled: 27\n  - Active: 27\n  - Statin Concomitant: 8\n- Site 08\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 09\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 10\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 5\n- Site 12\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup\n  - N: 53\n  - ALT (U/L) Mean: 133.5\n  - ALT (U/L) Median: 131.2\n  - AST (U/L) Mean: 98.1\n  - AST (U/L) Median: 96.3\n  - Bilirubin (mg/dL) Mean: 2.08\n  - Bilirubin (mg/dL) Median: 2.05\n  - ALP (U/L) Mean: 71.4\n  - ALP (U/L) Median: 70.4\n  - Creatinine (mg/dL) Mean: 0.97\n  - Creatinine (mg/dL) Median: 0.9\n  - BUN (mg/dL) Mean: 16.8\n  - BUN (mg/dL) Median: 16.2\n  - WBC (K) Mean: 6.9\n  - WBC (K) Median: 7.4\n  - Platelets (K) Mean: 253\n  - Platelets (K) Median: 237\n- Non-Statin Subgroup\n  - N: 120\n  - ALT (U/L) Mean: 21.8\n  - ALT (U/L) Median: 20.0\n  - AST (U/L) Mean: 19.6\n  - AST (U/L) Median: 18.7\n  - Bilirubin (mg/dL) Mean: 0.79\n  - Bilirubin (mg/dL) Median: 0.74\n  - ALP (U/L) Mean: 52.3\n  - ALP (U/L) Median: 69.0\n  - Creatinine (mg/dL) Mean: 0.94\n  - Creatinine (mg/dL) Median: 0.84\n  - BUN (mg/dL) Mean: 15.3\n  - BUN (mg/dL) Median: 12.6\n  - WBC (K) Mean: 8.0\n  - WBC (K) Median: 7.6\n  - Platelets (K) Mean: 248\n  - Platelets (K) Median: 246\n\n### Adverse Events\n- AE ID: AE-0095\n  - Description: upper respiratory infection\n  - Grade: 1\n  - Relatedness: not related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0096\n  - Description: fatigue\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0097\n  - Description: nausea\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: non_statin\n- AE ID: AE-0098\n  - Description: headache\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: non_statin\n- AE ID: AE-0099\n  - Description: hepatocellular injury\n  - Grade: 3\n  - Relatedness: probably related\n  - Resolved: false\n  - Subject Group: statin\n- AE ID: AE-0100\n  - Description: jaundice\n  - Grade: 2\n  - Relatedness: probably related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 27\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-048\n  - Description: Eligibility criterion reassessed, subject confirmed eligible\n  - Severity: minor\n  - Site: site_11\n- PD ID: PD-049\n  - Description: Lab sample mislabeled, corrected same day\n  - Severity: minor\n  - Site: site_08\n\n### Investigator Notes\n- IEC/IRB annual renewal submitted on schedule\n- Central lab results received within 48h turnaround\n- Query resolution rate at 94%\n- DSMB teleconference scheduled; cross-site statin subgroup hepatic data package compiled\n\n### Events\n- CRO quarterly oversight report submitted\n- IVRS system update deployed, randomization unaffected\n- DSMB meeting materials finalized and transmitted\n\n### Notes\n- Week 24: DSMB review pending. Statin subgroup hepatic data compiled across all sites.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_072",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-12T10:30:00",
          "text": "## 2024-05-20 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 103\n- Active: 99\n- Screen Failures Cumulative: 15\n- Withdrawals Cumulative: 4\n\n### Enrollment By Dose Group\n- Low Dose: 24\n- Mid Dose: 26\n- High Dose: 26\n- Placebo: 27\n\n### Immunogenicity By Group\n- Low Dose IGG Titer (GMU) Mean: 75.3\n- Low Dose IGG Titer (GMU) SD: 6.0\n- Low Dose IGM Titer (GMU) Mean: 16.4\n- Low Dose IGM Titer (GMU) SD: 4.0\n- Low Dose Neutralizing Ab ID50 Mean: 122.3\n- Low Dose Neutralizing Ab ID50 SD: 10.0\n- Low Dose CD4 Response (SFC/10^6) Mean: 199.0\n- Low Dose CD4 Response (SFC/10^6) SD: 15.0\n- Low Dose CD8 Response (SFC/10^6) Mean: 130.0\n- Low Dose CD8 Response (SFC/10^6) SD: 11.0\n- Low Dose Seroconversion Percentage: 33.6\n\n- Mid Dose IGG Titer (GMU) Mean: 130.2\n- Mid Dose IGG Titer (GMU) SD: 9.6\n- Mid Dose IGM Titer (GMU) Mean: 30.3\n- Mid Dose IGM Titer (GMU) SD: 6.4\n- Mid Dose Neutralizing Ab ID50 Mean: 211.4\n- Mid Dose Neutralizing Ab ID50 SD: 16.0\n- Mid Dose CD4 Response (SFC/10^6) Mean: 317.0\n- Mid Dose CD4 Response (SFC/10^6) SD: 24.0\n- Mid Dose CD8 Response (SFC/10^6) Mean: 216.0\n- Mid Dose CD8 Response (SFC/10^6) SD: 18.0\n- Mid Dose Seroconversion Percentage: 48.7\n\n- High Dose IGG Titer (GMU) Mean: 180.8\n- High Dose IGG Titer (GMU) SD: 13.2\n- High Dose IGM Titer (GMU) Mean: 38.6\n- High Dose IGM Titer (GMU) SD: 8.8\n- High Dose Neutralizing Ab ID50 Mean: 276.6\n- High Dose Neutralizing Ab ID50 SD: 22.0\n- High Dose CD4 Response (SFC/10^6) Mean: 420.0\n- High Dose CD4 Response (SFC/10^6) SD: 33.0\n- High Dose CD8 Response (SFC/10^6) Mean: 298.0\n- High Dose CD8 Response (SFC/10^6) SD: 24.0\n- High Dose Seroconversion Percentage: 75.0\n\n- Placebo IGG Titer (GMU) Mean: 18.4\n- Placebo IGG Titer (GMU) SD: 1.2\n- Placebo IGM Titer (GMU) Mean: 6.2\n- Placebo IGM Titer (GMU) SD: 0.8\n- Placebo Neutralizing Ab ID50 Mean: 32.8\n- Placebo Neutralizing Ab ID50 SD: 2.0\n- Placebo CD4 Response (SFC/10^6) Mean: 33.0\n- Placebo CD4 Response (SFC/10^6) SD: 3.0\n- Placebo CD8 Response (SFC/10^6) Mean: 23.0\n- Placebo CD8 Response (SFC/10^6) SD: 2.0\n- Placebo Seroconversion Percentage: 4.0\n\n### Injection Site Reactions\n- Pain Percentage: 49.7\n- Erythema Percentage: 12.1\n- Swelling Percentage: 14.6\n- Induration Percentage: 7.5\n- Mean Pain Duration (Hours): 35.1\n\n### Systemic Reactogenicity\n- Fever Percentage: 15.1\n- Fatigue Percentage: 23.5\n- Myalgia Percentage: 31.6\n- Headache Percentage: 22.5\n- Chills Percentage: 10.3\n\n### Safety Labs\n- WBC (K) Mean: 6.1\n- WBC (K) SD: 1.1\n- Lymphocyte Percentage Mean: 29.2\n- Lymphocyte Percentage SD: 7.9\n- Neutrophil Percentage Mean: 45.1\n- Neutrophil Percentage SD: 6.7\n- Platelets (K) Mean: 246\n- Platelets (K) SD: 39\n- CRP (mg/L) Mean: 5.5\n- CRP (mg/L) SD: 0.9\n- Hemoglobin (g/dL) Mean: 13.6\n- Hemoglobin (g/dL) SD: 1.5\n\n### Adverse Events\n- AE ID: VI-AE-1235\n  - Description: myalgia\n  - Grade: 2\n  - Relatedness: possibly related\n  - Resolved: true\n  - Dose Group: high_dose\n- AE ID: VI-AE-1270\n  - Description: malaise\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Dose Group: mid_dose\n\n### Events\n- Reactogenicity diary card collection rate: 94%\n- Vaccination day 2: 19 subjects received scheduled dose\n\n### Notes\n- Week 12: Immunogenicity assessments on schedule. 103 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_073",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-15T10:30:00",
          "text": "## 2024-05-27 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 105\n- Active: 100\n- Screen Failures Cumulative: 17\n- Withdrawals Cumulative: 5\n\n### Enrollment By Dose Group\n- Low Dose: 24\n- Mid Dose: 25\n- High Dose: 29\n- Placebo: 27\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 77.9\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 19.3\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 126.3\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 196.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 131.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 27.9\n- Mid Dose\n  - IgG Titer (GMU) Mean: 123.6\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 27.4\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 197.1\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 306.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 210.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 52.0\n- High Dose\n  - IgG Titer (GMU) Mean: 172.1\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 41.1\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 274.0\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 414.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 285.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 71.1\n- Placebo\n  - IgG Titer (GMU) Mean: 20.5\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 5.6\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 25.3\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 45.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 22.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 9.5\n\n### Injection Site Reactions\n- Pain Percentage: 35.6\n- Erythema Percentage: 23.6\n- Swelling Percentage: 6.5\n- Induration Percentage: 9.7\n- Mean Pain Duration (Hours): 16.6\n\n### Systemic Reactogenicity\n- Fever Percentage: 11.5\n- Fatigue Percentage: 24.5\n- Myalgia Percentage: 24.0\n- Headache Percentage: 17.8\n- Chills Percentage: 8.6\n\n### Safety Labs\n- WBC (K): Mean: 5.8\n- WBC (K) SD: 1.0\n- Lymphocyte Percentage: Mean: 34.7\n- Lymphocyte Percentage SD: 7.3\n- Neutrophil Percentage: Mean: 57.5\n- Neutrophil Percentage SD: 6.0\n- Platelets (K): Mean: 226\n- Platelets (K) SD: 41\n- CRP (mg/L): Mean: 5.1\n- CRP (mg/L) SD: 2.0\n- Hemoglobin (g/dL): Mean: 13.1\n- Hemoglobin (g/dL) SD: 1.2\n\n### Adverse Events\n- AE ID: VI-AE-1328, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1347, Description: lymphadenopathy, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1306, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1326, Description: fever, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- DSMB safety review teleconference completed\n- Immunology core lab QC report received\n\n### Notes\n- Week 13: Immunogenicity assessments on schedule. 105 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_074",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-17T10:30:00",
          "text": "## 2024-06-03 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 106\n- Active: 100\n- Screen Failures Cumulative: 17\n- Withdrawals Cumulative: 6\n\n### Enrollment By Dose Group\n- Low Dose: 24\n- Mid Dose: 27\n- High Dose: 26\n- Placebo: 29\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 74.0\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 18.3\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 124.6\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 186.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 124.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 31.2\n- Mid Dose\n  - IgG Titer (GMU) Mean: 126.1\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 29.5\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 187.2\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 285.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 204.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 53.2\n- High Dose\n  - IgG Titer (GMU) Mean: 166.2\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 39.7\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 261.8\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 403.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 284.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 63.0\n- Placebo\n  - IgG Titer (GMU) Mean: 15.5\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 6.7\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 20.9\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 35.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 30.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 8.4\n\n### Injection Site Reactions\n- Pain Percentage: 57.0\n- Erythema Percentage: 15.5\n- Swelling Percentage: 13.6\n- Induration Percentage: 10.0\n- Mean Pain Duration (hours): 34.6\n\n### Systemic Reactogenicity\n- Fever Percentage: 20.8\n- Fatigue Percentage: 42.4\n- Myalgia Percentage: 27.0\n- Headache Percentage: 16.6\n- Chills Percentage: 7.1\n\n### Safety Labs\n- WBC (K) Mean: 5.5\n- WBC (K) SD: 1.9\n- Lymphocyte Percentage Mean: 34.0\n- Lymphocyte Percentage SD: 5.5\n- Neutrophil Percentage Mean: 50.0\n- Neutrophil Percentage SD: 5.7\n- Platelets (K) Mean: 241\n- Platelets (K) SD: 44\n- CRP (mg/L) Mean: 3.6\n- CRP (mg/L) SD: 0.6\n- Hemoglobin (g/dL) Mean: 13.9\n- Hemoglobin (g/dL) SD: 1.2\n\n### Adverse Events\n- AE ID: VI-AE-1431, Description: injection site pain, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1450, Description: arthralgia, Grade: 1, Relatedness: related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-1414, Description: headache, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-1498, Description: chills, Grade: 1, Relatedness: related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Serology samples shipped to central immunology lab\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n\n### Notes\n- Week 14: Immunogenicity assessments on schedule. 106 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_025",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-19T10:00:00",
          "text": "## 2024-08-19 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 231\n- Active: 216\n- Screen Failures Cumulative: 42\n- Withdrawals Cumulative: 15\n\n#### Sites\n- Site 01 Enrolled: 23\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 21\n- Site 03 Active: 21\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 5\n- Site 05 Enrolled: 19\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 25\n- Site 07 Active: 25\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 19\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 6\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 21\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 56\n- ALT (U/L) Mean: 152.0\n- ALT (U/L) Median: 150.5\n- AST (U/L) Mean: 98.1\n- AST (U/L) Median: 97.3\n- Bilirubin (mg/dL) Mean: 2.41\n- Bilirubin (mg/dL) Median: 2.41\n- ALP (U/L) Mean: 63.2\n- ALP (U/L) Median: 66.9\n- Creatinine (mg/dL) Mean: 1.09\n- Creatinine (mg/dL) Median: 0.85\n- BUN (mg/dL) Mean: 12.9\n- BUN (mg/dL) Median: 11.7\n- WBC (K) Mean: 7.5\n- WBC (K) Median: 7.2\n- Platelets (K) Mean: 241\n- Platelets (K) Median: 246\n\n#### Non-Statin Subgroup\n- N: 122\n- ALT (U/L) Mean: 21.7\n- ALT (U/L) Median: 21.0\n- AST (U/L) Mean: 25.6\n- AST (U/L) Median: 23.7\n- Bilirubin (mg/dL) Mean: 0.89\n- Bilirubin (mg/dL) Median: 0.87\n- ALP (U/L) Mean: 67.1\n- ALP (U/L) Median: 59.1\n- Creatinine (mg/dL) Mean: 0.89\n- Creatinine (mg/dL) Median: 0.96\n- BUN (mg/dL) Mean: 17.3\n- BUN (mg/dL) Median: 14.8\n- WBC (K) Mean: 8.0\n- WBC (K) Median: 6.2\n- Platelets (K) Mean: 251\n- Platelets (K) Median: 243\n\n### Adverse Events\n- AE ID: AE-0101, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0102, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0103, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0104, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0105, Description: drug-induced liver injury, Grade: 3, Relatedness: definitely related, Resolved: false, Subject Group: statin\n- AE ID: AE-0106, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-050, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_02\n- PD ID: PD-051, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_10\n- PD ID: PD-052, Description: Missed visit window (4 days late), Severity: minor, Site: site_01\n\n### Investigator Notes\n- Query resolution rate at 94%\n- All CRFs current through prior visit cycle\n- DDI mechanism confirmed: LNS-4821 CYP3A4 inhibition leads to statin accumulation; protocol amendment drafted to exclude statin co-administration\n\n### Events\n- Site 01 new coordinator onboarding completed\n- Data management plan revision v2.5 distributed\n- CRO quarterly oversight report submitted\n- Protocol amendment v4.0 drafted; sponsor medical review initiated\n\n### Notes\n- Week 25: DDI confirmed. Protocol amendment drafted to exclude statin co-administration.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_075",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-19T10:30:00",
          "text": "## 2024-06-10 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 107\n- Active: 103\n- Screen Failures Cumulative: 18\n- Withdrawals Cumulative: 4\n\n### Enrollment By Dose Group\n- Low Dose: 25\n- Mid Dose: 27\n- High Dose: 26\n- Placebo: 29\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 76.1\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 21.7\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 120.7\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 177.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 129.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 29.8\n- Mid Dose\n  - IgG Titer (GMU) Mean: 117.8\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 27.5\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 181.5\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 290.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 207.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 45.1\n- High Dose\n  - IgG Titer (GMU) Mean: 159.6\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 43.6\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 263.7\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 390.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 278.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 62.5\n- Placebo\n  - IgG Titer (GMU) Mean: 10.1\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 5.3\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 29.9\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 41.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 23.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 8.2\n\n### Injection Site Reactions\n- Pain Percentage: 48.3\n- Erythema Percentage: 23.8\n- Swelling Percentage: 15.7\n- Induration Percentage: 6.7\n- Mean Pain Duration (Hours): 27.0\n\n### Systemic Reactogenicity\n- Fever Percentage: 11.9\n- Fatigue Percentage: 29.5\n- Myalgia Percentage: 26.1\n- Headache Percentage: 15.7\n- Chills Percentage: 14.7\n\n### Safety Labs\n- WBC (K): Mean: 7.7\n- WBC (K) SD: 1.5\n- Lymphocyte Percentage: Mean: 26.1\n- Lymphocyte Percentage SD: 7.5\n- Neutrophil Percentage: Mean: 64.4\n- Neutrophil Percentage SD: 6.6\n- Platelets (K): Mean: 218\n- Platelets (K) SD: 43\n- CRP (mg/L): Mean: 3.8\n- CRP (mg/L) SD: 1.9\n- Hemoglobin (g/dL): Mean: 13.6\n- Hemoglobin (g/dL) SD: 1.4\n\n### Adverse Events\n- AE ID: VI-AE-1587, Description: fatigue, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1524, Description: fatigue, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- Vaccination day 6: 22 subjects received scheduled dose\n- Immunology core lab QC report received\n\n### Notes\n- Week 15: Immunogenicity assessments on schedule. 107 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_076",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-22T10:30:00",
          "text": "## 2024-06-17 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 128\n- Active: 121\n- Screen Failures Cumulative: 23\n- Withdrawals Cumulative: 7\n\n### Enrollment By Dose Group\n- Low Dose: 31\n- Mid Dose: 32\n- High Dose: 32\n- Placebo: 33\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 76.3\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 18.9\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 117.6\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 177.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 118.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 28.1\n- Mid Dose\n  - IgG Titer (GMU) Mean: 115.9\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 27.1\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 189.8\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 270.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 203.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 49.9\n- High Dose\n  - IgG Titer (GMU) Mean: 155.2\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 40.0\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 257.9\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 380.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 267.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 64.4\n- Placebo\n  - IgG Titer (GMU) Mean: 12.0\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 1.8\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 27.3\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 35.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 28.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 10.2\n\n### Injection Site Reactions\n- Pain Percentage: 50.9\n- Erythema Percentage: 25.4\n- Swelling Percentage: 12.2\n- Induration Percentage: 3.7\n- Mean Pain Duration (Hours): 33.0\n\n### Systemic Reactogenicity\n- Fever Percentage: 18.8\n- Fatigue Percentage: 41.0\n- Myalgia Percentage: 26.6\n- Headache Percentage: 27.6\n- Chills Percentage: 6.9\n\n### Safety Labs\n- WBC (K) Mean: 7.6\n- WBC (K) SD: 1.1\n- Lymphocyte Percentage Mean: 34.4\n- Lymphocyte Percentage SD: 6.2\n- Neutrophil Percentage Mean: 61.1\n- Neutrophil Percentage SD: 5.2\n- Platelets (K) Mean: 229\n- Platelets (K) SD: 41\n- CRP (mg/L) Mean: 6.3\n- CRP (mg/L) SD: 0.6\n- Hemoglobin (g/dL) Mean: 14.8\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-1658\n  - Description: fever\n  - Grade: 2\n  - Relatedness: possibly related\n  - Resolved: true\n  - Dose Group: mid_dose\n- AE ID: VI-AE-1626\n  - Description: lymphadenopathy\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Dose Group: mid_dose\n\n### Events\n- Vaccine lot VX-825 temperature excursion assessed: within acceptable range\n- Immunology core lab QC report received\n\n### Notes\n- Week 16: Immunogenicity assessments on schedule. 128 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_077",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-24T10:30:00",
          "text": "## 2024-06-24 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 126\n- Active: 119\n- Screen Failures Cumulative: 25\n- Withdrawals Cumulative: 7\n\n### Enrollment by Dose Group\n- Low Dose: 31\n- Mid Dose: 30\n- High Dose: 33\n- Placebo: 32\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 71.4\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 20.6\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 105.5\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 169.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 122.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 32.9\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 108.4\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 29.3\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 186.2\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 270.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 192.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 44.0\n\n#### High Dose\n- IgG Titer (GMU) Mean: 150.2\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 39.5\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 245.1\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 379.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 254.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 58.8\n\n#### Placebo\n- IgG Titer (GMU) Mean: 16.1\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 6.2\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 18.0\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 35.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 29.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 6.5\n\n### Injection Site Reactions\n- Pain Percentage: 37.5\n- Erythema Percentage: 19.9\n- Swelling Percentage: 18.6\n- Induration Percentage: 7.5\n- Mean Pain Duration (Hours): 33.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 17.4\n- Fatigue Percentage: 33.5\n- Myalgia Percentage: 27.9\n- Headache Percentage: 25.0\n- Chills Percentage: 8.7\n\n### Safety Labs\n- WBC (K): Mean: 7.0\n- WBC (K) SD: 1.5\n- Lymphocyte Percentage: Mean: 30.1\n- Lymphocyte Percentage SD: 7.7\n- Neutrophil Percentage: Mean: 49.5\n- Neutrophil Percentage SD: 7.7\n- Platelets (K): Mean: 241\n- Platelets (K) SD: 40\n- CRP (mg/L): Mean: 5.1\n- CRP (mg/L) SD: 1.6\n- Hemoglobin (g/dL): Mean: 13.7\n- Hemoglobin (g/dL) SD: 0.9\n\n### Adverse Events\n- AE ID: VI-AE-1745, Description: lymphadenopathy, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1743, Description: fatigue, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1715, Description: chills, Grade: 1, Relatedness: related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-1782, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Vaccine lot VX-857 temperature excursion assessed: within acceptable range\n- Vaccine lot VX-943 temperature excursion assessed: within acceptable range\n\n### Notes\n- Week 17: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_026",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-26T10:00:00",
          "text": "## 2024-08-26 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 234\n- Active: 220\n- Screen Failures Cumulative: 69\n- Withdrawals Cumulative: 14\n\n#### Sites\n- Site 01 Enrolled: 24\n- Site 01 Active: 23\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 22\n- Site 03 Active: 21\n- Site 03 Statin Concomitant: 7\n- Site 04 Enrolled: 16\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 5\n- Site 05 Enrolled: 19\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 6\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 25\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 19\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 16\n- Site 10 Active: 16\n- Site 10 Statin Concomitant: 5\n- Site 11 Enrolled: 22\n- Site 11 Active: 21\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 17\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 148.8\n- ALT (U/L) Median: 148.6\n- AST (U/L) Mean: 104.7\n- AST (U/L) Median: 102.9\n- Bilirubin (mg/dL) Mean: 2.32\n- Bilirubin (mg/dL) Median: 2.32\n- ALP (U/L) Mean: 81.8\n- ALP (U/L) Median: 62.7\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 15.9\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 6.1\n- WBC (K) Median: 6.5\n- Platelets (K) Mean: 260\n- Platelets (K) Median: 247\n\n#### Non-Statin Subgroup\n- N: 132\n- ALT (U/L) Mean: 31.3\n- ALT (U/L) Median: 31.2\n- AST (U/L) Mean: 29.1\n- AST (U/L) Median: 28.1\n- Bilirubin (mg/dL) Mean: 0.89\n- Bilirubin (mg/dL) Median: 0.87\n- ALP (U/L) Mean: 58.0\n- ALP (U/L) Median: 69.6\n- Creatinine (mg/dL) Mean: 1.0\n- Creatinine (mg/dL) Median: 0.91\n- BUN (mg/dL) Mean: 17.6\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 7.5\n- WBC (K) Median: 5.9\n- Platelets (K) Mean: 232\n- Platelets (K) Median: 238\n\n### Adverse Events\n- AE ID: AE-0107, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0108, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0109, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0110, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 46\n- ACE Inhibitor Count: 28\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-053, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_05\n- PD ID: PD-054, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_07\n- PD ID: PD-055, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_03\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- All CRFs current through prior visit cycle\n- Protocol amendment v4.0 submitted to IRB: statin exclusion criterion added, CYP3A4 substrate screening required\n- In-vitro CYP3A4 Ki data received: LNS-4821 Ki = 0.8 uM, consistent with clinical DDI magnitude\n\n### Events\n- CRO quarterly oversight report submitted\n- Site 06 new coordinator onboarding completed\n- Investigator meeting minutes distributed\n- Protocol amendment v4.0 submitted to central IRB\n\n### Notes\n- Week 26: Protocol amendment v4.0 under IRB review/approval. Statin subjects transitioning.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_078",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-26T10:30:00",
          "text": "## 2024-07-01 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 124\n- Active: 117\n- Screen Failures Cumulative: 31\n- Withdrawals Cumulative: 7\n\n#### By Dose Group\n- Low Dose: 29\n- Mid Dose: 31\n- High Dose: 32\n- Placebo: 32\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 72.1\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 17.8\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 115.7\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 164.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 118.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 30.5\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 108.4\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 29.4\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 175.5\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 259.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 192.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 44.5\n\n#### High Dose\n- IgG Titer (GMU) Mean: 149.7\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 41.4\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 240.2\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 363.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 249.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 63.8\n\n#### Placebo\n- IgG Titer (GMU) Mean: 10.4\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 4.1\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 21.8\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 39.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 18.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 1.2\n\n### Injection Site Reactions\n- Pain Percentage: 35.6\n- Erythema Percentage: 23.4\n- Swelling Percentage: 11.5\n- Induration Percentage: 7.7\n- Mean Pain Duration (Hours): 17.2\n\n### Systemic Reactogenicity\n- Fever Percentage: 16.1\n- Fatigue Percentage: 28.4\n- Myalgia Percentage: 20.3\n- Headache Percentage: 25.5\n- Chills Percentage: 5.7\n\n### Safety Labs\n- WBC (K) Mean: 8.7\n- WBC (K) SD: 2.0\n- Lymphocyte Percentage Mean: 33.9\n- Lymphocyte Percentage SD: 6.1\n- Neutrophil Percentage Mean: 55.2\n- Neutrophil Percentage SD: 8.3\n- Platelets (K) Mean: 226\n- Platelets (K) SD: 39\n- CRP (mg/L) Mean: 2.3\n- CRP (mg/L) SD: 0.6\n- Hemoglobin (g/dL) Mean: 13.8\n- Hemoglobin (g/dL) SD: 1.3\n\n### Adverse Events\n- AE ID: VI-AE-1847, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-1879, Description: fatigue, Grade: 2, Relatedness: related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1884, Description: chills, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- DSMB safety review teleconference completed\n- Serum sample aliquoting completed for 18 subjects\n\n### Notes\n- Week 18: Immunogenicity assessments on schedule. 124 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_079",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-28T10:30:00",
          "text": "## 2024-07-08 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 125\n- Active: 118\n- Screen Failures Cumulative: 32\n- Withdrawals Cumulative: 7\n\n### Enrollment by Dose Group\n- Low Dose: 29\n- Mid Dose: 32\n- High Dose: 32\n- Placebo: 32\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 61.2\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 17.2\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 110.5\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 168.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 120.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 22.4\n- Mid Dose\n  - IgG Titer (GMU) Mean: 107.3\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 32.1\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 171.3\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 252.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 183.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 43.1\n- High Dose\n  - IgG Titer (GMU) Mean: 147.3\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 39.1\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 229.3\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 350.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 244.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 55.5\n- Placebo\n  - IgG Titer (GMU) Mean: 13.0\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 0.8\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 23.0\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 39.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 23.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 1.7\n\n### Injection Site Reactions\n- Pain Percentage: 51.7\n- Erythema Percentage: 26.0\n- Swelling Percentage: 15.0\n- Induration Percentage: 8.5\n- Mean Pain Duration (hours): 31.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 16.3\n- Fatigue Percentage: 42.7\n- Myalgia Percentage: 29.4\n- Headache Percentage: 23.2\n- Chills Percentage: 14.0\n\n### Safety Labs\n- WBC (K) Mean: 8.4\n- WBC (K) SD: 1.8\n- Lymphocyte Percentage Mean: 25.7\n- Lymphocyte Percentage SD: 5.2\n- Neutrophil Percentage Mean: 54.4\n- Neutrophil Percentage SD: 5.6\n- Platelets (K) Mean: 220\n- Platelets (K) SD: 39\n- CRP (mg/L) Mean: 7.4\n- CRP (mg/L) SD: 0.8\n- Hemoglobin (g/dL) Mean: 13.1\n- Hemoglobin (g/dL) SD: 1.5\n\n### Adverse Events\n- AE ID: VI-AE-1934, Description: lymphadenopathy, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1973, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-1920, Description: malaise, Grade: 2, Relatedness: related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1954, Description: fatigue, Grade: 1, Relatedness: related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-1911, Description: injection site pain, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- Serology samples shipped to central immunology lab\n- Vaccination day 2: 12 subjects received scheduled dose\n\n### Notes\n- Week 19: Immunogenicity assessments on schedule. 125 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_080",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-31T10:30:00",
          "text": "## 2024-07-15 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 126\n- Active: 117\n- Screen Failures Cumulative: 35\n- Withdrawals Cumulative: 9\n\n#### By Dose Group\n- Low Dose: 30\n- Mid Dose: 31\n- High Dose: 31\n- Placebo: 34\n\n### Immunogenicity By Group\n\n#### Low Dose\n- IgG Titer (GMU) Mean: 64.1\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 18.9\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 96.6\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 161.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 111.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 29.5\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 106.8\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 29.9\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 169.4\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 246.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 179.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 42.5\n\n#### High Dose\n- IgG Titer (GMU) Mean: 140.6\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 41.9\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 222.9\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 329.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 242.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 53.7\n\n#### Placebo\n- IgG Titer (GMU) Mean: 15.3\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 3.1\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 19.1\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 39.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 28.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 6.7\n\n### Injection Site Reactions\n- Pain Percentage: 55.1\n- Erythema Percentage: 23.9\n- Swelling Percentage: 11.5\n- Induration Percentage: 10.5\n- Mean Pain Duration (Hours): 34.3\n\n### Systemic Reactogenicity\n- Fever Percentage: 16.4\n- Fatigue Percentage: 21.9\n- Myalgia Percentage: 31.5\n- Headache Percentage: 23.0\n- Chills Percentage: 11.5\n\n### Safety Labs\n\n#### WBC\n- Mean: 5.7\n- SD: 1.7\n\n#### Lymphocyte Percentage\n- Mean: 38.6\n- SD: 6.7\n\n#### Neutrophil Percentage\n- Mean: 51.5\n- SD: 8.0\n\n#### Platelets\n- Mean: 225\n- SD: 44\n\n#### CRP\n- Mean: 6.9\n- SD: 1.0\n\n#### Hemoglobin\n- Mean: 14.7\n- SD: 1.2\n\n### Adverse Events\n- AE ID: VI-AE-2068, Description: chills, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-2023, Description: headache, Grade: 1, Relatedness: related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-2009, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2054, Description: nausea, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n\n### Events\n- DSMB safety review teleconference completed\n- Reactogenicity diary card collection rate: 95%\n- Site 03 monitoring visit, 3 minor findings\n\n### Notes\n- Week 20: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_027",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-02T10:00:00",
          "text": "## 2024-09-02 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 218\n- Active: 202\n- Screen Failures Cumulative: 68\n- Withdrawals Cumulative: 16\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 16\n- Site 02 Active: 15\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 4\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 15\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 53\n- ALT (U/L) Mean: 162.5\n- ALT (U/L) Median: 160.5\n- AST (U/L) Mean: 108.1\n- AST (U/L) Median: 106.5\n- Bilirubin (mg/dL) Mean: 2.44\n- Bilirubin (mg/dL) Median: 2.41\n- ALP (U/L) Mean: 69.2\n- ALP (U/L) Median: 55.0\n- Creatinine (mg/dL) Mean: 0.98\n- Creatinine (mg/dL) Median: 0.99\n- BUN (mg/dL) Mean: 17.4\n- BUN (mg/dL) Median: 15.0\n- WBC (K) Mean: 8.2\n- WBC (K) Median: 7.6\n- Platelets (K) Mean: 236\n- Platelets (K) Median: 223\n\n#### Non-Statin Subgroup\n- N: 129\n- ALT (U/L) Mean: 22.1\n- ALT (U/L) Median: 21.7\n- AST (U/L) Mean: 23.2\n- AST (U/L) Median: 21.7\n- Bilirubin (mg/dL) Mean: 0.63\n- Bilirubin (mg/dL) Median: 0.62\n- ALP (U/L) Mean: 52.7\n- ALP (U/L) Median: 53.7\n- Creatinine (mg/dL) Mean: 0.82\n- Creatinine (mg/dL) Median: 0.99\n- BUN (mg/dL) Mean: 13.9\n- BUN (mg/dL) Median: 15.8\n- WBC (K) Mean: 8.0\n- WBC (K) Median: 7.5\n- Platelets (K) Mean: 232\n- Platelets (K) Median: 213\n\n### Adverse Events\n- AE ID: AE-0111, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0112, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0113, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0114, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 38\n- ACE Inhibitor Count: 30\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-056, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_10\n- PD ID: PD-057, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_06\n- PD ID: PD-058, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_08\n\n### Investigator Notes\n- Query resolution rate at 94%\n- Central lab results received within 48h turnaround\n- IRB approved protocol amendment v4.0; all sites notified\n- Statin co-administered subjects transitioning off statins per amended protocol\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- Site 10 pharmacy temperature log reviewed: compliant\n- Protocol amendment v4.0 approved; site distribution initiated\n\n### Notes\n- Week 27: Protocol amendment v4.0 under IRB review/approval. Statin subjects transitioning.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_081",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-02T10:30:00",
          "text": "## 2024-07-22 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 128\n- Active: 121\n- Screen Failures Cumulative: 34\n- Withdrawals Cumulative: 7\n\n### Enrollment By Dose Group\n- Low Dose: 31\n- Mid Dose: 31\n- High Dose: 33\n- Placebo: 33\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 58.5\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 17.3\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 96.3\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC per 10^6) Mean: 158.0\n  - CD4 Response (SFC per 10^6) SD: 15.0\n  - CD8 Response (SFC per 10^6) Mean: 102.0\n  - CD8 Response (SFC per 10^6) SD: 11.0\n  - Seroconversion Percentage: 27.6\n- Mid Dose\n  - IgG Titer (GMU) Mean: 99.0\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 28.8\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 154.1\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC per 10^6) Mean: 235.0\n  - CD4 Response (SFC per 10^6) SD: 24.0\n  - CD8 Response (SFC per 10^6) Mean: 171.0\n  - CD8 Response (SFC per 10^6) SD: 18.0\n  - Seroconversion Percentage: 40.5\n- High Dose\n  - IgG Titer (GMU) Mean: 133.7\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 44.0\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 219.7\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC per 10^6) Mean: 334.0\n  - CD4 Response (SFC per 10^6) SD: 33.0\n  - CD8 Response (SFC per 10^6) Mean: 227.0\n  - CD8 Response (SFC per 10^6) SD: 24.0\n  - Seroconversion Percentage: 58.0\n- Placebo\n  - IgG Titer (GMU) Mean: 14.9\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 5.3\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 15.4\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC per 10^6) Mean: 36.0\n  - CD4 Response (SFC per 10^6) SD: 3.0\n  - CD8 Response (SFC per 10^6) Mean: 13.0\n  - CD8 Response (SFC per 10^6) SD: 2.0\n  - Seroconversion Percentage: 6.8\n\n### Injection Site Reactions\n- Pain Percentage: 43.2\n- Erythema Percentage: 28.9\n- Swelling Percentage: 19.6\n- Induration Percentage: 3.6\n- Mean Pain Duration (Hours): 21.8\n\n### Systemic Reactogenicity\n- Fever Percentage: 21.8\n- Fatigue Percentage: 20.5\n- Myalgia Percentage: 23.5\n- Headache Percentage: 15.2\n- Chills Percentage: 12.5\n\n### Safety Labs\n- WBC (K): Mean: 6.2\n- WBC SD: 1.6\n- Lymphocyte Percentage: Mean: 27.0\n- Lymphocyte Percentage SD: 5.2\n- Neutrophil Percentage: Mean: 52.2\n- Neutrophil Percentage SD: 8.2\n- Platelets (K): Mean: 242\n- Platelets SD: 41\n- CRP (mg/L): Mean: 3.1\n- CRP SD: 1.2\n- Hemoglobin (g/dL): Mean: 13.6\n- Hemoglobin SD: 1.2\n\n### Adverse Events\n- AE ID: VI-AE-2166, Description: myalgia, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2141, Description: malaise, Grade: 1, Relatedness: related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- Vaccine lot VX-877 temperature excursion assessed: within acceptable range\n- Reactogenicity diary card collection rate: 96%\n- Vaccination day 1: 25 subjects received scheduled dose\n\n### Notes\n- Week 21: Immunogenicity assessments on schedule. 128 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_082",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-04T10:30:00",
          "text": "## 2024-07-29 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 125\n- Active: 116\n- Screen Failures Cumulative: 30\n- Withdrawals Cumulative: 9\n\n### Enrollment by Dose Group\n- Low Dose: 29\n- Mid Dose: 31\n- High Dose: 32\n- Placebo: 33\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 59.3\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 16.1\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 96.7\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 146.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 102.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 27.5\n- Mid Dose\n  - IgG Titer (GMU) Mean: 97.2\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 30.3\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 153.1\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 236.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 166.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 41.6\n- High Dose\n  - IgG Titer (GMU) Mean: 136.3\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 43.9\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 210.0\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 308.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 224.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 51.7\n- Placebo\n  - IgG Titer (GMU) Mean: 7.0\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 5.9\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 11.2\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 20.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 14.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 4.3\n\n### Injection Site Reactions\n- Pain Percentage: 36.1\n- Erythema Percentage: 29.8\n- Swelling Percentage: 19.6\n- Induration Percentage: 5.5\n- Mean Pain Duration (Hours): 32.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 11.0\n- Fatigue Percentage: 28.3\n- Myalgia Percentage: 20.3\n- Headache Percentage: 23.2\n- Chills Percentage: 12.5\n\n### Safety Labs\n- WBC (K): Mean: 8.9\n- WBC (K) SD: 1.4\n- Lymphocyte Percentage: Mean: 37.5\n- Lymphocyte Percentage SD: 5.4\n- Neutrophil Percentage: Mean: 47.8\n- Neutrophil Percentage SD: 9.5\n- Platelets (K): Mean: 253\n- Platelets (K) SD: 40\n- CRP (mg/L): Mean: 7.1\n- CRP (mg/L) SD: 1.3\n- Hemoglobin (g/dL): Mean: 13.8\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-2255, Description: myalgia, Grade: 1, Relatedness: related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2265, Description: fever, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Serology samples shipped to central immunology lab\n- Immunology core lab QC report received\n- Immunology core lab QC report received\n\n### Notes\n- Week 22: Immunogenicity assessments on schedule. 125 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_083",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-07T10:30:00",
          "text": "## 2024-08-05 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 127\n- Active: 119\n- Screen Failures Cumulative: 30\n- Withdrawals Cumulative: 8\n\n### Enrollment By Dose Group\n- Low Dose: 29\n- Mid Dose: 32\n- High Dose: 32\n- Placebo: 34\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 62.1\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 18.8\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 99.1\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 143.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 106.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 22.2\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 90.7\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 29.3\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 152.4\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 223.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 166.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 34.8\n\n#### High Dose\n- IgG Titer (GMU) Mean: 124.8\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 40.0\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 196.6\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 316.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 215.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 49.5\n\n#### Placebo\n- IgG Titer (GMU) Mean: 15.7\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 1.3\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 26.5\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 27.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 18.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 1.5\n\n### Injection Site Reactions\n- Pain Percentage: 48.5\n- Erythema Percentage: 28.2\n- Swelling Percentage: 15.2\n- Induration Percentage: 8.5\n- Mean Pain Duration (Hours): 16.6\n\n### Systemic Reactogenicity\n- Fever Percentage: 12.7\n- Fatigue Percentage: 37.2\n- Myalgia Percentage: 19.9\n- Headache Percentage: 26.9\n- Chills Percentage: 10.4\n\n### Safety Labs\n- WBC (K) Mean: 5.9\n- WBC (K) SD: 1.3\n- Lymphocyte Percentage Mean: 35.8\n- Lymphocyte Percentage SD: 6.1\n- Neutrophil Percentage Mean: 53.8\n- Neutrophil Percentage SD: 6.6\n- Platelets (K) Mean: 252\n- Platelets (K) SD: 38\n- CRP (mg/L) Mean: 7.2\n- CRP (mg/L) SD: 1.3\n- Hemoglobin (g/dL) Mean: 13.8\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-2361, Description: chills, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2378, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2331, Description: lymphadenopathy, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n\n### Events\n- DSMB safety review teleconference completed\n- Site 03 monitoring visit, 1 minor findings\n- Serum sample aliquoting completed for 20 subjects\n\n### Notes\n- Week 23: Immunogenicity assessments on schedule. 127 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_028",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-09T10:00:00",
          "text": "## 2024-09-09 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 220\n- Active: 200\n- Screen Failures Cumulative: 48\n- Withdrawals Cumulative: 20\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 15\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 15\n- Site 10 Active: 15\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 51\n- ALT (U/L) Mean: 166.2\n- ALT (U/L) Median: 164.2\n- AST (U/L) Mean: 115.1\n- AST (U/L) Median: 113.9\n- Bilirubin (mg/dL) Mean: 2.84\n- Bilirubin (mg/dL) Median: 2.8\n- ALP (U/L) Mean: 67.4\n- ALP (U/L) Median: 79.6\n- Creatinine (mg/dL) Mean: 0.91\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 12.2\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 5.6\n- WBC (K) Median: 7.3\n- Platelets (K) Mean: 242\n- Platelets (K) Median: 246\n\n#### Non-Statin Subgroup\n- N: 123\n- ALT (U/L) Mean: 29.1\n- ALT (U/L) Median: 28.5\n- AST (U/L) Mean: 21.3\n- AST (U/L) Median: 20.1\n- Bilirubin (mg/dL) Mean: 0.58\n- Bilirubin (mg/dL) Median: 0.56\n- ALP (U/L) Mean: 57.4\n- ALP (U/L) Median: 49.0\n- Creatinine (mg/dL) Mean: 1.03\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 12.9\n- BUN (mg/dL) Median: 13.0\n- WBC (K) Mean: 7.8\n- WBC (K) Median: 6.4\n- Platelets (K) Mean: 256\n- Platelets (K) Median: 213\n\n### Adverse Events\n- AE ID: AE-0115, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0116, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0117, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0118, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0119, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 31\n- ACE Inhibitor Count: 28\n- Metformin Count: 22\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-059, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_07\n- PD ID: PD-060, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_12\n\n### Investigator Notes\n- EDC data entry backlog cleared, queries resolved\n- Study drug accountability reconciled, no discrepancies\n- Regulatory binder audit: all documents current\n- 10 of 12 sites have implemented protocol amendment; 2 sites pending local IRB\n\n### Events\n- Medical monitor weekly call completed\n- Bioanalytical lab shipment tracking confirmed for 4 samples\n- IVRS system update deployed, randomization unaffected\n- Site implementation tracking: 10/12 sites active on amended protocol\n\n### Notes\n- Week 28: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_084",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-09T10:30:00",
          "text": "## 2024-08-12 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 124\n- Active: 116\n- Screen Failures Cumulative: 34\n- Withdrawals Cumulative: 8\n\n### Enrollment By Dose Group\n- Low Dose: 31\n- Mid Dose: 30\n- High Dose: 31\n- Placebo: 32\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 57.2\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 19.7\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 86.3\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 131.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 99.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 24.5\n- Mid Dose\n  - IgG Titer (GMU) Mean: 92.9\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 31.8\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 146.1\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 217.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 153.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 37.7\n- High Dose\n  - IgG Titer (GMU) Mean: 123.9\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 43.1\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 194.1\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 292.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 214.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 44.4\n- Placebo\n  - IgG Titer (GMU) Mean: 11.2\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 1.3\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 15.1\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 34.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 24.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 5.4\n\n### Injection Site Reactions\n- Pain Percentage: 45.5\n- Erythema Percentage: 14.6\n- Swelling Percentage: 17.8\n- Induration Percentage: 3.5\n- Mean Pain Duration (Hours): 16.0\n\n### Systemic Reactogenicity\n- Fever Percentage: 21.8\n- Fatigue Percentage: 28.7\n- Myalgia Percentage: 27.9\n- Headache Percentage: 24.7\n- Chills Percentage: 14.0\n\n### Safety Labs\n- WBC (K) Mean: 8.1\n- WBC (K) SD: 1.6\n- Lymphocyte Percentage Mean: 35.2\n- Lymphocyte Percentage SD: 7.3\n- Neutrophil Percentage Mean: 57.8\n- Neutrophil Percentage SD: 9.9\n- Platelets (K) Mean: 227\n- Platelets (K) SD: 40\n- CRP (mg/L) Mean: 4.4\n- CRP (mg/L) SD: 1.5\n- Hemoglobin (g/dL) Mean: 14.0\n- Hemoglobin (g/dL) SD: 1.4\n\n### Adverse Events\n- AE ID: VI-AE-2478, Description: myalgia, Grade: 1, Relatedness: related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2443, Description: fatigue, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-2424, Description: fatigue, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-2476, Description: myalgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Site 01 monitoring visit, 0 minor findings\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n- Vaccine lot VX-153 temperature excursion assessed: within acceptable range\n\n### Notes\n- Week 24: Immunogenicity assessments on schedule. 124 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_085",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-11T10:30:00",
          "text": "## 2024-08-19 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 126\n- Active: 115\n- Screen Failures Cumulative: 43\n- Withdrawals Cumulative: 11\n- By Dose Group:\n  - Low Dose: 30\n  - Mid Dose: 31\n  - High Dose: 32\n  - Placebo: 33\n\n### Immunogenicity By Group\n- Low Dose:\n  - IgG Titer (GMU) Mean: 58.2\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 17.0\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 92.2\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10e6) Mean: 139.0\n  - CD4 Response (SFC/10e6) SD: 15.0\n  - CD8 Response (SFC/10e6) Mean: 90.0\n  - CD8 Response (SFC/10e6) SD: 11.0\n  - Seroconversion Percentage: 17.8\n- Mid Dose:\n  - IgG Titer (GMU) Mean: 90.9\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 31.4\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 135.4\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10e6) Mean: 211.0\n  - CD4 Response (SFC/10e6) SD: 24.0\n  - CD8 Response (SFC/10e6) Mean: 145.0\n  - CD8 Response (SFC/10e6) SD: 18.0\n  - Seroconversion Percentage: 36.9\n- High Dose:\n  - IgG Titer (GMU) Mean: 118.7\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 41.4\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 193.2\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10e6) Mean: 278.0\n  - CD4 Response (SFC/10e6) SD: 33.0\n  - CD8 Response (SFC/10e6) Mean: 201.0\n  - CD8 Response (SFC/10e6) SD: 24.0\n  - Seroconversion Percentage: 46.8\n- Placebo:\n  - IgG Titer (GMU) Mean: 14.4\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 3.1\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 16.7\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10e6) Mean: 32.0\n  - CD4 Response (SFC/10e6) SD: 3.0\n  - CD8 Response (SFC/10e6) Mean: 26.0\n  - CD8 Response (SFC/10e6) SD: 2.0\n  - Seroconversion Percentage: 3.8\n\n### Injection Site Reactions\n- Pain Percentage: 40.6\n- Erythema Percentage: 23.2\n- Swelling Percentage: 7.1\n- Induration Percentage: 7.5\n- Mean Pain Duration (Hours): 45.0\n\n### Systemic Reactogenicity\n- Fever Percentage: 8.6\n- Fatigue Percentage: 21.6\n- Myalgia Percentage: 28.2\n- Headache Percentage: 24.5\n- Chills Percentage: 8.9\n\n### Safety Labs\n- WBC (K) Mean: 6.4\n- WBC (K) SD: 2.0\n- Lymphocyte Percentage Mean: 35.6\n- Lymphocyte Percentage SD: 8.0\n- Neutrophil Percentage Mean: 52.9\n- Neutrophil Percentage SD: 6.1\n- Platelets (K) Mean: 250\n- Platelets (K) SD: 38\n- CRP (mg/L) Mean: 3.7\n- CRP (mg/L) SD: 1.5\n- Hemoglobin (g/dL) Mean: 14.8\n- Hemoglobin (g/dL) SD: 1.3\n\n### Adverse Events\n- AE ID: VI-AE-2506, Description: nausea, Grade: 1, Relatedness: related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2547, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n- Site 05 monitoring visit, 2 minor findings\n- Immunology core lab QC report received\n\n### Notes\n- Week 25: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_086",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-13T10:30:00",
          "text": "## 2024-08-26 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 126\n- Active: 116\n- Screen Failures Cumulative: 34\n- Withdrawals Cumulative: 10\n\n### Enrollment by Dose Group\n- Low Dose: 31\n- Mid Dose: 31\n- High Dose: 31\n- Placebo: 33\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 54.7\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 18.6\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 86.4\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 126.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 83.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 24.3\n- Mid Dose\n  - IgG Titer (GMU) Mean: 81.4\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 27.3\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 132.5\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 195.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 145.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 34.2\n- High Dose\n  - IgG Titer (GMU) Mean: 116.7\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 38.7\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 188.6\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 270.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 196.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 42.1\n- Placebo\n  - IgG Titer (GMU) Mean: 10.8\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 5.6\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 16.1\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 25.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 15.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 0.8\n\n### Injection Site Reactions\n- Pain Percentage: 37.3\n- Erythema Percentage: 26.0\n- Swelling Percentage: 15.8\n- Induration Percentage: 4.5\n- Mean Pain Duration (hours): 32.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 24.8\n- Fatigue Percentage: 26.8\n- Myalgia Percentage: 32.6\n- Headache Percentage: 28.7\n- Chills Percentage: 12.0\n\n### Safety Labs\n- WBC (K) Mean: 7.3\n- WBC (K) SD: 1.6\n- Lymphocyte Percentage Mean: 27.3\n- Lymphocyte Percentage SD: 7.7\n- Neutrophil Percentage Mean: 52.7\n- Neutrophil Percentage SD: 6.4\n- Platelets (K) Mean: 252\n- Platelets (K) SD: 43\n- CRP (mg/L) Mean: 4.1\n- CRP (mg/L) SD: 1.9\n- Hemoglobin (g/dL) Mean: 14.0\n- Hemoglobin (g/dL) SD: 1.2\n\n### Adverse Events\n- AE ID: VI-AE-2612, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2638, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Reactogenicity diary card collection rate: 93%\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n\n### Notes\n- Week 26: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_029",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-16T10:00:00",
          "text": "## 2024-09-16 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 222\n- Active: 202\n- Screen Failures Cumulative: 69\n- Withdrawals Cumulative: 20\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 4\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup N: 52\n- Statin Subgroup ALT (U/L) Mean: 171.6\n- Statin Subgroup ALT (U/L) Median: 169.8\n- Statin Subgroup AST (U/L) Mean: 118.2\n- Statin Subgroup AST (U/L) Median: 118.1\n- Statin Subgroup Bilirubin (mg/dL) Mean: 2.77\n- Statin Subgroup Bilirubin (mg/dL) Median: 2.74\n- Statin Subgroup ALP (U/L) Mean: 82.0\n- Statin Subgroup ALP (U/L) Median: 68.1\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.87\n- Statin Subgroup Creatinine (mg/dL) Median: 0.82\n- Statin Subgroup BUN (mg/dL) Mean: 13.3\n- Statin Subgroup BUN (mg/dL) Median: 11.4\n- Statin Subgroup WBC (K) Mean: 8.2\n- Statin Subgroup WBC (K) Median: 5.7\n- Statin Subgroup Platelets (K) Mean: 234\n- Statin Subgroup Platelets (K) Median: 228\n- Non-Statin Subgroup N: 126\n- Non-Statin Subgroup ALT (U/L) Mean: 21.3\n- Non-Statin Subgroup ALT (U/L) Median: 21.0\n- Non-Statin Subgroup AST (U/L) Mean: 19.4\n- Non-Statin Subgroup AST (U/L) Median: 18.3\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.52\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.49\n- Non-Statin Subgroup ALP (U/L) Mean: 69.3\n- Non-Statin Subgroup ALP (U/L) Median: 68.1\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.85\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.91\n- Non-Statin Subgroup BUN (mg/dL) Mean: 16.6\n- Non-Statin Subgroup BUN (mg/dL) Median: 12.7\n- Non-Statin Subgroup WBC (K) Mean: 6.4\n- Non-Statin Subgroup WBC (K) Median: 7.6\n- Non-Statin Subgroup Platelets (K) Mean: 232\n- Non-Statin Subgroup Platelets (K) Median: 258\n\n### Adverse Events\n- AE ID: AE-0120, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0121, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0122, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0123, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0124, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0125, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0126, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 23\n- ACE Inhibitor Count: 30\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-061, Description: Missed visit window (2 days late), Severity: minor, Site: site_09\n\n### Investigator Notes\n- Source document verification complete for prior monitoring visit\n- Training log updated for new study coordinator\n- All sites now operating under amended protocol v4.0\n\n### Events\n- Site 12 monitoring visit completed, 1 findings\n- Drug accountability audit at Site 05: no discrepancies\n\n### Notes\n- Week 29: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_087",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-16T10:30:00",
          "text": "## 2024-09-02 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 126\n- Active: 118\n- Screen Failures Cumulative: 42\n- Withdrawals Cumulative: 8\n\n#### By Dose Group\n- Low Dose: 30\n- Mid Dose: 31\n- High Dose: 31\n- Placebo: 34\n\n### Immunogenicity By Group\n\n#### Low Dose\n- IgG Titer (GMU) Mean: 49.5\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 19.4\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 82.5\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 130.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 85.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 22.0\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 84.9\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 30.8\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 124.1\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 182.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 137.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 32.9\n\n#### High Dose\n- IgG Titer (GMU) Mean: 106.8\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 40.4\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 168.7\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 271.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 181.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 44.2\n\n#### Placebo\n- IgG Titer (GMU) Mean: 14.2\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 5.7\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 14.3\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 23.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 24.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 1.3\n\n### Injection Site Reactions\n- Pain Percentage: 38.5\n- Erythema Percentage: 22.4\n- Swelling Percentage: 13.6\n- Induration Percentage: 3.1\n- Mean Pain Duration (Hours): 29.0\n\n### Systemic Reactogenicity\n- Fever Percentage: 12.8\n- Fatigue Percentage: 40.2\n- Myalgia Percentage: 20.0\n- Headache Percentage: 24.6\n- Chills Percentage: 11.6\n\n### Safety Labs\n\n#### WBC\n- Mean (K): 7.1\n- SD: 1.9\n\n#### Lymphocyte Percentage\n- Mean: 33.7\n- SD: 6.8\n\n#### Neutrophil Percentage\n- Mean: 51.7\n- SD: 9.7\n\n#### Platelets\n- Mean (K): 226\n- SD: 43\n\n#### CRP\n- Mean (mg/L): 1.8\n- SD: 1.4\n\n#### Hemoglobin\n- Mean (g/dL): 13.9\n- SD: 1.0\n\n### Adverse Events\n- AE ID: VI-AE-2770, Description: fatigue, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2712, Description: arthralgia, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2707, Description: myalgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-2768, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-2721, Description: lymphadenopathy, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Vaccine lot VX-944 temperature excursion assessed: within acceptable range\n- Site 01 monitoring visit, 0 minor findings\n\n### Notes\n- Week 27: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_088",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-18T10:30:00",
          "text": "## 2024-09-09 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 127\n- Active: 116\n- Screen Failures Cumulative: 50\n- Withdrawals Cumulative: 11\n\n### Enrollment by Dose Group\n- Low Dose: 31\n- Mid Dose: 30\n- High Dose: 32\n- Placebo: 34\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 43.8\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 21.0\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 77.7\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC per 10^6) Mean: 108.0\n  - CD4 Response (SFC per 10^6) SD: 15.0\n  - CD8 Response (SFC per 10^6) Mean: 89.0\n  - CD8 Response (SFC per 10^6) SD: 11.0\n  - Seroconversion Percentage: 16.0\n- Mid Dose\n  - IgG Titer (GMU) Mean: 79.8\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 29.3\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 120.1\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC per 10^6) Mean: 188.0\n  - CD4 Response (SFC per 10^6) SD: 24.0\n  - CD8 Response (SFC per 10^6) Mean: 138.0\n  - CD8 Response (SFC per 10^6) SD: 18.0\n  - Seroconversion Percentage: 31.7\n- High Dose\n  - IgG Titer (GMU) Mean: 103.7\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 40.4\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 165.8\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC per 10^6) Mean: 261.0\n  - CD4 Response (SFC per 10^6) SD: 33.0\n  - CD8 Response (SFC per 10^6) Mean: 173.0\n  - CD8 Response (SFC per 10^6) SD: 24.0\n  - Seroconversion Percentage: 46.3\n- Placebo\n  - IgG Titer (GMU) Mean: 12.7\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 4.8\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 20.3\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC per 10^6) Mean: 28.0\n  - CD4 Response (SFC per 10^6) SD: 3.0\n  - CD8 Response (SFC per 10^6) Mean: 10.0\n  - CD8 Response (SFC per 10^6) SD: 2.0\n  - Seroconversion Percentage: 0.8\n\n### Injection Site Reactions\n- Pain Percentage: 42.3\n- Erythema Percentage: 27.5\n- Swelling Percentage: 6.6\n- Induration Percentage: 11.3\n- Mean Pain Duration (Hours): 26.1\n\n### Systemic Reactogenicity\n- Fever Percentage: 10.6\n- Fatigue Percentage: 36.8\n- Myalgia Percentage: 31.4\n- Headache Percentage: 20.1\n- Chills Percentage: 13.7\n\n### Safety Labs\n- WBC (K): Mean: 8.1\n- WBC (K) SD: 1.3\n- Lymphocyte Percentage: Mean: 33.4\n- Lymphocyte Percentage SD: 7.5\n- Neutrophil Percentage: Mean: 61.2\n- Neutrophil Percentage SD: 7.8\n- Platelets (K): Mean: 230\n- Platelets (K) SD: 41\n- CRP (mg/L): Mean: 1.8\n- CRP (mg/L) SD: 1.6\n- Hemoglobin (g/dL): Mean: 14.0\n- Hemoglobin (g/dL) SD: 0.8\n\n### Adverse Events\n- AE ID: VI-AE-2852, Description: fever, Grade: 2, Relatedness: related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2869, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-2810, Description: fatigue, Grade: 2, Relatedness: related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2891, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2868, Description: arthralgia, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n- Vaccination day 1: 25 subjects received scheduled dose\n- Cold chain temperature log reviewed: all within -70C +/- 5C\n\n### Notes\n- Week 28: Immunogenicity assessments on schedule. 127 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_089",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-20T10:30:00",
          "text": "## 2024-09-16 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 126\n- Active: 112\n- Screen Failures Cumulative: 50\n- Withdrawals Cumulative: 14\n\n### Enrollment by Dose Group\n- Low Dose: 29\n- Mid Dose: 32\n- High Dose: 33\n- Placebo: 32\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 48.2\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 21.4\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 68.8\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 101.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 71.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 17.3\n- Mid Dose\n  - IgG Titer (GMU) Mean: 76.7\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 27.6\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 114.2\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 180.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 124.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 33.8\n- High Dose\n  - IgG Titer (GMU) Mean: 102.4\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 43.7\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 163.8\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 235.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 178.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 36.0\n- Placebo\n  - IgG Titer (GMU) Mean: 7.7\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 5.9\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 11.5\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 28.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 20.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 5.3\n\n### Injection Site Reactions\n- Pain Percentage: 58.9\n- Erythema Percentage: 23.1\n- Swelling Percentage: 16.4\n- Induration Percentage: 3.6\n- Mean Pain Duration (Hours): 22.2\n\n### Systemic Reactogenicity\n- Fever Percentage: 6.3\n- Fatigue Percentage: 39.6\n- Myalgia Percentage: 19.0\n- Headache Percentage: 20.2\n- Chills Percentage: 10.2\n\n### Safety Labs\n- WBC (K) Mean: 7.1\n- WBC (K) SD: 1.3\n- Lymphocyte Percentage Mean: 28.9\n- Lymphocyte Percentage SD: 6.4\n- Neutrophil Percentage Mean: 53.7\n- Neutrophil Percentage SD: 5.1\n- Platelets (K) Mean: 227\n- Platelets (K) SD: 42\n- CRP (mg/L) Mean: 7.3\n- CRP (mg/L) SD: 1.5\n- Hemoglobin (g/dL) Mean: 14.3\n- Hemoglobin (g/dL) SD: 0.9\n\n### Adverse Events\n- AE ID: VI-AE-2903, Description: fever, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2980, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2908, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2931, Description: chills, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-2964, Description: headache, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Serology samples shipped to central immunology lab\n- Site 02 monitoring visit, 3 minor findings\n- Vaccine lot VX-588 temperature excursion assessed: within acceptable range\n\n### Notes\n- Week 29: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_030",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-23T10:00:00",
          "text": "## 2024-09-23 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 224\n- Active: 207\n- Screen Failures Cumulative: 78\n- Withdrawals Cumulative: 17\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 21\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 19\n- Site 05 Active: 19\n- Site 05 Statin Concomitant: 6\n- Site 06 Enrolled: 13\n- Site 06 Active: 13\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 23\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 19\n- Site 09 Active: 19\n- Site 09 Statin Concomitant: 6\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 21\n- Site 11 Active: 21\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 181.8\n- ALT (U/L) Median: 179.2\n- AST (U/L) Mean: 120.0\n- AST (U/L) Median: 119.0\n- Bilirubin (mg/dL) Mean: 3.1\n- Bilirubin (mg/dL) Median: 3.1\n- ALP (U/L) Mean: 57.0\n- ALP (U/L) Median: 75.7\n- Creatinine (mg/dL) Mean: 0.96\n- Creatinine (mg/dL) Median: 0.96\n- BUN (mg/dL) Mean: 16.1\n- BUN (mg/dL) Median: 13.6\n- WBC (K) Mean: 7.8\n- WBC (K) Median: 6.3\n- Platelets (K) Mean: 219\n- Platelets (K) Median: 249\n\n#### Non-Statin Subgroup\n- N: 131\n- ALT (U/L) Mean: 28.8\n- ALT (U/L) Median: 26.9\n- AST (U/L) Mean: 28.3\n- AST (U/L) Median: 27.9\n- Bilirubin (mg/dL) Mean: 0.6\n- Bilirubin (mg/dL) Median: 0.56\n- ALP (U/L) Mean: 67.0\n- ALP (U/L) Median: 64.9\n- Creatinine (mg/dL) Mean: 1.02\n- Creatinine (mg/dL) Median: 0.97\n- BUN (mg/dL) Mean: 14.1\n- BUN (mg/dL) Median: 13.9\n- WBC (K) Mean: 6.3\n- WBC (K) Median: 7.9\n- Platelets (K) Mean: 252\n- Platelets (K) Median: 229\n\n### Adverse Events\n- AE ID: AE-0127, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0128, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0129, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0130, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0131, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0132, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 14\n- ACE Inhibitor Count: 29\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-062, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_06\n- PD ID: PD-063, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_03\n\n### Investigator Notes\n- Enrollment on track per protocol timeline\n- All CRFs current through prior visit cycle\n- Post-amendment statin subgroup n=8 (subjects who could not discontinue); hepatic monitoring frequency doubled\n\n### Events\n- Drug accountability audit at Site 05: no discrepancies\n- Investigator meeting minutes distributed\n- End-of-phase safety data compilation initiated for regulatory briefing\n\n### Notes\n- Week 30: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_dx_090",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-23T10:30:00",
          "text": "## 2024-09-23 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 126\n- Active: 115\n- Screen Failures Cumulative: 40\n- Withdrawals Cumulative: 11\n\n### Enrollment By Dose Group\n- Low Dose: 29\n- Mid Dose: 31\n- High Dose: 33\n- Placebo: 33\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 42.4\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 16.3\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 63.7\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 109.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 79.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 12.6\n- Mid Dose\n  - IgG Titer (GMU) Mean: 74.5\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 28.3\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 119.2\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 177.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 117.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 30.5\n- High Dose\n  - IgG Titer (GMU) Mean: 100.2\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 38.5\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 157.3\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 228.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 167.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 38.4\n- Placebo\n  - IgG Titer (GMU) Mean: 13.5\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 5.8\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 13.9\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 23.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 16.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 6.1\n\n### Injection Site Reactions\n- Pain Percentage: 60.2\n- Erythema Percentage: 24.2\n- Swelling Percentage: 14.1\n- Induration Percentage: 6.4\n- Mean Pain Duration (hours): 33.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 16.8\n- Fatigue Percentage: 37.2\n- Myalgia Percentage: 31.9\n- Headache Percentage: 18.9\n- Chills Percentage: 12.8\n\n### Safety Labs\n- WBC (K) Mean: 5.6\n- WBC (K) SD: 1.3\n- Lymphocyte Percentage Mean: 27.5\n- Lymphocyte Percentage SD: 4.9\n- Neutrophil Percentage Mean: 63.9\n- Neutrophil Percentage SD: 7.0\n- Platelets (K) Mean: 254\n- Platelets (K) SD: 43\n- CRP (mg/L) Mean: 3.4\n- CRP (mg/L) SD: 1.8\n- Hemoglobin (g/dL) Mean: 14.7\n- Hemoglobin (g/dL) SD: 1.0\n\n### Adverse Events\n- AE ID: VI-AE-3077, Description: arthralgia, Grade: 1, Relatedness: related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-3067, Description: injection site pain, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- DSMB safety review teleconference completed\n- Serology samples shipped to central immunology lab\n\n### Notes\n- Week 30: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
          "meta": {
            "episode_type": "distractor",
            "theme": "vaccine_immunogenicity"
          }
        }
      ]
    }
  ],
  "questions": [
    {
      "question_id": "cs03_q01_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 46,
      "question_type": "longitudinal",
      "prompt": "Based on the trial data so far, are there any emerging safety signals in the lab panels?",
      "ground_truth": {
        "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    {
      "question_id": "cs03_q02_null",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 46,
      "question_type": "null_hypothesis",
      "prompt": "What was the enrollment count at Site 03 in the Week 6 summary?",
      "ground_truth": {
        "canonical_answer": "The enrollment figure as documented in the Week 6 site summary.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006"
        ],
        "key_facts": []
      }
    },
    {
      "question_id": "cs03_q03_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 99,
      "question_type": "longitudinal",
      "prompt": "What is driving the hepatic adverse events in this trial?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    {
      "question_id": "cs03_q04_action",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 119,
      "question_type": "action_recommendation",
      "prompt": "What protocol amendments should the DSMB recommend?",
      "ground_truth": {
        "canonical_answer": "Exclude concomitant statin use from the trial. Add CYP3A4 interaction screening. Implement more frequent hepatic panel monitoring for enrolled subjects. Consider dose adjustment studies for the LNS-4821/statin interaction.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_019",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_026"
        ],
        "key_facts": [
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    {
      "question_id": "cs03_q05_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 58,
      "question_type": "negative",
      "prompt": "Is there evidence of nephrotoxicity or renal dysfunction in enrolled subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal panels (creatinine, BUN, eGFR) remain within normal limits throughout the trial. The emerging safety signal is hepatic, not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q06_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 99,
      "question_type": "paraphrase",
      "prompt": "Why are liver enzymes elevated in a subset of trial participants?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations"
        ]
      }
    },
    {
      "question_id": "cs03_q07_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 99,
      "question_type": "temporal",
      "prompt": "When did ALT elevations first become apparent, and how many weeks elapsed before subjects met Hy's Law criteria?",
      "ground_truth": {
        "canonical_answer": "ALT elevations in the statin subgroup first became apparent during the early signal phase. It took approximately 7-13 weeks from initial detection to subjects meeting Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN) during the escalation phase.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013",
          "clinical_signal_03_ep_017"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    {
      "question_id": "cs03_q08_counterfactual",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 99,
      "question_type": "counterfactual",
      "prompt": "If the Site 07 lab equipment calibration issue were responsible for the ALT elevations, what pattern would you expect across sites? Does that match the data?",
      "ground_truth": {
        "canonical_answer": "If Site 07 equipment were the cause, ALT elevations would be confined to Site 07 and resolve after recalibration. Instead, the ALT signal appears across multiple sites and correlates with statin co-administration, not site. The cross-site pattern rules out a site-specific equipment explanation.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_015",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_024"
        ],
        "key_facts": [
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    {
      "question_id": "cs03_q09_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 18,
      "question_type": "longitudinal",
      "prompt": "Based on the first five weeks of trial data, are there any safety signals in the lab panels?",
      "ground_truth": {
        "canonical_answer": "No. All lab panels are within normal limits across all sites. Hepatic, renal, and hematology markers show no adverse trends. The trial is in the enrollment ramp-up phase.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_003",
          "clinical_signal_03_ep_005"
        ],
        "key_facts": []
      }
    },
    {
      "question_id": "cs03_q10_evidence",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 18,
      "question_type": "evidence_sufficiency",
      "prompt": "Is there sufficient data at this point to evaluate the safety profile of LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Only 5 weeks of data from the enrollment ramp phase are available. The subject population is too small and exposure duration too short to draw conclusions about the drug's safety profile.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_003"
        ],
        "key_facts": []
      }
    },
    {
      "question_id": "cs03_q11_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 79,
      "question_type": "longitudinal",
      "prompt": "What is the emerging safety profile of LNS-4821, and which patient subgroup is most affected?",
      "ground_truth": {
        "canonical_answer": "Hepatotoxicity in the statin co-administered subgroup. ALT elevations reaching 2-3x ULN across multiple sites, with two subjects meeting Hy's Law criteria. Non-statin patients remain stable. The cross-site distribution rules out the Site 07 equipment hypothesis.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    {
      "question_id": "cs03_q12_severity",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 79,
      "question_type": "severity_assessment",
      "prompt": "How would you assess the severity of the hepatic signal and the urgency of protocol intervention?",
      "ground_truth": {
        "canonical_answer": "High severity. Two subjects have met Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN), which is a recognized indicator of potential drug-induced liver injury. The signal is escalating and protocol amendment is urgent to prevent further SAEs.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    {
      "question_id": "cs03_q13_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 46,
      "question_type": "paraphrase",
      "prompt": "Are any laboratory parameters trending outside normal limits in specific patient populations?",
      "ground_truth": {
        "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    {
      "question_id": "cs03_q14_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 99,
      "question_type": "paraphrase",
      "prompt": "Why is there a difference in liver enzyme levels between patient subgroups?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy via CYP3A4 inhibition causes hepatotoxicity in the statin subgroup. The signal appears across all sites, not just Site 07, ruling out the equipment calibration hypothesis.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations"
        ]
      }
    },
    {
      "question_id": "cs03_q15_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 79,
      "question_type": "negative",
      "prompt": "Is there evidence of an immune-mediated reaction or immunogenicity issues with LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Immunogenicity markers and antibody responses are not related to the hepatic safety signal. The mechanism is a pharmacokinetic drug-drug interaction via CYP3A4, not an immune-mediated reaction.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_005",
          "clinical_signal_03_ep_012"
        ],
        "key_facts": [
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity"
        ]
      }
    },
    {
      "question_id": "cs03_q16_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 99,
      "question_type": "negative",
      "prompt": "Are there musculoskeletal or pain-related adverse events associated with LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Pain and musculoskeletal endpoints show no drug-related adverse trends. The safety signal is hepatic, confined to the statin co-administered subgroup.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q17_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 79,
      "question_type": "temporal",
      "prompt": "How rapidly are ALT values escalating in the affected subgroup?",
      "ground_truth": {
        "canonical_answer": "ALT values in the statin subgroup have progressed from baseline normal (15-35 U/L) through subtle elevation (45-65 U/L) to clinically significant levels (80-120 U/L, 2-3x ULN) over the course of the signal and escalation phases. The rate of increase has accelerated.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns"
        ]
      }
    },
    {
      "question_id": "cs03_q18_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 58,
      "question_type": "temporal",
      "prompt": "When did the first hepatic enzyme elevations appear relative to drug exposure initiation?",
      "ground_truth": {
        "canonical_answer": "Hepatic enzyme elevations first appeared during the early signal phase, approximately weeks 9-10 of the trial, several weeks after subjects began receiving LNS-4821 with concomitant statin therapy.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    {
      "question_id": "cs03_q19_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 58,
      "question_type": "distractor_resistance",
      "prompt": "Are novel urinary biomarkers (KIM-1, NGAL) showing any abnormalities in trial subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal biomarkers remain within normal limits. The emerging safety signal is hepatic (ALT/AST elevation), not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q20_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 99,
      "question_type": "distractor_resistance",
      "prompt": "Is there any relationship between seroconversion rates and the adverse event pattern?",
      "ground_truth": {
        "canonical_answer": "No. Immunogenicity measures including seroconversion rates are not related to the hepatotoxicity signal. The adverse events are driven by a CYP3A4-mediated drug-drug interaction with statins.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_005",
          "clinical_signal_03_ep_023"
        ],
        "key_facts": [
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity"
        ]
      }
    },
    {
      "question_id": "cs03_q21_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 79,
      "question_type": "distractor_resistance",
      "prompt": "Are VAS pain scores or functional assessments correlating with the laboratory abnormalities?",
      "ground_truth": {
        "canonical_answer": "No. Pain endpoints are stable and unrelated to the hepatic safety signal. The ALT elevations correlate with statin co-administration, not pain or functional measures.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006",
          "clinical_signal_03_ep_017"
        ],
        "key_facts": [
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q22_counterfactual",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 79,
      "question_type": "counterfactual",
      "prompt": "If the ALT elevations were caused by a viral hepatitis outbreak among trial subjects, what pattern would you expect? Does the data match?",
      "ground_truth": {
        "canonical_answer": "Viral hepatitis would show clustered onset at specific sites, associated symptoms (fatigue, jaundice), and positive viral serologies. Instead, the elevations are distributed across sites and correlate with statin co-administration, not geography or viral exposure. The pattern is consistent with a pharmacokinetic interaction, not infection.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q23_null",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 79,
      "question_type": "null_hypothesis",
      "prompt": "How many protocol deviations were reported at Site 03 in the most recent weekly summary?",
      "ground_truth": {
        "canonical_answer": "The protocol deviation count as documented in the weekly site summary.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_018"
        ],
        "key_facts": []
      }
    },
    {
      "question_id": "cs03_q24_evidence",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 58,
      "question_type": "evidence_sufficiency",
      "prompt": "Is there sufficient evidence at this point to convene a DSMB safety review?",
      "ground_truth": {
        "canonical_answer": "Borderline. The ALT trend in the statin subgroup is concerning but individual values are still below protocol action thresholds. A few more weeks of data showing continued escalation would strengthen the case for DSMB review.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    }
  ]
}